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Abstract 
Background 
Cancer survivorship is recognised as an integral component of the cancer 
continuum. Robust evidence on how best to deliver tailored survivorship 
care is limited, particularly for individuals affected by rarer cancers such as 
lymphoma, a potentially curable haematological cancer. These survivors may 
face long-term and late effects affecting quality of life due to the 
aggressiveness of the disease and treatment that may not be adequately 
addressed in current follow-up models of care.  
 
Aim 
To develop and pilot test a nurse-led model of survivorship care intervention 
that utilises an individualised survivorship care plan and treatment 
summary (SCPTS), motivational interviewing, tailored support and 
resources with lymphoma patients who have completed active treatment. 
 
Method 
A four-phase prospective study was undertaken: Phase One consisted of 
integrative/systematic reviews; Phase Two focused on development of the 
survivorship model of care; Phase Three comprised a pragmatic randomised 
controlled trial (RCT) to test the intervention; and Phase Four elicited 
qualitative feedback from intervention participants and their general 
practitioners’ (GP). A published pilot pragmatic RCT protocol was 
implemented and participants were randomised to a control group (n=30) or 
intervention group (n=30). Four patient reported outcome measures were 
administered to both groups at three time points; baseline (Time 1), 3 months 
(Time 2) and six months (Time 3). 
 
xi 
Data Analysis 
Descriptive, univariate and multivariate statistical techniques were applied 
to quantitative data. Content analysis was performed on qualitative 
interview data and GP evaluations. 
 
Results 
Three comprehensive integrative/systematic reviews were undertaken, 
published (survivorship models of care, SCPTS, survivorship needs 
assessment measures) and informed the development of a unique and 
concise evidence-based SCPTS and other model of care (intervention) 
components. The intervention comprised three face-to-face appointments 
over six months to deliver the lymphoma survivorship model of care. 
Intervention participants reported increased self-empowerment and less 
unmet needs. Test–retest reliability analysis was performed and published 
for the Short-Form Survivor Unmet Needs Survey (n=40). Ten intervention 
participants interviewed at completion of the RCT reported a positive 
experience of the model of care. Feedback from 18/28 (64%) GPs confirmed 
the SCPTS was a useful tool for patient consultations. 
 
Conclusion  
Findings add to a limited body of knowledge in lymphoma survivorship care 
and nurse-led models of care. They highlight the importance and perceived 
value of providing individualised, tailored support to lymphoma survivors 
from treatment completion. The evidence produced from this study provides 
baseline data to support future rigorous testing of nurse-led models of 
lymphoma survivorship care with larger samples. 
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Chapter One — Introduction 
 
 
 
 
 
 
 
 
 
 
“When I finished treatment, it was a bit like an anti-climax, it was – okay you 
have finished treatment, see you later. I felt like I had just been forgotten” 
Female_NHL 
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 2 
1.0 Introduction  
This thesis consists of six related papers that provide a comprehensive 
account of the development and testing of a pilot nurse-led lymphoma 
survivorship model of care. 
 
This chapter provides a brief background to lymphoma cancer, the issues 
survivors face and the need to develop better models of follow-up care for 
lymphoma patients who finish curative-intent treatment. An overview of the 
purpose of this study, the research questions that guided all aspects of this 
study are then presented. The chapter concludes with an overview of the 
structure of the thesis and a glossary of terms. 
 
The Problem 
Lymphoma is a blood cancer originating from B and T cells in the lymphatic 
system which undergo a malignant change. Although there are around 30 
different types, they can be categorised into two main types; non-Hodgkin 
lymphoma (NHL) or Hodgkin lymphoma (HL) (Cancer Australia, 2018).  
 
In Australia, HL is considered a rarer cancer, accounting for only 0.5% of all 
cancer diagnosed. It is estimated about 683 cases will be diagnosed, with 
mortality around 30 cases in 2018 (Australian Institute of Health and 
Welfare, 2017). Five-year relative survival at diagnosis is 87.5% (Australian 
Institute of Health and Welfare, 2017). It is the most common cancer of the 
adolescent and young adult population, with over a third of all incidences in 
the 15–30-year age group. Unlike other types of lymphoma, HL is diagnosed 
when the presence of what are termed Reed-Sternberg cells are seen in the 
biopsy material (Kuppers & Hansmann, 2005).  
CHAPTER 1. INTRODUCTION 
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The majority (80%) of NHL arises from B cells and is the most common type 
of lymphoma, especially in those over 50 years of age where incidence 
increase with age (Australian Institute of Health and Welfare, 2017). An 
estimated 5,720 cases will be diagnosed, and an estimated 1,443 deaths in 
2018. Five-year relative survival at diagnosis is approximately 74% 
(Australian Institute of Health and Welfare, 2017). 
 
Combined, lymphomas represent the sixth most common cancer diagnosis in 
Australia and worldwide (Cancer Australia, 2018; Howlader et al., 2016) and 
tend to occur more frequently in men (Australian Institute of Health and 
Welfare, 2017). Incidence and survival in Australia are increasing. An 
estimated 6,232 cases were diagnosed in 2017, equating to 4.6% of all cancer 
cases (Australian Institute of Health and Welfare, 2017). Conversely, an 
estimated 1,481 people will have died from lymphoma, equating to 3.1% of 
all cancer deaths in 2017. Improved survival rates have been attributed 
predominantly to developments in treatment and supportive care options. 
These include chemotherapy and/or radiotherapy and may involve 
haematopoietic stem cell transplantation or immunotherapy or targeted 
therapies (Carey et al., 2012). An estimated 76% of those diagnosed survive at 
least five years; this is a marked increase from 52% in the mid-1980s.  
 
With increased remission and survival rates, many survivors are living with 
issues and concerns, called unmet needs, due to the aggressive nature of the 
cancer and the intensity of treatment (Carey et al., 2012; Sant et al., 2014). 
These long-term and late effects may have an ongoing impact on health and 
quality of life (QoL) (Leeuwen & Ng, 2017; Oerlemans, Mols, Nijziel, Lybeert, 
& van de Poll-Franse, 2011; Sarker et al., 2017). Difficulties faced by 
lymphoma survivors may relate to: fatigue; poor nutritional intake; 
decreased exercise capacity; cognition impairment; fear of recurrence; 
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depression and anxiety; fertility issues; relationship stress; financial concerns; 
employment issues; and difficulty in obtaining particular types of insurance, 
for example health and/or travel insurance (Arboe et al., 2017; Bryant et al., 
2015; Daniels, Oerlemans, Krol, Creutzberg, & van de Poll-Franse, 2014; 
Daniels, Oerlemans, Krol, van de Poll-Franse, & Creutzberg, 2013; de Lima et 
al., 2017; Hall et al., 2016; Jones et al., 2015; Kreissl et al., 2016; Krolak, 
Collins, Weiss, Harris, & Van der Jagt, 2017; Leeuwen & Ng, 2017; Linendoll 
et al., 2016; Magyari et al., 2017; Mojs, Warchol-Biedermann, & Samborski, 
2017; Oerlemans et al., 2014; van de Wal, van de Poll-Franse, Prins, & 
Gielissen, 2016; Zimmer et al., 2015). Furthermore, health can be 
compromised by an increased risk of developing other diseases such as 
cardiovascular disease and second cancers (Leeuwen & Ng, 2017; Schaapveld 
et al., 2015). These are often experienced earlier than the general population 
(Panek-Hudson, 2013), an escalating problem in those diagnosed at a 
younger age (Grinyer, 2010; Hemminki, Lenner, Sundquist, & Bermejo, 2008), 
which is further elevated if treatment involves radiotherapy (Ng, LaCasce, & 
Travis, 2011; Travis et al., 2012). Survivor lifestyle behaviours, such as 
smoking, can likewise have an effect on secondary disease development (Ng 
et al., 2011). It is important that health care providers, survivors and their 
families have an awareness of potential late effects, to ensure timely and 
appropriate follow-up (Ng et al., 2011).  
 
Regardless of what is currently known about the issues faced by lymphoma 
survivors, compared with other more common cancers such as breast, 
prostate and colorectal, this cancer remains understudied in survivorship 
literature. This gap in the published literature is important to address as 
inadequate service provision at treatment completion may be leading to 
unmet needs along the survivorship continuum (De Leeuw & Larsson, 2013). 
When this research was proposed in 2014, no RCTs were identified that 
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related to adult lymphoma survivor cohorts. Since that time there has been 
one published RCT reporting a 12-week exercise intervention in 
haematological cancer survivors (mainly lymphoma n=33, 89%), assessing 
cancer-related fatigue (Furzer et al., 2016).  
 
The lack of published evidence-based guidelines for the ongoing 
management of cancer survivors has previously been acknowledged in the 
cancer literature (Phillips & Currow, 2010; Rechis, Arvey, & Beckjord, 2013). 
Current follow-up care for lymphoma patients has traditionally been led by 
the haematologist (Taylor, Chan, & Monterosso, 2015), with a focus largely 
on recurrence surveillance (Molassiotis et al., 2017) that overlooks needs-
based tailored support and information (Earle & Ganz, 2012; Jefford et al., 
2008). Likewise, no consensus exists on whether other health care providers, 
such as nurses or GPs could deliver holistic care to transition survivors into 
the survivorship phase upon treatment completion.  
 
Cancer nurses have established expertise in the areas of health promotion, 
information, support and resource provision (Jackson, Scheid, & Rolnick, 
2013). Findings from recent studies have supported nurse-led models of 
survivorship care that utilised the existing skills of experienced cancer nurses 
(Beaver et al., 2012; Gates, Seymour, & Krishnasamy, 2015; Howell et al., 
2012; Jefford et al., 2016; John & Armes, 2013; Maly, Liang, Liu, Griggs, & 
Ganz, 2017). An important aspect of these models was the administration of 
survivor-specific and patient-centred assessment measures to accurately 
ascertain and address concerns or issues that are important to the survivor. 
Equally it is proposed these measures may empower survivors to seek out 
information and support to manage their concerns and ongoing symptoms, 
and to adopt healthy lifestyle behaviours (Fitch, 2008; Ganz, Casillas, & 
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Hahn, 2008; McDowell, Occhipinti, Ferguson, Dunn, & Chambers, 2010; 
Stricker et al., 2011).  
 
Patient empowerment or activation (Klemanski, Browning, & Kue, 2016) in 
this context, indicates the degree to which an individual comprehends that 
he or she has a role in managing health and health care. It likewise includes 
the extent to which the individual feels capable of fulfilling that role 
(Hibbard, Mahoney, Stock, & Tusler, 2007). It could be argued that self-
efficacy is an important indicator of a successful transition into survivorship 
(Rosenberg et al., 2016).  
 
National and international professional cancer organisations have 
recommended the use of survivorship care plans and treatment summaries 
(SCPTS) as an important aspect in the facilitation of holistic survivorship 
follow-up care (Clinical Oncology Society of Australia, 2016; MacMillan 
Cancer Support & NHS Improvement, 2010; McCabe, Bhatia, et al., 2013). 
The provision of a written, individualised SCPTS should increase the amount 
of information that is communicated to the survivor and other health 
professionals such as the GP who may be responsible for future ongoing care 
of survivors. A treatment summary succinctly documents an individual’s 
disease and treatment information, along with potential late effects and 
recommended management. The survivorship care plan is then 
individualised to each patient and should guide personalised follow-up care 
with recommendations, screening guidelines, information and healthy 
lifestyle promotion and support (Alfano, Ganz, Rowland, & Hahn, 2012; 
Grant & Economou, 2008; Hausman, Ganz, Sellers, & Rosenquist, 2011; 
Hewitt, Greenfield, & Stovall, 2005; Jabson & Bowen, 2013; Panek-Hudson, 
2013; Taylor & Monterosso, 2015). 
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Aim and Objectives 
The purpose of this research was to develop and empirically test an 
evidence-based nurse-led lymphoma survivorship model of care to transition 
lymphoma survivors into the survivorship phase, using a pilot pragmatic 
randomised controlled trial (RCT). This research aimed to facilitate the 
participant randomised to the intervention group to normal functioning 
sooner and to produce a reduction in perceived unmet informational, 
practical and emotional needs or concerns and an increase in participant self-
management compared with those randomly assigned to the current 
standard of care (usual care). This research will furthermore provide baseline 
data to support hypothesis development, and the calculation of sample sizes 
for future multisite randomised controlled trials. It thereby fills a gap in 
lymphoma survivorship care where evidence-based research and outcome 
evaluation of models of care is lacking (Irwin, Klemp, Glennon, & Frazier, 
2011).  
 
Design 
The thesis comprised a four-phase prospective study that incorporated 
quantitative and qualitative research methodology (Figure 1.1). The main 
focus of this thesis was the phase II pilot pragmatic randomised controlled 
trial (RCT). Pragmatic RCTs are customarily conducted in the “real-world” 
setting where patients receive their usual care (Thorpe et al., 2009). In this 
case, participants were recruited from the haematology department of a large 
tertiary cancer centre in Perth, Western Australia. As is the case with 
pragmatic RCTs, recruitment is offered to potentially all eligible patients 
receiving care in the participating location. Intervention delivery and 
participant follow-up are closely aligned to usual care to understand the real-
world implications of the intervention and to determine the effects of the 
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intervention in conditions where it would normally be applied (Thorpe et al., 
2009). Qualitative research was undertaken to complement the quantitative 
findings of this study and occurred concurrently with the pragmatic RCT. 
The qualitative interviews were undertaken with a subset of intervention 
participants at the completion of all study measures to explore participant 
perceptions of the nurse-led lymphoma survivorship clinic (NLSC) 
intervention, assessment measures and SCPTS. Feedback was also sought 
from intervention participants’ GPs to determine the usefulness and utility of 
the SCPTS to inform practice. As there was no published test–retest 
reliability data for one of the chosen assessment measures (Short-Form 
Survivor Unmet Needs Survey), this process was also undertaken as part of 
this thesis.  
 
Research Questions 
A number of questions guided each of the four phases. 
 
Phase One: Systematic/Integrative Literature Reviews 
1. Models of survivorship care 
a. What are the common attributes of survivorship models of care 
developed generally for cancer patients and specifically for 
haematology cancer patients? 
b. What resources are required to support these models? 
c. What are the potential benefits and shortfalls of these models?  
d. What outcome measures have been used to evaluate these models 
and what are the findings?  
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2. Survivorship care plans and treatment summaries (SCPTS) 
a. What are the common attributes of SCPTS developed for 
haematological cancer patients? 
b. What resources are required to develop SCPTS? 
c. What are the potential benefits and limitations of SCPTS?  
d. What outcome measures have been used to evaluate SCPTS and 
what are the findings? 
3. Needs assessment measures 
a. What reliable and valid measurement tools are currently available 
to measure the informational and practical needs of lymphoma 
cancer survivors? 
b. What are the implications of the findings from the review for 
future research and clinical practice? 
 
Phase Two: Intervention Development 
1. What assessment instruments will be chosen to measure: survivor-
specific informational, practical and emotional needs; depression, anxiety 
and stress; mental adjustment; and patient empowerment? 
2. What components are required for an SCPTS designed for lymphoma 
survivors?  
a. How will these be tested for content validity (apparent internal 
consistency, clarity and reliability)? 
3. What information and resources will be required to develop a tailored 
resource pack, including health promotion strategies? 
 
Phase Three: Pilot Pragmatic Randomised Controlled Trial (RCT) 
1. Do participants assigned to the nurse-led lymphoma survivorship clinic 
intervention demonstrate a reduction in perceived unmet informational, 
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practical and emotional needs compared with those randomly assigned to 
usual care?  
2. Do participants assigned to the nurse-led lymphoma survivorship clinic 
demonstrate a reduction in self-reported anxiety, depression and stress 
and an increase in patient self-management behaviours compared with 
participants randomly assigned to usual care? 
3. Does the SF-SUNS demonstrate test–retest stability and reliability over 
time? 
 
Phase Four: Qualitative Interviews / General Practitioner Evaluation 
1. What questions will best elicit participant perceptions of the assessment 
measures, the nurse-led survivorship model of care and the SCPTS? 
a. Who should assist with the interview schedule development and 
who should undertake the interviews to reduce bias? 
2. What questions and format will work best to elicit general practitioner 
(GP) perceptions of the utility and usefulness of the SCPTS. 
a. Who is best suited to provide advice and suggestions regarding 
the development of an evaluation survey and cover letter that will 
maximise response rates from GPs? 
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1Figure 1.1. Overall study design. 
 
Components of the RCT 
The main focus of this thesis has been the pragmatic RCT to test the nurse-
led model of lymphoma survivorship care intervention. This intervention 
comprised three core components:  
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GP feedback RCT 
Models of survivorship 
care 
Survivorship care plans 
and treatment 
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Needs assessment tools 
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specific needs 
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interviews 
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Phase 3 Phase 4 
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1. The administration of four self-reporting assessment measures over three 
time periods 
a. Baseline (Time 1), Three months' post-treatment completion 
b. Three months' post-baseline (Time 2), Six months' post-
treatment completion 
c. Six months' post-baseline (Time 3), Nine months' post-
treatment completion 
2. Provision of an individualised SCPTS consisting of  
a. Diagnosis and treatment information  
b. A tailored list of potential late effects with recommendations 
for the GP to follow-up  
c. Participant-derived concerns, health goals and proposed 
actions 
d. General health information, screening recommendations and 
healthy lifestyle behaviour support 
3. Provision of tailored evidence-based education, information and 
resources to address participant-reported needs, likely post-treatment 
physical and emotional concerns and maximising participant 
involvement in healthy lifestyle behaviours. 
 
Overview of the Thesis 
The very nature of a thesis by publication will involve some repetition of 
information, necessary to ensure the readers of the published papers can 
understand the wider context. As each paper was published from 2015 to 
2018, the background and literature have been constantly updated; however, 
the intent of the research remains unchanged. An introduction and summary 
of content are given for each chapter.  
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Chapter Two is the literature review section of the thesis and comprises three 
published papers. The integrative review of lymphoma models of 
survivorship care was published in the internationally peer-reviewed journal 
Supportive Care in Cancer. The integrative review of haematological cancer 
survivorship care plans and treatment summaries was published in the 
internationally peer-reviewed journal Oncology Nursing Forum. The final 
paper in this chapter is a systematic review of needs assessment measures 
used with lymphoma survivors and was published in the peer-reviewed 
journal The Australian Journal of Cancer Nursing. Although some papers 
included other haematology cancers to ensure a wide range of literature was 
gathered, the primary focus has always been lymphoma. Included after each 
paper is an updated literature review of current published research on the 
three topics previously described.  
 
Chapter Three describes the conceptual framework that guided the 
development of the nurse-led lymphoma survivorship model of care. 
 
Chapter Four describes the development of the essential elements of the 
nurse-led lymphoma survivorship model of care: the advisory committee; 
the unique survivorship care plan and treatment summary (SCPTS); the 
assessment measures; and the resource pack. In addition, it provides further 
details on the GP evaluations that were used in Phase Four. Where possible, 
repetitive information contained in the methodology section (Chapter Five) 
has been reduced in this chapter.  
 
Chapter Five provides an account of the methodology of this thesis. This 
consists of a protocol paper published in the prestigious and internationally 
peer-reviewed journal British Medical Journal Open. It also includes the ethical 
considerations of this study.  
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Chapter Six is the results of the Phase Three pragmatic RCT, GP evaluations 
and qualitative interviews undertaken in Phase Four and the test–retest 
reliability analysis of one of the chosen assessment measures; the Short-Form 
Survivor Unmet Needs Survey (SF-SUNS). This chapter provides a reporting 
of the results of the pragmatic RCT and GP evaluations and is followed by 
two published papers. Qualitative interviews were conducted with a subset 
of intervention participants when they completed all aspects of the study. 
These results have been published in the internationally peer-reviewed 
journal European Journal of Oncology Nursing. Test–retest reliability of the SF-
SUNS was conducted during the pragmatic RCT, results of this analysis have 
been published in the internationally peer-reviewed journal Asia-Pacific 
Journal of Oncology Nursing. 
 
Chapter Seven presents a discussion of Phase One literature reviews, Phase 
Three pragmatic RCT and Phase Four GP evaluations and qualitative 
interviews. Additionally, a summary of the test–retest analysis is presented. 
This chapter includes the limitations and strengths of this thesis research. 
 
Chapter Eight concludes the thesis and discusses the implications of the 
study findings and makes recommendations relevant to nursing research 
and practice, education and future research directions.  
 
References throughout the thesis, including published papers, have been 
combined into a final reference list. All published papers are included in the 
appendix in their published form. Several supplementary elements of this 
thesis are included in the appendix and are listed throughout the thesis. 
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Glossary of Terms 
The following terms have been used in the thesis and are defined here. 
 
Active Treatment: Treatment that is used just after diagnosis until remission 
of the cancer is achieved. 
 
Assessment Measure: A questionnaire, scale or tool to assist in gathering 
information to identify and evaluate a range of issues or functional ability of 
the responder.  
 
Autologous Transplant: A stem cell transplant using the patient’s own stem 
cells that are given back as a “rescue” for high-dose, myeloablative 
chemotherapy. 
 
Cancer Nurse Coordinator: A registered nurse who is highly experienced 
and knowledgeable. A specialist in cancer nursing, cancer care and cancer 
treatments. 
 
Chemotherapy: Chemical drug agents used to treat cancer. 
 
De Novo: New diagnosis of a cancer that is not related to a previous cancer. 
 
GP: General Practitioner. 
 
HL: Hodgkin Lymphoma. One of two main types of lymphoma characterised 
by the presence of Reed-Sternberg cells. Cancer cells originate in the 
lymphatic system. Overall term given to several sub-types. 
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Immunotherapy: Treatment of cancer using drugs that enhance, induce or 
suppress an immune response in the person to fight cancer. They are thought 
to work by slowing the growth and spread of cancer cells and by helping the 
immune system to recognise and kill existing cancer cells. 
 
Informational Needs: Information to assist in decision making and the 
acquisition of skills to decrease fear, anxiety and misperception. 
 
Late Effects: Absent or subclinical toxicities of treatment that can manifest 
years later. 
 
Long-Term Effects: Toxicities or issues that appear during treatment and 
persist. 
 
MOC: Models of Care. 
 
Motivational Interviewing: A directive, patient-centred counselling style for 
eliciting behaviour change, by assisting patients to explore and resolve 
ambivalence.  
 
Myeloablative: High-dose chemotherapy that kills cells in the bone marrow 
spaces, including cancer cells and normal blood-forming cells. This treatment 
will cause death if untreated by a stem cell transplant. 
 
NHL: Non-Hodgkin Lymphoma. One of two main types of lymphoma, with 
cancer cells originating in both lymphoid tissue and other organs. Overall 
term given to several sub-types. 
 
NLSC: Nurse-led Lymphoma Survivorship Clinic. 
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PET: Positron emission tomography. An imagining scan that detects cancer 
tumours. Routinely used to assess for disease status. HL patients with a clear 
mid-treatment PET no longer have routine post-treatment scans. 
 
PCP: Primary Care Provider. 
 
Practical Needs: Direct interventions that support the survivor to complete a 
task or meet a concern. 
 
QoL: Quality of Life. 
 
RCT: Randomised Controlled Trial. 
 
SCPTS: Survivorship Care Plan and Treatment Summary. The care plan is a 
personalised document that guides and coordinates follow-up care after 
treatment has finished. It includes recommendations, information and 
resources for surveillance of the diagnosed disease, screening for potential 
long-term and late effects from treatment and health-promoting behaviours. 
The treatment summary section is a comprehensive summary on the disease 
and treatment and may include provider contact details. 
 
Self-efficacy: a belief in your ability to achieve a task or succeed in a specific 
situation.  
 
Self-empowerment: a belief that you know what is best for yourself, and 
therefore you can take control of your life through strength of mind, goal 
setting and positive choices.  
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Survivorship: The experience of living with, through and beyond a diagnosis 
of cancer. Including the impact on family and friends. 
 
Targeted Therapy: Used to treat cancer by blocking the growth of cancer 
cells by interfering with specific target molecules. 
 
Unmet Need: Concerns or issues where a lack of support or services is 
perceived by a person, thereby making it difficult to receive the help they feel 
they require. 
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Chapter Two — Phase One 
 
 
 
 
 
 
 
 
 
 
“You are not going to be left to your own devices when you are finished, there 
will be someone to talk to. I think that would be good yeah” Male_HL 
  
CHAPTER 2. PHASE I 
 20 
2.0 Literature Reviews 
Three manuscripts form this chapter. The literature reviews were an integral 
aspect of Phase One and guided the design of the intervention to be tested in 
the pragmatic randomised controlled trial used in this study. 
 
The first integrative review was undertaken to examine the types of 
survivorship models of care that are currently used in contemporary cancer 
care in Australia and internationally as well as lymphoma-specific (if any) 
models of care as reported in the published literature (Taylor, K., Chan, R.J., 
& Monterosso, L. (2015). Models of survivorship care provision in adult 
patients with haematological cancer: An integrative literature review, 
Supportive Care in Cancer, 23(5), 1447–1458). The complete PDF version is in 
Appendix A.1.  
 
An integrative review was also undertaken to assess the survivorship care 
plans and treatment summaries (SCPTS) that are being used in lymphoma 
patient cohorts (Taylor, K. & Monterosso, L. (2015). Survivorship care plans 
and treatment summaries in adult patients with haematological cancer: An 
integrative literature review, Oncology Nursing Forum, 42(3), 283–291). The 
review provided an understanding of the types of SCPTS currently used 
and/or tested including the barriers and facilitators to development and 
delivery of such tools. This work facilitated the creation of a unique SCPTS 
for this study. The complete PDF version is in Appendix A.2.  
 
Lastly, a systematic literature review of the needs assessment measures that 
have been used and tested for the assessment of unmet survivorship unmet 
needs was undertaken (Taylor, K. & Monterosso, L. (2016). Systematic review 
of the tools used to assess the informational and practical needs of acute 
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leukaemia and lymphoma survivors, The Australian Journal of Cancer Nursing, 
17(1), 6–12). This guided the selection of the Short-Form Survivor Unmet 
Needs Survey (SF-SUNS) as the key survivorship-specific measure to assess 
participants in the study. The complete PDF version is in Appendix A.3. 
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2.1 Models of Survivorship Care 
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Models of Survivorship Care Provision in Adult Patients with 
Haematological Cancer: An Integrative Literature Review. 
 
Abstract 
Purpose: Increasing numbers of haematology cancer survivors warrants 
identification of the most effective model of survivorship care to survivors 
from a diverse range of haematological cancers with aggressive treatment 
regimens. This review aimed to identify models of survivorship care to 
support the needs of haematology cancer survivors. 
 
Methods: An integrative literature review method utilised a search of 
electronic databases (CINAHL, Medline, PsycInfo, PubMed, EMBASE, 
PsycArticles, Cochrane Library) for eligible articles (up to July 2014). Articles 
were included if they proposed or reported the use of a model of care for 
haematology cancer survivors. 
 
Results: Fourteen articles were included in this review. Eight articles 
proposed and described models of care and six reported the use of a range of 
survivorship models of care in haematology cancer survivors. No 
randomised controlled trials or literature reviews were found to have been 
undertaken specifically with this cohort of cancer survivors. There was 
variation in the models described and who provided the survivorship care. 
 
Conclusion: Due to the lack of studies evaluating the effectiveness of models 
of care, it is difficult to determine the best model of care for haematology 
cancer survivors. Many different models of care are being put into practice 
before robust research is conducted. Therefore, well-designed high-quality 
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pragmatic randomised controlled trials are required to inform clinical 
practice. 
 
Introduction 
Internationally, survivorship care is recognised as a priority in the cancer 
care continuum. This has been principally guided by the Institute of 
Medicine (IOM) report in 2005, From Cancer Patient to Cancer Survivor: Lost in 
Transition (Hewitt et al., 2005). By 2008, sixteen European countries had 
defined national cancer plans, but to date very few have survivorship 
services operating (McCabe, Faithfull, Makin, & Wengstrom, 2013). The 
National Coalition for Cancer Survivorship (National Coalition for Cancer 
Survivorship, 2014) defines survivorship as the experience of living with, 
through and beyond a diagnosis of cancer and includes the impact on family, 
friends and caregivers. It is recognised throughout the literature, based on 
the IOM essential components of survivorship care, that survivorship care 
should include the following components (Grant & Economou, 2008; 
Landier, 2009): 
 Prevention; screening and interventions for recurrence, long-term and 
late effects; early detection of new cancers; 
 Assessment, support, management and information provision of 
physical, psychological, social and spiritual needs; 
 Monitoring, information, and promotion of healthy living behaviours and 
disease prevention; 
 Coordination of care between providers to communicate overall health 
needs. 
 
Current conventional models of survivorship care, including routine follow-
up, predominately focus on surveillance for recurrence and monitoring of 
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physical side effects, rather than provision of supportive care, health 
promotion, late effects monitoring and surveillance for new cancers (De 
Leeuw & Larsson, 2013; Oeffinger & McCabe, 2006). With an increasing 
awareness that communication between health care professionals and 
patients is suboptimal and that information provided to patients and 
primary care providers at treatment completion is often inadequate (Dicicco-
Bloom & Cunningham, 2013; McCabe & Jacobs, 2012), there is a growing 
movement to redesign how survivorship follow-up care is delivered. 
Furthermore, cancer patients frequently experience multiple health problems 
earlier than the general population (Panek-Hudson, 2013), suggesting a need 
for early and ongoing, comprehensive approaches to management designed 
to promote and support patient participation in maximising recovery.  
 
Haematology cancer patients are underrepresented and understudied in 
survivorship care (Swash, Hulbert-Williams, & Bramwell, 2014) despite 
international figures indicating an increase in five year relative survival rates 
(Sant et al., 2014). The most common haematological cancers are leukaemia, 
lymphoma and multiple myeloma (MM) (National Cancer Institute, 2006). 
Each of these has distinctive and complex treatment regimens that commonly 
involve aggressive high dose chemotherapy agents, and/or targeted 
therapies, radiotherapy and haematopoietic stem cell transplants (Carey et 
al., 2012). Unfortunately, the consequence of largely aggressive treatment 
includes long-term and late physical, practical and psychosocial effects 
which include: fear of recurrence; fertility; relationship; financial; 
employment and insurance issues (Allart, Soubeyran, & Cousson-Gélie, 2013; 
Arden-Close et al., 2011; Hall, Lynagh, Bryant, & Sanson-Fisher, 2013). A 
qualitative study on specialist-led follow-up with haematology cancer 
survivors reported a lack of preparation and support in finding information 
and resources with poor continuity of care as patients transitioned into the 
CHAPTER 2. PHASE I 
 26 
survivorship phase (Parry, Morningstar, Kendall, & Coleman, 2010). These 
patients therefore may require models of survivorship care with specific 
components that differ from those designed for the more common cancers 
(breast, prostate and colorectal).  
 
Two systematic reviews (Howell et al., 2012; Sussman et al., 2012) and a 
literature review (De Leeuw & Larsson, 2013) on survivorship models of care 
have been recently published. Sussman et al. (2012) reviewed 12 randomised 
controlled trials (RCTs) and four systematic reviews. De Leeuw and Larsson 
(2013) reviewed 21 nurse-led follow-up studies and Howell et al. (2012) 
evaluated 10 practice guidelines and nine RCTs. All primary outcomes in the 
reviewed studies were related to recurrence detection and in some cases 
health-related quality of life and/or patient satisfaction (De Leeuw & Larsson, 
2013; Howell et al., 2012; Sussman et al., 2012). Importantly, all studies 
included cancers with similar trajectories of care (breast, prostate, colon) 
making generalisations to other complex cancers such as haematological 
cancers difficult. Therefore, the haematology focus of this integrative 
literature review will add to the limited body of knowledge currently 
available in this cohort of survivors. 
 
This integrative literature review undertook an analysis of the literature to 
examine the following questions: 
1. What are the common attributes of survivorship models of care 
developed generally for cancer patients and specifically for 
haematology cancer patients?  
a. What resources (human, financial, tools, care plans) are required to 
support these models of care?  
b. What are the potential benefits and shortfalls of these models of 
care?  
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c. What outcome measures have been used to evaluate these models 
of care and what are the findings? 
 
Method 
The integrative literature review method was chosen as the theoretical 
framework to guide this review. It is structured according to five stages: 
problem formulation; literature search; data evaluation; data analysis and 
presentation. This allows for an in-depth evaluation of the issues 
encompassing the empirical, theoretical and clinical approaches within a 
structured systematic methodology (Whittemore & Knafl, 2005).  
 
Problem formulation 
To date, the term ‘Model of Care’ (MOC) has not been well defined in 
published literature. In this review, MOC, as defined by the Robert Wood 
Johnson Foundation (Robert Wood Johnson Foundation, 2014), is a 
conceptual outline of how to plan all current and future facility and clinical 
services to guide and direct a patient’s experience within a health care 
system. Essential elements of any MOC include: a clear identification of 
health professionals responsible for planning and coordination of care; care 
delivery setting (Sussman et al., 2012); promotion of health maintenance; 
effective illness interventions; and establishing and evaluating expected 
clinical outcomes (Gerber, Stout, Schmitz, & Stricker, 2012).  
 
The medical specialist has traditionally led haematology cancer care follow-
up, however other models of cancer survivorship follow-up are now 
emerging (Weaver, Jessup, & Mayer, 2013). Therefore, the focus of this 
integrative literature review was to identify models of care used by health 
care providers to ensure quality survivorship follow-up for haematology 
cancer survivors.   
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Literature search 
The primary search utilised the following electronic databases: Cumulative 
Index to Nursing and Allied Health Literature (CINAHL); Medline; PsycInfo; 
PubMed; EMBASE; PsycArticles and Cochrane Library from earliest records 
to July 2014. Combinations of the following search terms were used: (model 
of care or follow-up or nurse-led or shared care or primary care provider-led 
or General Practitioner-led or oncology-led or end of treatment or post 
treatment) and (survivorship or cancer survivor or survivorship care) and 
(cancer or neoplasm or oncology) and (haematology or leukaemia or 
lymphoma or multiple myeloma). A hand search of the reference lists from 
full text articles was correspondingly employed. Searches were restricted to 
the English language, humans and adults. Inclusion criteria used were: 
clinician experiences of MOC for the post treatment phase of haematological 
cancer; articles that reported on models of care; and articles that reported on 
the structure of survivorship services. Exclusion criteria were: studies with 
less than a 50% haematology cancer patient/haematologist cohort; studies 
that reported MOC for patients who received curative surgery only (i.e. no 
chemotherapy and/or radiotherapy treatment); studies reporting MOC from 
child, adolescent or adult survivors of a childhood cancer; non-cancer MOC 
studies; MOC studies that lacked provider of survivorship care information; 
and opinion papers, letters, editorials, commentaries, conference abstracts, 
conference proceedings or case studies.  
 
Data evaluation stage 
Abstract titles were reviewed by one author [KT] to assess eligibility. A 
summary of the selection process (Moher, Liberati, Tetzlaff, Altman, & The 
PRISMA Group, 2009) is provided in Figure 2.1.1. The initial search yielded 
2907 abstracts. Following removal of duplicate articles and screening using 
the exclusion and inclusion criteria, 61 full-text articles were retrieved. Of 
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these, 14 articles met the inclusion criteria and were included in this review. 
Methodological characteristics documented included: authors; publication 
year; country; study design; model; provider; disease; years post treatment; 
sample size and response rate; resources required; potential benefits; 
potential deficits; outcome measures; results and level of evidence developed 
by (Melynyk & Fineout-Overholt, 2011) shown in Table 2.1.1. Due to 
variations in study population and methodologies used, meta-analysis was 
not possible.  
 
 
 
2Figure 2.1.1. Flowchart of literature search results. 
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Table 2.1.1 Levels of Evidence 
Level Evidence 
I Systematic review of all relevant randomised controlled trials 
II At least one well designed randomised controlled trial 
III Well-designed controlled trials without randomisation 
IV Well-designed cohort studies, case control studies, interrupted time 
series with a control group, historically controlled studies, interrupted 
time series without a control group or with case-series 
V Systematic reviews of descriptive and qualitative studies 
VI Single descriptive and qualitative studies 
VII Expert opinion from clinicians, authorities and/or reports of expert 
committees or based on physiology 
 
Results 
Study characteristics  
No systematic reviews of haematology cancer survivorship models of care 
were found. In total, 14 articles were included in this review. Eight articles 
described and proposed different models of survivorship care (Cooper, Loeb, 
& Smith, 2010; Hahn & Ganz, 2011; Hewitt et al., 2005; Landier, 2009; Leigh, 
2008; McCabe, Bhatia, et al., 2013; McCabe & Jacobs, 2012; Oeffinger & 
McCabe, 2006) (Table 2.1.2). An additional six articles reported the use of a 
range of models of care for haematology cancer survivors: two reported 
nurse-led studies (Gates, Seymour, & Krishnasamy, 2012; John & Armes, 
2013) and four referred to physician-led studies (Chubak et al., 2012; Dicicco-
Bloom & Cunningham, 2013; Frew et al., 2010; Greenfield et al., 2009) (Table 
2.1.3). The included articles reported views from Australia (n=1), United 
States of America (USA) (n=10) and United Kingdom (UK) (n=3), shown in 
Table 2.1.3. The eight articles that described and proposed various models of 
survivorship care were categorised into three main settings: hospital-based; 
primary care-based and shared care and included models, providers, and 
characteristics. The results are shown in Table 2.1.2.   
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These included articles used multiple terms to describe clinicians. For clarity, 
the following terms have been used: primary care provider (PCP) to denote 
community-based general practitioners (GP) or family physicians; specialist 
to represent the main hospital consultant oncologist (medical, radiation, 
surgical) or haematologist; and nurse which includes nurse specialist, nurse 
practitioner (NP) or nurse coordinator. 
 
Of the six studies that reported the use of specific models of survivorship 
care, four were quantitative and two were qualitative studies. Studies 
reflected moderate (IV) to low (VI) levels of evidence. 
 
2Table 2.1.2 Existing or Proposed Models of Cancer Survivorship Care  
Setting Model  Provider Model Characteristics 
Hospital Multi-
disciplinary 
survivorship 
clinic 
(Oeffinger & 
McCabe, 2006) 
Oncologist, network 
of consulting 
physicians, oncology 
or haematology nurse 
practitioner (NP), 
psychologist, social 
worker 
 Can be consultative or 
ongoing  
 Multiple providers seen 
at same visit  
 Complex and resource 
intense 
 Co-morbid and treatment 
related conditions can be 
addressed  
 Can be extension of care, 
embedded in treatment 
team  
 Disease-specific specialist 
defines follow-up plan 
 NP follow-up who 
communicates with PCP 
to initiate shared care 
 Large patient cohort 
needed 
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Consultative 
clinic (Cooper 
et al., 2010; 
Leigh, 2008) 
Specialist   Ongoing (rarely 
Oncologist takes on 
primary carer role) 
Consultative 
clinic 
(Oeffinger & 
McCabe, 2006) 
Specialist  One-time comprehensive 
visit  
 Treatment summary and 
survivorship care plan 
 Review of 
recommendations – 
surveillance, screening, 
health promotion 
Survivorship 
follow-up 
clinic (Hewitt 
et al., 2005; 
McCabe, 
Bhatia, et al., 
2013) 
Specialist   Separate from routine 
care  
 Holistic assessment of 
survivor 
 End of treatment or on 
maintenance therapy 
 Treatment summary, 
survivorship care plan 
and individualised 
information provision 
 Can have telephone 
follow-up 
Late effects 
clinic 
[(McCabe & 
Jacobs, 2012) 
Nurse and/or 
specialist  
 Haematology /Oncology 
treatment centres  
Nurse-led 
(Cooper et al., 
2010; Hewitt et 
al., 2005) 
Oncology nurse or NP  Comprehensive, long-
term follow-up to assess, 
and provide primary care 
needs 
 ASCO surveillance 
recommendations used 
 Clinic and/or telephone 
follow-up 
Primary General Nurse collaboration  Referral for services or 
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Note. ASCO American Society of Clinical Oncology; NP Nurse practitioner; PCP 
primary care physician 
 
Data Analysis and Presentation 
Cancer survivorship MOC 
The first component of this integrative literature review was to identify 
different models of survivorship care (Table 2.1.2). Characteristically, 
hospital-based follow-up care is commonly specialist-led, with often no end 
point (Cooper et al., 2010; Leigh, 2008). Survivors may acquire an impression 
the specialist has become their primary carer, particularly if they have 
assessed and treated co-morbid conditions during the treatment phase 
(Oeffinger & McCabe, 2006). Multidisciplinary disease-specific clinics 
(Landier, 2009; McCabe & Jacobs, 2012; Oeffinger & McCabe, 2006) and 
survivorship clinics were most often a one-time consultation for an 
assessment, plan of follow-up care provision and referrals to other health 
Care survivorship 
clinic (Hahn & 
Ganz, 2011; 
Landier, 2009) 
with practice 
specialist PCP (i.e. 
breast care PCP) 
refers to specialists 
PCP-led 
(McCabe & 
Jacobs, 2012) 
PCP  Full transition to PCP 
after treatment 
completion  
 Can have communication 
from specialist: late 
effects management and 
surveillance 
 Usually low risk for 
recurrence or late effects 
Shared 
Care 
 
Shared care  
(Hewitt et al., 
2005; Oeffinger 
& McCabe, 
2006) 
Specialist & PCP  Oncologist for oncology 
related issues 
 PCP for co-morbidities, 
other cancer screening 
and prevention 
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care providers (Hewitt et al., 2005; McCabe, Bhatia, et al., 2013). Clinics 
within this framework frequently consulted on one aspect of post treatment 
care, such as late effects (McCabe & Jacobs, 2012). 
 
Nurse-led survivorship clinics, as described, were mostly hospital based and 
delivered a number of interventions including: information; symptom 
management; psychosocial support; allied health referrals and health 
promotion strategies (Cooper et al., 2010). They can involve longer 
consultations and more frequent patient contact (Cooper et al., 2010; De 
Leeuw & Larsson, 2013). PCP-led models involved a complete transition of 
all care from the hospital specialist to PCP (Hahn & Ganz, 2011; Landier, 
2009; McCabe & Jacobs, 2012). This can be challenging for specialists who 
decide to transition care, as the level of knowledge and experience amongst 
PCPs can differ (Landier, 2009; McCabe, Bhatia, et al., 2013). 
 
Shared care models involved more than two providers sharing care and 
responsibility (Hewitt et al., 2005; McCabe & Jacobs, 2012). According to 
Oeffinger and McCabe (2006) after treatment completion, the PCP assumes 
responsibility for: maintenance of survivor health; management of any co-
morbid conditions; ongoing physical and psychosocial concerns; and health 
promotion. The medical specialist provides a survivorship care plan and 
treatment summary and ongoing consultation for recurrence or problematic 
late effects if required. Both providers are to undertake monitoring, therefore 
a clear delineation of responsibility for particular screening and surveillance 
is important (Landier, 2009). Landier (2009) identified shared care as 
appropriate for low risk and even some moderate risk patients, however 
intensively treated patients (i.e. haematological cancers) require specialist 
monitoring.   
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Nurse-led 
The two studies that evaluated nurse-led follow-up in lymphoma survivors 
predominately targeted late effects and health promotion. Gates et al. (2012) 
studied a nurse-led component of a haematology late effects survivorship 
multidisciplinary team, whereas John and Armes (2013) reported on nurses 
replacing specialist-led follow-up, independently delivering comprehensive 
survivorship care. Both clinics assessed for supportive care needs and 
concerns and delivered health promotion and information (Gates et al., 2012; 
John & Armes, 2013). John and Armes (2013) provided an annual clinic with 
nurse contact details, whereas Gates et al. (2012) delivered four consultations 
over a six month period. Both studies measured different outcomes and 
utilised different comparative groups, thereby making them difficult to 
compare, especially as Gates et al. (2012) has only published preliminary 
results. John and Armes (2013) prospective comparative study of 61 patients 
concluded that patient satisfaction was equivalent in the nurse-led clinic 
cohort compared with the medical-led clinic cohort and was in some cases 
preferred. However, the number in each group was not reported and it is 
possible patient satisfaction was related more to the decrease in wait times. It 
would likewise be difficult to attribute lifestyle changes to the clinic as 
patients were seen annually.  
 
Physician-led 
The included physician-led studies (n=4) presented comparisons of self-
reported practices in survivorship follow-up (Dicicco-Bloom & Cunningham, 
2013) and clinician perceptions of survivorship follow-up (Chubak et al., 
2012; Frew et al., 2010; Greenfield et al., 2009). A qualitative exploratory 
study by Chubak et al. (2012) reported the views of clinicians and 
administrators (n=40) from 10 integrated cancer centres. All respondents 
reported shared care was being practised. This was based on the assumption 
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that all survivors have a PCP, and despite respondents reporting a lack of 
standard approaches to sharing care between clinicians. Support for 
survivorship-specific care appeared lacking, with 22% (n=9) observing it 
would not add to current care and may decrease care integration. The 
authors concluded that interviewing respondents from sites without 
survivorship care would give an unbiased account. However, there may 
have been a lack of awareness related to the benefits of survivorship care. 
 
Dicicco-Bloom and Cunningham (2013) qualitatively assessed the feasibility 
of a shared care survivorship model with 21 primary care clinicians. The 
overall perception was that primary carers are already involved in survivor 
follow-up, despite poor information provision from specialists. They 
perceived electronic medical records are often inaccessible. The authors 
further concluded survivorship care plan reasearch is limited. PCPs felt 
excluded once patients entered the hospital system, especially when follow-
up extended well past treatment, to healthy patients with no recurrent 
cancer. This was reflected in the study by Greenfield et al. (2009) who 
reported the views of clinicians (n=475) regarding long-term follow-up and 
found only 5% (n=14) of haematology cancer survivors are discharged after 
two years, and only 42% (n=45 lymphoma) and 32% (n=10 leukaemia) are 
discharged after five years. This finding may be explained by the complex 
and ongoing late effect sequelae in haematology patients and their 
expectation of long-term specialist follow-up. Although respondent numbers 
were not reported, it was perceived that long-term specialist follow-up gave 
survivors false reassurance and perpetuated the illness role. Whereas the 
PCP-led model was perceived as normalising the survivors’ experience, with 
a corresponding increase in co-morbid disease management. The authors 
concluded by proposing a risk stratification process whereby low risk 
survivors are transitioned early to PCP and high risk survivors stay within 
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the hospital model or become part of a shared care model supported by 
survivorship care plans. 
 
Frew et al. (2010) studied survivor (n=626) and clinican (n=2302) views on 
different models of care. Respondents could choose from a number of follow-
up models, but were not asked if they would reject a particular model. What 
was evident in the study by Frew et al. (2010) was specialist follow-up was 
the most experienced by survivors (84% n=528) and clinicians (95% n=2167). 
However specialists who had experienced non-specialist models of follow up 
(60% n=819) preferred this model over all others including specialist-led 
(87%). 
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3Table 2.1.3 Methodological Characteristics of Models of Haematological Cancer Survivorship Care (n=6) 
Author  
Year 
Country 
Level of 
Evidence 
Study 
Design 
MOC  
Provider 
Disease 
Years' Post-
Treatment 
Sample Size 
(Response 
Rate %) 
Resources 
Required 
Potential 
Benefits 
Potential 
Deficits 
Outcome 
Measures 
Results 
Chubak et al.  
2012 
USA 
VI 
Exploratory 
study 
Semi-
structured 
telephone 
interviews  
Shared care  10 Cancer 
Research 
Network sites 
Cancer types 
not identified 
40/48 (83%) 
Administrators
/clinical 
leaders/provid
ers in 
oncology, 
primary care 
SCP—only 5 
responders 
identified the 
use of Support 
groups  
Time and lack 
of specialists to 
follow-up 
survivors 
Clearer 
evidence to 
support 
survivorship 
care needed 
6/10 sites 
survivor-
specific tools 
not being used  
Perspectives 
on: survivor 
needs; current 
survivorship 
practices; 
barriers; areas 
for future 
research 
Only 2/10 sites had 
formal survivorship 
programs (1 nurse-led, 
1 physician assistant-
led) 
Responses for 
survivorship care 
needs: address fear 
recurrence 35%; 
information on long-
term effects 40%; 
nutritional and 
exercise support 27%; 
psychosocial support 
62.5% 
Overall uncertainty 
about best models of 
survivorship care 
DiCicco-Bloom In-depth Shared care  21 Primary Electronic Primary care No guidelines Understand Absence of systematic 
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& 
Cunningham  
2013 
USA 
VI 
interviews 
on 
information 
sharing 
to/from 
specialist & 
patients 
care clinicians 
(PCC) (11 PCP 
& 10 NP)  
Unknown 
patient types 
or 
survivorship 
period 
medical 
records access 
SCP 
perspective 
Information 
sharing 
ensures 
effective care 
transitions 
or consensus 
for many 
cancers on 
screening, 
surveillance, 
late effects (LE) 
nature of 
interactions 
between 
primary care, 
specialist & 
patient  
information sharing 
among PCP, patient, 
specialist 
Some patients continue 
to see PCC during 
treatment 
Reliance on patients to 
provide clinical 
information from 
specialists (not always 
reliable for complex 
conditions/treatment) 
Academic hospital 
settings were worst in 
communication to PCC  
SCP effect on patient 
outcomes—limited 
evidence 
Frew et al.  
2010 
UK 
IV 
Comparison 
survey on 
models of 
follow-up 
Models 
presented for 
perception & 
experience: 
hospital-based; 
telephone; 
non-specialist; 
group; patient 
managed; no 
Cancer 
diagnosis or 
treatment not 
disclosed 
Range to over 
10 years 
626 (21%) 
survivors/carer  
Nil described Non-specialist 
models tend to 
provide more 
psychological 
support 
Survey did not 
ask for 
survivor 
diagnosis & 
treatment 
which may 
alter model 
preference 
Survey did not 
Perceptions of 
reasons for 
follow-up; 
levels of 
preference for 
different 
follow-up 
models; effect 
of individual 
experience on 
Reasons for follow-up: 
monitoring for early 
complications; 
detecting recurrence; 
detecting LE, 
providing information 
& support (70%) 
Preference for model of 
follow-up experienced: 
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follow-up 940 (32%) PCP 
804 specialists 
including 
haematology 
558 
nurses/allied 
health (47%) 
ask if any 
models would 
be rejected so 
potential 
deficits not 
identified 
follow-up 
model 
preference 
86% survivors 
preferred hospital-
based follow-up, 
which was experienced 
most (84%) 
Clinicians had 
experience of more 
models of follow-up  
Specialists endorsed 
non-specialist or 
patient managed 
follow-up (87%)  
PCP endorsed 
hospital-based and 
patient managed 
follow-up (83%) 
Gates et al.  
2012 
Australia 
IV 
Quasi-
experimental 
comparison 
healthy 
cohort versus 
Hodgkin 
lymphoma 
(HL) 
survivors 
Late effects 
MDT 
haematology 
transplant 
physician, 
radiation 
oncology, 
cardiology, 
endocrinology, 
primary care 
liaison, 
psychology, 
HL 
5 years 
30 HL + 30 
healthy 
participants 
(91%) 
Education 
package 
Screening tools 
(Late Effects 
Supportive 
Care Needs 
Screening Tool; 
The General 
Health Index; 
The Health 
Promoting 
Health 
promotion  
Psychosocial 
issues 
identified & 
resources and 
support given 
Importance of 
surveillance  
Survivor sees 
all relevant 
SCP not given 
until 2nd visit 
(at 4 months) 
Primary 
outcome: 
health 
promotion 
intervention 
from nurse to 
improve HL 
survivors 
knowledge 
and motivation 
to adopt health 
promoting 
No final published 
results from this study 
Anecdotal analysis 
shows appreciation of: 
SCP; screening 
assessment  
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LE social 
worker, LE 
CNC) 
Nurse-led 
clinic for 
health 
promotion: 2 
visits + 2 
phone calls  
Lifestyle 
Profile II) 
SCP copy to 
survivor/PCP 
providers on 
same day 
behaviours 
Secondary 
outcomes: 
improved 
perception of 
health status; 
reduced LE 
unmet needs; 
reduced LE 
worry 
Greenfield et 
al.  
2009 
UK 
IV 
E-survey 
comparison 
of clinician 
views on 
long-term 
follow-up 
PCP-led 18–45-year-old 
breast, 
lymphoma, 
leukaemia, or 
germ cell 
survivors 
>2 years 
421 cancer 
clinicians (36% 
haematologist, 
33% 
oncologist, 
18% surgeon, 
10% nurse, 2% 
other)  
54 PCP 
Communicatio
n 
Specialist 
nurse support 
(91% most 
important 
resource) 
Risk 
stratification—
low risk to 
PCPs, high risk 
hospital 
follow-up 
SCP & TS 
Specialists can 
focus on acute 
care 
Lower costs 
PCP: existing 
relationship 
with survivor; 
accessible; 
convenient; 
knowledge of 
local support; 
expertise in 
chronic health 
Potential loss 
of outcome 
data, LE 
information to 
specialists 
PCP: Lack 
expertise in 
survivor-ship 
issues, 
increases 
survivor 
anxiety, time 
issues 
No tumour 
specific follow-
up guidelines 
Compare long-
term follow-
up: reasons for 
follow-up; 
advantage/disa
dvantage of 
PCP-led 
follow-up; 
current 
practice; 
resources and 
support 
required 
Specialists rated 
clinical reasons for 
follow-up higher  
Nurses and PCP rated 
both clinical & 
supportive reasons 
higher 
Reasons for follow-up: 
PCP rated recurrence 
(96%) 
Specialists rated LE 
(76%) recurrence (71%) 
Haematologist use of 
follow-up protocol for 
leukaemia and 
lymphoma 19%  
Discharge to PCP: 5% 
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at 2 years  
42–32% by 5 years  
John & Armes  
2013 
UK 
IV 
Prospective 
comparison 
specialist-led 
versus nurse-
led 
Survivorship 
follow-up 
clinic 
Nurse-led 
(replaces 
specialist 
follow-up) 
Lymphoma 
3 years 
50 notes 
audited (25 per 
group) 
120 survivors 
(60 per group) 
assessed wait 
time 
 61 (82%) 
survivors 
assessed 
patient 
satisfaction 
(unclear split 
medical-led 
versus nurse-
led) 
2 CNS 
Information 
prescription 
Longer 
consultations 
Written 
information 
provision 
Holistic needs 
assessment 
Monitoring for 
late effects  
Health 
promotion 
Post-treatment 
contact 
Annual clinic 
visit Preferred 
clinic not 
assessed 
Documentatio
n 
Wait time 
Patient 
satisfaction 
Documentation 
improved—50% of 
psychological & sexual 
issues still not 
recorded  
Wait times reduced 
from average 65 mins 
(specialist) to 10 mins 
(Nurse) 
Nurse-led was equal to 
specialist-led clinic and 
preferred in some 
areas  
Nursing telephone 
workload increased  
Note. CNC Cancer Nurse Consultant; CNS Cancer Nurse Specialist; HL Hodgkin Lymphoma; LE Late effects; MDT multi-disciplinary team; MM multiple 
myeloma; NHL Non-Hodgkin Lymphoma; NP Nurse practitioner; PCP primary care provider; SCP survivorship care plan; TS treatment summary 
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Discussion 
Deciding upon a model of survivorship follow-up care for haematology 
cancer survivors is difficult due to the considerable variability between the 
types of haematological cancers, range of treatment regimens and long-term 
and late effects that impact the survivorship phase of the cancer continuum 
(Hall, Lynagh, et al., 2013). For haematology cancer survivors, different 
models have been proposed and utilised. However, we are unable to 
determine the best or the most appropriate model. This finding is consistent 
with those of Campbell et al. (2011), reporting that no model was identified 
as better than any others. The reasons for these findings are that most of the 
articles were not evaluative in nature, and do not allow comparison. Patients 
who have only received a single model of care would not be able to comment 
on potential benefits of other models of care, therefore further research in 
understanding survivors’ perspectives of follow-up care is required. 
 
The transition of survivor care to the PCP requires PCP willingness. A study 
involving PCP views reported the willingness to accept exclusive care for 
lymphoma patients was three years after treatment completion (Del Giudice, 
Grunfeld, Harvey, Piliotis, & Verma, 2009). This may be due to the complex 
nature and length of the treatment regimens (Allart et al., 2013) and a lack of 
tumour specific follow-up protocols used by haematologists (Greenfield et 
al., 2009). With a lack of guidance and comprehensive information 
communicated from the haematologist (Dicicco-Bloom & Cunningham, 2013; 
Greenfield et al., 2009), PCPs may be reluctant to accept exclusive care of 
what they perceive as complex and ‘high risk’ patients (Del Giudice et al., 
2009). Shared care maybe more satisfatory to haematologists, survivors and 
PCPs as it encompasses the strengths and expertise of providers from more 
than one discipline. As a study of follow-up care providers has reported, a 
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high proportion of survivors are followed up by multiple providers 
(Forsythe et al., 2014). Therefore, it is important that good coordination and 
communication is in place to reduce the possibility of either incomplete or 
duplication of services between multiple providers. Cooper et al. (2010) 
proposed that patients’ transition into survivorship phase and out to primary 
care through specialist nurses so that monitoring for recurrence, psychosocial 
needs and health promotion are addressed and communicated to survivors 
and health care providers. This too has implications with John and Armes 
(2013) demonstrating that increased nurse workload occurred with patients 
utilising telephone contact between the scheduled clinic visits. 
 
Establishing survivorship care provision will require careful planning and 
robust prospective evaluations. It is important to note that coordinated 
survivorship care interventions are complex interventions (Medical Research 
Council, 2000) and can be resource intensive, requiring robust evaluations 
using patient and system outcomes. This integrative review identified the 
three models of care: physician-led, nurse-led and shared care models. 
Ultimately, high quality pragmatic RCTs are required to test the effectiveness 
of these models. There is an urgent need for health research funders to 
understand the need for good survivorship cancer care and fund the 
development and evaluation of the effects of various models of survivorship 
care. 
 
To the best of our knowledge, this review is the first that examines the 
characteristics, resources required and effectiveness of survivorship care 
models specifically for patients with haematological cancer. A number of 
limitations of this review are acknowledged. The search revealed only a 
relatively small number of articles that met the inclusion criteria. 
Furthermore, the variation of study methodology, range of measures, 
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populations and follow-up approaches made it difficult to compare models 
of care and enabled only tentative conclusions (Gates et al., 2012; John & 
Armes, 2013). Additionally, short-term follow-up or the timing of 
interventions may have been insufficient to report whether different models 
have impacted survivorship care. Finally, an inherent bias in interpretation 
might be due to the evaluator.  
 
Conclusion 
There is a paucity of effectiveness research related to haematology cancer 
survivors and specifically models of survivorship care in this cohort. Shared 
care models have been suggested as an alternative to exclusive specialist 
care. For shared care to work effectively ongoing communication channels 
need to be established and maintained. Nurse-led models have been 
proposed as another feasible model, where a specialist nurse intervenes 
directly and acts as the conduit between patient, hospital-based treatment 
team and PCP. However, more research is needed to define how these 
models should be best configured and evaluated for their effectiveness. For 
future development, a haematology-specific survivor-based needs 
assessment tool, individualised treatment summary and survivorship care 
plan would be integral. These would assist in guiding survivor-centred 
screening, health promotion and identification of needs to be monitored and 
managed. This approach may address many of the barriers that have been 
postulated. 
 
Future research will need to account for increasing cancer incidence and 
survival rates, making extensive specialist follow-up care more difficult to 
maintain for new patients and survivors. To provide quality survivorship 
care, new and innovative models of haematology survivorship follow-up are 
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required that address the need for long-term follow-up that accounts for 
potential late treatment effects, risks of secondary cancers, development of 
treatment related co-morbid conditions and psychosocial well-being. This 
review revealed a lack of high quality evidence suggesting the effectiveness 
of any single model of care. A well-designed pragmatic randomised 
controlled trial, assessing patient and system outcomes including costs, is 
required to inform clinical practice. 
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Literature Review Update 
The same search criteria, terms and databases were reviewed to ascertain 
recent developments or research in lymphoma models of survivorship care 
in the published literature. The search period was 2014 to January 2018. In 
this period, no new models of haematology or lymphoma-specific 
survivorship care were proposed or tested. 
 
Results revealed 10 abstracts worthy of further assessment. Five articles 
either did not include lymphoma cohorts (Downs-Holmes, Dracon, 
Svarovsky, & Sustin, 2014; Hebdon, Abrahamson, McComb, & Sands, 2014; 
Jefford et al., 2016; Ye, Cheung, Goddard, Horvat, & Olson, 2015) or used a 
lymphoma cohort of less than 50% (Sharp et al., 2014). One article reported 
the perception of quality care rather than a model of survivorship care 
(Tzelepis et al., 2015). Of the remaining articles reviewed, three studies were 
related to follow-up care that was already occurring with survivors (Christen 
et al., 2016; Franco et al., 2017; Matheson et al., 2016), and the fourth article 
reported a study of nurses opinions regarding survivorship care 
(Langbecker, Ekberg, Yates, Chan, & Chan, 2016). Although these articles 
would not have met the original inclusion criteria, they have been described 
below as they continue to inform current follow-up practices which may not 
be meeting the needs of lymphoma survivors.  
 
Two articles reported studies of survivors who had been diagnosed with 
cancer, including lymphoma, when they were aged between 16–39 years 
(Christen et al., 2016; Matheson et al., 2016). Christen et al. (2016) reported 
the preferences for support from survivors who were more than five years' 
post-diagnosis and showed that 92 (57%) were still receiving follow-up with 
a medical focus. There was a clear preference for oncology specialist follow-
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up. Conceivably this could be due to a lack of exposure to other models of 
survivorship care and the need for late effects monitoring. A study of HL 
survivors (n=10), two and seven months' post-treatment (Matheson et al., 
2016) described the loss of security when treatment completed. Survivors 
wanted better preparation and information for the future regarding recovery, 
such as mitigating the effects of fatigue; body image; fertility; sexuality; 
employment; socialising; and how to assess for lymphoma recurrence. No 
model of survivorship care was proposed; however, the authors suggested 
informal peer support and use of patient navigators as a worthwhile support 
mechanism when treatment completes. 
 
Two qualitative studies examined specialist-led discussions (Franco et al., 
2017) and haematology cancer nurses’ opinions on survivorship care 
(Langbecker et al., 2016). The specialist-led qualitative study recorded 21 
discussions led by doctors who were transitioning their lymphoma patients 
into the survivorship phase (n=40 patient visits recorded) (Franco et al., 
2017). The study revealed a lack of consistency in discussion content or 
format. Data revealed that patients were seeking normalisation of their 
current health problems and trying to understand their general health in the 
future. Doctors did not provide reassurance or predictions of long-term 
outcomes. Patients were encouraged by their doctors to seek routine follow-
up with other health care providers once specialist follow-up ceased after 
five years. Health promotion discussions were haphazard, with few specific 
recommendations, assistance or referrals. Social issues and emotional health 
and well-being were not widely discussed. The authors indicated that if 
discussions on the important areas of health promotion and psychosocial 
issues had occurred, it might have decreased fear of recurrence, distress and 
uncertainty. Likewise, the authors suggested these types of discussions may 
have acknowledged and supported patients who have experienced a major 
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life event which could have ongoing impacts on personal relationships, 
finances and employment (Franco et al., 2017). The study of haematology 
cancer nurses’ opinions (n=136) of survivorship care (Langbecker et al., 2016) 
revealed two main themes; the ongoing focus on active treatment, and which 
health professional should be responsible for providing survivorship care. 
The authors indicated nurses were interested in developing models of 
survivorship care; however, there were many challenges to overcome before 
this type of survivorship care could be utilised.  
 
These articles support the continuing need to explore survivorship models of 
care that are patient-centred, structured and address concerns of perceived 
importance to the survivor when treatment is completed. 
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2.2 Survivorship Care Plans and Treatment 
Summaries 
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Survivorship Care Plans and Treatment Summaries in Adult 
Patients with Hematological Cancer: An Integrative Literature 
Review. 
 
Abstract 
Problem Identification: Survivorship care plans [SCPs] and treatment 
summaries [TS] have been recommended by the Institute of Medicine as 
facilitators to deliver holistic survivorship follow-up care. An integrative 
literature review was undertaken to identify current SCPs and TS to meet 
haematological cancer survivors needs. 
 
Literature Search: A search of relevant electronic databases for eligible 
articles was executed. Included articles described SCP and/or TS use with 
haematological cancer survivors or haematologists. 
 
Data Evaluation: Four articles that reported on experience, dissemination or 
components of SCPs and/or TS were included. Haematology-specific 
literature was limited and no randomized control trials or literature reviews 
were found for the haematological cancer survivor cohort. 
 
Synthesis: Content analysis was used to summarize the findings.  
 
Conclusions: This review revealed a lack of high quality evidence evaluating 
the effectiveness of SCPs and/or TS on haematological survivorship follow-
up care. Nurses have established expertise in health promotion, information, 
support and resource provision, and therefore can develop and disseminate 
SCPs and TS to facilitate communication between the survivor, specialist and 
primary care. 
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Implications for Practice or Research: Well-designed randomized control 
trials on SCPs and TS are required, especially for cancers not well 
represented in the literature. 
 
Introduction 
Survivorship, as defined by the National Coalition for Cancer Survivorship 
(2014), is the experience of living with, through and beyond a diagnosis of 
cancer including the impact on family, friends and caregivers. Survivorship 
care is recognized as a priority in the cancer care continuum and, has largely 
been driven by the Institute of Medicine [IOM] report in 2005, From Cancer 
Patient to Cancer Survivor: Lost in Transition (Hewitt et al., 2005). A key 
recommendation of this report was provision of a survivorship care plan and 
treatment summary (SCPTS) for all survivors (Palmer et al., 2014). Following 
the report many countries around the world developed and initiated national 
cancer initiatives (McCabe, Faithfull, et al., 2013). Utilising IOM essential 
elements, SCPTS, survivorship care should include the following 
components (Grant & Economou, 2008; Landier, 2009; Rechis et al., 2013):  
 Prevention; screening and intervention for recurrence, long-term and late 
effects; early detection of new cancers or second malignancies (including 
recommended surveillance guidelines such as colonoscopy, skin checks, 
mammogram, pap smear); and co-morbidities;  
 Psychosocial well-being assessment, support, management and 
information provision for physical, psychological, social and spiritual 
needs; 
 Monitoring, information, and promotion of healthy living behaviours and 
disease prevention including: diet and exercise recommendations; 
tobacco cessation; decreasing alcohol consumption; sun protection; and 
healthy weight management; and 
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 Coordination of care between providers to communicate overall health 
needs.  
 
Currently, routine follow-up focuses largely on surveillance for recurrence 
and monitoring physical side effects; thus, neglecting supportive care, health 
promotion, late effects monitoring and surveillance for new cancers (De 
Leeuw & Larsson, 2013). There is an increasing awareness that 
communication between health care professionals, including primary care 
providers [PCPs] and patients is suboptimal, and that important information 
is often not provided at treatment completion (Dicicco-Bloom & 
Cunningham, 2013; McCabe & Jacobs, 2012). Furthermore it is reported that 
cancer patients frequently experience multiple health problems earlier than 
the general population (Panek-Hudson, 2013). This suggests a need for 
comprehensive early and ongoing approaches to management that should 
take advantage of ‘teachable moments’ at the end of active treatment to 
promote and support patient participation in maximising recovery by the 
adoption of healthy lifestyle behaviours (Alfano et al., 2012; Grant & 
Economou, 2008; Hewitt et al., 2005; Panek-Hudson, 2013). 
 
The provision of SCPTS have been seen as important elements of 
communication with survivors and the numerous multi-disciplinary health 
care providers. What appears as an obvious solution to ensuring optimal 
follow-up and recommendation adherence is hampered by the complexity of 
cancer types and treatment. Especially evident within haematological cancers 
which are made up of diverse blood, immune and bone marrow diseases that 
make standardisation of inclusions very difficult (Rechis et al., 2013). 
Furthermore, in this survivor cohort there is an absence of clear guidelines 
for follow-up care (Earle, 2007; Phillips & Currow, 2010; Rechis et al., 2013). 
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The most common haematological cancers are leukaemia, lymphoma and 
multiple myeloma [MM] (National Cancer Institute, 2006). Each cancer type 
has distinctive and complex treatment regimens that commonly involve high 
dose chemotherapy agents, and/or targeted therapies, radiotherapy and 
hematopoietic stem cell transplants (Carey et al., 2012), often at different 
institutions. Unfortunately, the outcome of these largely aggressive 
treatments is a number of long-term and late physical, practical and 
psychosocial effects which commonly include: fear of recurrence; fatigue; 
nutrition; exercise; fertility; relationship; financial; employment; and 
insurance issues (Allart et al., 2013; Hall, Lynagh, et al., 2013). These patients 
therefore require SCPTS that reflect disease-specific differences rather than 
those designed for the more common cancers (breast, prostate and colorectal) 
who follow similar patterns of survivorship and for whom SCPTS templates 
are widely available.  
 
Haematological cancer patients are understudied and underrepresented in 
survivorship care (Swash et al., 2014) despite increasing five-year relative 
survival rates internationally (Sant et al., 2014). Consequently, the 
haematology focus of this integrative review will add to the limited body of 
knowledge currently available in this cohort of survivors. 
 
This integrative review undertook an analysis of the literature to examine the 
following questions: 
1. What are the common attributes of SCPs and TS developed for 
haematological cancer patients? 
a. What resources (human, templates) are required to develop 
these SCPs and TS?  
b. What are the potential benefits and limitations of these SCPs 
and TS?  
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c. What outcome measures have been used to evaluate these SCPs 
and TS and what are the findings? 
 
Method 
The integrative review method was chosen as the theoretical framework to 
guide this literature review as it allows for an in-depth evaluation of the 
issues encompassing the empirical, theoretical and clinical approaches within 
a structured systematic methodology (Whittemore & Knafl, 2005). The 
method is structured according to five stages: problem formulation; literature 
search; data evaluation; data analysis and presentation (Whittemore & Knafl, 
2005). 
 
Problem formulation 
In this review, a SCP is defined as a personalised document that guides and 
coordinates follow-up care, including recommended surveillance, screening, 
and health promoting behaviours, in addition to providing information, 
education and resources for management of potential long-term and late 
effects of cancer treatment (Hausman et al., 2011; Salz et al., 2014). Within 
cancer survivorship, TS specifically refer to comprehensively summarised 
information on disease, procedures and treatments received for a particular 
cancer (Hausman et al., 2011; Jabson & Bowen, 2013). The aim of these tools 
is to provide written communication from the treatment team to survivor, 
and current and future health care providers with clear delineation of 
responsibility of care (Earle, 2006; McCabe, Bhatia, et al., 2013). A number of 
components have been proposed for inclusion in SCPTS based on 
recommendations from the IOM (Hewitt et al., 2005). An overview of 
relevant components for haematological cancer survivors have been listed in 
Box 2.2.1 and have been adapted from the published literature (Ganz et al., 
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2008; Hewitt et al., 2005; McCabe, Bhatia, et al., 2013; Palmer et al., 2014; Salz 
et al., 2014). 
 
There is consensus that responsibility for the creation and dissemination of 
these tools rests with the treating team (Earle, 2007; Hausman et al., 2011; 
Hewitt, Bamundo, Day, & Harvey, 2007; McCabe, Faithfull, et al., 2013; Salz 
et al., 2014; Stricker et al., 2011). However, it has been identified that 
development of such individualised tools are time consuming, especially if 
treatment occurs across multiple sites and there is a lack of integration or 
absence of electronic records (Earle, 2007; McCabe, Bhatia, et al., 2013; Parry, 
Kent, Forsythe, Alfano, & Rowland, 2013; Rechis et al., 2013; Salz et al., 2014). 
Accordingly, nurses have been suggested as the logical choice to create and 
deliver SCPTS, not only to “free up” specialists time but also because of their 
well-established role in providing information to patients that is holistic and 
individualised (Jackson et al., 2013; Marbach & Griffie, 2011). 
 
4Box 2.2.1 Components for Haematological Survivorship Care Plan and 
Treatment Summary 
Survivorship Care Plan 
 Follow-up schedule including all relevant health care providers responsibility  
 Recovery timeframes for treatment toxicities  
 Health care providers responsible for (including provision of referral/tests): 
o monitoring of long-term effects and onset of potential late effects 
o monitoring and screening for recurrence and second cancers 
o recommended cancer screenings (e.g. mammogram, pap smear, skin 
checks, colonoscopy) 
o co-morbid conditions  
 Monitoring for potential physical, psychological, social issues and referrals for:  
o fear of recurrence 
o anxiety / depression 
o relationship issues (marital, parenting, family and friends) 
o fertility and sexual functioning 
o employment, financial assistance, insurance, legal aid 
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o counselling 
 Promotion of healthy lifestyle behaviours 
o smoking cessation  
o alcohol reduction 
o healthy dietary modifications, weight reduction 
o physical activity  
 Resource list and where to find information on: 
o support groups 
o other allied health providers 
o specific disease and treatment information 
Treatment Summary 
 Diagnosis, tests performed, results 
 Disease characteristics, site, stage / classification 
 Date of treatment initiation and completion 
 Chemotherapy / targeted therapy drugs and cycles: amount, alterations 
(reduction / escalation) 
 Type of Surgery (if applicable) 
 Radiotherapy: site, dosage, timeframe 
 Clinical trials 
 Blood product support 
 Transplant: Allogeneic / Autologous 
 Maintenance treatments and impact on health 
 Adverse reactions or complications 
 Contact information for each modality 
 Coordinator of continuing care contact information 
 Psychosocial, nutritional, and other supportive services used 
 
Templates can reduce the time required to complete SCPTS, providing 
information is readily accessible. The American Society of Clinical Oncology 
[ASCO] and NursingCenter Prescription for Living provide three page 
downloadable templates (McCabe, Partridge, Grunfeld, & Hudson, 2013). 
Internet-based SCP tools such as the Journey Forward™ Survivorship Care 
Plan Builder and LIVESTRONG™ Care Plan (Hausman et al., 2011) deliver a 
comprehensive summary and detailed long-term follow-up plan of care once 
pertinent information is provided. However their utility is limited by the 
length (14 pages) of the tool (McCabe, Partridge, et al., 2013). For survivors 
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and health care professionals outside the USA, educational and supportive 
care resources may not be applicable. Hill-Kayser et al. (2013) studied use 
and satisfaction of the LIVESTRONG Care Plan and found responding 
survivors rated the provision and amount of information as good to excellent 
(93% n=276). Interestingly it was reported that 65% (n=186) of responding 
survivors had not been given information contained in the SCP by health 
care providers after treatment completion. Furthermore, psychosocial 
concerns or risks were often not addressed, thereby necessitating later 
delivery after a health care professional had performed a follow-up needs 
assessment (Belansky & Mahon, 2012). Ganz et al. (2008) and Stricker et al. 
(2011) proposed a dedicated survivorship visit is ideal to assess needs and 
deliver SCPTS, however, they did not stipulate when that visit should take 
place.  
 
The majority of studies on SCPTS are largely descriptive or exploratory and 
have not established evidence that use of SCPTS improve survivor outcomes 
(Grant & Economou, 2008; McCabe, Faithfull, et al., 2013). A randomised 
control trial of breast cancer patients by Grunfeld et al. (2011) compared SCP 
provision to PCPs with usual care (no SCP), and showed no difference in 
patient-reported outcomes between the two groups. This study has been 
criticised (Jefford, Schofield, & Emery, 2012; Stricker, Jacobs, & Palmer, 2012) 
as control PCPs received a comprehensive discharge letter that may have 
contained recommendations for follow-up. Since both groups may have 
received similar information albeit in different formats, results should be 
viewed with caution due to potential contamination of the control group. 
Since published literature in haematological cancer survivorship is rare the 
focus of this integrative review was to identify SCPTS used with 
haematological cancer survivors to facilitate development of tools that can be 
used with this unique survivor cohort. 
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Literature search 
The primary search utilised the following electronic databases: Cumulative 
Index to Nursing and Allied Health Literature [CINAHL]; Medline; PsycInfo; 
PubMed; EMBASE; PsycArticles and the Cochrane Library from January 
2000 to July 2014. Combinations of the following search terms were used: 
(survivorship care plan or treatment summary or follow-up care plan or post 
treatment plan or written follow-up instructions) AND (survivorship or 
cancer survivor) AND (cancer or neoplasm or oncology) AND (haematology 
or leukaemia or lymphoma or multiple myeloma). A hand search of 
reference lists from full texts was also employed. Searches were restricted to 
the English language, humans and adults. Inclusion criteria were: studies 
that reported on SCP and TS use in post treatment phase of haematological 
cancer survivorship; and studies that reported usage perceptions of SCPTS 
experienced by health care providers and/or survivors. Exclusion criteria 
were: studies with less than a 25% haematological cancer patient cohort or 
haematologist viewpoint; studies reporting SCPTS from child, adolescent, 
adult survivors of a childhood cancer or non-cancer populations; and 
opinion papers, letters, editorials, commentaries, conference abstracts, 
conference proceedings or case studies.  
 
Data evaluation stage 
Abstract titles were reviewed by one author [KT] to assess eligibility. A 
summary of the selection process (Moher et al., 2009) is provided in Figure 
2.2.1. The initial search yielded 697 abstracts. Duplicate articles were 
removed and abstracts were screened against the inclusion and exclusion 
criteria. Abstracts that did not provide cancer or provider type were sought 
for further screening. Twenty full-text articles were retrieved; of these four 
articles were reviewed. Documented methodological characteristics 
included: authors and study information; intervention; sample characteristics 
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including participant details, response rate and years' post treatment; 
outcome measures; results; limitations and comments and level of evidence 
as developed by (Melynyk & Fineout-Overholt, 2011). Due to variations in 
study population and methodologies used, meta-analysis was not possible. 
Results are shown in Table 2.2.1. 
 
The haematology component in the majority of studies was low. No 
systematic reviews on studies related to SCPTS were identified. The four 
included studies were all from the USA. They assessed both survivor and 
clinician views on the experience of receiving or disseminating SCPTS. 
Included articles used various terms to describe treating clinicians. For clarity 
in this integrative review, the term specialist will refer to the following 
treating consultants: haematologist, medical or radiation oncologist. The 
research studies all used quantitative approaches and reflected a low level 
(IV) of quantitative evidence. Reviewed studies were related to the 
survivorship phase of the cancer trajectory. 
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3Figure 2.2.1. Flowchart of literature search results. 
 
5Table 2.2.1 Levels of Evidence 
Level Evidence 
I Systematic review of all relevant randomised control trials 
II At least one well designed randomised control trial 
III Well-designed controlled trials without randomisation 
IV Well-designed cohort studies, case control studies, interrupted time 
series with a control group, historically controlled studies, interrupted 
time series without a control group or with case series 
V Systematic reviews of descriptive and qualitative studies 
VI Single descriptive and qualitative studies 
VII Expert opinion from clinicians, authorities and/or reports of expert 
committees or based on physiology 
(Melynyk & Fineout-Overholt, 2011) 
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Data Analysis and Presentation 
 
Characteristics of reviewed articles are detailed in Table 2.2.2. 
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6Table 2.2.2 Methodological Characteristics of Haematological Cancer Survivorship Care Plans and Treatment Summaries (n=4) 
Author Study 
Design 
Intervention  Sample 
Characteristics 
Outcome Measures Results Limitations and 
Comments 
Level of 
Evidence  
Curcio et al 
2012 
USA 
Pre/post-
test 
question-
naire 
Survivorship 
protocol with 
SCPTS 
developed by 
specialist and 
NP (40–75 
minutes to 
complete) 
Delivered by NP 
using ASCO-
generic template  
30 survivors 
convenience sample 
included: 
breast (53%); NHL 
(26%); lung (10%); 
gastrointestinal 
(10%) 
<2 years' post-
treatment 
10/24 (41%) PCP 
8/10 (80%) staff 
Improved disease 
knowledge 
Decreased anxiety 
Satisfaction 
Fidelity to NCCN 
follow-up guidelines 
Cost-benefit analysis 
Increased knowledge: disease, 
treatment, follow-up, signs of 
recurrence, LE 
Decreased anxiety  
High satisfaction in survivors 
(76%) and staff (100%)  
PCP satisfied (100%) 
Consistent fidelity to NCCN 
guidelines 
Low anxiety 
scores at baseline 
Small samples 
No cost-benefit 
analysis 
SCPTS to 
survivor/PCP 
IV 
Friedman 
et al 
2010 
USA 
Mailed 
question-
naire  
SCP and rating 
of the most 
important 
informational 
needs 
67/164 (41%) NHL 
survivors 
9 months–12.6 years' 
post-treatment 
22/76 (29%) 
physicians involved 
in survivorship care 
Informational SCP 
needs of survivors / 
physicians 
Congruence between 
survivors / 
physicians 
Survivor needs: recurrence 
screening, LE, treatment, 
overall health monitoring, 
nutrition, exercise, insurance, 
finances 
Physician needs: treatment 
complications 
Higher concordance on 
medical issues compared to 
psychosocial issues 
Small samples 
Same questions 
for 
survivors/physicia
ns 
Disease specific 
cohort 
IV 
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Merport et 
al 
2012 
USA 
Mailed 
question-
naire 
SCPTS 
developed / 
delivered by 
specialist 
TS inclusions 
reported: 
diagnosis; stage; 
treatment; start 
dates; treatment 
fields; drugs 
108/369 (29%) 
specialists 
[Haematologist 
(32%)] 
400/3568 (11%) PCP  
Cancers reported: 
breast (44%); prostate 
(36%); colorectal 
(35%); lung (31%); 
haematology (20%)  
SCP and TS use and 
obstacles among 
specialists 
SCP and TS receipt 
and informational 
preferences among 
PCPs 
Use: 56% prepare TS  
14% prepare SCP (sent to 
PCP/patient) 
Obstacles: 47% no training; 
46% no template; 40% no 
reimbursement  
Receipt of TS 54%  
Information preferences: 95% 
treatment summary; 89% 
follow-up schedule; 89% 
recommendations; 84% 
potential side effects; 67% 
treatment-related health risks 
Low response 
rates 
Self-reported 
practices 
Responder bias 
(potential over 
estimation of use) 
Reported lack of 
routine use of 
TS/SCP 
IV 
Sabatino et 
al 
2013 
USA 
2010 
National 
Health 
Interview 
Survey 
[NHIS] data 
Survivor 
reported receipt 
of TS or written 
follow-up plan 
1345 (60.8%) 
survivors including: 
breast (20%); prostate 
(14%); cervix/uterus 
(13%); melanoma 
(11%); colorectal 
(8%); other (31%) 
[including 
haematology] 
<4 years and >4 years 
post treatment 
Receipt of TS and/or 
follow-up 
instructions 
Recent surveillance 
for recurrence, other 
cancer screening 
Survivors <4 years received: 
38% TS 
58% written follow-up  
29.4% both  
33.1% neither 
More treatment modalities—
lower TS provision 
Higher income and clinical 
trial participation—higher 
written instruction provision 
Haematology 
sample % not 
specified 
Self-reported data 
may not reflect 
actual documents 
received 
Separate reporting 
of survivors 
diagnosed after 
IOM report  
(<4 years)  
IV 
Note. ASCO-American Society of Clinical Oncology; IOM-Institute of Medicine; LE-late effects; NCCN-National Comprehensive Cancer Network; NHL-non-
Hodgkin lymphoma; NP-nurse practitioner 
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The study by Sabatino et al. (2013) reported a subset of survivors (n=407) 
who were within four years of diagnosis, a timeframe that corresponded to 
the IOM report calling for all survivors to receive SCPTS. Survivors were 
asked if they had ever received a SCP and /or TS. The authors found that 38% 
(n=155) of survivors acknowledged receipt of a treatment summary and 58% 
(n=236) written follow-up instructions or plan. The authors reported that 
written follow-up instructions were received more often in those recipients 
who were part of a clinical trial (85% n=346) and demographically were 
reported as having a higher income (67% n=274). Hematopoietic stem cell 
transplant survivors were included, however numbers were not reported.  
 
Curcio, Lambe, Schneider, and Khan (2012) studied both survivors and 
clinicians. Haematological cancer survivors accounted for 26% (n=8) of the 
overall survivor cohort studied (n=30). Survivors were highly satisfied with 
the provision of SCPTS and reported an increase in knowledge. Anxiety 
levels decreased, although levels were not high at baseline, and may have 
decreased naturally with time. Equally survivor satisfaction may have been 
related to the survivorship visit and follow-up telephone call rather than SCP 
provision. PCPs were reported as being satisfied (100% n=10) with SCPTS. 
The authors reported PCPs appreciated the content, which aided 
communication and were useful tools to provide clarification of the 
survivor’s follow-up plan. 
 
Friedman, Coan, Smith, Herndon II, and Abernethy (2010) studied non-
Hodgkin lymphoma survivors (n=67) and physicians (n=22) involved in 
survivorship care. The informational needs on the SCP were reported as 
being congruent between the PCP and survivor. Interestingly all respondents 
rated medical content more important than psychosocial issues, perhaps 
reflecting survivor expectations in the current model of survivorship follow-
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up. Furthermore, survivors ranked the plan to monitor overall health the 
sixth most important element of the SCP compared to physicians who 
ranked it thirteenth. This led the authors to conclude that survivors’ view 
follow-up as part of general health maintenance, whereas physicians 
separate cancer survivorship care and non-cancer related care.  
 
Merport, Lemon, Nyambose, and Prout (2012) evaluated clinician (n=108) use 
and PCP (n=400) receipt of SCPTS. Fifty-four percent (n=216) of PCPs 
received a TS. However, the study reported that only 42% (n=46) of 
specialists (including haematologists) prepared a TS. SCP preparation by 
specialists was low at 14% (n=15), nonetheless the authors reported all SCP 
were sent to survivors and PCPs. Barriers identified in this study included: 
no template was provided; no training was given to health care professionals 
on how to develop SCPTS; and specialists perceived no financial 
reimbursement was given for their time in developing and delivering SCPTS. 
Therefore, a lack of support from treating clinicians may mean development 
and dissemination remains low, with the possibility SCP remains medically 
focused.  
 
All these studies showed a lack of routine use of SCP TS even though 
survivors and PCPs valued the tools and the direction for survivorship 
follow-up they provided.  
 
Discussion 
Published haematology research regarding SCPTS is limited. Currently no 
randomised control trials or literature reviews exist for this understudied 
cohort of cancer survivors. This is despite the current belief that SCPTS are 
beneficial in complex and rare cancer survivor groups such as haematology 
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(Mor Shalom, Hahn, Casillas, & Ganz, 2011) where health problems may take 
many years to develop (Sabatino et al., 2013). With the increased risk of 
psychosocial, physical and economic long-term and late effects from disease 
and cancer therapy, patients often experience difficulties accessing post 
treatment follow-up which may potentially lead to poorer overall health 
outcomes (Friedman et al., 2010).  
 
Within the literature that reported the development and dissemination of the 
SCPTS (Curcio et al., 2012; Merport et al., 2012) there was a lack of 
information regarding resources used by the specialist to develop the SCPTS 
(Merport et al., 2012). Similarly, information on how generic ASCO templates 
were tailored by the specialist and nurse practitioner for the different cancer 
survivors was not provided (Curcio et al., 2012). Details on any evidenced-
based guidelines for follow-up care used in SCP (Merport et al., 2012), and 
the clinical expertise of the health professionals creating SCPTS was equally 
lacking. 
 
Standardised templates linked to electronic health records that would 
directly populate TS have been proposed to provide health providers with 
diagnosis and treatment information (Merport et al., 2012; Salz et al., 2014), 
particularly relevant when survivors have had treatment across a number of 
sites (Merport et al., 2012). Sabatino et al. (2013) similarly found low TS and 
SCP delivery when survivors had more than one treatment modality. 
Furthermore, the long duration of treatment that occurs in some 
haematological cancer regimens can make it difficult to find and summarise 
dose modifications and issues that have occurred over the entire treatment 
phase. It is clear that haematology-specific cancer SCPTS templates and 
guidelines are necessary as generic cancer templates cannot convey all the 
appropriate information required, adding to the complexity of this issue 
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(Friedman et al., 2010). As recommended by Curcio et al. (2012) and Sabatino 
et al. (2013) provision of SCPTS soon after treatment completion is required 
to assess the need for information and resources.  
 
Friedman et al. (2010) argued that providing extra information to survivors 
could overload and dilute the impact of the most important information that 
needs to be conveyed. This view is supported by Cox and Faithfull (2013) 
who reported clinicians consider late effects information impacts 
psychological adjustment and increases the amount of late effects through 
autosuggestion. However, these authors reflect the perception of clinicians 
rather than patients and as Hill-Kayser et al. (2013) argue this paternalistic 
approach is no longer acceptable. Providing tailored SCPTS to cancer 
survivors, empowers individuals to learn about their disease and treatment 
and assume responsibility for future surveillance and disease management, 
facilitating engagement in a future healthy lifestyle (Jackson et al., 2013). This 
is particularly vital for younger survivors given the expectation of a longer 
survivorship period (Jabson & Bowen, 2013). 
 
Multidisciplinary collaboration has been suggested (Mor Shalom et al., 2011) 
as a strategy for developing SCPTS. Interdisciplinary education needs to 
acknowledge the value of each provider’s contribution within the team. 
Recommendations that clearly detail provider responsibility can ensure 
survivors are not over or under tested and adhere to recommendations that 
are evidenced or consensus based (Curcio et al., 2012).  
 
Nurses can be a key component in implementing care plans, and providing 
comprehensive information, education and resources, especially in 
preventative health and screening as reported by Curcio et al. (2012). Mor 
Shalom et al. (2011) revealed nurse practitioner-developed SCP may not be 
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read by PCPs, and indeed 100% PCPs (n=15) reported they would not act 
upon expensive testing recommendations. Therefore, specialists need to 
reinforce the importance of nurses as an essential element in survivorship 
care planning (Hewitt et al., 2007).  
 
It is important that SCPTS be developed in conjunction with a robust model 
of haematological survivorship follow-up care that will address the issues 
and barriers related to implementation. Many professional organisations are 
calling for SCP development for accreditation, but there is risk that cancer 
programs that develop SCP to meet professional requirements may be 
reluctant to make the organisational changes necessary to actually deliver the 
SCP to survivors and PCPs (Birken, Mayer, & Weiner, 2013). Institutions 
and/or specialists who perceive a lack of financial reimbursement and 
support for the additional time required to prepare and deliver SCPTS 
maybe be disinclined to support widespread implementation (Earle, 2007; 
McCabe, Partridge, et al., 2013; Salz et al., 2014). 
 
A number of limitations of this review are acknowledged. The search 
revealed a small number of articles meeting inclusion criteria. All studies 
reviewed had low sample numbers and/or response rates, especially for 
those studies which explored PCP experiences of SCPTS. Haematological 
survivor and haematologist numbers were limited, decreasing the 
applicability to haematological cancer survivors. The reliance on self-
reported practices in all the studies and a lack of comparison groups restricts 
the conclusions that can be drawn. Study participants may have had more 
experience with and/or a bias towards or against SCPTS implementation. 
This lack of standardisation makes it difficult to compare and draw 
conclusions regarding the benefits for survivors with the dissemination of 
CHAPTER 2. PHASE I 
70 
these tools. Finally, an inherent bias in interpretation might be due to the 
evaluator.  
 
Conclusion and Implications for Nursing 
This integrative review identified published literature on SCPTS and their 
applicability to haematological cancer survivors. Treatment advances in 
haematological cancer means patients are living longer (Sant et al., 2014), 
however the extended recovery trajectory involves a heavier symptom 
burden and post treatment complications due to the aggressive nature of 
both the haematological disease and the treatment required. Therefore, these 
haematological cancers are unlike the other cancers that are currently used as 
benchmarks such as breast or prostate (Parry et al., 2010).  
 
Nurses can influence and guide the development of relevant survivorship 
care recommendations, thereby facilitating a paradigm shift to encompass all 
aspects of the cancer trajectory. Nurses with advanced research skills (e.g. 
PhD prepared) would be well placed to take the lead in adopting and 
translating current follow-up guidelines for haematological cancer patients 
into evidenced-based and disease-specific templates. Nurses are in a position 
to provide and disseminate SCPTS comprising individualised and relevant 
resources, information and education to ensure the needs of haematological 
cancer survivors are met. Correspondingly nurses need to support and 
empower survivors to take control of and ultimately self-manage their 
ongoing needs.  
 
This review revealed a lack of high quality evidence related to 
haematological cancer survivor care. Addressing specific and ongoing 
concerns of these patients, along with the dissemination of this information 
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to survivors and clinicians, especially in primary care is important. As 
survival rates continue to increase, the successful integration of 
haematological survivorship care into the cancer continuum is vital.  
 
Future Research 
Further research will need to account for the inclusion of each component of 
the SCP, the survivor’s desire for this knowledge and information, as well as 
the best way to develop and deliver haematological cancer specific SCPTS. 
Research is required on the types of models of care most suitable for 
delivering SCPTS to haematological cancer survivors, including their 
perspectives on follow-up provision. Nurse-led haematology survivorship 
clinics that facilitate shared care between the treating team and primary care 
may be the most appropriate model to deliver SCPTS to achieve the best 
outcomes for patients transitioning into the survivorship period and require 
further evidence-based research. Methods that will optimise communication 
and clarity with provider responsibility, thereby decreasing over or under 
use of surveillance and screening tests are fundamental aspects of this 
research. Finally, research in how best to decrease the amount of time needed 
to prepare SCPTS, and the ideal time to effectively deliver SCPTS is 
necessary. Well-designed pragmatic randomised controlled trials are 
required to inform clinical practice. As the amount of outcome-based 
research increases so too will our understanding of providing optimal 
survivorship care. 
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Literature Review Update 
The same search criteria, terms and databases were reviewed to ascertain 
recent developments or research in lymphoma survivorship care plans and 
treatment summaries in the published literature. The search period was 2014 
to January 2018. Results found 17 abstracts worthy of further assessment.  
 
Assessment of the articles revealed no new articles that meet the inclusion 
criteria of the original integrative review (Behrend, 2014; Brennan, Gormally, 
Butow, Boyle, & Spillane, 2014; Frick et al., 2017; Jabson, 2015, 2015; 
Klemanski et al., 2016; Kvale et al., 2016; Maly et al., 2017; Mayer, 2014; 
Mayer, Birken, Check, & Chen, 2015; Mayer, Green, et al., 2015; Palos et al., 
2014; Playdon et al., 2016; Rosenberg et al., 2016; van de Poll-Franse, 
Nicolaije, & Ezendam, 2017). The majority of articles included breast cancer 
cohorts and, therefore, predominantly female participants, which may not 
accurately reflect the perceptions and use of SCPTS by lymphoma survivors 
or men. Two articles of interest that did not meet the inclusion criteria have 
been described (Brant et al., 2016; Mayer et al., 2016). Both articles relate to 
SCP use and primary care, a specific area of interest examined in this thesis. 
 
The study by Brant et al. (2016), reporting satisfaction with an SCP, evaluated 
breast (n=52, 78%) and lymphoma (n=15, 22%) survivors, carers (n=39) and 
n=23 primary care providers (PCP). Results from the lymphoma cohort 
revealed higher quality of life (QoL) scores compared with breast cancer 
survivors, and that PCPs of lymphoma survivors were highly satisfied with 
the SCP. The authors suggested that an SCP may contribute to improved 
patient confidence in PCPs who provide survivorship care. Conversely the 
study of a breast cancer cohort (which may not be applicable to lymphoma 
survivors) randomised 34 females into two groups; SCP only group, where 
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an SCP was delivered by an oncology nurse practitioner (NP) and an SCP 
plus PCP group, where participants received an SCP from the NP and 
attended a six-week follow-up visit with their PCP. Both groups reported 
improved confidence in survivorship information; however the SCP only 
group were identified as having increased worry compared with the group 
who were able to discuss the SCP with their PCP at the six-week follow-up 
visit (Mayer et al., 2016).  
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2.3 Needs Assessment Measures 
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Systematic Review of the Tools Used to Assess the 
Informational and Practical Needs of Acute Leukaemia and 
Lymphoma Survivors. 
 
Abstract 
Purpose: To identify validated measurement tools to assess the informational 
and practical concerns of leukaemia and lymphoma survivors. Cancer nurses 
have the potential to lead the way in providing quality post-treatment 
survivorship care. 
 
Method: This systematic review utilised a search of electronic databases for 
eligible articles published to March 2014. Included articles described a tool to 
assess informational and/or practical concerns of leukaemia and/or 
lymphoma survivors. 
 
Results: Seven full text articles were identified that described cancer-specific 
tools used to assess informational and/or practical needs of this survivor 
cohort. There was variation in the use of cancer survivor-specific tools and 
generic cancer tools.  
 
Conclusions: No haematology-specific needs assessment tools were 
identified. Therefore, only tentative conclusions on the best tool for this 
cohort can be made. Further research is required to develop reliable and 
validated tools that will support the selection of the most appropriate tool for 
leukaemia and lymphoma survivors. 
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Introduction 
Leukaemia and lymphoma are the most common blood and bone marrow 
cancers (National Cancer Institute, 2006). Effective treatments are largely 
aggressive and cause a number of long-term and late physical, practical and 
psychosocial effects, which significantly impact lifestyle in the survivorship 
phase (Arden-Close et al., 2011). Survivorship is defined as the experience of 
living with, through and beyond a diagnosis of cancer (National Coalition for 
Cancer Survivorship, 2014). As with other cancers the haematology cancer 
health professional role has extended to include provision of patient care in 
the survivorship phase. This important step forward has been driven largely 
by the 2005 Institute of Medicine (IOM) report From Cancer Patient to Cancer 
Survivor: Lost in Transition (Hewitt et al., 2005), considered the seminal paper 
for cancer survivorship. The report recommended survivorship care as a 
priority in the cancer trajectory with a number of specific issues relevant to 
the survivorship phase. These issues can be categorised according to the 
seven domains of Fitch (2008) supportive care framework; physical, 
informational, emotional, psychological, social, spiritual and practical 
concerns. The framework can be used across the cancer continuum including 
haematology survivorship care (Hall, Campbell, et al., 2013). Whilst 
survivorship care is developing for other cancers, haematology cancers 
remain understudied in survivorship literature (Swash et al., 2014) despite 
increasing five-year relative survival rates internationally (Hall, Lynagh, et 
al., 2013; Rowland & Bellizzi, 2008; Sant et al., 2014).  
 
The purpose of this review was to source tools that could be used to assess 
two domains from the supportive care framework: informational and 
practical concerns. These were chosen as a result of our findings from a 
qualitative study undertaken with leukaemia and lymphoma patients that 
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revealed a number of unmet needs, predominately informational and 
practical (Monterosso et al., 2015), thought to relate in part to the extensive 
nature of the treatment and the uncertainty around long term remission and 
potential late effects. 
 
The terms ‘informational needs’ and ‘practical needs’ are rarely considered 
or defined as separate entities in the literature. For clarity and consistency 
Fitch’s definitions (Fitch, 2008) of needs have been used. Informational needs 
are defined as information to assist in decision-making and acquiring of 
skills to decrease fear, anxiety and misperception (Fitch, 2008). Fear of 
recurrence is often reported as an informational need for this cohort (Koch, 
Jansen, Brenner, & Arndt, 2013). Two recent systematic reviews on this topic 
reported tools used to measure fear of recurrence; tools to measure other 
informational needs were not reported (Koch et al., 2013; Thewes et al., 2012). 
Practical needs are defined as direct interventions or help that support the 
survivor to complete a task or meet a concern (Fitch, 2008). Insurance and 
employment issues are often cited as unmet needs for leukaemia and 
lymphoma survivors (Chen et al., 2012). Other common informational and 
practical needs reported in haematology survivorship literature include late 
effects, fatigue, nutrition, exercise, fertility and sexual concerns, relationship 
issues, financial issues, personal care and accessing support services (Allart 
et al., 2013; Arden-Close et al., 2011; Beckjord, Arora, Bellizzi, Hamilton, & 
Rowland, 2011; Behringer et al., 2013; Gates et al., 2015; Hall, Lynagh, et al., 
2013; Hawkins et al., 2008). 
 
Gates et al. (Gates et al., 2015) argued that haematology cancer nurses have 
an important role in this changing dynamic, especially in developing 
sustainable, nurse-led survivorship care. If nurses are to take on a greater 
role in survivorship care they require accurate, reliable and validated tools to 
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assess patients entering the post-treatment phase (Muzzatti & Annunziata, 
2013). Hawkins et al. (2008) proposed that tools designed for patients to self-
identify perceived needs are required to support survivorship care. These 
tools could then guide the development of appropriate models of care, 
resources and tailored support that are patient-centred rather than based on 
the perceptions of health professionals (Fitch, 2008; McDowell et al., 2010). 
The timing of patient needs assessments is equally important. Research 
showing interventions and assessments undertaken in the early survivorship 
phase (up to two years post-diagnosis) can lead to fewer unmet needs 
moving into the extended survivorship phase (over five years)(Aziz, 2007; 
McDowell et al., 2010). 
 
There is a dearth of published literature that has critically evaluated tools 
used to measure the perceived unmet needs of leukaemia and lymphoma 
survivors (Arden-Close, Pacey, & Eiser, 2010; Muzzatti & Annunziata, 2013). 
Tools specifically developed for these patients in the treatment phase such as 
the Functional Assessment of Cancer Therapy: Lymphoma or Leukaemia 
(FACT-LYM, FACT-Leu) have also been in the survivor population (Cella et 
al., 2012; Hlubocky, Webster, Cashy, Beaumont, & Cella, 2013). Hence, it is 
possible survivor-specific needs may not be captured. 
 
Given that each cancer patient’s journey is unique it is important to measure 
individual needs and match practical support to meet these needs. Therefore, 
the leukaemia and lymphoma-specific focus of this paper will add to the 
limited body of knowledge currently available in this survivor cohort. 
  
CHAPTER 2. PHASE I 
79 
The following questions guided this systematic review: 
1. What reliable and valid measurement tools are currently available to 
measure the informational and practical needs of acute leukaemia and 
lymphoma cancer survivors?  
2. What are the implications of the findings from this review for future 
research and clinical practice?  
 
Method 
A systematic review methodology was chosen to guide this review. To guide 
literature searches and analysis of articles, a study protocol was devised. As 
the use of needs assessment tools dictates a quantitative study method, 
qualitative studies and the qualitative component of quantitative studies 
were excluded. Mixed methods research was included with only the 
quantitative element evaluated.  
 
Literature search 
The primary search utilised the following electronic databases: Cumulative 
Index to Nursing and Allied Health Literature (CINAHL), Medline, 
PsychInfo, PubMed, EMBASE, PsychArticles, and the Cochrane Library from 
earliest records to March 2014. Search terms related to leukaemia and 
lymphoma cancers, assessment, survivorship and needs. A hand search of 
the reference lists from full text articles was also employed. Searches were 
restricted to English and adult acute leukaemia or lymphoma survivors. 
Inclusion and exclusion criteria are shown in Table 2.3.1. Studies with only 
multiple myeloma participants were excluded as these patients are living 
with cancer (Osborne et al., 2012). Likewise, studies with only allogeneic 
transplant participants were excluded as they have ongoing conditions such 
as Graft-versus-Host-Disease. 
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7Table 2.3.1 Inclusion and Exclusion Criteria 
Inclusion Criteria 
 Use of a cancer survivor-specific or generic cancer tool or instrument  
 Validity and reliability of tool tested with leukaemia and/or lymphoma 
cancer survivors 
 Informational and/or practical needs reported 
 Adult leukaemia and lymphoma cancer survivors only 
Exclusion Criteria 
 Tools used in the treatment or diagnostic phase 
 Tools used with relapse or secondary leukaemia or lymphoma cancer 
survivors only 
 Studies reporting survivors of a childhood leukaemia or lymphoma cancer 
 Studies related to caregivers, or comparative studies between caregivers and 
survivors 
 Studies with less than 50% leukaemia or lymphoma cancer survivor cohort  
 Opinion papers, letters, editorials, commentaries, conference proceedings, or 
case studies 
 
Quality appraisal and data extraction 
Abstract titles were reviewed by author (KT) to assess eligibility. The 
instrument/tool(s) used in eligible full text articles were then appraised (KT 
and LM) to determine whether they measured informational and/or practical 
needs of the leukaemia or lymphoma survivor. A summary of the selection 
process using the PRISMA 2009 Flow Diagram (Moher et al., 2009) is 
provided in Figure 2.3.1. 
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4Figure 2.3.1. Flowchart of literature search results. 
 
The methodological characteristics documented included: authors; 
publication year; study design; comparison group; outcome measures; 
disease; sample size and response rate; survivorship period; cancer-specific 
and non-cancer specific tools; reported unmet informational and practical 
needs; results and study quality (Fowkes & Fulton, 1991) shown in Table 
2.3.2. Due to variations in study population, methodologies and tools used, 
meta-analysis was not possible. Study quality was assessed using Fowkes 
and Fulton (1991) guidelines and checklist for critically appraising 
quantitative research. Assessment of the methodological quality of studies 
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utilised a classification system of poor (under 40% of quality items), good 
(40–70% of quality items) or very good (over 70% of quality items) as 
reported by Hall, Lynagh, et al. (2013). In addition, the validity of each tool 
was assessed according to: how the tool covered the informational and/or 
practical needs of the participants; correlation with other generic cancer or 
survivor-specific tools; and whether results confirmed study outcomes. Tool 
reliability was determined by internal consistency of the items and whether 
test–retest reliability had been performed. Generalisability of the tool to 
leukaemia or lymphoma survivors was gauged from the study results, along 
with the clinical usefulness of the tool for these survivors. 
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8Table 2.3.2 Methodological Characteristics of Selected Articles (n=9) 
Authors 
Year 
Country 
Study Design 
Comparison Group  
Outcomes Measured 
Disease 
Sample Size 
(Response 
Rate %) 
Survivorship 
Period 
Tools  
Cancer Survivor-
specific 
Non-cancer 
Tools/Investigator 
Questions 
Unmet 
Information/Pr
actical Needs 
Reported 
Results Study 
Quality 
Arden-Close 
et al 
2011 
UK 
Cross sectional  
Administered 
questionnaires 
Gender comparison 
Health related quality 
of life, late effects and 
perceived vulnerability; 
satisfaction with care; 
expectations and 
satisfaction of clinic 
visit 
Lymphoma 
n=115 (79.9%)  
>5 yrs  
QoL-CS (Quality of 
Life Cancer 
Survivors)  
Yes 
SF-12v2 (Medical 
Outcomes Study 
Health Survey Short 
Form 12 version 2)  
Princess Margaret 
Hospital Satisfaction 
with Doctor 
Questionnaire 
18 late effects & 10 
general issues at 
consultation 
Only questions 
related to 
discussion of 
topics, late 
effects 
No gender difference in late 
effects or perceived vulnerability 
Men: more late effects, worse 
health related quality of life, 
wanted to discuss more topics 
(women discussed the topics) 
Shorter wait time=more topics 
discussed 
Health related quality of life 
dependent on whether survivors’ 
follow-up expectations are met 
Good 
Friedman et 
al 
2010 
USA 
Cross sectional 
Mailed questionnaire 
Comparison of 
survivors and 
Non-Hodgkin 
lymphoma 
n=67 (41%) 
9 months–12.6 
Investigator 
questionnaire  
Informational 
needs to be 
included in 
survivorship 
Survivorship care plan tailored 
for particular survivors 
Survivor: survivorship care plan 
inclusions: screening for 
Poor 
  
 
84 
physicians  
Informational 
survivorship care plan 
needs of survivors and 
physicians 
Congruence between 
survivors / physicians 
years 
Physicians 
involved in 
survivorship 
care 
n=22 (29%) 
care plan  recurrence/late effects; treatment 
summary; monitor overall 
health/nutrition/exercise; 
insurance 
Survivor/Physician concordance 
higher on medical issues 
compared to psychosocial issues 
No differences reported between 
survivorship length 
Hall et al 
2013 
Australia  
Canada 
Cross sectional  
Cross cultural 
Mailed questionnaires 
Comparison of 
Australian and 
Canadian haematology 
survivors 
Percentage of survivors 
reporting unmet needs; 
domain scores; 10 most 
prevalent high unmet 
needs  
Leukaemia, 
lymphoma, 
multiple 
myeloma 
Australia: 
n=268 (37%) 
>3 years 
Canada: n=169 
(45%) 
1–5 years 
SUNS (Survivors’ 
Unmet Needs 
Survey) 
Yes 
Informational 
needs: cancer 
recurrence and 
spread 
Work & 
financial needs 
Similar levels of unmet needs 
Fatigue highest concern across 
both cohorts 
Multiple areas of need found in; 
females, younger age, expense 
due to cancer, vocational 
education level, seeing Dr re 
treatment or concerns 
Work & financial needs higher for 
Australian survivors 
Good 
Hjermstad et 
al 
2003 
Norway 
Prospective cohort at 4 
time points 
Administered 
questionnaires 
Comparison of 
autologous lymphoma 
Leukaemia, 
lymphoma 
n=123 (94%) 
<1 year post- 
transplant 
CARES-SF (CAncer 
Rehabilitation 
Evaluation System 
Short Form) 
No 
EORTC QLQ-C30 
Financial, 
insurance, 
weight gain, 
transport, fear 
of recurrence, 
employment, 
Few patients requested help with 
any items 
CARES-SF useful for assessing 
sexual, marital, medical 
interaction to address specific 
issues at follow-up 
Good 
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with allogeneic 
leukaemia transplant 
patients 
Rehabilitation needs 
and health related 
quality of life; physical 
function measures of 
CARES-SF compared to 
EORTC QLQ-C30 
(European 
Organization for 
Research and 
Treatment Quality of 
Life Core 
questionnaire) 
No 
fatigue High correlation with physical 
function between the two scales 
Lobb et al 
2009 
Australia 
Cross sectional 
Mailed questionnaire 
No comparison group 
Assessment of unmet 
informational and 
emotional needs after 
treatment 
Leukaemia, 
lymphoma, 
multiple 
myeloma 
n=66 (50%) 
6 weeks–1 year 
post-treatment 
CaSUN (Cancer 
Survivors Unmet 
Needs Survey)  
Yes 
Concerns: fear 
of recurrence; 
care 
coordination; 
information on 
services  
Care coordination after treatment 
important, significant for 
unmarried or working patients 
Fear of recurrence, emotional & 
relationship needs greater in 
younger patients 
Top endorsed needs: managing 
health with medical team; 
communication between doctors; 
best medical care 
Good 
Parry et al 
2012 
USA 
Mixed methods 
Cross sectional 
Mailed questionnaire 
 
No comparison group 
Health service and 
psychosocial needs of 
adult leukaemia and 
Lymphoma, 
leukaemia 
n=477 (45%) 
< 4 years 
Houts et al Service 
Need Inventory, 
refined by Kornlith 
et al. 
14 items 
Practical needs: 
child care; 
financial 
Unmet need highest in: sexual 
issues; handling medical and 
living expenses; emotional 
difficulties; employment; health 
insurance 
Women more likely to report 
unmet child care needs 
Relationships were observed 
Poor 
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lymphoma survivors among service needs, 
overlapping areas of unmet need 
Zebrack 
2000 
USA 
Mixed methods  
Cross sectional 
Mailed questionnaires / 
semi structured 
interviews 
No comparison group 
Experience of quality of 
life in long term 
survivors at various life 
stages 
Leukaemia, 
lymphoma 
n=53 (50%) 
10 years 
QoL-CS (Quality of 
Life Cancer 
Survivors) 
Yes 
27 in depth 
interviews 
Fear of 
recurrence, 
fatigue, 
employment, 
support, 
financial, family 
Fatigue, pain, fear of recurrence—
ongoing issues 
Family distress and finances 
continue to impact survivors 
Financial issues worse in older 
survivors  
Relapse not related to quality of 
life 
Income rated significantly to 
quality of life 
Positive associations with ability 
to cope after cancer 
Good 
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Data Analysis  
The initial search yielded a large number of abstracts (n=5234). Following 
removal of duplicate articles and abstract screening using exclusion and 
inclusion criteria, 32 full text articles were sought and further appraised. Of 
these, seven articles were reviewed and referred to one or more relevant 
tools (Arden-Close et al., 2011; Friedman et al., 2010; Hall, Campbell, et al., 
2013; Hjermstad et al., 2003; Lobb et al., 2009; Parry, Lomax, Morningstar, & 
Fairclough, 2012; Zebrack, 2000). No tool had been specifically developed for 
exclusive use with leukaemia or lymphoma survivors. Two studies reported 
researcher-developed questionnaires (Arden-Close et al., 2011; Friedman et 
al., 2010).  
 
The seven included articles reporting haematological cancer survivor cohort 
studies from Australia (n=2), Canada (n=1), the United States of America 
(USA) (n=3), Norway (n=1) and United Kingdom (UK) (n=1). The periods of 
survivorship ranged from six weeks post-treatment through to 12 years after 
diagnosis (Arden-Close et al., 2011; Friedman et al., 2010; Hall, Campbell, et 
al., 2013; Hjermstad et al., 2003; Lobb et al., 2009; Parry et al., 2012; Zebrack, 
2000). Of the reviewed studies, four utilised comparative groups related to 
unmet needs among different: treatment types (Hjermstad et al., 2003); 
countries (Hall, Campbell, et al., 2013); gender (Arden-Close et al., 2011); and 
survivors and physicians (Friedman et al., 2010). Outcome measures varied 
across all studies, although the majority related to unmet needs after 
treatment completion (Table 2.3.2). The assessment of methodological quality 
(Fowkes & Fulton, 1991) revealed most studies (n=5) were ‘good’; two were 
classified as ‘poor’. Two studies (Parry et al., 2012; Zebrack, 2000) utilised 
mixed method designs, six studies (Arden-Close et al., 2011; Friedman et al., 
2010; Hall, Campbell, et al., 2013; Lobb et al., 2009; Parry et al., 2012; Zebrack, 
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2000) were cross sectional and one (Hjermstad et al., 2003) was prospective. 
Methodological quality varied with sample sizes ranging from 22 to 477 
participants and response rates varying from between 29% and 94%. 
 
Results  
Five tools were identified and could be dichotomised as either those 
designed for cancer survivors (survivor-specific) or those developed for 
cancer patients undergoing treatment and used with a cancer survivor cohort 
(generic cancer tools). Utilising the definitions of informational and practical 
needs as previously described ensured consistency with the data extracted 
from the articles. Comparisons of the five main assessment tools identified in 
this review are shown in Table 2.3.3.  
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9Table 2.3.3 Comparison of Assessment Tools 
 
 
 
 
 
Tool Cancer 
Survivor-
specific 
Content  Scale  
Scoring 
Information 
Needs  
Practical 
Needs 
CARES-SF (CAncer 
Rehabilitation Evaluation 
System Short Form) 
No 59 items—degree problem applies  
5 summary scales: physical; psychosocial; 
sexual; marital; medical interaction  
5 point 
Lower scores = 
fewer problems 
No Yes 
CaSUN (Cancer Survivors 
Unmet Needs Survey)  
Yes 35 supportive care needs items, 6 positive 
outcome items, 1 open ended item 
5 needs domains: existential survivorship; 
comprehensive cancer care; information; 
quality of life; relationships 
5 point 
Higher scores = 
greater needs 
Yes  Yes 
EORTC QLQ-C30 (European 
Organization for Research 
and Treatment Quality of 
Life Core questionnaire)  
No 5 functioning scales: physical; role; 
emotional; social; cognitive 
3 symptom scales: pain; fatigue; nausea & 
vomiting 
6 items: dyspnoea; sleep; appetite; diarrhoea; 
constipation; financial impact 
8 point 
Function: higher 
scores = better 
function 
Symptom: higher 
scores = more 
problems  
No Yes 
QoL-CS (Quality of Life 
Cancer Survivors) 
Yes 4 domains: physical well-being (8 items), 
psychological well-being (18 items), social 
well-being (8 items), spiritual/existential 
well-being (7 items) 
10 point 
Higher scores = 
best QoL 
No Yes 
SUNS (Survivors’ Unmet 
Needs Survey) 
Yes 5 domains: informational needs (8 items), 
financial concerns (11 items), access & 
continuity of care (22 items), relationships (15 
items), emotional health (33 items) 
5 point 
Higher scores = 
greater need 
Yes Yes 
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The generic cancer tools: CAncer Rehabilitation Evaluation System Short 
Form (CARES-SF); and European Organization for Research and Treatment 
Quality of Life Core questionnaire (EORTC QLQ-C30) were not survivor-
specific and no data in relation to previous use in any haematology survivor 
cohorts was described (Hjermstad et al., 2003). Reliability scores and validity 
information was variable in the detail reported. Similarly, the three cancer 
survivor-specific tools: Cancer Survivors Unmet Needs Survey (CaSUN); 
Quality of Life Cancer Survivors (QoL-CS); and Survivors’ Unmet Needs 
Survey (SUNS) provided variable reliability and validity data (Arden-Close 
et al., 2011; Hall, Campbell, et al., 2013; Lobb et al., 2009; Zebrack, 2000). 
 
All studies documented tool domains and scoring scales. Only two tools 
addressed both informational and practical needs (CaSUN, SUNS) (Hall, 
Campbell, et al., 2013; Lobb et al., 2009). The SUNS is the only tool developed 
using a mixed cohort that included haematological cancer survivors (Hall, 
Campbell, et al., 2013). All reviewed articles reported the clinical usefulness 
of the tools to the haematological cohort studied.  
 
The majority of studies (n=5) assessed the informational needs of survivors 
(Table 2.3.2). Of the survivor-specific tools used to assess informational 
needs, the CaSUN (Lobb et al., 2009) includes an explicit information domain 
with response items such as: “I need up to date information”; “I need 
understandable information”. It is assumed that follow-up is required for 
those patients who score highly for such items. The SUNS tool similarly 
includes an informational domain with questions targeted to “Finding 
information …” or “Dealing with fears … or feelings…”(Hall, Campbell, et 
al., 2013). In general, a high score allows the assessor to identify areas of 
need. However, neither tool explicitly asks if the survivor would like help 
with their issue or concern.   
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Arden-Close et al. (2011) measured gender-related informational needs using 
the cancer survivor-specific tool QoL-CS. Although this article made gender-
specific recommendations, it did not provide insight into what assessment 
tools best identify gender differences. Friedman et al. (2010) developed a 
questionnaire that focused on information that should be included in 
survivorship care plans such as: specific information about cancer 
recurrence; nutrition and exercise; screening plan; information for family 
members. This questionnaire both identified needs and enquired whether 
respondents wanted information. On the other hand, the CARES-SF 
(Hjermstad et al., 2003) does enquire if patients would like assistance with 
their concerns. However, it does not explicitly identify survivor 
informational needs. In contrast, Parry et al. (2012) used a non-validated 
survey that identified informational and practical needs of haematology 
survivors examining if participants received the help they required.  
 
The definition of `practical need’ differed between authors, making 
identification of suitable tools somewhat difficult. The QoL-CS tool (Arden-
Close et al., 2011; Zebrack, 2000) examined practical concerns including: 
employment; sexuality; financial burden and fatigue. Unlike the other cancer 
survivor-specific tools, a higher score indicated a better quality of life 
outcome. It was unclear if the tool recommended users to follow-up concerns 
that generated low scores. Similarly, the EORTC QLQ-C30 assessed the 
practical need of financial concerns but focused on more treatment related 
concerns that are unlikely in the survivorship phase (Hjermstad et al., 2003). 
Needs relating to fatigue management, fertility, sexuality, nutrition, exercise, 
insurance, finances and employment were explored by the majority of tools 
or investigator-derived questionnaires to varying degrees. The late effects of 
treatment were reported as both an informational need and a practical area 
where a plan for screening should occur (Arden-Close et al., 2011; Friedman 
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et al., 2010). Likewise, fear of recurrence issues were similarly reported 
(Friedman et al., 2010; Hall, Campbell, et al., 2013; Hjermstad et al., 2003; 
Lobb et al., 2009; Zebrack, 2000).  
 
Although a variety of tools were used, there was consensus regarding the 
most prevalent leukaemia and lymphoma survivor informational and 
practical needs. The commonly reported informational needs were: treatment 
late effects; cancer recurrence including fear of recurrence; care coordination; 
and information on available resources (Friedman et al., 2010; Hall, 
Campbell, et al., 2013; Hjermstad et al., 2003; Lobb et al., 2009; Zebrack, 2000). 
The most consistently identified practical needs were: fatigue management; 
employment; financial; insurance; family; and sexuality (Hall, Campbell, et 
al., 2013; Hjermstad et al., 2003; Lobb et al., 2009; Parry et al., 2012; Zebrack, 
2000). Arden-Close et al. (2011) addressed potential differences in gender and 
found men wanted more information however were often unable to receive 
this from the medical consultation. Women, on the other hand, were able to 
discuss the topics they wanted. Other studies found women had higher 
unmet needs related to family issues (Hall, Campbell, et al., 2013; Lobb et al., 
2009; Parry et al., 2012); similarly younger survivors had higher unmet 
informational and practical needs (Hall, Campbell, et al., 2013; Lobb et al., 
2009). Conversely disease and treatment type did not identify those with 
greater unmet needs. 
 
Discussion 
Providing information across the cancer continuum is one of the most 
important aspects of care, yet it is a frequently reported unmet need 
especially in the survivorship phase (Husson et al., 2013). Leukaemia and 
lymphoma patients differ from other cancer patients in the considerable 
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variability between their cancer types and the range of treatments affecting 
many aspects of their lives (Hall, Lynagh, et al., 2013). With improving 
survival rates, those diagnosed younger (18–45 years) can now expect to live 
longer, raising additional concerns and unmet needs (Arden-Close et al., 
2011). Information provision must be individualised and tailored to specific 
patients’ needs (Husson et al., 2013; Parry et al., 2012). As highlighted by 
Friedman et al. (2010) survivorship care plans need to account for differing 
informational and practical needs of survivors, primary care providers and 
haematologists. 
 
Generic cancer tools include items related to diagnosis and treatment issues, 
which are not necessarily specific to the survivorship phase. This review has 
shown that survivor-specific tools can be used to assess unmet needs of 
leukaemia and lymphoma participants in the survivorship phase. Therefore, 
tools specific to the survivorship phase would be more appropriate to assess 
for unmet needs and concerns in this cohort. 
 
Arden-Close et al. (2011) and Aziz (2007) have argued that survivors should 
be afforded the opportunity to obtain support and access resources earlier in 
the survivorship continuum. They assert survivors  need information about 
immediate and long-term impacts of the cancer, together with practical needs 
related to fatigue, exercise, nutrition, fertility, sexuality, insurance, finances, 
employment and late effects. Leukaemia and lymphoma survivors may also 
want resources to address healthy lifestyle choices (Arden-Close et al., 2011; 
Boyes, Girgis, D’Este, & Zucca, 2012) or support to deal with the 
psychosocial aspects such as relationships, anxiety and fear of recurrence, 
reported in many studies as the highest unmet needs (Hall, Campbell, et al., 
2013; Hjermstad et al., 2003; Lobb et al., 2009).  
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We acknowledge a number of limitations. There was variation in tools used 
across a wide range of survivors from the early survivorship phases (under 
two years) (Hall, Campbell, et al., 2013; Hjermstad et al., 2003; Lobb et al., 
2009; Parry et al., 2012) through to 12 years post diagnosis (Friedman et al., 
2010; Zebrack, 2000). This made comparative generalisations of informational 
and practical needs difficult and enabled only tentative conclusions. Our 
findings are limited to comparing those areas surveyed with the assessment 
tools. As such, the review could not determine a broader range of supportive 
care needs for all haematological cancer survivors. Further, the relatively low 
response rate reported for some studies reduces the likelihood of the sample 
being representative of leukaemia and/or lymphoma survivor populations, 
and sampling bias could result in distorted conclusions. Extracting the 
psychometric properties of the tools was hampered by a lack of detailed data 
to support validity and reliability (Hall, Campbell, et al., 2013; Hjermstad et 
al., 2003; Lobb et al., 2009). Finally, an inherent bias in interpretation might 
be considered. 
 
Notwithstanding the limitations, this review identified a consensus on the 
most prevalent informational and practical needs of leukaemia and 
lymphoma survivors. This important finding can assist haematology cancer 
nurses when making decisions regarding the most appropriate tools to use 
and may assist in the development of haematology cancer survivor-specific 
tools that measure: perceived informational and practical needs; the extent to 
which needs are being met; and the survivors’ need for support across all 
supportive care domains. In this way nurses are ideally positioned to 
provide individualised information and resources to these survivors and 
further this area of research. 
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Conclusion  
There is a paucity of studies related to leukaemia and lymphoma survivors 
and specific validated tools that can be used to identify and measure the 
informational and practical needs of this cohort. While cancer survivor-
specific needs assessment tools do exist and have been used with more 
common cancer groups, further research is required to determine their 
relevance and applicability to leukaemia and lymphoma survivors to ensure 
specific concerns are heard and addressed via appropriate support and 
information. Equally, generating psychometric data will ensure valid and 
reliable tools are utilised. As the only tool developed that included a 
haematology cohort, the use of the SUNS tool in further leukaemia and 
lymphoma survivor populations will allow a greater body of knowledge to 
be developed.  
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Literature Review Update 
The same search criteria, terms and databases were reviewed to ascertain 
recent developments and published research on needs assessment measures 
used with lymphoma survivors. The search period was 2014 to January 2018. 
Results found 30 abstracts worthy of further assessment, however no articles 
met the original inclusion criteria.  
 
Of these, six articles did not include lymphoma survivor cohorts (Burg et al., 
2015; Czerw, Marek, & Deptała, 2015; de Jong, Tamminga, de Boer, & Frings-
Dresen, 2016; Faller et al., 2016; Smith, Klassen, Coa, & Hannum, 2016) or the 
lymphoma survivor cohort was less than 50% (Klassen et al., 2017). 
 
Seventeen articles did not discuss needs assessment measures and reported 
health care provider perceptions (Coa et al., 2015; Daniel, Emmons, Fasciano, 
Fuemmeler, & Demark-Wahnefried, 2015; Karvinen, Bruner, & Truant, 2015; 
Spector et al., 2015) or measured only one informational or practical need, 
such as fear of recurrence (van de Wal et al., 2016), distress (Hall et al., 2016; 
Magyari et al., 2017; Mojs et al., 2017; Oerlemans et al., 2014; Raphael, Frey, & 
Gott, 2017), fatigue (Daniels et al., 2014; de Lima et al., 2017; Kreissl et al., 
2016; Linendoll et al., 2016), cognition impairment (Krolak et al., 2017; 
Zimmer et al., 2015) or employment (Arboe et al., 2017). Five articles assessed 
the impact of cancer on the survivor rather than their practical and 
informational unmet needs (Bryant et al., 2015; Drost et al., 2016; Jones et al., 
2015; Sarker et al., 2017; Smith, Samsa, Ganz, & Zimmerman, 2014). 
 
Two articles included information from studies that had been identified and 
reviewed in the systematic review article of this thesis (Hall, D'Este, Tzelepis, 
Lynagh, & Sanson-Fisher, 2014; Jiao et al., 2017). Hall, D'Este, et al. (2014) 
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undertook a sub-analysis of the participants who had indicated high or very 
high unmet needs in the SUNS. Jiao et al. (2017) undertook a rapid review of 
needs assessment measures for post-treatment survivors. The authors 
identified six studies that described five needs assessment measures. Two 
measures were specific to survivors of a childhood cancer, and the three 
other measures had been used in studies previously examined in this review.  
 
Chapter Summary 
Published literature related to models of post-treatment follow-up cancer 
care and cancer survivorship care was reviewed and discussed in the 
published model of cancer survivorship care review and updated review. 
There was a lack of robust evidence to guide development of evidence-based 
survivorship models of care including recommendations for the health 
professional best placed to lead and/or deliver this care. Therefore, as the 
researcher is a nurse, it was important to develop and test the viability of a 
nurse-led survivorship model of care. 
 
Similarly, the second integrative literature review revealed a lack of evidence 
in the published literature regarding the use of SCPTS with lymphoma 
survivors, and the methods and frameworks that could be used to develop 
and deliver these tools. Further, there was a lack of personalisation of the 
SCPTS to the patient. Consequently, this prompted the researcher to develop 
and test a unique lymphoma-specific SCPTS for this study, the detail of 
which is outlined in Chapter Four. 
 
There is still a need for strong research that tests the appropriateness of 
currently validated cancer survivorship-specific measures that will best 
assess unmet needs in lymphoma survivor cohorts. The final systematic 
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literature review assessed validated needs assessment measures that had 
been developed and/or tested with lymphoma survivors. This work resulted 
in the Short-Form Survivor Unmet Needs Survey (SF-SUNS) being chosen as 
the most appropriate measure for this study. Further details are outlined in 
Chapter Four. 
 
In summary, at the completion of these reviews, clear gaps were evident in 
some areas: the most suitable model of care for lymphoma survivors; the 
most appropriate SCPTS to use with this cohort; and the best measures to 
capture lymphoma survivorship-specific unmet needs. The outcomes from 
these reviews supported the need for high-quality research such as the 
pragmatic randomised controlled trial used for this thesis. The following 
chapter outlines the conceptual framework that guided this thesis. 
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Chapter Three — Conceptual Framework 
 
 
 
 
 
 
 
 
 
 
“Being able to put my thoughts and feelings into words, being able to just say it 
out loud to someone was quite therapeutic and then discussing some solutions 
was really really helpful” Female_HL 
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3.0 Conceptual Framework 
The purpose of this chapter is to outline the conceptual framework that 
guided the development and/or pilot testing of essential elements of the 
nurse-led lymphoma survivorship model of care. These included the unique 
survivorship care plan and treatment summary, choice of assessment 
measures and development of a resource pack. These essential elements will 
be further detailed in Chapter Four. Included in the discussion of the 
conceptual framework is a description of motivational interviewing, a 
technique that was used with participants randomised to the intervention of 
the pragmatic RCT. 
 
Conceptual Framework 
This study is guided by Bandura’s theory of self-efficacy; defined as one’s 
ability to succeed in a specific situation or achieve a specified skill, such as 
making a difficult decision or, within the context of this study, 
communicating with a health care professional (Bandura, 1977). Within the 
area of health, self-efficacy is identified as an affirmative personal resource 
that can contribute to managing one’s health generally and how an 
individual manages a crisis (Schumacher, Sauerland, Silling, Berdel, & 
Stelljes, 2014). In this instance a lymphoma diagnosis, treatment and life 
thereafter. An individual’s sense of self-efficacy can have a major influence 
on how challenges, tasks and goals are approached (Bandura, 1977). This is 
the principal concept underpinning self-management education, which 
teaches patients to identify their problems and provides skills in decision 
making and developing an appropriate action plan (Bodenheimer, Lorig, 
Holman, & Grumbach, 2002; Philip, Merluzzi, Zhang, & Heitzmann, 2013).  
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Empowering patients to become responsible for the management of their 
health and well-being can contribute to the influence and control patients 
(self-efficacy) ultimately have over their health. Positive effects of 
empowerment in patients who are managing the consequences of a cancer 
diagnosis and treatment can lead to improved quality of life and survival 
through improved health outcomes including physical and emotional well-
being (Bodenheimer et al., 2002; Foster et al., 2015; Kuijpers, Groen, & 
Aaronson, 2013). It has been reported that encouraging self-efficacy and 
assisting patients to become self-empowered may help lymphoma survivors 
adjust to the challenges of their lives during and after treatment and assist in 
the resumption of “normal” life activities (Schumacher et al., 2014). 
 
Notwithstanding the positive influences of individual or self-empowerment 
and self-efficacy, previous life experiences held by the patient can impact 
upon how he/she will cope and function from diagnosis, throughout 
treatment and in the post-treatment phase of life (Richardson, 2002). 
Perceived self-efficacy has a direct influence on the choices that individuals 
make and how they cope once they have initiated a course of action 
(Bandura, 1977). Self-efficacy, as mentioned previously, is task-specific and 
therefore an individual can learn in a specific setting, regardless of previous 
failure in other contexts. Similarly, motivation can be influenced by self-
efficacy. Individuals with high self-efficacy are more likely to actively persist 
and complete a task. Individuals with low self-efficacy may sometimes be 
motivated to learn more about a subject or situation they are unfamiliar with. 
However it may also lead to a state of learned helplessness and lack of 
motivation (Bandura, 1977). Consequences of inadequate support may 
include lower levels of self-management, reduced utilisation of appropriate 
support services and worsening health (Foster et al., 2015; Hoffman, Lent, & 
Raque-Bogdan, 2013). It is therefore imperative that a patient’s life 
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experiences be explored and considered when developing a model of 
survivorship care in order to provide an appropriate level of support that is 
tailored to the individual. 
 
Working with individuals (i.e. cancer survivors in the context of this study) 
to develop a personalised patient action plan (i.e. survivorship care plan) that 
includes tailored healthy lifestyle resources will likely result in a reduction in 
the perceived need for support from the health care system by patients 
(Bodenheimer et al., 2002; Foster & Fenlon, 2011). Maintaining patients’ 
motivation to enact healthy lifestyle changes and “follow through” is 
important particularly for those individuals who may have lower levels of 
empowerment and/or self-efficacy (Foster et al., 2015), since it is known that 
people who give up a task before completion will retain their self-debilitating 
and/or limiting expectations (Bandura, 1977).  
 
In keeping with the concepts underpinning self-empowerment and self-
efficacy, it was recognised that a nurse-led model of survivorship care 
developed specifically for this study needed to incorporate self-reported 
assessment measures to accurately identify an individual survivor’s ability to 
self-manage his/her health and well-being (Philip et al., 2013). Further, it was 
anticipated there would be variations across domains measured (i.e. 
survivorship needs; depression, anxiety and stress; mental adjustment to 
cancer; self-empowerment). Patient self-assessment can facilitate targeted 
support that will allow lymphoma survivors to improve self-efficacy and 
management of the effects of a lymphoma diagnosis and treatment (Foster et 
al., 2015). The conceptual framework guiding this study’s nurse-led 
lymphoma survivorship model of care is outlined in Figure 3.1.1. 
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Motivational interviewing was explored as a credible technique to use in the 
nurse-led lymphoma survivorship model of care. This form of interviewing 
is defined as a directive, patient-centred counselling style for prompting 
behaviour change by facilitating patients to explore and resolve uncertainty 
(Litt, 2006). The researcher was guided by the four principles of motivational 
interviewing when developing the study intervention: resisting the urge to 
fix participant problems; gaining understanding of the participant’s 
motivations; listening with empathy; and empowering the participant to 
have hope for the future and be positive they could make changes if desired 
(Rollnick, Miller, & Butler, 2008). 
 
To assist intervention participants with the process of making changes to 
unhealthy lifestyle behaviours such as cigarette smoking and excessive 
alcohol consumption, the researcher customised a motivational chart based 
on work by Rollnick et al. (2008) to provide to these participants (Appendix 
J.2 ). During a motivational interview, questions can be posed to the 
interviewee as he/she works with the researcher through the process of 
change to help guide thoughts and motivations. Questions such as: ‘why do  
you want to make a change?’; ‘what important benefits do you anticipate will 
come from the change?’; ‘how will you make the change?’; ‘what are you 
already doing towards making the change?  
 
Once a motivational chart has been completed, the role of the interviewer is 
to summarise the benefits and barriers posed by the interviewee and reflect 
all the positive change behaviours the interviewee has committed to 
undertake. Interviewees who are not ready to make changes at the first 
nurse-led lymphoma survivorship clinic (NLSC) appointment will be 
encouraged to address these issues at subsequent NLSC appointments. The 
success of this approach requires interviewees to feel in control of these 
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changes since permanent behaviour changes can only be made by 
individuals who are motivated (Rollnick et al., 2008). Bandura’s theory of 
self-efficacy (Bandura, 1977) is also a principal concept in self-management 
education, which teaches patients to identify their problems and provides 
skills in decision making and developing an appropriate action plan 
(Bodenheimer et al., 2002). Empowering patients to become more responsible 
for the management of their health and well-being can contribute to the 
influence and control patients have over their health which has the 
advantage of improving quality of life (Bodenheimer et al., 2002; Kuijpers et 
al., 2013). It is anticipated that increasing a patient’s empowerment and 
providing healthy lifestyle resources will result in a reduction in the 
perceived need for support from the health care system by patients 
(Bodenheimer et al., 2002). 
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5Figure 3.1.1. Conceptual diagram of the nurse-led lymphoma survivorship model of care 
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Chapter Summary 
In summary, the nurse-led model of survivorship care utilised a conceptual 
model based on self-efficacy and the development of a self-management plan 
with actions to assist lymphoma survivors to recover their health and well-
being and to engage in healthy lifestyle behaviours.  
 
Development of a survivor-centred SCPTS, the identification of assessment 
measures that would allow survivors to self-report issues and concerns and 
the assembly of appropriate and targeted resources facilitated lymphoma 
survivors to transition into the survivorship phase with support. An 
important element of the conceptual framework of this model of care was to 
understand the life experiences and factors that were important to the 
individual before they were diagnosed with lymphoma and how these 
experiences and factors may have influenced their motivation for self-
efficacy and empowerment. 
 
The following chapter of this thesis details the development of the essential 
elements of the survivorship model of care which were used in the pragmatic 
RCT.  
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Chapter Four — Phase Two 
 
 
 
 
 
 
 
 
 
 
“Because you do feel a bit sometimes like you are just treated like a number. 
Having things individualised helped a lot” Female_NHL 
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4.0 Intervention Development 
The purpose of this chapter is to describe in detail the processes related to the 
development of a nurse-led lymphoma survivorship model of care. While the 
following information has been presented using separate headings for 
clarity, it does not necessarily reflect that development occurred linearly. 
Development of some components occurred concurrently where necessary. 
The rationale for concurrent development was to progress the proposed 
research as expeditiously as possible to meet candidacy and Human 
Research Ethics Committee (HREC) submission requirements promptly since 
the estimated time frames required for approval were somewhat lengthy.  
 
This chapter begins with a brief section that describes the haematology 
survivorship research advisory committee that was initiated to guide the 
nurse-led lymphoma survivorship model of care. The model of care 
comprised the following essential components: development of a lymphoma 
survivorship care plan and treatment summary (SCPTS); assessment 
measures; and development of a resource pack. These components are 
described briefly in Chapter Five of this thesis, with more detail given in this 
chapter to provide clarity on development. Likewise, the final section of the 
chapter provides detail on the development of the GP evaluation (Phase 
Four), which is briefly discussed in Chapter Five. 
 
Haematology Survivorship Research Advisory Committee 
(HSRAC) 
This committee was convened in 2014, at the beginning of the research 
process and comprised academic and clinical health professionals (doctors, 
nurses and psychologists), a community support group executive and two 
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consumers who met monthly at the study site for the duration of the study. 
The committee was guided by Terms of Reference, with the primary aim to 
provide insight, feedback and guidance on the development of the 
intervention components for the pragmatic RCT, including 
inclusion/exclusion criteria, timeframes and recruitment strategies. The 
opinions of all members were valued, especially those of the consumers who 
had a unique insight into lymphoma post-treatment follow-up at the study 
site. 
 
Survivorship Care Plan and Treatment Summary 
The unique lymphoma-specific survivorship care plan and treatment 
summary (SCPTS ) developed for this RCT is described in Chapter Five, in 
the form of a published protocol article (Taylor, Joske, Bulsara, Bulsara, & 
Monterosso, 2016). However, detail is provided in this chapter regarding 
how the SCPTS was created. 
 
At the completion of the integrative review on SCPTS, no Australian or 
international SCPTS were perceived as appropriate for use in the study 
centre. Therefore, an SCPTS was developed that was more patient-centred 
and unique to this study cohort. The first full draft comprised two pages of 
diagnosis and treatment information including chemotherapy drug names 
and information on administration, dosing, protocol changes and potential 
long-term and late effects which included recommended follow-up by the 
GP. This was followed by a page that allowed lymphoma survivors an 
opportunity to document their health concerns and health goals. Two further 
pages listed general health screening and healthy lifestyle behaviour 
information. This draft was presented to the SCGH Haematology 
Department for review prior to content validation. The draft SCPTS was sent 
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to health professionals including GPs and consumers to ascertain apparent 
internal consistency, clarity and reliability. Appendix F.2 contains the 
validation document that was sent with the SCPTS. All reviewers received 
the same document to review.  
 
Each item was assessed for: 
 Content clarity—whether each item was clearly defined (Yes/No) 
 Apparent internal consistency  
o a) whether each item belonged in the SCPTS (Yes/No)  
o b) the general fit with other items (Yes/No)  
 Content validity—level of relevance of each item 
o 4-point Likert-type rating scale (1=not relevant to 4=highly 
relevant). 
 
The content validity index (CVI) (Polit & Beck, 2006) score was generated for 
each item. “Yes” scores (content, clarity and apparent internal consistency) 
and scores of 3 or 4 (content validity) were added. The intent of the 
evaluation was to remove low scoring items and to assess for agreement of 
greater than 80% per item. A comments section was provided for each item 
to gain further feedback. 
 
Six consumers completed an evaluation. Results indicated consumers were 
unsure what late effects meant or what was meant by extra-nodal disease. 
There was however, overwhelming consensus on the clarity (CVI: .98), the 
apparent internal consistency (CVI: 100) and relevancy (CVI: .95) of the 
items. Consumer comments related to the meaning of late effects and made 
suggestions on the wording of elements of the SCPTS, i.e. ‘could it say main 
aims, not goals?’. Two consumers felt the general lifestyle information 
should already be known to patients. 
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Six clinicians completed the evaluation; these included haematology nurses 
(n=4) and GPs (n=2). Consensus was achieved on clarity (CVI: .99). Apparent 
internal consistency was slightly lower (CVI: .91), this result was evident 
from GPs who did not find all the treatment summary information was 
required, although the result of whether each item generally belonged within 
the SCPTS was high (CVI of .99). Relevancy of items generated a low result 
(CVI: .84). This was again attributed to the GPs who indicated all the detailed 
drug information and disease information was not relevant. Comments 
reflected that a long treatment summary with information thought more 
relevant to the haematologist should be removed. One GP commented that it 
would be inappropriate to ask a patient what their main health concerns 
would be, this should be specified by the doctor.  
 
One of the evaluated GPs sent the document to other GPs (n=6) for comment. 
Feedback was emailed to the researcher; however, no evaluation forms were 
completed. It was unclear what information had been provided on the intent 
of the SCPTS. All feedback was considered, however not all comments were 
relevant. Suggestions for inclusion on the SCPTS that were not deemed 
relevant by the HSRAC were: listing all past medical history; all allergies and 
adverse reactions not related to treatment; travel immunisation schedules; 
information on sexually transmitted diseases; contraception advice; 
stratification of recurrence risk; male and female versions; and doctor-
derived concerns not patient-derived. Comments that were relevant 
included: reducing the treatment summary section and removing the 
chemotherapy drug lists; giving the general health information to the 
survivor only (GPs indicated they know this information); and moving the 
potential late effects section to after the treatment summary section. 
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A section for haematologists to sign the TS and late effects section was added 
as research had indicated nurse-led SCPTS might not be valued by GPs (Mor 
Shalom et al., 2011). Once consensus was reached from HSRAC on changes 
to the treatment section and the wording of a few items, the final document 
was a TS (half a page in length) and SCP (one and a half pages in length), 
with the general health information in a two-page document for survivors 
(Appendix F.1). The final SCPTS was reviewed and approved by the 
haematologists at the study site for provision to patients recruited to the trial.  
 
A search of the literature was undertaken for potential late effects that can 
affect lymphoma survivors. Two documents in chart form were created for 
NHL and HL late effects, including recommendations for follow-up. These 
documents were circulated to the SCGH haematologists and radiation 
oncologists for review and comment. Once approved, they were used when 
completing potential late effect information on the SCPTS.  
 
Measures 
At the completion of the needs assessment systematic review (Taylor & 
Monterosso, 2016) and in consultation with the HSRAC, four assessment 
measures were chosen for the pragmatic RCT. These measures were required 
to ascertain: survivor-specific informational, practical and emotional needs; 
anxiety, depression and stress; mental adjustment to cancer; and patient 
empowerment. Copies of the assessment measures are located in Appendix 
E.2 to E.5. 
 
The needs assessment systematic review (Chapter 2.3) identified the 
importance of a survivor-specific measure that had been developed with a 
cohort of survivors including lymphoma survivors. The measure chosen was 
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the Short-Form Survivor Unmet Needs Survey (SF-SUNS)(Campbell et al., 2014). 
Further information on this measure is found throughout the thesis and 
particularly in Chapter 6.3. 
 
The prevalence of the symptoms of distress are often overlooked in 
survivorship research (Holland et al., 2010). Therefore, it was imperative that 
a measure be found that would allow participants an opportunity to self-
report items that encompass distress such as depression, anxiety and stress. 
Thus, the Depression Anxiety Stress Scale (DASS21)(Antony, Bieling, Cox, 
Enns, & Swinson, 1998; Lovibond & Lovibond, 1995) was chosen for this 
study. Distress has been defined as a multifactorial disagreeable emotional 
experience that may interfere with the ability to cope effectively with cancer, 
and can be psychological, social and/or spiritual in nature (Holland et al., 
2010). To improve the identification and management of distress, screening 
in survivors is essential as many aspects of distress, such as fear of cancer 
recurrence, uncertainty about the future, loss of health, anger and 
preoccupation with thoughts around cancer may continue after treatment 
completion (McCarter et al., 2018). Patient outcomes are improved when 
distress screening is implemented and interventions provided (Mitchell, 
2013), however many research studies that report a lack of benefit with 
screening are more likely due to a lack of appropriate follow-up for those 
identified with distress (Meijer et al., 2013). During this study, as items of 
distress were identified, the appropriate support and resources were offered 
to the intervention group participants during the study period. For those in 
the control group, support was offered after they had completed all elements 
of the study. 
 
Leading on from the selection of the DASS21 to measure components of 
distress, an assessment measure that has items that are similarly related to 
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aspects of distress and coping was considered appropriate to gauge a wider 
view on patient-reported concerns and issues in this area. Therefore the Mini 
Mental Adjustment to Cancer Scale (Mini-MAC) (Watson, Law, & dos Santos, 
1994) was selected.  
 
The fourth measure chosen was the Patient Empowerment Scale (PES) (Bulsara 
& Styles, 2013) as it was important to measure the self-reported level of a 
patient’s coping ability and self-efficacy in managing their illness and 
making decisions about support strategies. Empowerment can be seen as a 
proactive strategy in acknowledging what an individual feels they can 
control, and equally importantly, what lies outside of their control (Bulsara & 
Styles, 2013). This was meaningful for the study as the SCPTS involved 
participant-derived aspects. Consequently, it was important to assess the 
level of a participant’s empowerment, especially when they would be 
encouraged to seek out support and information for themselves as required.  
 
Assessment measures would be posted to those randomised to the control 
group after baseline; therefore, a letter was created to remind them about the 
study and to encourage them to complete and return the assessment 
measures. (Appendix G). 
 
Resource Pack 
A resource pack was developed after consideration of the evidence (reported 
haematology survivor unmet needs and concerns) from the integrative 
reviews undertaken in Phase One. The information assembled for 
dissemination to the intervention group participants needed to address 
anticipated participant-identified unmet needs, likely post-treatment 
physical and emotional concerns, and to encourage optimal participant 
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involvement in healthy lifestyle behaviours. Information currently in use by 
established cancer support sources such as the Cancer Council Australia and 
the various state-based Cancer Council websites were assessed. Standardised 
Australian Government information (as referenced below) was likewise 
obtained. Where information was insufficient or not targeted to the 
lymphoma cohort, the researcher adapted the information using a variety of 
credible cancer sources including Australian, North American and United 
Kingdom oncology websites.  
 
All participants were offered the following booklets and information sheets: 
 Living Well After Cancer (Bell & Fagan, 2015) 
 Exercise for People Living with Cancer (Bruce, 2016) 
 New insurance policies (Cancer Council Western Australia, 2016) 
 Australian Guide to Healthy Eating (Australian Government, 2015) 
 Coping with fear of recurrence (American Society of Clinical 
Oncology, 2015) 
 Coping with cancer fatigue (Cancer Council Victoria, 2015) 
 Coping with memory and concentration impairment (developed by 
the researcher) 
 Cancer survivor exercise program (Edith Cowan University, 2015) 
 Cancer Council WA “Life Now” information and dates (Cancer 
Council Western Australia, 2015–2017) 
o A programme of supportive care activities such as exercise, 
yoga, meditation for any person who has or had cancer 
 
Targeted information was offered based on responses to the baseline 
measures or requested from the participant at the first NLSC appointment. 
This could include the following booklets and/or information sheets: 
 “Cancer and Your Finances” (Bruce, 2015) 
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 “Sexuality, Intimacy and Cancer” (Bruce, 2016) 
 Rekindle study information, University of Sydney, Australia 
o This was a study to test an online resource to promote sexual 
well-being for patients and partners. Once recruitment closed 
in 2016 this information was no longer offered. 
 Cancer Council Pro Bono programs (legal, financial and workplace 
advisory) (Cancer Council Australia, 2015) 
 Information on insurance and countries with reciprocal health care 
agreements with Australia (developed by the researcher) 
 Quit smoking (Cancer Council, 2016) 
 Motivational chart (developed by the researcher) 
 Mental Health Plan information (Australian Government, 2015) 
 Canteen (CanTeen, 2015) 
o A support group to help young people (12–25 years) cope with 
cancer in their family, or their own cancer 
 Centrelink (Australian Government, 2015) 
o An Australian Government department delivering social and 
health payments and services.  
 
A checklist was created of resources and information given to the 
intervention participants throughout the study period (Appendix J.1).  
 
General Practitioner (GP) Evaluation 
The completed SCPTS was given to all intervention participants and sent to 
GPs. Participants were encouraged to share this document with future health 
professionals and discuss with their GP during the trial. It was important 
therefore to gain an understanding of the thoughts and perceptions of GPs 
who received the SCPTS. This was to gauge the use and usefulness of the 
document.   
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An evaluation based on the proposed SCPTS was developed. Advice on the 
document was sought from the GP on the HSRAC to make the evaluation 
targeted and succinct and to ensure that the cover letters to accompany the 
evaluation and SCPTS similarly were clear and concise. The final evaluation 
was one and a half pages in length and was checked by a GP researcher from 
the University of Melbourne, not involved in the research. His comments 
indicated the size and content was appropriate to gain the information 
required.  
 
The evaluation collected a small amount of demographic information: years 
working as a GP; gender; and if the intervention participant had been seen in 
the last six months. The first section of the evaluation comprised ‘yes/no/not 
applicable’ questions related to the SCPTS, receipt and discussions (7 items). 
The next section rated elements of the SCPTS and used a Likert-type scale: 
1=very poor; 2=poor; 3=adequate; 4=good; 5=very good (4 items). Five open 
questions followed and ascertained if: further information was required; 
information did not belong on the SCPTS; any general comments; further 
haematology education required; and the preferred format for education. 
The final evaluation form is found in Appendix H. 
 
The GP cover letters were each one page in length. The introductory cover 
letter was attached to the initial posting of the SCPTS after the intervention 
participant had completed the first NLSC intervention appointment. The 
content gave a brief overview of their patient’s involvement in the RCT and 
the intent of the SCPTS. Any urgent clinic concerns were directed to the 
haematology department at the study site (SCGH). As previously described 
GP input had indicated a listing of chemotherapy drug names was not 
required, therefore a link to EviQ (an Australian evidence-based cancer 
treatment protocols and information website for health professionals) with 
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username and password were included if GPs wanted to look drug 
information up for themselves. The subsequent cover letter was attached 
with the evaluation and a further copy of the SCPTS to remind the GP their 
patient had participated in an RCT and to ask if they would complete an 
evaluation. Both cover letters are found in Appendix H. 
 
Chapter Summary 
In summary, a number of important elements were developed that guided 
the thesis and the components that would be tested in the pragmatic RCT. A 
unique lymphoma-specific SCPTS was developed. However, it was 
important to ensure the content validity of the SCPTS items prior to use in 
the pragmatic RCT. Likewise, it was important the haematologists were 
confident that evidence-based late effects information and recommendations 
were going to be given to their patients. In addition, this chapter discussed 
the assessment measures chosen and the resource pack that was developed. 
Furthermore, the creation of an evaluation of the SCPTS by GPs has been 
detailed in this chapter as only condensed detail was provided in Chapter 
Five, methodology and Chapter Six, pragmatic RCT results.  
 
The following methodology chapter of this thesis is in the format of the 
protocol journal article that was published in the British Medical Journal Open, 
and which provides a complete overview of the pragmatic RCT. 
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Chapter Five — Methodology 
 
 
 
 
 
 
 
 
 
 
“A bit more confidence to go ahead in the future” Female_HL  
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5.0 Protocol and Methods 
The protocol and methods used to conduct Phase Three and Four of this 
thesis are represented by the manuscript published in the British Journal of 
Medicine Open access in 2016. This manuscript has been reproduced here, and 
the complete PDF version is in Appendix A.4. A detailed discussion was 
limited by the journal word count requirement. Therefore, further details are 
in Chapter Four. 
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Protocol for Care After Lymphoma (CALy) Trial: A Phase II 
Pilot Randomised Controlled Trial of a Lymphoma Nurse-led 
Model of Survivorship Care. 
 
Abstract 
Introduction: Lymphoma is the sixth most common cancer diagnosed in 
Australia and internationally. Due to the aggressive nature of the disease and 
intensity of treatment, survivors face long-term effects that impact on quality 
of life. Current models of follow-up post-treatment fail to address these 
complex issues. Given that 74% of lymphoma cancer patients now survive 
five years beyond diagnosis and treatment, it is important to address this gap 
in care.  
 
Aim: To determine self-reported informational and practical needs, anxiety, 
depression, stress, coping and empowerment at baseline, three and six 
months. 
 
Methods and Analysis: A pilot randomised controlled trial will test the effect 
of a nurse-led lymphoma survivorship clinic compared with usual post-
treatment care at a large tertiary cancer centre in Western Australia. The 
intervention will comprise three face-to-face appointments with delivery of 
tailored resources, a survivorship care plan and treatment summary (SCPTS). 
The SCPTS will be given to the participant and general practitioner. 
Intervention participants will be interviewed at completion to explore the 
perceived value of the intervention components and preferred dose. 
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An evaluation developed for GPs will assess receipt and use of SCPTS. The 
primary intent of analysis will be to address the feasibility of a larger trial 
and requisite effect and sample size. 
 
Ethics and Dissemination: Ethics approval has been granted by the 
University of Notre Dame Australia and Sir Charles Gairdner Hospital in 
Western Australia. Peer-reviewed publications and conference presentations 
will report the results of this phase II trial.  
 
Trial Registration: Australian New Zealand Clinical Trial Registry 
ANZCTRN12615000530527. 
 
Introduction 
Lymphoma is a general term for over 20 blood cancers that originate from T 
and B cells in the lymphatic system (American Cancer Society, 2014), where 
lymphocytes undergo a malignant change and multiply uncontrollably. 
Lymphomas, when combined, represent the sixth most commonly diagnosed 
cancer worldwide (Surveillance Epidemiology and End Results (SEER), 
2014), with Hodgkin (HL) and non-Hodgkin lymphoma (NHL) the two main 
forms. Hodgkin lymphoma represents 11.5% of all lymphomas and is the 
third most common cancer in the adolescent and young adult population 
(American Cancer Society, 2014). With the exception of Hodgkin lymphoma, 
incidence increases with age, thus non-Hodgkin lymphoma is predominantly 
a cancer of the older population (over 65 years) (American Cancer Society, 
2014; Quaresma, Coleman, & Rachet, 2015). 
 
The incidence of lymphoma in Australia is increasing, with a projected 
diagnosis of 5680 cases in 2015. This will equate to 4.5% of all cancer cases 
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(Australian Institute of Health and Welfare, 2014). In Australia, the overall 
survival rate has improved and approximately 74% of people diagnosed with 
lymphoma are reported as being alive at 5 years compared with 49% in the 
1980s (Australian Institute of Health and Welfare, 2014). Despite these 
encouraging results (Sant et al., 2014), this group of cancers remain under-
studied and subsequently under-represented in survivorship care (Swash et 
al., 2014). 
 
Lymphoma treatment regimens commonly involve aggressive high dose 
chemotherapy and/or targeted therapy agents, radiotherapy and 
haematopoietic stem cell transplants (Carey et al., 2012). Such treatments 
result in distressing long-term and late physical, practical and psychosocial 
effects, which can produce ongoing unmet needs. These needs relate to 
physical and psychosocial impacts such as: fear of recurrence; fatigue; poor 
nutrition; exercise; fertility; relationship; financial; employment; and 
insurance issues (Taylor et al., 2015). Furthermore, these patients commonly 
experience related health problems earlier than the general population 
(Panek-Hudson, 2013) and are at risk of specific late effects. Cardiovascular 
disease is particularly pertinent in this cohort due to chemotherapy 
combinations and cumulative dosing (Aleman et al., 2007; Ng et al., 2011) as 
well as mediastinal radiotherapy (Travis et al., 2012; van Leeuwen-
Segarceanu et al., 2011). Patient health and lifestyle behaviours, for example 
smoking, likewise have an effect on disease development (Ng et al., 2011). 
Lymphoma patients have an increased relative risk of second cancers, higher 
when diagnosed at a younger age (Grinyer, 2010; Hemminki et al., 2008) and 
further elevated when treatment includes radiotherapy (Ng et al., 2011; 
Travis et al., 2012). The potential for the development of bone marrow 
disease is greater in the first decade, however unlike second cancer risk, this 
decreases and then plateaus in the second decade (Ng et al., 2011). Patients 
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who require a haematopoietic stem cell transplant have additional transplant 
related late effects risks (Bishop et al., 2010; Choi et al., 2008). Although 
patients may be unable to modify some late effect risks, awareness of 
relevant potential late effects may ensure timely follow-up for 
symptomology (Ng et al., 2011). 
 
The traditional model of haematological cancer care follow-up has largely 
been haematologist-led within the acute hospital setting (Taylor et al, 2015). 
Information at treatment completion is often inadequate (Dicicco-Bloom & 
Cunningham, 2013; McCabe & Jacobs, 2012), with a lack of clear guidelines 
for the ongoing management of survivors (Phillips & Currow, 2010). This has 
led to an emerging focus on redesigning survivorship follow-up care and 
delivery.  
Lobb et al. (2009) demonstrated patient-reported needs amongst Western 
Australian haematological cancer survivors (n=66) not addressed during 
routine follow-up post-treatment completion and thereby classified as unmet 
needs. Almost two thirds of respondents (59%) would have found it helpful 
to talk with a health professional at treatment completion. A recent 
qualitative study conducted by the authors with lymphoma and leukaemia 
cancer survivors (n=19) in Western Australia (Monterosso et al., 2015) found 
unmet needs relating to information, practical support, coping strategies and 
transitioning from active treatment into the survivorship phase. Findings 
suggested that tailored, end of treatment interventions should form a key 
component of survivorship care. Participants suggested a cancer coordinator 
nurse as an important element to initiate and transition patients into the 
survivorship phase. 
 
Nurse-led models of care have demonstrated potentially satisfactory 
outcomes (Gates et al., 2015; Howell et al., 2012; John & Armes, 2013) and are 
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proposed as an acceptable pathway to transition into the survivorship phase 
(Cooper et al., 2010). A dedicated nurse-led survivorship clinic to administer 
patient-centred survivor-specific needs assessments is an important aspect of 
survivorship care to address patient concerns and empowering survivors to 
manage their own health and ongoing symptoms (Fitch, 2008; Ganz et al., 
2008; McDowell et al., 2010; Stricker et al., 2011).  
 
Empowering patients enables them to become more responsible for the 
management of their own health and well-being and can contribute to the 
influence and control patients have over their own health which has the 
advantage of improving quality of life (Bodenheimer et al., 2002; Kuijpers et 
al., 2013). Bandura’s theory of self-efficacy (Bandura, 1977), the principal 
concept in self-management education, teaches patients to identify their 
problems and provides skills in decision making and developing an 
appropriate action plan (Bodenheimer et al., 2002). It is anticipated that 
increasing empowerment and providing healthy lifestyle resources will 
result in a reduction in the patient perceived need for support from the 
health care system (Bodenheimer et al., 2002). 
 
Survivorship care plans (SCPs) and treatment summaries (TS) have been 
recommended as facilitators to deliver holistic survivorship follow-up care 
by: the Institute of Medicine (Palmer et al., 2014); the American Society of 
Clinical Oncology (McCabe, Bhatia, et al., 2013); the UK National Cancer 
Survivorship Initiative (MacMillan Cancer Support & NHS Improvement, 
2010); and the proposed Clinical Oncology Society of Australia survivorship 
guidelines (Clinical Oncology Society of Australia, 2014). A personalised SCP 
would guide follow-up care by including recommendations, information and 
resources for surveillance, screening of potential long-term and late effects, 
and health promoting behaviours (Taylor & Monterosso, 2015). The TS 
CHAPTER 5. METHODOLOGY 
126 
would comprehensively summarise information on diagnosis and treatments 
(Hausman et al., 2011; Jabson & Bowen, 2013). Cancer nurses have 
established expertise in the areas of health promotion, information, support 
and resource provision (Jackson et al., 2013), and therefore can develop and 
disseminate SCPs and TS to facilitate communication between the survivor, 
specialist and primary care.  
 
Aim 
The aim of the Care After Lymphoma (CALy) study is to develop and 
empirically test an evidence-based nurse-led lymphoma survivorship clinic 
to transition participants into the survivorship phase, using a pilot 
randomised controlled trial (RCT) design. This phase II trial of an 
intervention is aimed at reducing the immediate and long-term physical and 
psychosocial consequences of haematological cancer treatment and to enable 
the participant to return to normal functioning sooner. The nurse-led 
lymphoma survivorship clinic has three core components: 1) needs 
assessments to determine individual informational or practical issues or 
concerns; 2) provision of a tailored SCPTS to enhance communication 
between the participant and all other health professionals with whom the 
patient has contact post-treatment; and 3) provision of individualised 
evidence-based education, information and resources to address patient-
reported needs, likely post-treatment physical and emotional concerns and 
maximising participant involvement in healthy lifestyle behaviours. The 
aims are aligned with the Australian national research priority for 
preventative healthcare to reduce comorbid diseases in cancer survivors. 
 
The Medical Research Council framework for the development and 
evaluation of complex interventions has guided the development of this trial 
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(Campbell et al., 2007; Medical Research Council, 2000). The evaluation of a 
model for nurse-led evidence-based survivorship care will provide level II 
baseline data to: endorse the suitability of outcome measures; establish 
acceptability of the intervention and randomisation; provide recruitment and 
attrition rates; support hypothesis development; and calculate sample sizes 
for future phase III multisite randomised controlled trials. In addition, it will 
add psychometric information on the Short-Form Survivor Unmet Needs 
Survey (SF-SUNS) and will provide data on a test–retest analysis. 
 
Research Questions 
The following research questions guide this pilot RCT:  
1. Do participants assigned to the nurse-led lymphoma survivorship 
clinic demonstrate a reduction in perceived unmet informational and 
practical needs compared with those randomly assigned to usual 
care?  
2. Do participants assigned to the nurse-led lymphoma survivorship 
clinic demonstrate a reduction in self-reported anxiety, depression 
and stress and an increase in patient self-management behaviours 
compared with participants randomly assigned to usual care? 
3. What is the perceived efficacy and value of the nurse-led lymphoma 
survivorship clinic from the perspective of a subset of survivors in the 
intervention group?  
4. To what extent does the provision of a SCPTS to GPs improve the 
communication between the treating hospital, GP and the participant? 
5. Does the Short-Form Survivor Unmet Needs Survey (SF-SUNS) 
demonstrate stability and reliability over time? 
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Methods 
Design  
The evidence to support the development of this phase II CALy trial 
comprised a qualitative study using a focus group methodology with 
lymphoma, leukaemia and multiple myeloma survivors (Monterosso et al., 
2015). The evidence also encompassed three systematic reviews regarding: 
models of haematological survivorship care; survivorship care plans and 
treatment summaries in haematological cancer patients; and tools used to 
assess the informational and practical needs of acute leukaemia and 
lymphoma survivors (Taylor et al., 2015; Taylor & Monterosso, 2015; Taylor 
& Monterosso, 2016). Information gained from this preliminary work guided 
the intervention components to be developed and the operationalisation of 
the feasibility and acceptability of a nurse-led RCT. 
 
The randomised controlled trial framework has been developed using the 
Consolidated Standards of Reporting Trials (CONSORT) statement and 
checklist (Moher et al., 2010; Schulz, Altman, & Moher, 2010). Outcomes will 
be measured using validated needs assessment instruments. Reporting will 
include: inclusion and exclusion criteria; missing data; drop out; and early 
closure of the trial if required (Figure 5.1.1). The survivorship cancer nurse 
coordinator (CNC) is a specialist cancer nurse with an extensive haematology 
nursing background and formal counselling qualifications, including 
motivational interview techniques. 
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6Figure 5.1.1. Trial flow chart. 
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Population and setting  
A convenience sample of lymphoma cancer patients from a specialised 
haematology department in a comprehensive cancer centre of a large acute 
tertiary hospital in Perth, Western Australia, will be used. Follow-up by a 
haematologist occurs every three months for the first 12 months. The nurse-
led survivorship clinic intervention will be an additional care activity to the 
medical haematology follow-up and will involve three appointments over six 
months. It will commence at three months post-treatment completion and 
cease at nine months post-treatment. 
 
Inclusion criteria 
1. Pathologically confirmed new diagnosis of Hodgkin or non-Hodgkin 
lymphoma. 
2. Completed first-line curative-intent chemotherapy or second-line 
curative-intent autologous stem cell transplant within the previous three 
months. 
3. No evidence of lymphoma disease on mid-treatment interim PET scan or 
post-treatment PET scan where these are performed. 
4. Able to understand and read English. 
5. Over 18 years of age.  
 
Exclusion criteria 
1. Diagnosis of other haematological malignancy or an incurable 
lymphoma. 
2. Did not undergo chemotherapy. 
3. Further treatment and follow-up at another hospital. 
4. Intellectually impaired or experiencing an acute mental health condition 
that precludes the ability to provide informed consent. 
5. Comorbid condition requiring monthly visits with GP. 
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To measure selection bias, minimal data will be completed on eligible 
participants who decline to participate. Reasons for refusal will be recorded 
to gain valuable information for future research. 
 
Recruitment 
Identification of eligible participants will be undertaken by haematology 
clinicians who will provide details to the survivorship cancer nurse 
coordinator. Ongoing education of clinicians (haematologists and nurses) 
regarding all aspects of the study, its progress and recruitment will facilitate 
cooperation and support. Eligible participants will be met after treatment 
completion by the CNC who will discuss the study and provide a Participant 
Information and Consent Form (PICF). Consenting participants randomised 
to the intervention group (n=30) will be offered the opportunity to consent to 
a qualitative interview at completion of all time points. Approximately one 
third of participants (n=10) will be required for this phase. Participant’s 
names and contact details will be entered onto a master-coding sheet and 
assigned a numerical identifier code after randomisation.  
 
Survivorship Care Plan (SCP) and Treatment Summary (TS) 
An extensive review of the literature (Taylor & Monterosso, 2015) and 
available survivorship care plans and treatment summaries was undertaken. 
Many institutions in Australia are utilising USA based templates that are 
large (up to 20 pages), not tailored to the individual and provide resources 
that are not contextualised to the Australian healthcare setting. Therefore, we 
developed a lymphoma SCPTS in collaboration with a haematology 
consultant, GP and other multidisciplinary team members (e.g. consumers, 
psychologist, cancer nurses, and academic cancer researchers). This has been 
created as a word document template to be filled in by the nurse. The 
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perspectives of lymphoma survivors (n=6) and clinicians (including GPs) 
(n=6) were sought to determine the relevance of the proposed SCPTS items. 
Each item was assessed for content and apparent internal consistency 
(whether items should be included and the general fit with other items) 
using either yes or no responses to the items. Content validity utilised a 
rating scale (1=not relevant to 4=highly relevant). The content validity index 
(CVI) (Polit & Beck, 2006) was generated for each item by adding the number 
of “yes” scores (content, clarity and apparent internal consistency) and scores 
of 3 or 4 (content validity). The mean CVI consumer results were as follows: 
clarity 0.98; apparent internal consistency 100; content validity 0.95. 
Consumers demonstrated complete agreement of 1.0 for internal consistency 
items. The mean CVI clinician results were as follows: clarity 0.99; apparent 
internal consistency 0.95; content validity 0.84. Feedback in the comments 
section of the evaluation interestingly indicated GPs did not value or require 
a large treatment summary document. Consensus of the research team was 
reached for the TS (half a page in length) and SCP (one and a half pages in 
length).  
 
The TS is completed using existing medical record information such as: 
diagnosis; treatment; complications; and use of allied health providers. The 
first section of the SCP includes a table for the inclusion of individualised 
potential late effects. This table comprises: the late effect; information for the 
GP about tests or follow-up required and when; and the symptomology the 
participant needs to be aware of, with encouragement to follow these up 
with the GP. Prior to recruitment a comprehensive list of potential late effects 
and follow-up required was developed for each lymphoma type using 
available published literature and guidelines (KT). This list was circulated, 
discussed and amended by the haematologists who were aware these would 
be used to guide their population of the table. Tailored individualised 
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potential late effects will be documented based on treatments administered, 
participant’s demographics and health characteristics. Once the TS and this 
aspect of the SCP are completed it will be emailed to the haematologist for 
final approval. Once amendments (if any) are made the haematologist signs 
the TS. The second page of the SCP is patient-centred and populated by the 
nurse in consultation with the participant. Participants will be asked to 
identify three main concerns, health goals and proposed actions to achieve 
these goals.  
 
Sample size 
The calculation of a sample size is not required for pilot RCTs as effect size is 
not yet known. Rather the purpose of the pilot is to determine variability in 
measures from which effect sizes can be calculated. Approximately 75 
patients are seen per year at the study setting; however, this figure is 
inclusive of new and existing patients. Therefore, a consecutive sample of 60 
participants will be recruited and randomised 1:1 to either control or 
intervention group (30 participants are expected in each group). It is 
necessary to establish test–retest reliability for the SF-SUNS by 
demonstrating a minimum intraclass correlation (ICC) of 0.8. Therefore, a 
sample size of 39 (rounded up to 40 participants) administered on two 
consecutive occasions no more than five days apart (baseline and 5 days 
later) is required to achieve 80% power to detect this ICC of 0.8 (Walter, 
Eliasziw, & Donner, 1998). 
 
Patient-reported outcome measures 
A review of the literature (Taylor & Monterosso, 2016) has resulted in four 
assessment instruments being selected to measure the outcomes proposed: 
Short-Form Survivor Unmet Needs Survey (SF-SUNS); Depression Anxiety Stress 
Scale (DASS21); Mini Mental Adjustment to Cancer Scale (Mini-MAC); and 
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Patient Empowerment Scale (PES). These instruments have demonstrated 
reliability and validity with haematological cancer survivors as shown in 
Table 5.1.1.  
 
10Table 5.1.1 Outcomes Assessment Instruments 
Instrument Use Items and 
Factors  
Internal 
Consistency 
Additional 
Issues 
Short-Form 
Survivor 
Unmet 
Needs 
Survey (SF-
SUNS) 
(Campbell et 
al., 2014) 
Developed 
for cancer 
survivors to 
assess unmet 
needs. Assess 
the gap 
between 
patient self-
reported 
concerns and 
the level of 
support they 
require  
Discriminates 
between 
survivors at 
different 
stages post-
treatment 
completion 
30 items—0 
(no unmet 
need) to 4 
(very high 
unmet need) 
Four factors: 
information 
(3 items); 
financial 
concerns (8 
items); access 
and 
continuity of 
care (6 
items); 
relationships 
and 
emotional 
health (13 
items) 
Cronbach’s 
alpha scores 
for all domains 
were ≥ 0.85  
ICC across all 
domains high 
i.e. ≥0.9 
indicating SF-
SUNS reliably 
measured the 
level of unmet 
need 
Test–retest 
reliability not 
established 
Will be 
undertaken 
during this 
study 
Depression 
Anxiety 
Stress Scale 
(DASS-21) 
(Lovibond & 
Lovibond, 
1995) 
Measures 
multiple 
dimensions 
of 
depression, 
anxiety and 
stress 
Three 7 item 
scales—0 
(did not 
apply to me 
at all) to 3 
(applied to 
me very 
much, or 
most of the 
time) 
5 severity 
ratings: 
normal; mild; 
moderate; 
severe; and 
Cronbach’s 
alpha 
subscales 
scores were: 
0.94 
depression; 
0.87 anxiety; 
and 0.91 for 
stress (Antony 
et al., 1998) 
Used to support 
SUNS 
psychometric 
properties in 
haematology 
cancer survivors 
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extremely 
severe 
Mini Mental 
Adjustment 
to Cancer 
Scale (Mini-
MAC) 
(Boyes, 
Girgis, 
D'Este, & 
Zucca, 2011) 
Measures 
cancer-
specific 
coping 
strategies 
29-item—5 
cancer-
specific 
coping 
strategies: 
helplessness-
hopelessness 
(8 items); 
anxious 
preoccupatio
n (8 items); 
fighting spirit 
(4 items); 
cognitive 
avoidance (4 
items); and 
fatalism (5 
items).  
Scale—1 
(Definitely 
does not 
apply to me) 
to 4 
(definitely 
applies to 
me) 
Reliability 
using 
Cronbach’s 
alpha 
coefficients for 
each subscale 
ranged from 
0.62–0.88 
Used with small 
sample of 
haematology 
cancer survivors 
Patient 
Empowerme
nt Scale (PES) 
(Bulsara & 
Styles, 2013) 
Measures 
level of 
patient’s 
coping ability 
and self-
efficacy in 
terms of 
managing 
their illness 
and making 
decisions 
about 
support 
strategies 
15-item 4-
point Likert-
type scale 
A high degree 
of reliability 
has been 
established 
using the 
Rasch 
Extended 
Model with 
the Person 
Separation 
Index of 0.926 
Used in 
haematology / 
oncology 
patients 
Note: Cronbach’s alpha is considered a measure of scale reliability and a high score 
indicates good internal consistency reliability of the test. 
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Baseline data collection 
Baseline data collection from consenting participants will occur three months 
after treatment completion. All participants will self-report demographic 
information and complete the four assessment instruments. In addition, they 
will receive a second SF-SUNS instrument to complete no later than five days 
after the baseline testing. These will be returned via a reply-paid envelope to 
allow the researchers to undertake test–retest reliability testing. Medical 
demographic information obtained will include: type of haematological 
cancer; stage of disease; type of treatment received (chemotherapy, 
immunotherapy, radiotherapy); date of diagnosis; time since diagnosis; 
treatment complications or dose modifications; and comorbidities. Personal 
demographic information collected will include: sex; age; marital status; age 
of children (if any); postcode; occupation; income level; education level; 
health behaviours such as smoking, alcohol consumption and weight.  
 
Randomisation 
After baseline assessment participants will be randomised to either the 
current standard of care or intervention group. Computer generated random 
numbers using a four-digit sequence have been generated and linked to 
group allocation by an independent statistician. An independent member of 
the research team, to ensure confidentiality and offset bias in randomisation, 
has sealed a hard copy of each individual number and group in an opaque 
envelope. The envelopes are consecutively numbered and will be distributed 
to consenting participants in this order. Control group participants will be 
made aware that another researcher will follow-up non-questionnaire return 
with a telephone call to the participant after two weeks. 
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Control group 
Control group participants will receive follow-up care as per haematologists’ 
usual practice. At three and six months after baseline, the same four 
assessment instruments will be sent to the participant and they will self-
report any issues or unmet supportive care needs. An addressed reply-paid 
envelope will be provided to return assessments. Participants who score high 
unmet needs will be encouraged to discuss these with their haematologist at 
their usual follow-up appointment.  
 
Intervention group 
Following baseline data collection, intervention group participants will have 
an appointment at the nurse-led lymphoma survivorship clinic. The first 
page of the SCPTS will be populated prior to this appointment. At the first 
nurse-led lymphoma survivorship clinic, any concerns the participant has 
regarding the end of treatment will be discussed and normalised. The nurse 
will discuss the TS and potential late effects. The second page of the SCP will 
be completed by the nurse using an electronic template in collaboration with 
the participant. At this time the importance of follow-up recommendations 
will be emphasised. The SCP will then be printed, signed and dated by the 
participant and the nurse. The completed SCPTS will then be copied, with 
the original given to the participant, a copy placed in the participant’s 
medical records, and a copy sent to their GP. Motivational interviewing 
techniques will be employed for healthy lifestyle behaviours and to assess for 
readiness to make behavioural change. Participants will be encouraged to 
identify and explore behaviours they would like to modify using a chart that 
enables them to list likes and dislikes of specific behaviours and potential 
impacts of perceived behavioural change. By listening to concerns, 
highlighting conflicts arising from behaviour and documenting on the chart 
will potentially enable participants to assume control of decision making 
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related to behavioural change. Participants will be encouraged to set realistic 
timeframes and identify habits and beliefs that may possibly be hindering 
change. Tailored evidenced-based information and advice in a resource pack 
will then be issued. It is anticipated that a consultation of 60 minutes will be 
required in a private clinic room.  
 
A further two appointments will be made at three and six months after 
baseline, where the same four assessment instruments will be completed by 
the participant and they will self-report any issues or unmet supportive care 
needs. These will be discussed and the appropriate resources support and 
information provided. Participants will be encouraged to discuss their health 
concerns, goals and progress with any action they may have taken. 
Participants will be asked if they have seen their GP in the last three months 
and if they took the SCPTS and discussed any of the late effects screening 
recommendations, their participant-identified concerns or goals. This will aid 
the transition to GP follow-up where the benefits of shared care will be 
explained. A checklist for each participant of the resources provided will be 
kept. 
 
Data Analysis 
Quantitative data will be analysed using univariate and multivariate 
statistical techniques with SPSS data analysis software. Descriptive statistics 
will be used to analyse the demographic variables collected. Responses to the 
SF-SUNS, DASS21, Mini-MAC and PES will be scored according to the 
algorithms in the instrument manuals. Measures from all instruments will be 
checked for normal variance within the two groups. Within each group, 
paired t-test comparisons will be made between baseline measurements and 
at each time point: baseline; three months; six months. Differences between 
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intervention and control groups will then be assessed at each time point. 
Test–retest reliability using ICC will be undertaken on the SF-SUNS 
instrument. The minimum ICC value required for this scale is 0.8. 
Participants who drop out or are lost to follow up or need to be excluded 
after commencement will be accounted for by intention to treat analyses. 
Confidence intervals will reflect the contrast between groups to show 
treatment effect. Missing data, incomplete answers and non-response will be 
recorded. 
 
Qualitative interviews 
Supplementary in-depth semi-structured interviews will occur with 
approximately 10 consenting participants when they have completed all 
intervention components (after six months). This number will allow for 
saturation of themes (Crouch & McKenzie, 2006; Onwuegbuzie & Leech, 
2007; Sandelowski, 1995). Telephone interviews will be digitally recorded 
and undertaken by an independent researcher to ensure participants are 
given the opportunity to freely express both positive and negative 
perceptions of their experience. The use of a qualitative approach will 
provide depth of information regarding the personal impact of the nurse-led 
lymphoma survivorship clinic on the participant. The interviews will also 
highlight any issues or challenges for this group that could be better 
addressed in the future. 
Interviews will be transcribed verbatim and thematic analysis used to 
determine themes and patterns within the text (Grbich, 1998; Patton, 2014; 
Smith, 2007). QSR NVivo qualitative analysis data management software will 
be used to manage interview data.  
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GP evaluations 
A non-validated evaluation will be sent to GPs who have received the 
SCPTS. This was developed in consultation with a GP and will ascertain if 
GPs made use of the SCPTS and to elicit perceptions of the value and 
effectiveness of this document in facilitating communication between the 
treating hospital and GP, and GP and participant. This will guide future 
refinement of the SCPTS. Analysis will utilise descriptive statistics and 
distribution analysis techniques. Open-ended questions will utilise content 
analysis techniques. GPs will be called by the researcher after two weeks for 
non-return of the questionnaire to remind them to fill in and return the 
evaluation in the reply-paid envelope. 
 
Discussion 
A significant culture change is required for providers to recognise 
survivorship care as a standard component of quality cancer care that 
involves all health professionals, participants and families. The gap in 
knowledge contributes to a current model of survivorship care that is 
fragmented, with inadequate service provision at treatment completion, 
leading to unmet needs along the survivorship continuum (De Leeuw & 
Larsson, 2013). The cancer specialist is not necessarily required for routine 
screening and follow-up. However, the involvement of other health 
professionals, including primary care, necessitates the need for an awareness 
of the treatment delivered and the long-term and late effect risks (Taylor & 
Monterosso, 2015). 
 
This study will address the lack of robust empirical evidence in haematology 
survivorship care. A nurse-led model of care would assist patients 
transitioning from the end of treatment to the survivorship phase. 
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Furthermore, the provision of an individualised SCPTS is a means to 
empower individuals with knowledge about their disease and treatment and 
to assume responsibility for future surveillance and disease management. It 
will likewise take advantage of ‘teachable moments’ at the end of active 
treatment to support and promote patient participation in healthy lifestyle 
behaviours (Taylor et al., 2015). This is particularly vital for younger 
survivors, given the expectation of a longer survivorship period (Jabson & 
Bowen, 2013). 
 
The intervention has been timed to occur in the early survivorship phase. 
This has been supported by preliminary focus group work including 
lymphoma cancer survivors who indicated they often felt abandoned at 
treatment completion (Monterosso et al., 2015). This timing also concords 
with McDowell et al. (2010) who found assessments and interventions 
undertaken in the early survivorship phase (up to two years post diagnosis) 
led to fewer unmet needs moving into the extended survivorship phase (over 
five years). 
  
The CALy trial will examine the impact and effectiveness of the nurse-led 
lymphoma survivorship clinic intervention through an assessment of the 
important clinical outcomes: unmet informational and practical needs; 
depression, anxiety and stress; coping; and self-empowerment as measured 
by the instruments chosen. It is therefore designed to improve the 
identification of unmet needs. Testing of such an intervention by a 
randomised controlled trial has not been published in lymphoma 
survivorship studies to date. Consequently, it will make a significant 
contribution to the planning and delivery of survivorship care. Likewise, it 
represents a substantial and original contribution to knowledge and support 
for haematology survivorship care as few studies aim to improve the 
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psychosocial and supportive care of this cohort. If the intervention achieves 
its intended outcomes, it may potentially lead to the development of nurse-
led haematology survivorship clinics across the tertiary health sector in 
Western Australia that could ultimately be expanded to all cancer survivors.  
 
Ethics 
Ethics approval has been gained from the relevant hospital (2015-020) and 
university (015007F) Human Research Ethics Committees (HRECs). The trial 
is registered at the Australian and New Zealand Clinical Trials Registry 
(ACTRN 1261500530527) and the Western Australia Cancer Clinical Trials 
Registry. The trial is open to patient recruitment. It is not expected 
participants will be exposed to any undue risks or harm by participation. 
Participant information will remain confidential and de-identified where 
appropriate. Economic harm will be minimised by providing appointments 
when the participant is already attending the hospital. Exploring concerns 
may be distressing and if this occurs, participants will be referred to the 
appropriate counselling services as per usual clinical practice. Collected data 
will be securely stored at the university for 15 years after study completion 
and will only be accessible with written permission from the researcher and 
relevant university and hospital sites. 
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Chapter Summary 
In summary, this published article outlines the development of the nurse-led 
lymphoma survivorship model of care and the components that were 
required to undertake a high-quality phase II pilot pragmatic RCT. These 
include: 
 Development and review of a unique tailored survivorship care plan and 
treatment summary (SCPTS) 
 Selection of four assessment measures 
 Motivational interviewing chart 
 Development of a resource pack 
 Three structured appointments in the nurse-led lymphoma survivorship 
intervention  
 Creation of a General Practitioner (GP) evaluation of the SCPTS 
 Development of the interview schedule  
Where detail is limited, further information is in Chapter Four of this thesis.  
 
The following chapter of this thesis reports in the first section on the results 
that were obtained from the pragmatic RCT and the GP evaluations. The 
following two sections are the results of the qualitative interviews and the 
test–retest reliability analysis of the SF-SUNS. These are presented in the 
format of journal articles that were published in the European Journal of 
Oncology Nursing and the Asia-Pacific Journal of Oncology Nursing respectively.  
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Chapter Six — Results 
 
 
 
 
 
 
 
 
 
 
“I got the chance to talk over my concerns and I think that is very important.” 
Female_HL 
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6.0 Results of Phase Three and Phase Four  
Four sections form this chapter. The first two sections describe the statistical 
techniques applied to the data followed by results for the pragmatic 
randomised controlled trial (RCT) and general practitioner (GP) evaluation 
surveys. The third section of this chapter presents the sixth and final 
published paper that reports the results from the qualitative semi-structured 
interviews undertaken with a subset of intervention participants after their 
completion of the study. Interviews were conducted by an independent 
researcher to minimise potential bias and allow participants an opportunity 
to speak freely about their perceptions and experiences. This published 
manuscript has been reproduced in this chapter (Taylor, K., Monterosso, L., 
& Bulsara, C. (2018). Qualitative results from a phase II pilot randomised 
controlled trial of a lymphoma nurse-led model of survivorship care, 
European Journal of Oncology Nursing, 35, 9–14). The complete PDF version is 
in Appendix A.5.  
 
The final section comprises the fifth published journal article that reports the 
test–retest reliability of the SF-SUNS, the survivorship-specific needs 
assessment measure selected for this research. This testing was undertaken 
as published test–retest reliability data was not yet available when the study 
protocol was developed. This manuscript has been reproduced in this 
chapter (Taylor, K., Bulsara, M., & Monterosso, L. (2018). Test–retest 
reliability of the Short-Form Survivor Unmet Needs Survey, Asia-Pacific 
Journal of Oncology Nursing, 5(2), 165–171). The complete PDF version is in 
Appendix A.6.  
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6.1 Results of the Pragmatic Pilot 
Randomised Controlled Trial 
Statistical Techniques  
Quantitative data were analysed using IBM SPSS version 25 (IBM Corp, 
2017). Demographic variables were described using mean, standard 
deviation, median and range where applicable. The degree of sample 
generalisation between groups (control and intervention) was ascertained 
and reported using a Pearson Chi-square test, except when cell counts were 
below five in which case a Fisher’s Exact test result was reported. Subjective 
data such as lifestyle factors was not tested. Responses to the SF-SUNS, 
DASS21, Mini-MAC and PES used Likert-type scales and were scored 
according to the algorithms provided in the relevant instrument manuals. 
Analysis was by intention to treat, unanswered items on questionnaires were 
recorded. Statistical significance was set at 0.05 (2-tailed) unless otherwise 
stated. 
 
Non-parametric tests were used where measures were not normally 
distributed as determined by the Shapiro Wilk test. The Kruskal–Wallis test 
was used to compare total scale and domain scores of each instrument at 
each time point across age, gender, and lymphoma type. Within each group, 
paired t-test (or non-parametric alternative Wilcoxon Paired Rank Sum test) 
comparisons on the total scale and domain scores of each instrument were 
made between Time 1 (baseline) and Time 2 (3 months) and Time 1 and Time 
3 (6 months). Independent t-tests (or non-parametric Mann–Whitney U test) 
were used to assess the differences on the total scale and domain scores and 
each item between the two groups at each time point. The Friedman test was 
used to measure the intervention participants across the three time points on 
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the total scale and domain scores of each instrument. 
 
Linear Mixed Modelling (LMM) with Bonferroni post-hoc comparisons were 
used to examine change over the study timeframe between the control and 
intervention groups. LMM is suitable for data where: multiple measures are 
repeatedly taken from the same individuals; data is not necessarily normally 
distributed; and permits missing data points (missing at random) (West, 
Welch, & Galecki, 2015). Therefore, LMM provides flexibility of modelling 
data means along with the variances and covariances (IBM Corp, 2017). Each 
assessment measure, including the domains within each measure, were 
treated as a separate dependent variable model. Covariates were treated as 
fixed effects and included group (control versus intervention), time (1, 2 and 
3), with cofounders of age, gender and lymphoma type. Individuals were 
treated as a random effect. Group x time and gender x time interactions were 
examined for each model and were included in the final reported model only 
if statistically significant. Place of residence was not modelled due to the low 
numbers from regional or rural areas. Final model residuals were assessed 
for normality to check the assumption for the LMM was met. All models 
were assessed to meet this assumption with only some slight deviation in the 
tails for some models.  
 
Spearman’s Rho correlation coefficient analysis was used to describe the 
relationship between the SF-SUNS and each of the other measures; PES, 
DASS21, Mini-MAC. Combined scores from the two groups were used at 
each time point to describe the strength and direction of the correlation. The 
strength of the correlation coefficient was determined using the following 
values: small r=.10 to .29; medium r=.30 to .49; large r=.50 to 1.0 (Cohen, 
1988). 
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The CONSORT (Consolidated Standards of Reporting Trials) diagram 
(Moher et al., 2010) depicting the flow of participants through this trial is 
presented in Figure 6.1.1. Missing data were minimal and estimated not to 
exceed 1–1.5% of the total data volume. Recruitment commenced in July 2015 
and was completed in January 2017. All participants had completed the 
study by October 2017. 
 
Quantitative analysis tables demonstrating the depth of analysis undertaken 
in this thesis are found in Appendix L for the following: 
 Reliability of assessment measures (Table 1) 
 Wilcoxon Singed Rank Sum test (Table 2) 
 Linear mixed models, non-significant results of the SF-SUNS (Table 3) 
and Mini-MAC (Table 4).  
 Paired t-tests (Table 5) 
 Independent t-tests (Table 5) 
 Kruskal–Wallis tests (Tables 6–8) 
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7Figure 6.1.1. CONSORT flow diagram for pragmatic RCT. 
 
Results 
Demographic data 
Of 88 eligible patients (Figure 6.1.1), 60 consented to participate in the trial 
(68%). The 28 patients who were excluded had comparable demographic 
characteristics (obtained from their medical records) with those of 
participants; there were more males (n=16, 58%) than females (n=12, 42%) 
with a similar age range (24–82 years, M=63 years, SD=14). Like the 
participants, the majority of non-participants were in a relationship, had 
NHL, and were within the first eight months since diagnosis. Reasons for 
exclusion included: 
 Not meeting inclusion criteria due to relapse of disease (n=5) 
 
Assessed for eligibility (n=88) 
Enrolment 
Excluded (n=28) 
    Not meeting inclusion criteria 
(n=5) 
    Declined to participate (n=21) 
    Other reasons (n=2) 
  
Randomised (n=60) 
Allocation 
Allocated to intervention (n=30) 
  Received allocated intervention 
(n=30) 
 
Allocated to control (usual care) 
(n=30) 
 
Discontinued intervention (relapsed 
after Time 2) (n=1) 
Lost to follow-up (uncontactable /  
did not return assessment 
measures) (n= 1) 
 
Follow-Up 
Analysed (n=30) 
  Excluded from analysis at Time 3 
(n= 1) 
Analysed (n=30) 
  Excluded from analysis after 
baseline (n=1) 
 
Analysis 
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 Declined to participate (n=21) 
o Extra time required at the hospital (n=8) 
o Travel to the hospital for regional patients (n=2) 
o Feeling overwhelmed by treatment experience or wanting 
to move on and forget they had lymphoma (n=9) 
o Not interested with no other reason given (n=2) 
 Other reasons (n=2)  
o Died after assessment for eligibility 
 
Demographic and disease characteristics of study participants are shown in 
Table 6.1.1 for both control and intervention groups. More males (73%) than 
females (27%) were randomised to the intervention group indicating a 
statistically significant degree of generalisation which was not seen in the 
control group. Likewise, lymphoma type was disproportionate, with an 
increased number of HL cases in the intervention group (40%) compared 
with recognised worldwide trends in lymphoma distribution which were 
mirrored in the control group; NHL (80%), HL (20%) (Howlader et al., 2016). 
There were a greater number of participants within the first eight months of 
diagnosis, an expected result when recruiting participants after treatment 
completion. A statistically significant degree of sample generalisation in 
marital status was found; however, this difference was not significant when 
participants were grouped into ‘in a relationship’ or ‘not in a relationship’. 
There were more metropolitan residents in the study, although similar 
representation of residence was found in both groups. 
 
Three age group categories were chosen to reflect the adolescent and young 
adult age range (18–29 years), those with more likelihood of working and 
having children living at home (30–59 years) and those less likely to be 
working or have dependent children (>60 years). 
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11Table 6.1.1 Demographic Characteristics for RCT Participants (n=60)  
 Intervention 
n=30 
Control 
n=30 
Group Difference 
Characteristics N (%) N (%) Pearson 
Chi-
Square 
P Value 
Gender 
  Male 
  Female 
 
22 (73) 
8 (27) 
 
12 (40) 
18 (60) 
6.79 .018 
Age group (years) 
  18–29 
  30–59 
  60–86 
 
8 (27) 
12 (40) 
10 (33) 
 
5 (16) 
14 (47) 
11(37) 
0.89 .712 
Lymphoma diagnosis 
  Non-Hodgkin 
  Hodgkin 
 
18 (60) 
12 (40) 
 
24 (80) 
6 (20) 
2.86 .158 
 
Time since diagnosis 
  5–8 months 
  >9 months 
 
20 (67) 
10 (33) 
 
18 (60) 
12 (40) 
0.29 .789 
Marital status 
  Single 
  Married/defacto 
  Divorced/separated 
  Widowed 
 
9 (30) 
17 (57) 
4 (13) 
0 (0) 
 
5 (16) 
20 (67) 
2 (7) 
3 (10) 
5.14* .273 
 
Children^  
  <25 (living at home) 
  Adult children 
  No children 
 
12 (40) 
9 (30) 
9 (30) 
 
9 (30) 
13 (43) 
8 (27) 
  
Highest level of education 
  Secondary school or less 
  Trade/vocational college 
  University 
 
7 (23) 
9 (30) 
14 (47) 
 
11 (37) 
9 (30) 
10 (33) 
1.56 .498 
Employment status# 
  Working 
  Not working 
  retired 
  no return to work date 
 
15 (50) 
15 (50) 
7 (23) 
5 (16) 
 
12 (40) 
18 (60) 
9 (30) 
5 (16) 
1.09 .435 
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  looking for work 
  sick pension 
2 (7) 
1 (3) 
4 (13) 
0 (0) 
Income level 
  $0–$30,000 
  $30,001–$70,000 
  $70,001–100,000 
  $100,001–$130,000 
  >$130,000 
  chose not to answer 
 
13 (43) 
7 (23) 
4 (13) 
2 (7) 
4 (13) 
0 (0) 
 
15 (50) 
6 (20) 
5 (16) 
1 (3) 
1 (3) 
2 (7) 
4.10* .586 
Residence 
  Metropolitan 
  Regional 
 
24 (80) 
6 (20) 
 
26 (87) 
4 (13) 
0.48* .731 
 
Lifestyle factors^ 
Smoking 
  Current smoker 
  Quit <12 months 
  Quit >12 months 
  Never smoked 
Alcohol consumption 
  Current 
  Occasional <1 drink/week 
  2–3 drinks/week 
  4–5 drinks/week 
  6–7 drinks/week 
  Binge drinking weekends 
  2–3 drinks/night 
  Never 
Weight 
  Underweight (<50 kg) 
  Overweight (>95 kg) 
 
 
4 (13) 
2 (7) 
5 (16) 
19 (63) 
 
17 (57) 
9 (30) 
6 (20) 
1 (3) 
0 (0) 
1 (3) 
0 (0) 
13 (43) 
 
1 (3) 
5 (16) 
 
 
3 (10) 
2 (7) 
5 (16) 
20 (67) 
 
19 (63) 
10 (33) 
3 (10) 
0 (0) 
3 (10) 
0 (0) 
3 (10) 
11 (37) 
 
0 (0) 
6 (20) 
  
Note. Bolded p value indicates statistical significance p<.05; *Fisher’s Exact test result 
reported; #Two main groups examined— ‘Working’ or ‘Not working’; ^Subjective 
data not analysed  
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Assessment measures 
All participants completed all items on the SF-SUNS, DASS21 and Mini-
MAC. The PES gave participants the option of leaving a question blank; 
however, most participants completed all items across the three time points. 
The question most frequently left blank was “complementary therapies help 
me cope with my illness” (n=12, 48%). There were more missing items from 
the control group (19 vs 6 items). Across both groups, there were five missing 
items at Time 1, 12 items at Time 2 and eight items at Time 3.  
 
Cronbach’s alpha results supported scale reliability in all measures across the 
three time points. Cronbach’s alphas in the present study ranged from:  
 SF-SUNS = .70 to .96 
 DASS21 = .79 to .94 
 Mini-MAC = .58 to .90 
 PES = .75 to .79 
 
Unmet needs (as measured by the SF-SUNS) and patient empowerment (as 
measured by the PES) demonstrated a medium to strong, negative 
correlation between the two variables at: Time 1, r=–.51, n=60, p=<.001; Time 
2, r=–.35, n=59, p=<.001; and Time 3, r=–.56, n=58, p=<.001. High levels of 
empowerment were associated with lower levels of unmet needs. The 
relationship between SF-SUNS and psychological distress (as measured by 
the DASS21) revealed a strong, positive correlation between the two 
variables at: Time 1, r=.75, n=60, p=<.001; Time 2, r=.80, n=59, p=<.001; and 
Time 3, r=.77, n=58, p=<.001. Low levels of psychological distress were 
associated with lower levels of unmet needs. Likewise, the relationship 
between the SF-SUNS and mental adjustment to cancer (as measured by the 
Mini-MAC) indicated a strong, positive correlation between the two 
variables at: Time 1, r=.58, n=60, p=<.001; Time 2, r=.71, n=59, p=<.001; and 
CHAPTER 6. RESULTS 
154 
Time 3, r=.67, n=58, p=<.001. Lower levels of unmet needs were associated 
with better mental adjustment to the cancer diagnosis. 
 
Fidelity 
Control group 
No participant randomised to the control group received the SCPTS or the 
resource pack during the study. Four participants (13%) required at least one 
phone call at Time 2 for non-return of measures, resulting in three (75%) 
returned. At Time 3, 10 participants (33%) required at least one phone call for 
non-return of measures. Seven participants (70%) posted back the measures 
within a month and two (20%) brought the completed measures to their 
haematologist appointment. Twenty-nine participants completed Time 2 and 
Time 3 measurements. 
 
Intervention group 
All intervention participants completed the first NLSC appointment face-to-
face. The average time of consultation was 64.28 minutes (range 20–120 
minutes) and the average time from baseline was 9.63 days (range 0–56 
days). Four participants (13%), prior to the baseline appointment, indicated 
they would be unable to return to the hospital within the next few weeks if 
randomised to the intervention. Therefore, the first NLSC appointment was 
planned for the same day as baseline if required. Two participants (6%) did 
not present for their scheduled NLSC appointment and were eventually seen 
31 and 56 days later. The average time of the second NLSC appointment was 
46.13 minutes (range 19–90 minutes) and 44.31 minutes (range 15–70 
minutes) for the third NLSC appointment. Four participants (13%) requested 
a telephone appointment after their haematologist appointments had been 
cancelled and moved to a future date. Assessment measures were completed 
over the phone, and any written information requested was emailed or 
CHAPTER 6. RESULTS 
155 
posted. Thirty participants at Time 1 and Time 2 and 29 participants at Time 
3 completed all elements of the study. 
 
Intervention group 
Concerns and health goals 
Half of the participants identified fear of recurrence, and one-third identified 
fatigue and/or cognitive impairment as concerns on the SCPTS (Table 6.1.2). 
Counselling referrals to a clinical psychologist were offered to those who 
self-reported struggling with a psychosocial issue. Those who accepted a 
counselling opportunity (n=4, 13%) had issues with fear of recurrence and/or 
managing stress and anxiety. At study completion, one participant (3%) 
continued to self-report a high / very high level of fear of recurrence on the 
SF-SUNS. Fatigue was ongoing and remained a moderate to very high unmet 
need self-reported on the SF-SUNS in one third of participants (n=10, 34%). 
Cognition impairment likewise remained an issue with 52% (n=15) self-
reporting this as a moderate to high unmet need on the SF-SUNS.  
 
The majority of participants (n=25, 83%) wanted to increase or start physical 
exercise and over half wanted to make healthy lifestyle changes (Table 6.1.2). 
 
12Table 6.1.2 Top Five Concerns and Health Goals Identified from SCPTS 
Rank Participant-identified 
Concerns 
N (%) Participant-identified Health 
Goals 
N (%) 
1 Fear of recurrence or 
other cancer 
15 (50) Increasing or undertaking 
physical activity/exercise 
25 (83) 
2 Fatigue 10 (33) Healthy lifestyle (including 
weight loss, healthy diet, 
reducing alcohol intake) 
16 (53) 
3 Memory and 
concentration issues 
9 (30) Work (balancing with life 
now, taking opportunities) 
13 (43) 
4 Quit cigarette 4 (13) Travel 10 (33) 
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smoking 
5 Financial and 
insurance issues 
4 (13) Managing stress, anxiety and 
mental health 
8 (26) 
 
A motivational chart was used as an aid to list participant likes, dislikes and 
conflicts that might arise while trying to quit a particular behaviour. Four 
participants (13%) used the chart to assist with smoking cessation. Three 
participants (10%) were able to quit smoking by the end of the study, and 
one young person had reduced smoking to social situations only. Two young 
participants (6%) used the chart to address excessive or binge alcohol intake. 
At study completion, one participant indicated complete abstinence and felt 
this achievement had helped control other aspects of his life. The other 
participant had verbalised at her first NLSC appointment: “I am sick of 
cancer sucking the joy out of my life” and felt the peer pressure would be 
difficult to withstand if she made lifestyle changes. At study completion, she 
had reduced her alcoholic intake and acknowledged that getting healthy and 
taking back control of her life had included taking herself out situations 
where she felt pressured. 
 
Assessment of the nurse-led lymphoma survivorship model of care 
Survivorship unmet needs (SF-SUNS) 
Friedman tests were undertaken to measure total scale and domain scores to 
compare participants in the intervention group of the nurse-led lymphoma 
survivorship model of care at Time 1 (pre-intervention), Time 2 (3 months' 
post-intervention) and Time 3 (6 months' post-intervention). Total scale SF-
SUNS scores identified the highest unmet need at Time 2 (Md=22), then Time 
1 (Md=18) with Time 3 (Md=16) the lowest (X2 (2, N=29) = 7.60, p=.022). 
Significant results were evident in the financial concerns domain with greater 
unmet need reported at Time 1 (Md=6) and Time 2 (Md=6) with Time 3 
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(Md=4) the lowest X2 (2, N=29) = 6.08, p=.048. The access and continuity of 
care domain demonstrated higher unmet need at Time 1 (Md=1) with Time 2 
(Md=0) and Time 3 (Md=0) reporting no unmet need X2 (2, N=29) = 6.53, 
p=.038. The relationships and emotional health domain identified the highest 
unmet need at Time 1 (Md=12,) and Time 2 (Md=12) with Time 3 (Md=8) the 
lowest X2 (2, N=29) = 6.69, p=.035. A significant difference was not reported 
for the information domain (X2 (2, N=29) = 2.04, p=.360). 
 
In the intervention group, scores decreased from Time 1 to Time 3 for total 
scale (z=–2.15, p=.031, r=.28); and access and continuity of care domain scores 
(z=–2.31, p=.021, r=.30) both with a small–moderate effect size. All other 
results had a small effect size and were not statistically significant. 
 
The Kruskal–Wallis test revealed no significant distribution across 
lymphoma type. The intervention >60 years age group had very low scores 
for access and continuity of care domain at Time 2 compared with the other 
two age groups (Md=0 vs Md=2, 18–29 years and Md=2.5, >60 years; p=.012). 
Although there was a disproportionate number of males to females, women 
had significantly higher scores at Time 1 (Md=41 vs Md 16; p=.046), 
particularly evident in the relationships and emotional health domain 
(Md=21 vs Md=7; p=.007). Conversely, at Time 3, men recorded a significantly 
higher median than women (Md=2 vs Md=0; p=.024) in the information 
domain. The control group results revealed more unmet needs in the 30–59 
years age group at Time 1 (Md=25.5 vs Md=18, 18–29 years and Md=13, >60 
years; p=.016), and these were significantly higher in the financial concerns 
(Md=9 vs Md=3, 18–29 years and Md=6, >60 years; p=.019) and access and 
continuity of care domains (Md=2.5 vs Md=1, 18–29 years and >60 years; 
p=.012). This continued to be an unmet need for this age group at Time 3 for 
the access and continuity of care domain (Md=4 vs Md=1, 18–29 years and 
CHAPTER 6. RESULTS 
158 
Md=0, >60 years; p=.023). Women in the control group had significantly 
higher scores at Time 1 (Md=24 vs Md 17; p=.034), especially in the 
relationships and emotional health domain (Md=13 vs Md=5.5; p=.004). 
 
Intervention group mean scores were highest at Time 1 (M=27.33) and 
continued to decrease over the study period. The domain with the most 
significant decrease was the access and continuity of care domain. The 
control group scores were highest at Time 2 (M=28.62); nonetheless were not 
significant. 
 
Independent t-tests, conducted to compare total scale and domain scores 
across the time points, demonstrated higher mean scores in the control group 
compared with the intervention group. The relationships and emotional 
health domain scores for the control group increased over the study period. 
All scores had a small effect size and no results were significant. 
 
Individual items on the SF-SUNS were also assessed to identify specific 
aspects of unmet need. Significant differences were found indicating that the 
intervention group at Time 1 reported a higher level of need for finding 
information about complementary or alternative therapies (M=0.87, SD=1.04, 
Md=0) than the control group (M=0.27, SD=0.52, Md=0) [U 592, z 2.45, p=.014, 
r .32]. Time 3 results indicated the control group felt less able to speak to 
others about their emotions or deal with feeling depressed (Table 6.1.7). 
Although not significant, six control group participants (21%) continued to 
record high / very high unmet needs for fear of recurrence at Time 2 and 3. 
Likewise, the control group reported more unmet cognition impairment 
(n=20, 34%) at study completion. Both concerns documented by intervention 
participants on the SCPTS. 
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LMM analysis, adjusting for gender, lymphoma type and age, reported 
group (control or intervention), time (1, 2 or 3), and lymphoma type (NHL or 
HL) were not significantly associated with the SF-SUNS (Appendix L). The 
LMMs for the domains (Table 6.1.3) reported a significant effect for time in 
the information domain, showing Time 1 scores were higher (p=.025). The 
LMM for the financial domain reported those with NHL had higher scores 
compared to those with HL (p=.010). The access and continuity of care 
domain LMM reported those with NHL had higher scores compared to those 
with HL (p=.021) and as age increased, unmet needs in this domain 
decreased (p=.039). The LMM for the relationships and emotional health 
domain reported that women had more unmet needs compared to males 
(p=.010). 
 
13Table 6.1.3 Linear Mixed Model Results of SF-SUNS Domains  
Variable Beta 
Estimate 
Std. 
Error 
95% Confidence 
Interval 
P Value 
Lower Upper 
Information Domain      
Intercept 3.23 1.00 1.20 5.22 .002 
Group—Controla 0.37 0.67 –0.97 1.70 .585 
Lymphomab (NHL) 0.50 0.81 –1.12 2.13 .536 
Genderc (Male) –0.65 0.66 –1.97 0.68 .332 
Time 1d 0.76 0.33 0.10 1.42 .025 
Time 2d 0.36 0.33 –0.30 1.02 .287 
Age –0.02 0.02 –0.06 0.02 .276 
Financial Concerns 
Domain 
     
Intercept 7.70 2.62 2.44 12.94 .005 
Group—Controla –1.40 1.76 –4.93 2.14 .434 
Lymphomab (NHL) 5.70 2.15 1.40 10.00 .010 
Genderc (Male) –1.56 1.75 –5.06 1.94 .376 
Time 1d 0.83 0.66 –0.47 2.13 .209 
Time 2d 1.00 0.66 –0.31 2.30 .133 
Age –0.80 0.05 –0.18 0.02 .105 
Access and Continuity 
of Care Domain 
     
Intercept 4.23 1.58 1.12 7.44 .009 
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Group—Controla –0.81 1.06 –2.93 1.31 .448 
Lymphomab (NHL) 3.05 1.29 0.47 5.62 .021 
Genderc (Male) –0.97 1.05 –3.07 1.13 .360 
Time 1d 0.94 0.48 –0.01 1.90 .053 
Time 2d 0.49 0.48 –0.47 1.44 .316 
Age –0.06 0.03 –0.12 –0.00 .039 
Relationships and 
Emotional Health 
Domain 
     
Intercept 20.54 4.63 11.28 29.81 .000 
Group—Controla –1.75 3.11 –7.99 4.49 .577 
Lymphomab (NHL) 4.59 3.79 –3.00 12.18 .231 
Genderc (Male) –8.20 3.09 –14.39 –2.02 .010 
Time 1d 0.93 1.19 –1.42 3.28 .435 
Time 2d 1.97 1.19 –0.39 4.33 .100 
Age –0.11 0.09 –0.28 0.06 .211 
Note. Bolded p value indicates statistical significance p<.05; a Comparison group set 
to zero (Intervention); b Comparison group set to zero (HL); c Comparison group set 
to zero (Female); d Comparison group set to zero (Time 3) 
 
Psychological distress (DASS21) 
Friedman tests performed on the intervention group did not identify 
significant differences on the total scale and domain scores between the three 
time points. Total scale scores revealed the highest levels were at Time 1 
(Md=10) and Time 2 (Md=10) with Time 3 (Md=8) the lowest (X2 (2, N=29) = 
1.55, p=.462). Domain results revealed higher levels of depression at Time 2 
(Md=3), then Time 1 (Md=2), with Time 3 (Md=1) the lowest (X2 (2, N=29) = 
3.12, p=.210). This result was reflected in the stress domain with higher levels 
identified at Time 2 (Md=5) then Time 1 (Md=4) and Time 3 (Md=4) (X2 (2, 
N=29) = 4.00, p=.135). Greater levels of anxiety were identified at Time 1 
(Md=3) and Time 2 (Md=3) with Time 3 (Md=2) lower (X2 (2, N=29) = 0.16, 
p=.923). 
 
A Wilcoxon Signed Rank Sum test revealed no significant differences in the 
intervention group, and all results had a small effect size. There were no 
significant differences in the distribution of scores across age groups, gender 
CHAPTER 6. RESULTS 
161 
or lymphoma type in the intervention group. The control group 
demonstrated a significant difference in the distribution of total scale scores 
across gender at Time 2, with women reporting higher scores (Md=16 vs Md 
5; p=.022). Domain scores revealed women had higher levels in the 
depression domain at Time 1 (Md=2.5 vs Md 1; p=.039) and Time 2 (Md=6 vs 
Md 0; p=.016), and anxiety domain at Time 2 (Md=3.5 vs Md=1; p=.017). No 
significant results were reported across age group or lymphoma type. No 
significant results were identified in the control group; however, total scale 
scores did decrease over the study period. 
 
Independent t-tests revealed no significant results in either the control or 
intervention groups. Intervention group mean scores were highest at Time 2 
(M=15.63), and although they had decreased by Time 3 (M=13.03), they 
continued to reflect higher mean scores than at Time 1 (M=12.67). 
Intervention group mean anxiety (M=3.53) and stress (M=6.80) domain scores 
were slightly higher at Time 2, with stress mean scores higher at Time 3 
(M=5.66) than at Time 1 (M=5.17). Control group mean scores revealed Time 
1 (M=15.57) and Time 3 (M=15.14) scores were higher compared with the 
intervention group, with the Time 2 mean anxiety domain score highest 
(M=3.63) when compared with the intervention group. 
 
Individual items on the DASS21 were assessed to detect specific traits of 
psychological distress. Results did not reveal any significant differences in 
the items between the two groups at any time point. 
 
LMM examining DASS21 total scale score and domains (Table 6.1.4), 
adjusting for gender, lymphoma type and age, reported no significant group 
(control or intervention) or time (1, 2 or 3) effects. However, women reported 
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higher scores compared with men for all DASS21 models: Total scale 
(p=.013); depression (p=.032); anxiety (p=.007); and stress (p=.029). 
 
14Table 6.1.4 Linear Mixed Model Results of the DASS21 
Variable Beta 
Estimate 
Std. 
Error 
95% Confidence 
Interval 
P Value 
Lower Upper 
Total Scale      
Intercept 17.12 5.12 6.86 27.38 .001 
Group—Controla –2.75 3.45 –9.66 4.17 .429 
Lymphomab (NHL) 5.77 4.20 –2.64 14.19 .175 
Genderc (Male) –8.75 3.42 –15.60 –1.90 .013 
Time 1d 0.16 1.23 –2.28 2.60 .897 
Time 2d 0.95 1.23 –1.49 3.40 .441 
Age –0.02 0.09 –0.21 0.17 .857 
Depression Domain      
Intercept 4.67 1.99 0.68 8.66 0.23 
Group—Controla –1.34 1.34 –4.02 1.35 .322 
Lymphomab (NHL) 2.05 1.63 –1.21 5.32 .213 
Genderc (Male) –2.92 1.33 –5.58 –0.26 .032 
Time 1d –0.21 0.52 –1.24 0.82 .683 
Time 2d 0.53 0.52 –0.50 1.56 .309 
Age 0.01 0.04 –0.06 0.09 .744 
Anxiety Domain      
Intercept 3.91 1.44 1.03 6.79 .009 
Group—Controla –0.76 0.96 –2.69 1.12 .433 
Lymphomab (NHL) 1.06 1.17 –1.29 3.40 .370 
Genderc (Male) –2.70 0.96 –4.61 –0.78 .007 
Time 1d 0.56 0.43 –0.30 1.42 .202 
Time 2d 0.08 0.44 –0.78 0.94 .852 
Age 0.01 0.03 –0.39 0.07 .589 
Stress Domain      
Intercept 8.65 2.12 4.40 12.90 .000 
Group—Controla –0.74 1.43 –3.59 2.12 .607 
Lymphomab (NHL) 2.69 1.73 –0.78 6.17 .126 
Genderc (Male) –3.16 1.41 –5.99 –0.33 .029 
Time 1d –0.28 0.59 –1.44 0.88 .632 
Time 2d 0.24 0.59 –0.93 1.40 .685 
Age –0.04 0.04 –0.12 0.04 .276 
Note. Bolded p value indicates statistical significance p<.05; a Comparison group set 
to zero (Intervention); b Comparison group set to zero (HL); c Comparison group set 
to zero (Female); d Comparison group set to zero (Time 3) 
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Adjustment to cancer (Mini-MAC) 
Friedman tests on the intervention group did not identify significant 
differences on the total scale scores between the three time points (X2 (2, 
N=29) = 3.75, p=.154). However, a significant result in the fighting spirit 
domain was identified, with the highest level of fighting spirit evident at 
Time 1 (Md=13) then Time 3 (Md=12) with Time 2 (Md=11) the lowest (X2 (2, 
N=29) = 12.00, p=.002). Other domains reported no significant differences: 
fatalism (X2 (2, N=29) = 1.35, p=.508); helplessness/hopelessness (X2 (2, N=29) = 
1.12, p=.572); anxious preoccupation (X2 (2, N=29) = 0.73, p=.695); and 
cognitive avoidance (X2 (2, N=29) = 0.08, p=.959). 
 
A Wilcoxon Signed Rank test on the intervention group revealed a decrease 
in scores from Time 1 to Time 2 (z –2.60, p=.009, r .34) with a small–moderate 
effect size in the fighting spirit domain for the intervention group. All other 
results had a small effect size and were not significant. 
 
Those with NHL in the intervention group reported significantly lower 
median scores at Time 1 on the total scale scores (Md=58 vs Md 72.5; p=.009), 
in the anxious preoccupation (Md=13 vs Md 20.5; p=.010) and cognitive 
avoidance (Md=8 vs Md 10; p=.037) domains. Significant results were not 
identified at other time points or in gender or age groups. Conversely the 
control group’s 30–59 years age group had the highest total scale scores at 
each time point in comparison with the other two groups (Time 1: Md=72.5 
vs Md=64, 18–29 years and Md=63, >60 years; p=.040. Time 2: Md=77 vs 
Md=59, 18–29 years and Md=63, >60 years; p=.012. Time 3: Md=73 vs Md=61, 
18–29 years and Md=57, >60 years; p=.019). Higher scores in this group were 
notable at Time 2 in the helplessness/hopelessness (Md=15 vs Md=8, 18–29 
years and >60 years; p=.011) and anxious preoccupation (Md=21 vs Md=15, 
18–29 years and Md=14, >60 years; p=.011) domain scores. Anxious 
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preoccupation scores at Time 3 were likewise higher (Md=22 vs Md=17, 18–29 
years and Md=15, >60 years; p=.023). The cognitive avoidance domain 
revealed the 30–59 years age group had the highest scores compared with the 
other two groups at Time 1 (Md=12 vs Md=10, 18–29 years and Md=8, >60 
years; p=.005) and Time 3 (Md=12 vs Md=9, 18–29 years and >60 years; 
p=.017). One aberration to this trend was noted at Time 2 in the fatalism 
domain where scores revealed those >60 years of age had significantly higher 
scores compared with the other two groups (Md=16 vs Md=11, 18–29 years 
and Md=14, 30–59 years; p=.029). A significant distribution of fatalism scores 
revealed NHL participants recorded higher scores at Time 1 (Md=16 vs 
Md=12; p=.013), Time 2 (Md=15 vs Md=10; p=.010) and Time 3 (Md=14 vs 
Md=10; p=.015) compared with those diagnosed with HL. However, it should 
be noted there were more NHL participants in this group than HL. The 
fighting spirit domain at Time 3 showed a significant difference with NHL 
participants recording a higher median (Md=12 vs Md=10; p=.039). No 
significant differences in the distribution of gender scores were reported. 
 
The fighting spirit domain in the intervention group identified a significant 
decrease from Time 1 to Time 2 (p=.009). Likewise, the fighting spirit domain 
(p=.002), along with anxious preoccupation (p=.037) was significant in the 
control group at Time 1 to Time 3. Independent t-tests that compared both 
groups at each of the three time points did not identify significant 
differences. For the intervention group, total scale and domain mean scores 
decreased from Time 1 to Time 3, with the exception of cognitive avoidance 
domain mean score which was highest at Time 2 (M=8.80; p=.043). Results of 
the independent t-tests revealed the control group had a decrease in scores 
across the domains; fatalism, fighting spirit and anxious preoccupation over 
the study period. Fatalism and fighting spirit scores were lower for the 
control group when compared with the intervention group. In contrast, the 
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helplessness/hopelessness (M=12.62 vs M=12.00) and cognitive avoidance 
(M=10.14 vs M=8.52) domain scores continued to increase and were highest 
in this group when compared with the intervention group at Time 3; 
however, the results were not significant. 
Individual items on the Mini-MAC were evaluated to detect any specific 
areas where either group had greater concerns. Significant differences were 
found at Time 2 indicating the control group struggled more with having a 
cancer diagnosis and trying not to think about it (Table 6.1.7). For the control 
group, trying not to think about having cancer was still an issue at Time 3 
(Table 6.1.7). 
 
LMM analysis of the Mini-MAC and domains fighting spirit and fatalism, 
adjusting for gender, lymphoma type and age, reported group (control or 
intervention), gender and lymphoma type were not significant contributors 
(Table 6.1.5). For all Mini-MAC models, total scale (p=.020), fatalism (p=.035) 
and fighting spirit (p=.029) domain scores were higher at Time 1 (Table 6.1.5). 
In addition, for the LMM fatalism domain, scores increased as age increased 
(p=.005). For the fighting spirit domain, a significant interaction between 
group and time was found, reporting that the control group had a higher 
fighting spirit domain score at Time 2 (p=.049). No significant results were 
found in the LMM for other domains; helplessness/hopelessness, anxious 
preoccupation and cognitive avoidance (Appendix L). 
 
15Table 6.1.5 Linear Mixed Model Significant Results of Mini-MAC  
Variable Beta 
Estimate 
Std. 
Error 
95% Confidence 
Interval 
P 
Value 
Lower Upper  
Total scale      
Intercept 67.65 5.49 56.65 78.64 .000 
Group—Controla 1.38 3.70 –6.04 8.80 .711 
Lymphomab (NHL) 0.09 4.51 –8.93 9.12 .983 
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Genderc (Male) –5.29 3.67 –12.64 2.07 .155 
Time 1d 2.93 1.25 0.46 5.40 .020 
Time 2d 1.97 1.25 –0.50 4.44 .117 
Age –0.03 0.10 –0.23 0.17 .780 
Fatalism Domain      
Intercept 10.87 1.17 8.53 13.21 .000 
Group—Controla –0.65 0.79 –2.23 0.92 .411 
Lymphomab (NHL) 0.01 0.96 –1.91 1.93 .992 
Genderc (Male) –0.40 0.78 –1.96 1.16 .609 
Time 1d 0.69 0.32 0.05 1.33 .035 
Time 2d 0.57 0.32 –0.07 1.21 .081 
Age 0.06 0.02 0.02 0.11 .005 
Fighting Spirit Domain      
Intercept 11.71 0.95 9.82 13.61 .000 
Group—Controla –.031 0.70 –1.70 1.09 .665 
Lymphomab (NHL) 1.09 0.76 –0.44 2.62 .159 
Genderc (Male) 0.36 0.62 –0.89 1.60 .571 
Time 1d 0.83 0.38 0.08 1.58 .029 
Time 2d –0.24 0.38 –0.98 0.51 .531 
Age –0.02 0.02 –0.06 0.01 .211 
Group—Controla * Time 1 d 0.38 0.53 –0.68 1.43 .480 
Group—Controla * Time 2 d 1.06 0.53 0.01 2.12 .049 
Note. Bolded p value indicates statistical significance p<.05; a Comparison group set 
to zero (Intervention); b Comparison group set to zero (HL); c Comparison group set 
to zero (Female); d Comparison group set to zero (Time 3) 
 
Patient empowerment (PES) 
No significant difference was reported on the Friedman test conducted on 
the intervention group. Results identified an increase from Time 1 (Md=49) to 
Time 2 (Md=51) with Time 3 (Md=52) the highest empowerment scores (X2 (2, 
N=29) = 4.71, p=.095). A Wilcoxon Signed Rank test revealed no significant 
increase in empowerment scores at Time 1 to Time 2 or Time 1 to Time 3 in 
the intervention group; all results had a small effect size. 
 
The distribution of scores from the intervention group, as measured by the 
Kruskal–Wallis test, was similar across the age groups, gender and 
lymphoma types. In the control group, results indicated a significant 
distribution of higher scores for the >60 years age group at Time 1 (Md=54 vs 
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Md=46, 18–29 years and Md=47, 30–59 years; p=.010), Time 2 (Md=50 vs 
Md=44, 18–29 years and 30–59 years; p=.011) and Time 3 (Md=51 vs Md=44, 
18–29 years and Md=45, 30–59 years; p=.024), demonstrating more 
empowerment. At Time 2, men had the highest scores (Md=48 vs Md=44; 
p=.036). Those with NHL had the highest scores at Time 1 (Md=50.5 vs 
Md=43.5; p=.010) and Time 2 (Md=48 vs Md=42; p=.014). 
 
Paired-sample t-tests indicated the highest level of empowerment in the 
intervention group was at Time 2 and Time 3; however, these were not 
significant results. Whereas control group results identified a significant 
decrease from Time 1 to Time 2 (p=.005) in the level of empowerment this 
group recorded. Although not significant, the lowest scores were recorded at 
Time 3. The highest empowerment scores were identified in the intervention 
group compared with the control group at Time 2 (M=49.50 vs M=45.79; 
p=.016). No further significant results were identified. 
 
Individual items on the PES revealed significant differences for the control 
group. The results indicated the control group felt less adept at making 
lifestyle changes at Time 2 and Time 3 and at Time 1 indicated a need for 
support from family and friends. This was in contrast to the intervention 
group where results indicated they had all the information they needed to 
manage their health and adapt to and make lifestyle changes at Time 2 and 
Time 3 (Table 6.1.7). 
 
The LMM for the PES, adjusting for gender, lymphoma type and age, 
reported no significant group (control or intervention), lymphoma, gender or 
time (1, 2 or 3) effects (Table 6.1.6). However, a significant group x time 
interaction was reported indicating Time 1 scores were higher in the control 
group (p=.013) and then decreased over the study period. 
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16Table 6.1.6 Linear Mixed Model Results of PES 
Variable Beta 
Estimate 
Std. 
Error 
95% Confidence 
Interval 
P 
Value 
Lower Upper 
Intercept 45.19 2.07 41.05 49.32 .000 
Group—Controla –2.71 1.55 –5.79 0.38 .085 
Lymphomab (NHL) 0.95 1.65 –2.36 4.26 .569 
Genderc (Male) 1.70 1.35 –1.00 4.40 .213 
Time 1d –1.76 0.90 –3.55 0.04 .055 
Time 2d –0.59 0.90 –2.38 1.20 .516 
Age 0.06 0.04 –0.01 0.14 .093 
Group—Controla * Time 1 d 3.21 1.28 0.68 5.74 .013 
Group—Controla * Time 2 d –0.83 1.28 –3.36 1.71 .521 
Note. Bolded p value indicates statistical significance p<.05; a Comparison group set 
to zero (Intervention); b Comparison group set to zero (HL); c Comparison group set 
to zero (Female); d Comparison group set to zero (Time 3) 
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17Table 6.1.7 Assessment Measure Items that Demonstrated a Statistically Significant Difference between Control and Intervention 
Groups  
Measure  
Time 
Item 
Control 
Group 
Mean (SD) 
Median 
Intervention 
Group  
Mean (SD) 
Median 
Test Pool Effect* Effect 
Size # 
SF-SUNS 
Time 1  
Finding information about complementary or alternative therapies 
 
Time 3 
Telling others how I was feeling emotionally 
 
Dealing with feeling depressed 
 
 
0.27 (0.52) 0 
 
 
1.10 (1.01) 1 
 
1.24 (1.33) 1 
 
 
0.87 (1.04) 0 
 
 
0.21 (0.82) 0 
 
0.62 (0.98) 0 
 
 
U 592, z 2.45, p .014 
 
 
U 186.50, z –4.25, p .000 
 
U 302.50, z –1.99, p .047 
 
 
r .32 
 
 
r .55 
 
r .26 
Mini-MAC 
Time 2 
I have difficulty believing this happened to me 
 
I deliberately push all thoughts of cancer out of my head 
 
Time 3 
Not thinking about it helps me cope 
 
I deliberately push all thoughts of cancer out of my head 
 
 
2.76 (0.95) 3 
 
2.59 (0.98) 3 
 
 
2.48 (0.98)3 
 
2.48 (0.87) 3 
 
 
2.20 (1.03) 2 
 
2.03 (0.96) 2 
 
 
1.97 (0.98) 2 
 
2.03 (1.02) 2 
 
 
U 301, z –2.11, p .035 
 
U 301, z –2.12, p .034 
 
 
U 296, z –2.03, p .042 
 
U 297, z –2.00, p .046 
 
 
r .27 
 
r .28 
 
 
r .27 
 
r .26 
PES 
Time 1 
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I need the support of family and friends 
 
Time 2 
I have all the information I need to manage my illness 
 
I can adapt to changes in my lifestyle 
 
Health professionals are happy to include me in decisions related 
to my illness 
 
I accept that I have to change my lifestyle 
 
Time 3 
I am capable of handling my illness 
 
I have all the information I need to manage my illness 
 
I am capable of helping health professionals reach decisions related 
to my illness 
 
I accept that I have to change my lifestyle 
 
I have a lot of confidence in my local GP 
3.77 (0.43) 4 
 
 
3.03 (0.63) 3 
 
3.03 (0.78) 3 
 
3.28 (0.53) 3 
 
 
2.86 (0.74) 3 
 
 
3.28 (0.59) 3 
 
3.14 (0.64) 3 
 
3.31 (0.54) 3 
 
 
2.83 (0.89) 3 
 
3.03 (0.98) 3 
3.43 (0.73) 4 
 
 
3.47 (0.63) 4 
 
3.40 (0.68) 3 
 
3.53 (0.82) 4 
 
 
3.30 (0.65) 3 
 
 
3.62 (0.49) 4 
 
3.59 (0.57) 4 
 
3.62 (0.56) 4 
 
 
3.34 (0.67) 3 
 
3.59 (0.63) 4 
U 338, z –1.99, p .047 
 
 
U 590, z 2.66, p .008 
 
U 553, z –1.98, p .048 
 
U 570, z 2.33, p .020 
 
 
U 568, z 2.28, p .023 
 
 
U 547, z 2.24, p .025 
 
U 577, z 2.17, p .007 
 
U 546, z 2.23, p .026 
 
 
U 556, z 2.29, p .022 
 
U 564, z 2.45, p .014 
r .26 
 
 
r .35 
 
r .26 
 
r .30 
 
 
r .30 
 
 
r .29 
 
r .36 
 
r .29 
 
 
r .30 
 
r .32 
Note. Significance level 0.05 (2-tailed); *Mann–Whitney U test; #Effect size r=z/square root N (total number of cases). Therefore r=z/7.7 (60 cases), 
7.68 (59 cases), 7.6 (58 cases). 0.2=small effect, 0.5=moderate effect, 0.8=large effect  
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6.2 Results of the General Practitioner 
Evaluation 
Statistical Techniques 
The data collected from the GP evaluations were analysed using descriptive 
statistics and content analysis for open-ended items. A Likert-type scale was 
used to assess four items on the usefulness of the SCPTS content (1=very 
poor, 2=poor, 3=adequate, 4=good, 5=very good). Cronbach’s alpha of 0.93 
indicated these items were reliable. 
 
Results 
Twenty-eight GPs who had received an SCPTS six months previously for 
intervention participants were sent the SCPTS evaluation. Although the 
study randomised 30 participants to the intervention group, two participants 
did not have a GP during the study. One GP had two participants in the 
study and chose only to respond once. Five further participants had not seen 
their GP during the study; however, two GPs sent back an evaluation stating 
they had not seen the participant. The overall response rate was 64% (18 
evaluations returned). A number of strategies were employed to maximise 
evaluation return such as follow-up phone calls which resulted in one 
evaluation return. Although five medical practices were faxed another copy 
of the documents, this did not result in the return of an evaluation. 
Participants were also encouraged to remind the GP to fill out an evaluation. 
Three patients requested a copy of the evaluation they could personally hand 
over at their next GP visit, this resulted in one evaluation returned. 
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Of the GPs who did not return an evaluation (n=10, 36%), seven were male, 
eight had metropolitan medical practice addresses and two were regional. 
No further information was collected.  
 
Of the GPs who did return an evaluation (n=18, 64%), 11 (61%) were male, 
and the majority were metropolitan based (n=16, 89%). The range of years 
practicing as a GP were; 6–14 years (n=2, 11%), 15–20 years (n=6, 33%) and 
25–30 years (n=10, 56%). Responses to use of the SCPTS are reported in Table 
6.2.1. 
18Table 6.2.1 Responses to Use of SCPTS (n=18) 
Item Yes 
N (%) 
No 
N (%) 
Not Applicable 
N (%) 
Seen patient in last 6 
months 
16 (89) 2 (11)  
Received SCPTS 16 (89) 2 (11)  
Read on receipt 16 (89) 1 (5.5) 1 (5.5) 
GP initiated appointment 6 (33) 11 (61) 1 (5.5) 
Participant initiated 
appointment 
7 (39) 10 (55) 1 (5.5) 
Participant brought SCPTS 8 (44) 7 (39) 3 (17) 
SCPTS discussed with 
participant 
11 (61) 4 (22) 3 (17) 
GP Initiated Support 9 (50) 6 (33) 3 (17) 
 
GPs' perception of the usefulness of the SCPTS was evaluated. Sixteen GPs 
responded to this section and responses are reported in Table 6.2.2. 
Responses ranged from adequate to very good. As indicated, the majority of 
GPs (n=13, 81%) perceived the SCPTS was good to very good. 
 
An open-ended section investigated what further information GPs would 
like on the SCPTS. Ten (56%) GPs provided responses which included: 
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haematologist contact details or other treatment details (psychological 
support implemented or planned); frequency of haematology review; what 
blood tests the GP needed to order; drug names written in full rather than 
use of acronyms; vaccination schedule post-autologous transplant; 
peripheral neuropathy management; potential fertility issues; and ‘brain 
training’ (? for cognitive impairment).  
 
19Table 6.2.2 Description of GP Responses (n=16) 
 Raw Scoring (N) Mean (SD) [Range] 
Usefulness of treatment 
information 
Adequate (2) 
Good (8) 
Very good (6) 
4.25 (0.68) [3–5] 
Usefulness of survivorship 
care plan information 
Adequate (3) 
Good (7) 
Very good (6) 
4.19 (0.75) [3–5] 
Usefulness of patient-derived 
health concerns, goals and 
actions 
Adequate (1) 
Good (12) 
Very good (3) 
4.13 (0.50) [3–5] 
Usefulness of SCPTS for 
patient 
Adequate (2) 
Good (9) 
Very good (5) 
4.19 (0.66) [3–5] 
Total combined scores  16.75 (2.38) [12–20] 
 
GPs were queried if any information was not required on the SCPTS; n=6 
(34%) responded: four (67%) indicated no information needed to be 
removed; one GP wrote it was ‘all good’, and one indicated the information 
‘was really well presented’. 
 
Over half of GP respondents (n=10, 56%) took up the opportunity to make 
additional comments. Responses were dichotomised as: positive (“As far as 
questionnaires go this was excellent. Concise and brief”, “Great idea”); 
neutral (“Rang when I learnt of diagnosis to offer follow-up. I did not ring 
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again when I got the plan”, “Diagnosed the lymphoma and not seen him 
since”, “nothing further to add”); or negative (“Not clear what you expect GP 
to follow-up [or] what follow-up provided by haematology clinic. I expect a 
letter with instructions once you discharge from your service”, “further 
comments are pointless”). 
 
GPs were solicited if they would like further education on the management 
of haematology survivors, n=13 (72%) responded (yes=4, 31%, no=9, 69%). 
Those who responded ‘yes’, indicated they would like education either in a 
workshop or online n=1, online or a learning package n=1, online n=2. Three 
GPs indicated they would like further education on other haematology 
malignancies, case studies, post-treatment vaccinations. 
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6.3 Results of Qualitative Interviews  
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Qualitative Results from a Phase II Pilot Randomised 
Controlled Trial of a Lymphoma Nurse-led Model of 
Survivorship Care. 
 
Abstract 
Purpose: To explore and describe lymphoma survivors’ thoughts and 
perceptions of the components of a nurse-led lymphoma survivorship clinic 
intervention.  
 
Methods: An exploratory, qualitative descriptive study using interviews 
from 10 participants who had transitioned post-treatment into the 
survivorship phase via a nurse-led lymphoma survivorship clinic 
intervention. 
 
Results: Thematic analysis revealed three major themes: Reassurance and 
individualised care; Information and support; and Empowerment. 
Participants described the reassurance they gained from having contact with 
a health professional post-treatment who individualised information and 
support. A survivorship care plan and treatment summary was developed 
for this study and was believed to be very patient-centred and helpful. This 
enabled participants to take back control of their health and well-being and 
to rebuild confidence.  
 
Conclusions: In this study, participants expressed a need for patient-centred 
follow-up care that addressed their concerns and supported them in the 
survivorship phase to get their life back on track. Nurse-led follow-up may 
offer a viable model of post-treatment survivorship care to lymphoma cancer 
survivors. 
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Introduction 
Lymphomas are haematological cancers that originate from the lymphatic 
system, and are mainly categorised as either Hodgkin (HL) or non-Hodgkin 
lymphoma (NHL) (American Cancer Society, 2014). Worldwide, lymphomas 
represent the sixth most commonly diagnosed cancer (Surveillance 
Epidemiology and End Results (SEER), 2014). Australian incidence is 
increasing with an estimated 6,323 cases expected in 2017, which will equate 
to 4.6% of all cancer cases (Cancer Australia, 2017). However, developments 
in treatment and supportive care options such as chemotherapy, 
haematopoietic stem cell transplantation, radiotherapy and targeted 
therapies have improved five year survival to 76% (Cancer Australia, 2017). 
With increased remission and survival rates, many survivors experience 
issues and concerns, called unmet needs, which can impact quality of life and 
well-being (Carey et al., 2012; Sant et al., 2014). These can relate to issues 
such as: fatigue; poor nutrition; exercise capacity; cognition impairment; fear 
of recurrence; fertility, relationships; finances; employment; and insurance 
(Taylor et al., 2015; van der Poel et al., 2014). Health can be further 
compromised by late effects of treatment such as cardiovascular disease and 
second cancers (Grinyer, 2010; Ng et al., 2011; Travis et al., 2012), often 
experienced earlier than the general population (Panek-Hudson, 2013).  
 
Haematological survivorship studies mainly report on mixed haematological 
samples regardless of variations in clinical features, treatment, curability and 
relative survival (Hall, Campbell, et al., 2013; Lobb et al., 2009; McGrath, 
2014). A study of lymphoma (n=236) and myeloma (n=178) survivors on 
anxiety, depression and unmet needs in the early survivorship period (under 
two years) reported decreasing anxiety and depression rates in the myeloma 
cohort and increasing rates in the lymphoma cohort (Oberoi et al., 2017). The 
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authors indicated a need for cohort specific studies, especially in the early 
survivorship period (Oberoi et al., 2017) to ensure targeted support. 
Lymphoma only studies often reflect a survivorship period beyond two 
years at assessment (Ferrer, Huedo-Medina, Johnson, Ryan, & Pescatello, 
2011; Friedman et al., 2010; Oerlemans et al., 2014), which may not reflect the 
unique needs of those who have recently completed treatment, limiting 
generalisability. A recent study by the authors (Monterosso et al., 2017) 
reported on focus groups with lymphoma survivors (n=17), the majority 
(n=13, 76%) who were 12–30 months post-treatment completion. Participants 
recounted unmet needs related to information, coping strategies and 
support, especially when transitioning into survivorship. Findings suggested 
cancer nurse coordinators could be a feasible approach to delivering 
structured, individualised support early post-treatment (Monterosso et al., 
2017).  
 
Nurse-led models of survivorship care have been proposed to transition 
patients post-treatment and have demonstrated acceptable outcomes in 
haematology cohorts (Gates et al., 2015; Howell et al., 2012; John & Armes, 
2013). As a minimum, nurse-led models should include: administration of 
survivor-specific needs assessments to identify patient concerns (McDowell 
et al., 2010; Stricker et al., 2011); development and delivery of a survivorship 
care plan and treatment summary (SCPTS), to guide holistic follow-up 
(Clinical Oncology Society of Australia, 2016; MacMillan Cancer Support & 
NHS Improvement, 2010; McCabe, Bhatia, et al., 2013); and support to assist 
survivors to take ownership of their health and well-being (Bodenheimer et 
al., 2002; Kuijpers et al., 2013). To date, studies that have tested nurse-led 
models of care have focused on survivors of common cancers (breast, 
prostate, colon) (Jefford et al., 2016; Maly et al., 2017; Taylor et al., 2015), been 
based in acute care settings, used long consultations, and involved more 
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frequent patient contact (Cooper et al., 2010; De Leeuw & Larsson, 2013), 
which may preclude generalisability to other cancers or limit economic 
viability.  
 
In order to provide lymphoma survivors with specific and responsive 
supportive care, the unique issues and unmet concerns of this cohort need to 
be assessed in the early survivorship period (under one year). The aim of this 
sub-study was to provide qualitative semi-structured interview data from a 
sample of participants who had been randomised to the intervention group 
of the Care After Lymphoma (CALy) phase II randomised controlled trial 
study (RCT) (Taylor et al., 2016). The RCT aimed to develop and test a nurse-
led lymphoma survivorship clinic (NLSC) intervention to assist participants 
transitioning from treatment completion into the early survivorship phase. 
This study will add to the limited literature that exists in lymphoma specific 
early survivorship. 
 
Methods 
Methodological framework 
A qualitative descriptive methodology was utilised to provide a 
comprehensive summary of a specific experience by the participants 
(Neergaard, Olesen, Andersen, & Sondergaard, 2009; Sandelowski, 2000), 
using a semi-structured interview design. The interview schedule consisted 
of the same open-ended questions and was developed by the researchers. To 
ensure participants felt able to express themselves and their perceptions 
freely, interviews were conducted by an experienced independent 
researcher.   
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Sample and setting  
A purposive sample of lymphoma patients from a large tertiary hospital 
cancer centre in Perth, Western Australia were recruited from the 
intervention group of the RCT. A non-probability purposive sampling 
provides rich information from participants who have the greatest amount of 
in-depth knowledge and experience of a particular circumstance or event 
(Patton, 2014). Only participants who had completed all aspects of the NLSC 
intervention were approached by the survivorship cancer nurse conducting 
the clinic intervention. These participants had completed four measures: 
Short-Form Survivor Unmet Needs Survey (SF-SUNS); Depression Anxiety Stress 
Scale (DASS21); Mini Mental Adjustment to Cancer Scale (Mini-MAC); and 
Patient Empowerment Scale at three time points; baseline (prior to 
randomisation), 3 months and 6 months. At the first NLSC appointment 
(approximately one week after baseline), participants completed and 
received an individualised lymphoma SCPTS, developed for this study 
(Taylor et al., 2016). Participants’ GP were sent a copy. A motivational 
interview technique was used to provide evidenced-based information, 
advice and support at the first intervention appointment and reinforced with 
additional resources and support as required over the next two 
appointments.  
 
All participants approached agreed to be interviewed. Each participant was 
nine months’ post-treatment completion and the sample reflected an equal 
gender distribution and range of ages. Data saturation was achieved after ten 
interviews.  
 
Interviews 
The study was approved by the relevant hospital and university human 
research ethics committees. Informed written consent was obtained by all 
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participants prior to interview scheduling. Interviews were conducted from 
February 2016 to May 2017 and occurred after the last NLSC appointment. 
Telephone interviews were conducted at a time convenient for the 
participant and were digitally recorded. The following are examples of the 
interview questions: ‘Did you have any concerns or needs not addressed by 
any of the questions?’; ‘What aspects of the clinic would you want to stay the 
same for future patients?’; ‘Would you recommend the clinic to other 
patients finishing treatment?’; ‘How do you feel about having the health 
concerns, goals and actions individualised to yourself?’; and ‘Overall how 
useful was the SCPTS to you?’ Interviews were transcribed verbatim, de-
identified and an identifier code applied. Digital recordings and transcribed 
interviews were saved in a password-protected file on a secure server. After 
the first three interviews, the question order was slightly altered to enhance 
the flow of the interview. 
 
Data Analysis 
Interview transcripts were imported into NVivo 11 (NVivo 11, 2016) to 
facilitate management of data and completion of the analysis. Thematic 
analysis was used to establish patterns and themes within the text (Grbich, 
1998; Patton, 2014; Smith, 2007). Thematic analysis allows for participant 
diversity of ideas and perceptions (Smith, 2007), thus providing a depth of 
information regarding the personal impact of the NLSC on the participant. 
Subthemes were developed from the data and allowed for a logical 
organisation of the themes that emerged. The criteria of credibility, 
auditability and fittingness were applied to the data analysis process to 
ensure rigor (Beck, 1993). Credibility was maintained by triangulation with 
another member of the research team (Beck, 1993) to ensure independent 
reading and analysis of the transcripts by KT and CB who allocated codes 
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and themes to the generated data (Braun & Clarke, 2006). The researchers 
met to discuss the codes and any discrepancies before consensus on 
emerging themes was reached. The ample use of extracts or quotes from the 
data demonstrated fittingness to the agreed codes. A comprehensible audit 
trail maintained auditability, demonstrated by documentation of research 
planning through to analysis, and through a reflective discourse and debrief 
process with colleagues.  
 
Results 
Participants 
Ten semi-structured interviews were conducted with all participants willing 
to share an opinion for each of the interview guideline areas. Demographic 
and disease information is shown in Table 6.3.1. There were equal numbers 
of males and females, with similar age range (24 –74 years) and lymphoma 
type. The majority of participants resided within the metropolitan area (n=8, 
80%), were working (n=6, 60%), were married or defacto (n=6, 60%) and had 
a university degree or trade qualification (n=8, 80%). 
 
Time elapsed from end of study to interview ranged from 1 to 26 days (mean 
6.5 days, SD 7.8 days). The majority of interviews (n=8) were done within 5 
days. No time limit was set and interviews ranged from 17 minutes through 
to 48 minutes (mean 30.5 minutes).  
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20Table 6.3.1 Demographic Characteristics for Interview Participants (n=10) 
Characteristics Males n=5 
(50%) 
Females n=5 
(50%) 
Age group at baseline 
  24–25 
  48 
  65–74 
 
  2  
  1  
  2  
 
  2  
  1  
  2  
Lymphoma diagnosis 
  Non-Hodgkin 
  Hodgkin 
 
  2  
  3  
  
  2  
  3  
Highest level of education 
  Secondary school or less 
  Trade/vocational college 
  University 
   
  1  
  2  
  2  
   
  1  
  2 
  2 
Employment status 
  Working 
  Retired 
  No return to work date 
   
  4 
  1 
  – 
   
  2 
  2 
  1  
Marital status 
  Single 
  Married/defacto 
  Divorced 
  
  1 
  4 
  – 
   
  2 
  2 
  1  
Residence 
  Metropolitan 
  Regional 
  
  4  
  1  
  
  4 
  1 
 
Themes 
Three major themes emerged from analysis and coding of data: reassurance 
and individualised care; information and support; and empowerment. 
Subthemes have been included to add clarity. 
 
Reassurance and individualised care 
Overall, the NLSC was well received and deemed a positive experience for 
participants, although it would have been reassuring to know about the 
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clinic intervention during treatment. The assessment questionnaires and the 
SCPTS were perceived to facilitate individualised care.  
 
Timing of support 
Most participants indicated they would have liked knowledge of the clinic 
intervention during treatment so they could feel reassured that someone was 
still interested in supporting them and they were ‘not going to be 
abandoned’. This would take the form of a contact person they could trust.  
 
“Just knowing that I was still going to get some support” F_25yo_HL 
 
“But to know that look, don’t worry, after treatment you are going to see a 
nurse, that would have been very calming for me” F_64yo_HL 
 
The use of questionnaires to elicit unmet needs and concerns 
Questionnaires were used to elicit unmet needs and areas of concern that 
could be discussed with participants at the NLSC appointment. Participant 
responses served as a focus for the follow up appointment. Feedback about 
the questionnaires indicated some questions were hard to answer. 
 
“Sometimes I found that I couldn’t say yes or no to the questions, because they 
didn’t apply I suppose, and I had to answer” F_64yo_HL 
 
Nonetheless, the questionnaires were able to cover aspects thought to be 
important to participants’ overall wellbeing, as one said,  
 
“They covered a multitude of the different things like your emotional well-being, 
mental well-being and physical well-being, all the things that you know you can 
struggle with” F_24yo_HL  
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The supportiveness of the intervention  
All participants wanted the intervention structure to remain the same, 
describing the one-to-one, personalised nature of the intervention a valuable 
opportunity to talk to someone who was not family, friends or a doctor. They 
described being listened to and ‘feeling safe’ to ask questions on a range of 
topics, especially questions they felt they could not ask their haematologist. 
Participants indicated support was individualised and felt reassured they 
could get their life back on track.  
 
“The one-on-one was really helpful because then you felt like you could pretty 
much ask anything, or talk about anything, and you didn’t feel like there would 
be other people around to listen to your private conversations. A safe space, ask 
questions and get reassurance and the right answers. That was good” 
F_24yo_HL 
 
“Someone that you can speak to and address the problems that you don’t get the 
time with the doctors to talk about” F_64yo_HL 
 
Another participant also commented on how he could discuss other aspects 
of the cancer experience. He said, 
 
“What I particularly liked was the opportunity to have a conversation around 
things other than treatment. Dealing with some of the fears that you may have 
that you didn’t feel like you could ask your specialist about. Or where do I go for 
complementary therapies. The kind of questions that specialists I don’t think are 
necessarily geared for. Or don’t have time really to cover. The ability to have a 
chat to a nurse that can help you through the next part of the journey” 
M_48yo_NHL 
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A couple of participants indicated that the intervention should have been 
conducted according to patient preferences. This included a preference for 
the NLSC to be away from the hospital and closer to their home.  
 
“We should be providing services close to home where possible and I think there 
are some really great opportunities for the survivorship study to get out into the 
community even though they are still run by the hospital” M_48yo_NHL 
 
Although two participants found returning to the hospital traumatic, they 
felt the NLSC experience helped them to overcome their aversion as it was 
felt to be a safe place they could communicate their fears and receive 
reassurance. 
 
“The torture as a result of the treatment – going back to the hospital made me 
feel all that. It actually helped me deal with the fact that I can go to the hospital 
and not feel sick – so there was a positive to” M_48yo_NHL 
 
Nurse contact and rapport 
It was also felt contact should have been more frequent with telephone 
support between face to face visits, to provide extra support and to ‘check-in’ 
with the participant.  
 
“I think you need to make them a bit closer together – a bit more frequent. And 
also make it where patients can choose. Make it more patient-driven - where the 
patient tells you how often they want to see or talk to someone” F_48yo_NHL 
 
There was also an indication that many wanted the contact to go beyond the 
study timeframe. As one participant said, 
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“I don’t feel like I am on my own steam yet. I am thinking 2 years before I have 
got my confidence and hopefully my health back” F_64yo_HL 
 
All participants described the relationship with the nurse who ran the 
intervention as comfortable and flexible, and felt they could call or speak to 
her with any issues if they wanted to. Participants provided comment and 
perceptions of the nurse as follows:  
 
“And she did explain things so that I understood them more. She was really 
good at making you feel relaxed” F_48yo_NHL 
 
“You felt like you had enough time to talk about and ask questions you didn’t 
feel rushed and I think that was really good” F_24yo_HL 
 
Survivorship care plan and treatment summary 
The written patient-centred SCPTS was described as reassuring when it 
guided follow-up and for keeping on track with healthy lifestyle behaviours.  
 
“Yes, it was good because it is reassuring, it is a guideline of what to do which I 
needed and knowing what to look out for and should be doing” F_64yo_HL 
 
Feedback from participants regarding the SCPTS being sent to the GP 
indicated only two GPs discussed the SCPTS with them. Other participants 
indicated they either had not seen the GP or the GP acknowledged receipt 
but did not discuss.  
 
Information and support 
Participants appreciated the opportunity to discuss, record and receive 
written individualised information, support and resources. Although some 
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information such as late effects was confronting at the time, it was 
nevertheless appreciated. All felt the information received at the NLSC was 
relevant and appropriate because it was tailored to their unique needs. Most 
felt they had not received this information or support from the treating team, 
however, it was acknowledged that possibly verbal information had been 
given but not retained.  
 
Individualisation of the SCPTS 
Participants liked the individualisation of the health concerns, goals and 
actions, and the accompanying written information and/or contacts.  
“When I did have a concern, I was given printed notes about those issues and I 
think that is really good. Because I do have trouble with my memory now, and I 
can go back over those notes and sometimes it is like reading it anew, you know” 
F_64yo_HL 
 
The treatment summary was well-received with most participants describing 
it as ‘good to have’, especially as a tool for communication with other health 
professionals.  
 
“I think it was useful to sit down and have that initial meeting. I think it was 
really good that it was sent to my GP” F_25yo_HL 
 
However, one participant was unsure of the value to himself,  
 
“But I think this kind of treatment summary is the sort of thing I would give to 
my GP, or if I am seeing a new Dr, or if I was travelling and I got sick. I almost 
feel like it’s less useful for me, but more useful for other people” M_24yo_HL 
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One participant felt the terminology related to the disease location could 
have been put in simpler language and this helpful recommendation was 
utilised for subsequent treatment summaries.  
 
“Sometimes you don’t always understand the medical terms so I think putting it 
into more simpler language would be a bit more helpful” F_48yo_NHL 
 
Late effect information 
The potential late effect information given on the SCPTS was individualised 
to each participant. It came as a shock to many that heart disease and other 
cancers, for example, were possible consequences of the treatment received.  
 
“Well that was a bit of a shock to me because they hadn’t been mentioned prior 
to the treatment. … but at the same time, it was probably easier on me not 
knowing anyway” F_64yo_HL 
 
Participants appreciated having the information and felt it could help with 
GP consultations, specifically around planning of health management into 
the future. 
 
“That gave me something to go to my GP with and go okay I think I need to 
monitor this and this. And it helped me set out a care plan with my Dr as well” 
F_48yo_NHL 
 
“It is always a bit overwhelming, but I think it is a good way to highlight the 
possible things that could happen. I think it reduces you’re stress because you 
are not just in the dark about it. I think it is really important for yourself and the 
GP. If anything does change you know at least you are going to get it early” 
F_24yo_HL  
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One participant indicated they had heard the potential late effect information 
at diagnosis and another described being told there were some possible late 
effects after she had completed treatment,  
 
“Oh, he just briefly spoke about ‘you just need to be careful, you need to look 
after your skin, you need to do annual breast checks, you need to look after your 
heart. You know there is a possible risk you could get these problems in the 
future’. That is sort of how he mentioned it” F_24yo_HL 
 
Neither participant had received written information and did not feel they 
knew how to follow-up these risk factors. This was an important 
consideration when developing the SCPTS to ensure follow-up suggestions 
for the GP and participant were given. 
 
“[GP] just asked me to come in and discussed it with me and then he kind of just 
saved it and then he linked me in with support services to make sure I was 
monitoring all of my side-effects, so I think he thought it was good” F_25yo_HL 
 
Empowerment 
Most participants perceived the intent of the NLSC was to assist with 
transitioning away from a reliance on the treating team, to taking 
responsibility for monitoring and seeking support. 
 
Nurturing empowerment 
All participants described the SCPTS as useful and perceived it as a means to 
remind them to ‘stay on track’ with healthy lifestyle behaviours or for 
encouragement with achieving their goals. 
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“It just kind of helped remind me of my goals, and every time I had the meeting 
with [KT], it was like a kind of thing to remember my goals and I thought was a 
really beneficial thing” M_24yo_HL 
 
Although one participant described the initial discussion and plan as helpful, 
she felt she should not have had to seek out services and arrange 
appointments.  
 
“Maybe actually getting linked into the services they talk about. Rather than 
just getting the information and being left with it, it was kind of like I had to go 
and seek it out myself. I think it would have been really helpful to have someone 
contact me” F_25yo_HL 
 
It appeared she did not want to take responsibility for her follow-up care. 
The remaining participants described understanding and appreciating the 
need to take back control of their health and well-being. They described the 
opportunity to discuss and write down their own health concerns, health 
goals and the actions they planned to take with a health professional as 
confidence building and assisted in increasing their positivity post-treatment 
completion.  
“There are definitely days where you go thru and you start to question yourself, 
but being able to talk to someone about it made me feel more confident about 
being finished” M_25yo_HL 
 
“I started thinking a bit more positive” M_71yo_HL 
 
Participants noted that having the opportunity to record and discuss 
participant-specific issues had personalised both the appointment and the 
SCPTS.  
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“It identified what you personally were worried about and it wasn’t just a 
general thing that everyone can be worried about, but it was specific to you. And 
then having the specific needs addressed with a certain plan or the actions 
column that you could put in place. I think that was really helpful because you 
see how you could be proactive about things” F_24yo_HL 
 
Monitoring progress 
Participants felt the follow-up over the next six months in the NLSC allowed 
them to monitor their progress and see how they were going. 
 
“That was good. It was something to monitor my progress and it feels more 
personal” M_25yo_HL 
 
“It sort of crystallises your thinking for the future. If you don’t do something 
like that you tend to drift along day to day” F_74yo_NHL 
 
Receiving written and contact information for support allowed participants 
to engage and take ownership for how and when they dealt with their goals 
and concerns. Even when issues remained unmet, having the issue 
normalised was equally important. 
 
“Well the fatigue and the memory [problems] I have still got. It was useful to 
find that other people suffer the same things, that I am not alone on that!” 
F_64yo_HL 
 
Usefulness of general health information 
Participants received general health and screening information and felt it 
was helpful. Most read it again at home, then put it aside. They felt the value 
was in having it to refer to if needed.   
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“I think that it is really good to get the information and just have it there. I 
thought that was very handy” F_24yo_HL 
 
This document was not sent to the GP, as GPs involved in evaluating the 
SCPTS for content clarity, internal consistency and content validity, indicated 
they knew this information and did not want it. It was noteworthy that two 
participants had given it to the GP and it had guided follow-up care. 
 
“I basically took all the information into my GP and let him read thru it and he 
used it to help guide my care plan in the right direction” F_48yo_NHL 
 
Discussion 
This study contributes to the growing body of cancer-specific survivorship 
literature. The current model of specialist follow-up care for cancer survivors 
is inadequate, with many survivors experiencing unmet needs that can 
remain poorly addressed throughout the survivorship continuum (De Leeuw 
& Larsson, 2013). It is essential survivorship care incorporates an awareness 
of treatment and disease, long-term and late effect risks, as well as healthy 
lifestyle behaviours (Taylor et al., 2015), and facilitates communication 
amongst all health professionals and the patient and family. Expertise in the 
provision of health promotion, support and information has always been the 
purview of cancer nurses (Jackson et al., 2013), therefore nurse-led models 
should be considered within any proposed model of survivorship care. 
 
This study involved a cohort of lymphoma participants and specifically 
targeted those in the early survivorship phase (first nine months’ post-
treatment). Studies that involve a single subtype of haematological cancer are 
important in ascertaining the psychosocial and supportive care interventions 
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that are specific and most appropriate (Oberoi et al., 2017). Assessing and 
providing an intervention in the early survivorship period has been shown to 
lead to a reduction in the unmet needs as survivors continue beyond five 
years (McDowell et al., 2010). 
 
Participants described having time within the NLSC appointment to ask 
questions and seek individualised support as fundamentally helpful. An 
important point of difference with medical follow-up where participants 
perceived the specialist as too busy, or perhaps not interested when they 
were seeking reassurance and support. Interestingly, some participants 
would have preferred a follow-up appointment away from the hospital, an 
important consideration with future planning of nurse-led clinics. 
Participants had not previously met the nurse who provided the 
intervention, she is however, a cancer nurse coordinator with extensive 
haematology/oncology nursing and counselling experience and 
qualifications. A health professional who can quickly build a strong and 
positive rapport allows participants a greater opportunity to explore their 
own unmet needs (Ross, 2013). This may be why participants responded 
favourably to the intervention and is important when considering nurse-led 
models of survivorship care. 
 
Empowering participants with an individualised SCPTS that provided 
disease and treatment knowledge, and allowed them to assume 
responsibility for their future health and well-being (Taylor & Monterosso, 
2015), was described as helpful from all participants. The expectation of 
younger survivors living longer with potential issues is important (Jabson & 
Bowen, 2013), nevertheless all participants in this study, regardless of age, 
appreciated the follow-up guidance they could discuss and implement with 
their GP. Information on general health and screening allowed participants a 
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sense of independence of when and how they would seek follow-up. Of 
particular importance to participants was the opportunity to personalise the 
SCPTS and concentrate on what was important to them as they moved 
forward after treatment had completed. Conversely, our study revealed a 
small subset of participants who were not ready to take back control of their 
future health and well-being. It is important to acknowledge those patients 
and provide individualised support that meets their needs at the time, 
without building further dependency in the survivorship phase. 
 
Survivorship literature highlights the concept of ‘teachable moments’ (Alfano 
et al., 2012; Grant & Economou, 2008; Hewitt et al., 2005; Panek-Hudson, 
2013) at the end of active treatment to support and promote patient 
participation in healthy lifestyle behaviours. It was thought that participants 
in this study would need to be encouraged to engage in healthy lifestyle 
behaviours. However, it was evident that participants did feel a need to 
improve their health, and for some, change their lifestyle to adopt healthier 
lifestyle behaviours they had not been able to do during the stress of 
treatment. These participants particularly described the opportunity to 
revisit the SCPTS over the preceding months allowed them to monitor and 
reflect on their achievements and help them to keep focused on their goals. 
 
Limitations 
This study reflects the views of a subset of lymphoma participants who 
underwent a nurse-led clinic survivorship intervention and therefore could 
not be generalisable to the wider survivorship population who have 
experienced a nurse-led clinic. Nonetheless, the use of qualitative interview 
research allowed an opportunity to gain a deeper understanding of the 
experiences of this select group. The findings are presented to help build 
research that is based on patient experience and feedback. The small number 
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of participants is not a methodological limitation in qualitative research 
when data saturation is reached.  
 
Conclusion 
The interviews were conducted to ascertain the participant’s perception of 
the efficacy and value of the components of the nurse-led intervention and to 
highlight any issues or challenges for this cohort that could be better 
addressed in the future. Survivorship care offered by nurses may address the 
patient-perceived unmet needs at the conclusion of active treatment. 
Participants indicated the need for security in knowing there would be 
support when treatment completed and would likewise value the 
opportunity to have their concerns heard. An individualised SCPTS that 
empowers survivors to address healthy lifestyle issues and provide a follow-
up guide for late effects of the disease and treatment assists in refocusing 
responsibility back to the patient. Nurse-led survivorship care may offer an 
acceptable model to deliver patient-centred post-treatment follow-up. This 
model allows the time required to individualise and tailor supportive 
survivorship care. 
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6.4 Results of Test–retest of the SF-SUNS 
Analysis 
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Test–retest Reliability of the Short-Form Survivor Unmet Needs 
Survey. 
 
Abstract 
Background: Reliable and valid needs assessment measures are important 
assessment tools in cancer survivorship care. A new 30-item short form 
version of the Survivor Unmet Needs Survey (SF-SUNS) was developed and 
validated with cancer survivors, including haematology cancer survivors, 
however test–retest reliability has not been established.  
 
Aim: To assess test–retest reliability of the SF-SUNS with a cohort of 
lymphoma survivors (n=40). 
 
Design: Test–retest reliability of the SF-SUNS was conducted at two time 
points; baseline (time 1) and five days later (time 2).  
 
Methods: Test–retest data was collected from lymphoma cancer survivors 
(n=40) in a large tertiary cancer centre in Western Australia. Intra-class 
correlation (ICC) analyses compared data at time 1 (baseline) and time 2 (5 
days later). Cronbach’s alpha analyses were performed to assess internal 
consistency at both time points. 
 
Results: The majority (23/30, 77%) of items achieved test–retest reliability 
scores .429–.757 (fair to good). A high degree of overall internal consistency 
was demonstrated (time 1=.918, time 2=.945), with scores .646–.942 across 
subscales for both time points.  
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Conclusions: Mixed test–retest reliability of the SF-SUNS was established. 
Our results indicate the SF-SUNS is responsive to the changing needs of 
lymphoma cancer survivors. Routine use of cancer survivorship specific 
needs-based assessments are required in oncology care today. Nurses are 
well placed to administer these assessments and provide tailored 
information and resources. Further assessment of test–retest reliability in 
haematology and other cancer cohorts is warranted. 
 
Introduction 
Lymphoma blood cancers are malignant T or B cell lymphocytes in the 
lymphatic system and are categorized under two main types: non-Hodgkin 
lymphoma (NHL) and Hodgkin Lymphoma (HL). NHL represents 
approximately 88% of all lymphomas, while HL is predominately diagnosed 
in the adolescent and young adult population (Howlader et al., 2016). 
Combined, they represent the sixth most common cancer diagnosis 
worldwide (Howlader et al., 2016). Consistent with worldwide trends, the 
incidence of lymphoma in Australia is increasing, and with a projected 
diagnosis of 6232 cases in 2017, this equates to 4.6% of all cancer cases 
(Cancer Australia, 2017). An estimated mortality rate of 1481 equates to 3.1% 
of all deaths from cancer in 2017 (Cancer Australia, 2017). Projected figures 
for 2017 in the USA have a similar expected incidence of lymphoma of 4.8% 
and mortality of 3.6%. (Howlader et al., 2016). Treatment for lymphoma 
generally comprises high-dose chemotherapy and/or targeted 
immunotherapy agents and may include radiotherapy and hematopoietic 
stem cell transplants (Carey et al., 2012). These treatments have resulted in an 
improvement to overall survival of approximately 76% at five years 
compared with 52% at five years in the 1980s (Cancer Australia, 2017). 
Notwithstanding the positive impact treatment has had on survival rates 
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(Sant et al., 2014), the consequences of disease and treatment continue long 
after treatment completion (Campbell et al., 2014). Long-term and late effects 
may produce ongoing unmet needs such as fear of recurrence, fatigue, poor 
nutrition, exercise, fertility, relationship, financial, employment, and 
insurance issues (Taylor et al., 2015). 
 
To provide optimal supportive cancer care to lymphoma survivors, the 
identification of patients’ perceived concerns and level of support needed is 
required (Campbell et al., 2014). This is especially important for younger 
patients (18–45 years of age) where the expectation of long-term remission 
can raise additional concerns and unmet needs (Arden-Close et al., 2011). 
Receiving relevant information and practical support soon after treatment 
ends, especially resources related to healthy lifestyle behaviours (Arden-
Close et al., 2011; Boyes et al., 2012; Hall, Campbell, et al., 2013; Hjermstad et 
al., 2003; Lobb et al., 2009), can help mitigate the impact of disease and 
treatment and lead to fewer unmet needs further along the survivorship 
continuum (Aziz, 2007; McDowell et al., 2010). A qualitative study with 
lymphoma cancer survivors (n=17) undertaken in Western Australia 
(Monterosso et al., 2017) reported unmet informational and practical needs as 
participants transitioned from treatment to the survivorship phase. The 
findings suggested tailored post-treatment support and interventions are 
fundamental components of excellent survivorship care. 
 
The measures used to assess unmet needs are equally important. Generic 
cancer measures which comprise items related to diagnosis and treatment 
are often not specific enough for the survivorship phase (Taylor & 
Monterosso, 2016). Comprehensive, relevant, reliable, and validated needs 
assessment measures that are survivor-specific are essential to capture unmet 
needs that become evident when treatment ends (Taylor & Monterosso, 
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2016). These measures can guide health professionals in providing 
individualised information, support, and resources (Campbell et al., 2014; 
Taylor & Monterosso, 2016). Two recent systematic reviews (Jiao et al., 2017; 
Taylor & Monterosso, 2016) revealed that needs assessment tools are varied 
and may not capture all the possible unmet needs patients may have. The 
reviews likewise found validity and reliability evidence limited. The 
Survivor Unmet Needs Survey (SUNS) was identified as a measure that had 
strong psychometric properties and was developed and psychometrically 
tested with a large cross-sectional sample of cancer survivors (n=550) 
including a small cohort of haematology cancer participants (n=31, 5.6%) 
(Campbell et al., 2010). Campbell et al. (2010) confirmed a high overall 
internal consistency of items for their study with an overall Cronbach’s alpha 
of 0.99. The authors also reported high test–retest reliability although the 
results were not published (Campbell et al., 2010). Internal consistency of the 
SUNS was further tested in two studies of haematological cancer survivor 
cohorts. A cross-sectional study with 529 haematological cancer survivors 
(Hall, D’Este, Tzelepis, Sanson-Fisher, & Lynagh, 2014) demonstrated overall 
Cronbach’s alpha values >0.9, and a weighted Kappa coefficient score of >0.6 
for test–retest reliability; acceptability was reported for 40/89 (45%) items. 
Qualitative data from 17 semi-structured interviews indicated that the SUNS 
was considered relevant by this cohort of haematological cancer survivors 
(Hall, D’Este, et al., 2014). A cross-sectional study of haematological cancer 
survivors from Australia and Canada (n=437) reported similar levels of 
unmet needs across the two cohorts using the SUNS, with fatigue (n=76, 17%) 
and financial concerns (n=39, 9%) rated as high unmet needs (Hall, Campbell, 
et al., 2013). Despite the clinical utility of the original SUNS, it was 
considered potentially burdensome for use in the clinical setting given the 
large number of items (n=89). In 2014, the 30-item short-form-SUNS (SF-
SUNS) was developed and validated with a mixed sample of cancer 
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survivors (n=1589), including haematological cancer survivors (n=84, 5%) 
(Campbell et al., 2014). Construct validity and intraclass correlation 
coefficients (ICCs) of the SF were similar to those of the original SUNS. 
Cronbach’s alpha scores for the final four domains were ≥0.85, and ICCs for 
the three domains from the original SUNS (financial concerns, information, 
and access and continuity of care) and the SF-SUNS were high (>0.9). 
Discriminant validity demonstrated the SF-SUNS ability to discriminate 
between individuals who had recently received treatment and those who had 
not. The authors recommended further testing of the SF-SUNS for test–retest 
reliability (Campbell et al., 2014). The 30-item SF-SUNS was therefore judged 
to be more practical and likely to be completed by participants in our larger 
study, particularly as the SF-SUNS was one of four measures to be 
administered to participants in a pilot randomised trial to measure the effect 
of a nurse-led survivorship model of care (Taylor et al., 2016). 
 
For researchers and clinicians to develop targeted follow-up support for 
cancer cohorts underrepresented in survivorship literature, such as 
lymphoma (Swash et al., 2014), cohort-specific studies in the early 
survivorship phase are required (Oberoi et al., 2017). Therefore, this study 
recruited only those with a lymphoma diagnosis who had completed 
treatment. Discerning the issues and concerns of this group requires 
survivor-specific measures that are psychometrically sound and fully tested. 
The SF-SUNS has been used within the clinical setting; however, since test–
retest reliability of the SF-SUNS had not been established, the aim of the 
present study was to establish test–retest reliability of the SF-SUNS to add to 
the psychometric data available in the published literature on this 
instrument. 
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Methods 
Design 
Test–retest reliability of the SF-SUNS was conducted at two time points: 
baseline (time 1) and 5 days later (time 2). This time frame was chosen to 
reduce recall bias and change in the level of unmet needs (Terwee et al., 
2007). Ethical approval to conduct the study was obtained from the human 
research ethics committee of the study site (2015-020) and university 
(015007F). 
 
Population and setting 
A convenience sample of 40 lymphoma cancer patients who were 3 months’ 
post-treatment completion were recruited from the haematology department 
of a large tertiary hospital in Western Australia. Inclusion criteria were 
pathologically confirmed new diagnosis of NHL or HL; completed first-line 
curative-intent chemotherapy or second-line curative-intent autologous stem 
cell transplant within the previous 3 months; no radiological evidence of 
lymphoma posttreatment (on positron emission tomography [PET] scan); 
able to understand and read English; and over 18 years of age. Participants 
were excluded if they had not been treated with chemotherapy; had received 
further treatment at another hospital (as experiences or interventions may 
have introduced bias); or were cognitively impaired or experiencing an acute 
mental health condition that prohibited the provision of informed consent. 
 
Sample size 
The sample size calculation was derived from Walter et al. (1998) and used a 
fixed alpha of .05 from two observations with reliability values of R0=.6 
(acceptable) and R1=.8 (expected), indicating a minimum sample size of n=39. 
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Short-Form Survivor Unmet Needs Survey 
The SF-SUNS assesses unmet needs across four domains: information needs 
(3 items); work and financial needs (8 items); access and continuity of care 
needs (6 items); and coping, sharing, and emotional needs (13 items). Patient 
self-reported concerns and the level of support required are measured using 
a Likert-type scale: 0—no unmet need, 1—low unmet need, 2—moderate 
unmet need, 3—high unmet need, and 4—very high unmet need. Domain 
scores are generated by adding each item score and dividing by the total 
number of domain items (Filsinger, Burkhalter, & Campbell, 2011). 
 
Procedure 
The researcher identified and approached eligible participants after 
treatment completion to discuss the study and provide them with a 
participant information and consent form. Following informed consent, 
demographic and baseline (time 1) SF-SUNS questionnaires were then 
administered to participants. After completion of the questionnaires, 
participants were provided with another blank copy of the SF-SUNS 
accompanied by instructions to complete the questionnaire at home 5 days 
later and post back using the supplied reply-paid addressed envelope. 
Participants were advised to record the date of completion if this differed 
from the specified due date. 
 
Data collection 
At the request of the research team’s haematologist, baseline demographic 
and SF-SUNS data were collected from consenting participants 3 months 
post-treatment completion and PET scan to confirm the absence of disease. 
Demographic information obtained included lymphoma type, stage of 
disease, type of treatment received (chemotherapy +/− radiotherapy), date of 
diagnosis, time since diagnosis, comorbid conditions, gender, age, weight, 
CHAPTER 6. RESULTS 
205 
marital status, age of children (if any), postcode, occupation, income level, 
education level, and health behaviours such as smoking and alcohol 
consumption. Participants then completed the SF-SUNS at time 2 (5 days 
following time 1 completion) at home. 
 
Data Analysis 
All analyses were performed using IBM SPSS Statistics Version 25 data 
analysis software (IBM Corp, 2017). Descriptive statistics were used to 
analyse all data. Descriptive analyses were used to analyse and describe 
demographic data. To assess for absolute consistency of SF-SUNS items for 
test–retest reliability data, an ICC with a random-effects model was used to 
compare each item at time 1 and time 2. The ICC measure was chosen for its 
ability to discriminate between sets of scores ranked in the same order but 
not necessarily in agreement and adjusts for the degree of test–retest 
agreement expected by chance (Bujang & Baharum, 2017; Cicchetti, 1994). 
The closer the value of the ICC to 1.0, the greater the reliability of the item or 
measure (Weir, 2005). The guidelines developed by Cicchetti and Sparrow 
(1981) were used to determine the level of clinical significance of the ICC 
values obtained: <.40 = poor, .40–.59 = fair, .60–.74 = good, and >.75 = 
excellent. For this study, items classified as achieving “fair to excellent” 
reliability, ICC >.40 (Rosner, 2016), were reported. Cronbach’s alpha, a 
measure of internal consistency, was used to measure the scale reliability. 
 
To examine the distribution of unmet needs, the five levels of unmet need 
were collapsed to three levels. A score of 0 (no unmet need) remained the 
same. Scores of 1 or 2 (low and moderate unmet need) were reclassified as 1 
(low–moderate unmet need), and scores of 3 or 4 (high and very high unmet 
need) were classified as 2 (high–very high unmet need).  
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Results 
Participant characteristics 
There were slightly more male (n=22, 55%) participants, and a greater 
number of participants with NHL (n=29, 72.5%) compared with HL (n=11, 
27.5%) (Table 6.4.1). This was in keeping with the current disease statistics 
which reflect a greater number of NHL than HL diagnoses (Howlader et al., 
2016). Almost one-third of participants were aged between 18 and 39 years 
(32.5%), and a greater proportion had a university qualification (n=6, 40%) 
(Table 6.4.1). Although the majority of participants were currently working 
(n=15, 37.5%) and had been throughout their treatment, 30% (n=12) were 
looking for work or had no return to work date set. Over half the participants 
had a partner (n=25, 62.5%). Forty participants completed both time 1 and 
time 2 SF-SUNS. The majority of participants (n=35, 87.5%) completed time 2 
SF-SUNS 5 days after time 1 (range 4–7 days). 
 
21Table 6.4.1 Baseline Participant Demographic and Disease Characteristics 
(n=40) 
Characteristics N (%) 
Gender  
Male 22 (55.0) 
Female 18 (45.0) 
Age group (years)  
18–39 13 (32.5) 
40–59 12 (30.0) 
60–74 9 (22.5) 
75+ 6 (15.0) 
Marital status  
Single 10 (25.0) 
Married/de facto 25 (62.5) 
Divorced 3 (7.5) 
Widowed 2 (5.0) 
Lymphoma diagnosis  
Non-Hodgkin 29 (72.5) 
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Hodgkin 11 (27.5) 
Highest level of education  
Secondary school or less 11 (27.5) 
Trade, vocational college 13 (32.5) 
University or higher 16 (40.0) 
Employment status  
Working 15 (37.5) 
Retired 13 (32.5) 
Looking for work/no return to work date 12 (30.0) 
 
Test–retest 
ICCs, 95% confidence intervals, and clinical significance are shown in Table 
6.4.2. One (3%) item met the “excellent” criteria for clinical significance; 
Finding car parking I can afford at the hospital or clinic. Twelve (40%) items 
met the “good” criteria (.60–.74) and 11 (37%) items met the “fair” criteria 
(.40–.59). In summary, test–retest data showed “fair” to “good” reliability for 
the majority of items (23/30, 77%). 
 
Internal consistency 
Overall Cronbach’s alphas were .918 at time 1 and .945 at time 2, with 
subscales (Table 6.4.2) ranging from .744 and .695 for information needs, .646 
and .828 for work and financial needs, .891 and .853 for access and continuity 
of care, and .897 and .942 for coping, sharing, and emotional needs, 
respectively. These results support strong internal consistency for the overall 
scale. Item-to-total correlations between .40 and .70 indicate that items are 
not redundant or measuring needs similar to other items within the 
instrument (Leong & Austin, 2006). Using this criterion, the SF-SUNS 
demonstrated item-to-total correlations between .40 and .70 at time 1 for 24 
items (80%) and at time 2 for 19 items (63%) (Table 6.4.2). The majority of 
items were considered relevant and to be measuring unique needs. 
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22Table 6.4.2 Item Test–retest Reliability and Internal Consistency (n=40) 
Domain 
(n=4) 
Item Description ICC (95% CI) Level of 
Clinical 
Significance 
Cronbach’s 
Alpha 
Item-to-total 
Correlation 
Time 
1 
Time 
2 
Time 
1 
Time 
2 
Information 
needs 
Items (n=3)   .744 .695   
Finding information about complementary or alternative 
therapies 
.694 (.490–.825) Good   .304 .504 
Dealing with fears about cancer spreading .560 (.304–.740) Fair .589 .626 
Dealing with worry about whether treatment has worked .568 (.316–.746) Fair .654 .714 
Work and 
financial 
needs 
Items (n=8)   .646 .828   
Worry about earning money .631 (.401–.787) Good   .486 .466 
Having to take a pension or disability allowance .390 (.093–.623) Poor .446 .384 
Paying household bills or other payments .692 (.488–.825) Good .550 .597 
Finding what type of financial assistance is available and 
how to obtain it 
.700 (.499–.829) Good .668 .713 
Finding car parking that I can afford at the hospital or 
clinic 
.757 (.586–.864) Excellent .018 .455 
Understanding what is covered by my medical insurance 
or benefits 
.314 (.007–.568) Poor .203 .060 
Knowing how much time I would need away from work .736 (.553–.851) Good .545 .501 
Doing work around the house (cooking, cleaning, home 
repairs, etc.) 
.366 (.065–.606) Poor .122 .701 
Access and 
continuity of 
care 
Items (n=6)   .891 .853   
Having access to cancer services close to my home .446 (.159–.663) Fair   .437 .619 
Getting appointments with specialists quickly enough .377 (.078–.614) Poor .701 .436 
     209 
(oncologist, surgeon, etc.) 
Getting test results quickly enough .662 (.444–.806) Good .569 .507 
Having access to care from other health specialists 
(dietitians, physiotherapists, occupational therapists) 
.526 (.260–.718) Fair .508 .671 
Making sure I had enough time to ask my doctor or nurse 
questions 
.579 (.329–.753) Fair .590 .477 
Getting the health care team to attend promptly to my 
physical needs 
.529 (.264–.720) Fair .592 .497 
Coping, 
sharing and 
emotional 
needs 
Items (n=13)   .897 .942   
Telling others how I was feeling emotionally .429 (.140–.651) Fair   .577 .476 
Finding someone to talk to who understands and has been 
through a similar experience 
.329 (.023–.578) Poor .449 .573 
Dealing with people who expect me to be “back to 
normal” 
.620 (.386–.780) Good .568 .768 
Dealing with people accepting that having cancer has 
changed me as a person 
.509 (.239–.707) Fair .681 .812 
Dealing with reduced support from others when treatment 
has ended 
.673 (.406–.813) Good .824 .824 
Dealing with feeling depressed .734 (.550–.850) Good .535 .720 
Dealing with feeling tired .487 (.211–.692) Fair .566 .712 
Dealing with feeling stressed .552 (.294–.735) Fair .780 .691 
Dealing with feeling lonely .715 (.522–.838) Good .527 .615 
Dealing with not being able to feel “normal” .475 (.196–.683) Fair .570 .697 
Trying to stay positive .628 (.397–.785) Good .548 .646 
Coping with having a bad memory or lack of focus .639 (.412–.791) Good .496 .864 
Dealing with changes in how my body appears .275 (–.037–.537) Poor .229 .244 
Note. ICC: Intraclass correlation; CI: Confidence interval 
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Discussion 
Our study is the first to report test–retest data for the SF-SUNS. The majority 
of items met absolute consistency for reliability ICC scores of >.40 for test–
retest, categorized as “fair” to “good.” An “excellent” clinical significance 
score was achieved for only one item (3%), related to car parking costs which 
are unlikely to change over time. Needs-based instruments such as the SF-
SUNS measure the degree of an individual’s perceived unmet need at one 
point in time. Importantly, Cronbach’s alpha scores at time 1 and time 2 
demonstrated a high degree of internal consistency and high item-to-total 
correlations, confirming that items in the tool were reliable. 
 
A criterion for psychometrically sound needs-based tools is the requirement 
for an instrument to be responsive to changes over time (DeVellis, 2012; 
McDowell, 2006; Streiner & Norman, 2003). Although our ICC results may 
reflect the responsiveness of the SF-SUNS to changes in need over the data 
collection period, further research is required to detect clinically meaningful 
change for patients (Jiao et al., 2017). All participants completed the time 2 
questionnaire at home, well away from the haematology clinic where the 
time 1 questionnaire was completed. It is possible that participants may have 
had additional time to more accurately reflect on the level of unmet need. 
Similarly, time 1 scores may have been impacted by participants’ anxiety at 
the hospital appointment where patients often worry about test results and 
potential relapse (Thewes et al., 2012). In addition, fatigue is a recognized 
effect of lymphoma treatment (Arden-Close et al., 2011), and may have 
potentially affected participant responses at either time point. Finally, most 
items were similarly balanced for both time points from “no unmet need” to 
“low unmet need” or “low unmet need” to “no unmet need.” 
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It is important to allow cancer survivors the opportunity to self-identify 
unmet needs and issues of concern. Survivorship needs-based instruments 
provide a consistent method for this purpose (Hawkins et al., 2008). 
Furthermore, it is important that any tool is responsive to change as 
individuals’ issues, concerns, thoughts, and feelings can change from day-to-
day (McDowell, 2006; Streiner & Norman, 2003), particularly during 
survivorship transition as individuals move on with their lives after cancer 
treatment. Such reliable and valid instruments can facilitate individualized 
survivorship care and tailored support and resources (Taylor & Monterosso, 
2016). 
 
It is important to note that the original SUNS demonstrated low test–retest 
reliability acceptability (Hall, D’Este, et al., 2014), with the authors 
suggesting that the test–retest timeframe was too long at 28 days. Since our 
study was part of a larger study involving an intervention group, a 5-day 
later test–retest assessment was deemed an appropriate timeframe to ensure 
completion of the time 2 SF-SUNS before the implementation of any needs-
based interventions associated with the larger study (Taylor et al., 2016). 
Importantly, this time period was also in keeping with the recommended 2–
14-day time period for test–retest procedures (DeVellis, 2012; McDowell, 
2006; Streiner & Norman, 2003).  
 
A limitation of this sub-study may have been the sample size of 40 
participants, despite sample size calculations indicating that this number 
would be sufficient to adequately perform test–retest reliability with 
confidence. Many participants (n=16, 40%) attended the baseline 
appointment, where time 1 SF-SUNS was administered, accompanied by a 
support person (partner or family member). We acknowledge this may have 
influenced time 1 responses. Likewise, time 2 responses may have similarly 
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been influenced as the SF-SUNS was completed at home. We can confirm 
that participants did not receive any needs-based interventions between time 
1 and time 2 completion of the SF-SUNS. 
 
Conclusion 
We suggest that needs-based assessments should be used routinely during 
the survivorship period to facilitate survivorship care that is tailored and 
responsive to individuals’ changing needs. Valid and reliable survivor-
specific measures are essential for routine screening and follow-up. Nurses in 
particular are a valuable resource in the survivorship phase to assess for 
areas of concern or unmet needs and for the provision of information, 
support, and resources that are tailored to the individuals’ unique needs. 
Further testing of the SF-SUNS is recommended in haematology and other 
cancer populations to further understand and demonstrate the 
responsiveness of this instrument to changes in need over the survivorship 
period. 
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Chapter Summary 
This chapter has documented the analysis and findings of data collected in 
Phases Three and Four of this study and reports possibly the first published 
data from a pilot RCT to test a nurse-led lymphoma survivorship model of 
care.  
 
Results from the pragmatic RCT showed the proposed conceptual 
framework could guide a survivorship model of care that empowered 
survivors to make changes to improve their quality of life and engage in 
healthy lifestyle behaviours. This model allowed participants the time to 
individualise and tailor their own supportive survivorship care needs. 
Randomisation was found to be effective as both groups were well-matched 
for demographic variables. Univariate and multivariate analyses 
demonstrated that intervention participants who received the nurse-led 
lymphoma survivorship model of care had lower levels of unmet 
informational and practical needs and lower levels of depression, anxiety 
and stress at study completion compared to the control group participants. 
Likewise, better adjustment to the cancer diagnosis and self-empowerment 
was shown in those randomised to the intervention group.  
 
Findings from Phase Four GP evaluations indicated that GPs made use of 
and were satisfied with the unique lymphoma SCPTS they received for 
intervention participants.  
 
As previously stated the nurse-led lymphoma survivorship model of care 
used with this lymphoma cohort had not been previously reported in the 
published literature and was a new undertaking at the study site. Therefore, 
it was considered important to understand the experiences and perspectives 
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of intervention participants from a qualitative perspective. The qualitative 
study (Phase Four) provided strength to the quantitative data collected 
during the pragmatic RCT by documenting and analysing the personal 
experiences and perceptions of a group of intervention participants. Results 
demonstrated participants needed support when treatment finished. In 
particular, they valued: the opportunity to discuss and record their concerns 
on the individualised SCPTS; the record of treatment and guidelines for 
follow-up with the GP; and promotion of their engagement in healthy 
lifestyle behaviours. Likewise, participants appreciated the one-to-one nature 
of the appointments and the additional information and further support 
provided.  
 
As mentioned, test–retest reliability data for the SF-SUNS measure had not 
been previously published, and it was considered important to undertake 
this additional step during the pragmatic RCT. Findings indicated the 
majority of the SF-SUNS items achieved ‘fair’ to ‘good’ for reliability with 
this cohort. This published manuscript is considered an important 
contribution to the cancer survivorship literature.  
 
The following chapter provides a discussion of the results from this study 
including the pragmatic RCT, GP evaluations and qualitative interviews with 
intervention participants. The chapter will begin with a summary of findings 
from Phase One and will conclude with a discussion of the limitations and 
strengths of the thesis research. 
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7.0 Discussion 
The following discussion will present and explore the relevance of the major 
findings from this study in relation to theoretical and clinical issues. This will 
be followed by a discussion on the limitations and strengths of the study. The 
final chapter will present the conclusions from this study in addition to 
implications and recommendations for nursing practice, education and 
future research.  
 
The principal research question developed and tested in this study was that 
it might be possible to decrease the number and level of unmet 
informational, practical and emotional needs that may occur when 
lymphoma patients finish treatment, and promote self-empowerment using a 
nurse-led lymphoma survivorship model of care. This research was 
undertaken in four phases, and development of the components of the nurse-
led lymphoma survivorship model of care and their implementation are 
reported in detail in this thesis.  
It was intended that this study would build on Australian cancer 
survivorship research, in particular, lymphoma-specific survivorship. The 
conceptual framework for this study was based on Bandura’s theory of self-
efficacy. This was considered the most appropriate framework to guide the 
development of the nurse-led lymphoma survivorship model of care since it 
emphasises the importance of individual empowerment to enable the patient 
to take responsibility for their future health and well-being. In addition, 
providing support and encouragement may assist with better adjustment to 
having cancer and resumption of normal activities of daily living. To achieve 
this aim, a pragmatic RCT to examine a nurse-led model of survivorship care 
was conceptualised, developed and delivered to a cohort of lymphoma 
survivors at a large tertiary cancer centre in Perth, Western Australia. The 
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intervention comprised a patient-centred survivorship care plan and 
treatment summary (SCPTS), motivational interviewing to empower 
survivors to make healthy lifestyle changes and individualised support and 
tailored resources. To date, no RCTs have been published that report a nurse-
led survivorship model of care using a lymphoma survivor cohort.  
 
This study utilised and collaborated with a multidisciplinary advisory 
committee that included lymphoma survivor consumers. It was particularly 
important that this research engaged with consumers who had undergone 
previous lymphoma treatment at the study site and were thereby able to 
have input into the design, delivery and evaluation methods of this research. 
This research is, therefore, able to address the Australian Commission on 
Safety and Quality in Health Care, National Safety and Quality Health 
Service (NSQHS) Standard 2, Partnering with Consumers (Australian 
Commission on Safety and Quality in Health Care, 2017). Likewise, this 
research addresses the NSQHS Standard 5, Comprehensive Care, as it 
ensured the care given to participants was individualised and considered the 
impact of the disease and treatment on their health, quality of life and well-
being (Australian Commission on Safety and Quality in Health Care, 2017). 
 
A diagnosis of cancer is the beginning of a profound and life-changing 
experience that can have a long-lasting effect on the remainder of a person’s 
life and the lives of their family and friends (Corner & Bailey, 2009). Research 
is constantly striving to improve the treatment offered and therefore overall 
survival rates (Hewitt et al., 2005; Wait et al., 2017); however, a valuable 
opportunity is missed in supporting the quality of survival once treatment is 
completed (McConnell, White, & Maher, 2017). A cancer-free future may 
often be characterised by ongoing physical and psychosocial health concerns 
(Aaronson et al., 2014). Post-treatment, health professionals have an 
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opportunity to provide support for a range of biopsychosocial issues and 
have a positive effect on facilitating a change or improvement in healthy 
lifestyle behaviours. There is increasing evidence that a healthy lifestyle 
reduces the risk of morbidity and mortality and many interventions, such as 
exercise, are safe and effective (Aaronson et al., 2014); however, promotion 
and referral for these interventions is low (Boyes et al., 2012). 
 
The rationale for Phase One (the systematic and integrative reviews) was to 
examine: how lymphoma survivorship follow-up is occurring and the 
models of care currently in use; the use of survivorship care plans and/or 
treatment summaries with this cohort; and the assessment measures that are 
used to determine survivorship unmet needs. This was followed by Phase 
Two where components of the intervention were developed for use in Phase 
Three which comprised the pragmatic RCT. In Phase Four additional 
evaluation of the model of care and the SCPTS was conducted with GPs and 
a subset of intervention participants. 
 
A full discussion related to each of the three literature reviews, qualitative 
interviews with intervention participants and the SF-SUNS test–retest results 
is in each published article. The first section of this chapter will provide a 
summary of the three literature reviews. This will be followed by a 
presentation and exploration of the relevant major findings from the 
pragmatic RCT and GP evaluations. Furthermore, a summary of the 
qualitative interviews and the SF-SUNS test–retest is provided in this 
chapter. This chapter concludes with a consideration of the limitations and 
strengths of this thesis.  
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Summary of the Phase One Literature Reviews 
Published models of post-treatment cancer follow-up and/or survivorship 
care was explored in the models of survivorship care provision in adult patients 
with haematological cancer: an integrative literature review (Taylor et al., 2015). 
This review found a lack of guidance and consensus for follow-up care 
including determination of the appropriate health professional/s to deliver 
survivorship care. The review likewise highlighted a lack of consensus 
regarding the type of care model most appropriate for the early survivorship 
period. It was also evident that further lymphoma-specific models of 
survivorship care research are required. This particular cohort of cancer 
patients has different needs (Parry et al., 2010) than those of the more 
prevalent cancers such as breast, prostate and colorectal. These cancer types 
have similar trajectories of treatment and care and generate the most 
survivorship model of care research. Any model of care proposed for early 
lymphoma survivors needs to be offered in addition to haematologist follow-
up as the risk of lymphoma recurrence in the first two years' post-treatment 
is very high (Lymphoma Association, 2017).  
 
Haematology follow-up for at least five years appears the norm in the 
published literature (Franco et al., 2017); and concurs with follow-up 
provision undertaken by the haematology department in Western Australia 
where this research was undertaken. In this follow-up period other health 
professionals, including GPs, may be involved in care provision and 
therefore open and effective communication is essential (Dicicco-Bloom & 
Cunningham, 2013). Nurses have been proposed as a conduit to transition 
survivorship care from the treating team to the GP (Cooper et al., 2010). This 
will necessitate the communication of potential late effects of disease and 
treatment and the recommended surveillance and management. Research 
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has indicated many GPs may not be provided with this vital information 
(Hall, Lynagh, et al., 2013). Nurses may similarly have an important role in 
normalising post-treatment effects (Franco et al., 2017) and encouraging 
survivors to seek information and support on healthy lifestyle behaviours 
and how to return to "normal functioning" sooner (Cooper et al., 2010). These 
findings were the basis for conceptualising and developing a nurse-led 
lymphoma survivorship model of care. 
 
A key recommendation of the Institute of Medicine for survivorship care was 
the dissemination of SCPTS to all cancer survivors (Hewitt et al., 2005). The 
survivorship care plans and treatment summaries in adult patients with hematologic 
cancer: an integrative literature review (Taylor & Monterosso, 2015), reported a 
lack of evidence on their use with lymphoma survivors and furthermore on 
the most appropriate methods of developing and delivering this document. 
The reviewed literature (Taylor & Monterosso, 2015) and the researcher's 
recent search for newly published literature on lymphoma SCPTS usage 
demonstrated a continued lack of routine use.  
 
Experienced oncology nurses are able to provide holistic and individualised 
information provision and have therefore been recognised as a practical 
solution to the creation and delivery of SCPTS (Jackson et al., 2013; Marbach 
& Griffie, 2011). To provide timely information and resources, two authors 
(Curcio et al., 2012; Sabatino et al., 2013) proposed that dissemination of 
SCPTS should occur soon after treatment completion. This recommendation 
was endorsed by a recent qualitative study with lymphoma patients 
undertaken at the same treatment centre as this research. These participants 
indicated a lack of information and support when treatment ended 
(Monterosso et al., 2017). In the present study, delivery of the SCPTS to 
participants randomised to the intervention group occurred three months 
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after treatment completion to facilitate early identification of issues and 
concerns and provision of appropriate support, information and resources. 
The SCPTS review likewise reported a lack of detail on how standardised 
templates were completed and the evidence-based guidelines that were used. 
This was addressed in the development of a unique lymphoma-specific 
SCPTS for this thesis. A recent study with breast cancer participants (Mayer 
et al., 2016), as outlined in the literature review update in Chapter Two, 
reported a decrease in levels of anxiety in patients when SCPTS provision by 
a nurse was coupled with GP follow-up to discuss the SCPTS contents. 
Although this finding had not been available when this thesis was 
developed, participants in the present study who had received an SCPTS 
were encouraged to discuss the contents with their GP after the first NLSC 
appointment and then at each subsequent GP visit. Qualitative results from 
this thesis reported that participants experienced feelings of shock when 
potential late effects information was given. However, participants indicated 
an appreciation of this knowledge to empower them to follow-up in the 
future (Ng, 2014). This finding confirmed those of previous studies that 
reported tailored SCPTS could empower survivors to assume responsibility 
for future surveillance and disease management (Hill-Kayser et al., 2013; 
Jabson & Bowen, 2013; Jackson et al., 2013). 
 
Nurses and health professionals require reliable, validated and accurate 
measures to assess survivors for unmet issues and concerns once treatment 
has completed (Muzzatti & Annunziata, 2013). Early identification is 
important to ensure management and support is delivered effectively and 
appropriately (Girgis, Delaney, & Miller, 2015). The systematic review of the 
tools used to assess the informational and practical needs of the acute leukaemia and 
lymphoma survivors (Taylor & Monterosso, 2016) in this thesis reported a need 
for survivorship-specific needs assessment measures that had been used in 
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lymphoma survivor cohorts. Likewise, early assessment to mitigate unmet 
needs in the future was reported (McDowell et al., 2010) and considered 
applicable for this research. Therefore, a post-treatment timeframe of three 
months for baseline assessment was established. As the review found limited 
published literature on survivorship-specific measures to assess unmet needs 
in lymphoma survivor cohorts, this is an area that requires further research.  
 
In developing the SCPTS for this study, it was important to seek and act 
upon the feedback given by clinicians and survivors. GPs indicated a 
preference for a succinct treatment summary, a finding supported by a recent 
study delivering an SCP to primary care physicians (Ezendam et al., 2014). 
Therefore, a concise document was developed that was deliberately patient-
centred and only reported possible late effects that were pertinent to each 
participant. The SCPTS literature review undertaken as part of this thesis 
reported on large templates which covered all potential late effects and were 
therefore not tailored to the individual. As reported by Klemanski et al. 
(2016), the American Society of Clinical Oncology (ASCO) has recently 
reduced their SCPTS templates to two pages, in line with Commission on 
Cancer standards which clarified the type of information that an SCPTS was 
to include (Klemanski et al., 2016). The minimum information required is 
similar to that included in the SCPTS developed for this study (Deline, 2016); 
however, the care plan element differs. The new ASCO SCPTS templates 
provide a list of problem areas encountered by survivors, whereas 
participants in this study were able to generate their own lists.  
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Discussion of Phase Three Pragmatic Randomised Controlled 
Trial 
This pilot study contributes evidence-based data to the emerging body of 
nurse-led survivorship research, and in lymphoma-specific care. In Western 
Australia, the current model for all haematology cancer survivorship follow-
up is haematologist-led, however many survivors experience a range of 
unmet needs that may be poorly identified and addressed throughout the 
survivorship period (De Leeuw & Larsson, 2013; Monterosso et al., 2017). 
Health care providers need to recognise the importance of survivorship care 
as a standard component of optimal holistic cancer care that involves 
patients and families, along with other health professionals, including 
primary care. The objective of the study was to assist participants, 
randomised to the intervention, to transition from the end of treatment into 
follow-up care, often referred to as the early survivorship phase, up to two 
years' post-diagnosis (Aziz, 2007; McDowell et al., 2010). The aim was to 
assess if the intervention reduced the number and level of self-reported 
unmet informational, practical, emotional needs, depression, anxiety and 
stress and increased adjustment to cancer and patient empowerment. 
Additionally, the study assessed the use of an individualised SCPTS as a 
resource for participants and their GPs to have a written record of their 
disease, treatment and future surveillance of potential late effects (Taylor et 
al., 2015). Notably, the SCPTS was also a tool for participants to record their 
three most important concerns and three most important health goals, along 
with the actions required to deal with concerns and achieve health goals. The 
intervention likewise utilised the ‘teachable moment’ (Alfano et al., 2012; 
Panek-Hudson, 2013) that presents at treatment completion, to support and 
encourage healthy lifestyle behaviours (Taylor & Monterosso, 2015). This 
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was particularly salient for the younger participants, as there was an 
expectation of a longer survivorship period (Jabson & Bowen, 2013). 
 
The early survivorship phase was chosen to provide responsive, supportive 
care for the unique concerns and unmet needs of this cohort. A prospective 
longitudinal study found 30% (n=353) of survivors had five or more unmet 
needs at treatment completion that did not improve after six months (Armes 
et al., 2009). This concurs with research which has suggested less unmet 
needs were evident in the extended survivorship phase (over five years) if 
assessments and interventions were undertaken in the early survivorship 
phase (up to two years' post-diagnosis) (McDowell et al., 2010). It is possible 
this thesis study may have also decreased the feelings of abandonment 
survivors often feel at treatment completion (Matheson et al., 2016; 
Monterosso et al., 2017; Taylor, Monterosso, & Bulsara, 2018). 
 
The present pilot study suggests that survivors do have issues and concerns 
post-treatment that can remain unresolved over time. This may impact 
quality of life (QoL) (Hansen et al., 2013). Although statistical significance 
was not reached in this pilot study, a comparison of the mean results 
obtained from the two groups indicated a trend towards lower unmet needs 
in the intervention group at Time 3 with higher levels of empowerment 
revealed. Overall, those reporting no unmet needs at the completion of the 
study on the SF-SUNS (n=5, 9%) was very low. In contrast, a study of 
Canadian and Australian haematological survivors, one to 60 months' post-
diagnosis, found 21% (n=71) reported no unmet needs (Hall, Campbell, et al., 
2013). As a pilot study in the early survivorship phase, it is difficult to 
compare findings with larger studies with variable survivorship periods that 
found low levels of unmet needs in haematological survivor cohorts 
(Campbell et al., 2014; Hall, D'Este, et al., 2014). 
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The most endorsed concerns on the SCPTS were fear of recurrence, fatigue 
and cognition impairment. These findings are consistent with current 
research. A recent study of leukaemia and lymphoma survivors (n=477) 
reported the prevalence of fear of recurrence was higher in females and 
younger participants (Jones et al., 2015). This finding was supported by a 
study of different cancer types (n=2615) including lymphoma survivors 
(n=379), that found those in active follow-up and the early survivorship 
phase (0 to 5 years' post-diagnosis), experienced more fear of recurrence (van 
de Wal et al., 2016). Nonetheless, this study revealed satisfaction with 
information provision led to less reported fear of recurrence (van de Wal et 
al., 2016). This was reflected in the present study, where only one 
intervention participant recorded a high/very high level of unmet need for 
fear of recurrence at Time 2 and 3, compared with six control group 
participants at Time 2 and 3. 
 
A recent study of Dutch HL survivors compared with a normative 
population revealed higher fatigue prevalence (41–43% vs 23–28%). Those 
with fatigue also had higher levels of anxiety (23% vs 13%) and depression 
(18% vs 12%) (Daniels et al., 2014). The authors suggested coping strategies 
may provide a clinically meaningful reduction in fatigue (Daniels et al., 
2014). There may also be an association of fatigue with increasing age that 
may affect the ability to recover from fatigue (Kreissl et al., 2016). The present 
study found fatigue was still prevalent at nine months' post-treatment (Time 
3), with participants continuing to report a moderate to very high unmet 
need. 
 
Cognitive impairment is a condition that is not fully understood (Mojs et al., 
2017), however, is described as a treatment side-effect (Zimmer et al., 2015). 
A recent review of psychological outcomes found cognitive decline can range 
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from mild attention, memory and thinking problems to severe impairment 
such as dementia (Mojs et al., 2017). A recent study of lymphoma patients 
(n=262) demonstrated significantly lower cognitive scores (p .018) and greater 
frequency of impairment when compared with healthy controls (32% vs 7%) 
(Krolak et al., 2017). This was supported by a smaller study (n=30 vs n=10 
controls) which found a significant difference on objective and subjective 
cognition tests for lymphoma patients who were within 3 months of 
treatment completion (Zimmer et al., 2015). At the completion of the present 
study, cognition impairment remained an issue for many participants across 
both groups, however the control group reported more unmet need at the 
end of the study. This may indicate that normalisation, information and 
support may assist lymphoma survivors to cope with this condition. 
 
Survivorship unmet needs 
Participants in the intervention group demonstrated an increase in total scale 
median scores at Time 2, suggesting more unmet needs were evident in this 
group at this time point. However, all scores were lowest at Time 3 perhaps 
implying participants needs were met by study completion. Significantly, 
those participants aged >60 years had the lowest scores, and this may be due 
to their life stage where some practical issues such as finances, employment, 
relationship and emotional concerns are less of a concern than for younger 
age groups. Women in both groups had the highest Time 1 total scale median 
scores which concur with other Australian research indicating women had 
higher levels of unmet need (Lobb et al., 2009; Sanson-Fisher et al., 2000). In 
contrast, men in the intervention group at Time 3 had the highest median 
scores for the information domain, a finding reflected in a study of gender 
differences and survivorship follow-up which likewise found men had more 
unmet informational needs (Arden-Close et al., 2011). Unmet needs 
decreased across the study period suggesting intervention participants were 
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able to have their needs, issues and concerns resolved suggesting this may 
have been attributable to the nurse-led lymphoma survivorship model of 
care intervention. The control group scores were significantly higher in the 
30–59 years age group suggesting this age group may require more support 
when treatment ends to facilitate return to “normal” functioning and may 
warrant further exploration in future research. This finding concurs with 
those of a study that reported follow-up services should account for the 
distinctive burden of supportive care needs in different age groups (Sharp et 
al., 2014). The majority of results in the control group (total scale and domain 
mean scores) decreased by Time 3, however, were higher than intervention 
group scores at Time 3. Although not statistically significant, likely due to 
this pilot study being underpowered, the researcher suggests these higher 
scores may reflect a lack of targeted support when treatment completed. 
Conversely, the relationships and emotional health domain mean scores 
increased over the study period. Talking about emotions and depression 
were endorsed as a moderate to high unmet need by the majority of 
participants in the control group and the researcher proposes this may be an 
area that requires support at treatment completion to assist in mitigating 
escalating or unresolved unmet need. Those with NHL had significantly 
higher scores in the financial and access and continuity of care domains than 
those with HL across both groups at all time points suggesting a need for 
targeted support to this cohort when treatment completes.  
 
Psychological distress 
Scores on the three domains of the DASS21 remained similar for both cohorts 
across the study. The majority of domain scores were below population norm 
scores outlined in the DASS scoring manual: depression <4.5; anxiety <3.5; 
and stress <7.0 (Lovibond & Lovibond, 1995) and suggests the lymphoma 
cohort under study had good psychological coping mechanisms. Participants 
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in the intervention group showed a decrease in all scores by Time 3. This 
downward trend suggested psychological distress concerns were no longer 
evident and likely resolved at study completion. The data revealed an 
increase in the intervention group mean scores at Time 2, and although they 
had decreased by Time 3, they were nonetheless higher than Time 1 scores. 
The researcher proposes this may be due to discussions around these issues 
in the nurse-led lymphoma survivorship clinic (NLSC) appointment. Anxiety 
and stress were the highest at Time 2, and stress continued to be elevated at 
Time 3, an area highlighted as a concern in research with cancer survivors 
(Marker, 2015).  
 
Women in the control group, when compared with men, had higher total 
scale and anxiety median scores at Time 2, and higher depression scores at 
Time 1 and Time 2. This concurs with the findings from the SF-SUNS of 
unmet needs in the anxiety and depression domain. Although statistical 
significance was not reached, the direction of change revealed total scale 
mean scores decreased over the study period and remained higher in 
comparison with the intervention group mean scores. This was especially 
evident with anxiety being higher in the control group compared with the 
intervention group at Time 2. These findings concur with research that 
indicated depression and anxiety is a common psychological problem in 
haematology cancer survivors (Hall et al., 2016; Lobb et al., 2009; Mitchell et 
al., 2011). 
 
Mental adjustment to cancer 
Fighting spirit is described as a combination of optimism and confidence that 
the effects of cancer are controllable and the individual can actively deal with 
the situation (Wills & O'Carroll Bantum, 2012). Participants in the 
intervention group revealed significantly lower fighting spirit domain scores 
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at Time 1 and Time 2. These participants were given an opportunity to 
debrief about their diagnosis and treatment experiences and, therefore, the 
researcher suggests these participants may have felt they no longer had to 
‘fight’ or ‘beat’ their cancer. Helplessness/hopelessness, defined as a sense of 
incapacity or ‘giving into the cancer’ (Czerw et al., 2015), showed a decrease 
from Time 1 to Time 3 in the intervention group and may indicate this group 
were not incapacitated by having had cancer. The anxious preoccupation 
domain can be understood to reflect preoccupation with the cancer that 
cannot be controlled by the individual (Czerw et al., 2015; Watson et al., 
1994). The intervention group had a slight increase in median scores by Time 
3 revealing this group were thinking about the cancer more. However, these 
participants were also aware this was their last appointment in the NLSC 
and may have been experiencing some anxiety about the completion of this 
individualised support. Participants with NHL in the intervention group had 
the lowest total scale, and median anxious preoccupation and cognitive 
avoidance (defined as a tendency to avoid actively thinking about the cancer 
and its implications (Watson et al., 1994)) domain scores, perhaps reflecting 
this group's ability to think beyond the cancer after treatment has been 
completed. 
 
The 30–59 years age group in the control group had the highest median 
scores across all time points. Helplessness/hopelessness at Time 2, anxious 
preoccupation at Time 2 and Time 3, and cognitive avoidance at Time 1 and 
Time 3 had significantly higher median scores. These results may indicate 
that this age group, who continued with usual care, were not able to find 
ways to discuss their cancer concerns and were trying to actively avoid 
thinking about the cancer without success. Those control participants aged 
>60 years had significantly higher fatalism domain median scores at Time 2. 
The level of fatalism is said to impact whether an individual can control or 
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influence their cancer (Park, Edmondson, Fenster, & Blank, 2008), and may 
indicate the older age group felt they were not able to influence the 
diagnosis, perhaps due to age. Control participants with NHL had 
significantly higher median scores, especially in the fighting spirit domain at 
Time 3 suggesting the cancer was seen as a challenge they were still 
overcoming. 
 
Fatalism, fighting spirit and anxious preoccupation mean scores decreased 
and helplessness/hopelessness and cognitive avoidance scores increased in 
the control group over the study. This may suggest a sense of powerlessness 
in coping with the cancer diagnosis, regardless of treatment completion and 
remission status. This is reflected in mean fatalism and fighting spirit scores 
which were lower than those of the intervention group. In addition, the 
suggestion of a sense of powerlessness is supported by the majority of the 
control group participants (compared with the intervention group) at Time 2 
who significantly endorsed the items related to difficulty believing cancer 
had happened to them and trying to push all thoughts of cancer away, and at 
Time 3 indicating they did not want to think about cancer and were pushing 
thoughts of cancer away. 
 
Self-empowerment 
Participants in the intervention group demonstrated an increase in scores for 
self-empowerment from Time 1 through to Time 3. This study also found 
those >60 years of age, regardless of group allocation (intervention or 
control) were more empowered, especially compared with those in the 30–59 
years age group. The researcher suggests this may, in part, be due to the life 
experiences and previous exposure to adversity older adults may have 
encountered. At Time 1 and Time 2 those with NHL, characteristically a 
disease of older age (Cancer Australia, 2017), had higher median scores. The 
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researcher suggests these participants may have already been more 
empowered due to age. Conversely, mean scores in the control group were 
lowest at Time 3. This finding suggests this group of participants felt less 
able to control aspects of their cancer and move on with their life, although 
further research is required to explore this trend. 
 
The most endorsed items indicated the intervention group felt they had all 
the information they needed, were able to adapt and make changes to their 
lifestyle, felt health professionals included them in discussions and by Time 3 
were more confident in their GP. The researcher suggests this may be due to 
the SCPTS sent to their GPs which outline future follow-up 
recommendations. 
 
Nurse-led lymphoma survivorship model of care 
While this pilot study was not sufficiently powered to demonstrate a 
significant effect between the two groups, the direction of change in the 
results suggests the nurse-led lymphoma survivorship model of care may be 
an effective intervention for targeted cancer cohorts. For some participants in 
the intervention, one or two appointments in the NLSC would have been 
sufficient to impart the SCPTS and give individualised and tailored resources 
as these survivors do not require intensive support (Campbell et al., 2014). 
However, those with high levels of unmet need after the provision of the 
SCPTS and resources may need more support. This was evidenced by the 
increase in needs at Time 2. These needs had diminished in the most part by 
Time 3 indicating a sustained follow-up may not be warranted. 
 
Participants who utilised the motivational chart to make healthy lifestyle 
changes reported pressure to cease smoking or reduce alcohol during 
treatment. However, these participants indicated adequate support was not 
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provided at such a high-stress time. The participants acknowledged the 
motivational chart and support as a useful way to explore the unhealthy 
behaviour and their motivations in continuing. Likewise, these participants 
felt the motivational interviewing assisted them to be empowered to quit or 
reduce the unhealthy behaviours. Further study would be required to 
ascertain sustained change over a longer period than the study timeframe of 
six months. 
 
Discussion of the Phase Four General Practitioner Evaluations 
Data from the GP evaluations indicated the SCPTS had been received, read 
and in some cases prompted the GP to make an appointment (n=16, 89%) 
with the patient. However, not all GPs indicated they had discussed the 
SCPTS with their patient during the trial (n=11, 61%). Discussion of the 
SCPTS between participants and their GPs was encouraged; however, the 
participant could choose when and if they discussed the SCPTS during the 
trial. Five intervention participants indicated at the completion of the study 
they had not visited or discussed the SCPTS with their GP. As a copy of the 
SCPTS is held by the participant and his/her GP, it is envisaged the 
document could potentially be used at future appointments. 
 
Of those GPs who completed the Likert-type scale, the majority (n=13, 81%) 
found the SCPTS useful and rated it as good to very good. Just over half of 
GP responders (n=10, 59%) requested further haematology or medically 
related information be included on the SCPTS, perhaps indicating 
insufficient information was communicated from the haematology 
department. As a treatment summary document, it was not the intent of the 
SCPTS to provide all health-related information. The majority of responders 
indicated they did not want further education on the SCPTS (n=9, 69%). The 
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present study did not address the management of other medical conditions, 
and this may be an area that would need consideration for future inclusion, 
particularly in older cancer participants who have an increased likelihood of 
co-morbidities.  
 
Summary of the Phase Four Qualitative Interviews  
In quantitative research, participants may not have an opportunity to 
articulate their perceptions, thoughts and feelings as they complete 
questionnaires with set responses. The researcher sought to avoid this 
limitation by including a qualitative sub-study (Phase Four) using a cohort of 
intervention participants to add depth and further explore some aspects of 
the quantitative data obtained (Creswell & Clark, 2011). This process of 
triangulating the data, using multiple methods of data collection, 
strengthened and supported the study outcomes as a more holistic 
understanding of the key findings was obtained from different sources 
(Sarantakos, 2013). 
 
Additional support is particularly valuable when patients are transitioning 
from active treatment to life without treatment (Knott, Turnbull, Olver, & 
Winefield, 2012). Reality, however, suggests this period is characterised by 
the reduction or cessation of cancer care support in the acute setting (Rabin, 
Simpson, Morrow, & Pinto, 2011). The support conceptualised for the nurse-
led lymphoma survivorship model of care and offered by an experienced 
cancer nurse was appreciated by participants at a time when previous cancer 
patients have expressed the fear they would be abandoned once treatment 
had completed (Lobb et al., 2009; Matheson et al., 2016; Monterosso et al., 
2017). Participants who were interviewed highlighted both the importance of 
a safe environment to ask questions and expressed the importance of trust 
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and rapport developed between themselves and the researcher during the 
study. The majority of lymphoma survivors wanted to make healthy lifestyle 
behaviour changes; however, there were limited options that specifically 
target cancer survivors. Having an opportunity to discuss preferences and 
decisions with the researcher about individual goals and action plans was 
seen as very helpful. This can enhance self-efficacy leading to greater 
psychosocial well-being. This concurs with findings from a recent study 
which revealed a positive correlation between increased levels of self-efficacy 
and more emotional and functional well-being, alongside fewer cancer-
related issues (Papadopoulou et al., 2017). Participants particularly liked how 
the SCPTS was personalised to them and they were able to document the 
issues and concerns most important to them. 
 
Summary of the Test–retest Reliability Analysis 
The SF-SUNS test–retest reliability sub-study added psychometric data for 
this measure in a lymphoma-specific cohort of survivors. The results 
demonstrated the majority of items achieved fair to good reliability intraclass 
correlation (ICC) scores. It is essential that survivorship-specific needs 
assessment measures detect clinically meaningful changes over time in the 
survivorship phase (DeVellis, 2012; McDowell, 2006; Streiner & Norman, 
2003). An important consideration when issues and concerns are rapidly 
changing as survivors move beyond the diagnosis and treatment phases and 
begin to move forward with their lives. These results, now available in the 
published literature will allow other researchers an opportunity to make 
informed choices when choosing a survivorship-specific needs assessment 
measure for their cohorts. 
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Limitations of the Research 
Specific limitations are addressed in each published manuscript. Limitations 
of the pragmatic RCT included the recruitment by chance of more males than 
females in the intervention group, and a disproportionate number of HL to 
NHL that did not reflect current lymphoma statistics (Cancer Australia, 
2017). However, it is acknowledged this is a possibility when randomisation 
of groups occurs (Deaton & Cartwright, 2017). As a pilot study, a sample size 
calculation was not required, and it is acknowledged that 60 participants 
may not be adequate to see a true effect of the intervention. It must be 
highlighted the purpose of this pragmatic pilot RCT was to generate data 
that can be used to power future robust larger RCTs. This aim was achieved. 
 
Fidelity of the intervention was maintained, and no control group participant 
received the intervention while on the study. It is unknown if survivorship 
information was imparted to control group participants by haematologists. 
This is considered unlikely however as needs of this group were higher than 
those of the intervention group.  
 
The PhD candidate administered the intervention and entered the data from 
both groups. There is a potential for bias when the researcher evaluates their 
own service. Due to the constraints of a PhD which related to a lack of 
funding to employ an independent experienced cancer research nurse, a 
number of measures were employed to mitigate potential bias. Statisticians 
reviewed data and assisted with quantitative analysis to decrease the risk of 
bias in evaluation. Control group participants were only contacted by an 
independent member of the research team if this was required. 
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Alterations were made to how the NLSC appointments were conducted 
when haematologist appointments were altered. This was required to ensure 
timeframes were maintained. However, a strength of the NLSC intervention 
was its ability to be flexible to accommodate the requests of participants. 
 
As a pragmatic RCT, there was a usual care group who did not receive the 
nurse-led lymphoma survivorship model of care. It is important when 
examining new models that a comparison group is provided, especially as 
research on the benefits of an SCPTS is limited. Future research to investigate 
the provision of the intervention to the usual care group after study 
timeframes are completed may provide valuable data on the benefits of 
delayed delivery compared with no delivery.  
 
Assessment measures used in this study may not have captured all the 
concerns and issues that applied to lymphoma survivors. There were 
limitations to using the DASS21, for example, where a control group 
participant complained of a dry mouth it was unknown whether this was a 
sign of anxiety or an ongoing treatment effect. This was comparably true for 
the question related to lack of initiative which may have been related to 
fatigue rather than a sign of depression. Some participants expressed 
difficulty with answering particular questions on the Mini-MAC. Some 
participants at baseline indicated that some items, for example; ‘I take one 
day at a time’, ‘I am apprehensive’ or ‘I have difficulty believing that this 
happened to me’, both "applied" and "did not apply". Intervention 
participants who indicated similarly at the NLSC appointments were guided 
to reflect on how they felt at present, as per questionnaire instructions. Many 
participants at baseline needed to be reminded the assessment questionnaires 
were related to the present, not how they felt during treatment.  
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An economic evaluation of the cost of a nurse-led lymphoma survivorship 
model of care would have enhanced the research and added information on 
the viability of the model. This would correspondingly have examined the 
time and cost required for nurses to deliver this model of survivorship care. 
Likewise, an evaluation of lymphoma survivors’ utilisation of the primary 
healthcare system from Medicare data could have examined if there was an 
increase in GP visits with the intervention group participants who were 
encouraged to see the GP compared with control group participants who 
were not given any post-treatment support. The time constraints of this PhD 
thesis prevented this lengthy form of evaluation. Further, as the study was 
only conducted with participants from one haematology department, it 
would be difficult to generalise the findings of this thesis to the other two 
public tertiary haematology departments in Perth Western Australia.  
 
The time constraints of a PhD candidacy, as well as the significant size of this 
thesis, prevented an examination of the experience and needs of carers of 
RCT study participants. This is an important aspect of care and should be 
considered a potential future area for research. No data were collected from 
patients who declined the research. Therefore, it is unknown if these patients 
had more or diverse issues and unmet needs. Providing a nurse-led follow-
up appointment to all lymphoma patients when they complete treatment as 
standard practice may contribute to supporting patients who would 
otherwise not seek assistance. 
 
Finally, GP feedback could be improved with an investigation into whether 
and why some GPs did not receive the SCPTS. All medical centres were 
contacted if evaluations were not received with faxed copies being sent if 
medical practices indicated non-receipt. Whether the participant’s GP did 
eventually receive the SCPTS and evaluation remains unknown. Further, 
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some GPs may have chosen not to return the evaluation. Nevertheless, the 
response rate for evaluation returns was considered acceptable at 64% 
(Livingston & Wislar, 2012).  
 
Strengths of the Research 
The major strength of this research and a key aspect was the tailored and 
personalised nature of the nurse-led lymphoma survivorship model of care, 
delivered by one experienced cancer nurse clinician (the PhD candidate). 
This ensured consistency and accuracy of all data. Information provision that 
is tailored to the patient’s perceived needs is a significant factor in 
survivorship care, support and empowerment (Bulsara & Styles, 2013; Hall, 
D'Este, et al., 2014; Husson et al., 2013). Equally important was the early 
knowledge of late effects that may assist in timely follow-up with the GP 
when haematology department surveillance ends (Ng et al., 2011). An 
additional strength of this research was the lymphoma-specific cohort which 
allowed the researcher an opportunity to assess needs that were disease-
specific (Oberoi et al., 2017). The nurse-led survivorship model of care was 
developed for lymphoma survivors in the early survivorship period, a time 
when studies have indicated there is an increase in distress as treatment 
completes (Girgis & Butow, 2009; Hewitt et al., 2005; Jefford et al., 2008) and 
survivors may feel abandoned by the treating team (Matheson et al., 2016; 
Monterosso et al., 2017).  
 
Recent studies have indicated survivors want more detail and more 
information on healthy lifestyle behaviours, psychological support and 
resources (Keesing, McNamara, & Rosenwax, 2015; Mayer, Birken, et al., 
2015). A strength of the conceptualised model was to develop information 
that was delivered as part of the general health aspect of the SCPTS and 
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within the resource pack developed for the study. GP evaluations on the 
SCPTS indicated a content rating of good to very good from the majority of 
GP respondents. Therefore, the researcher suggests the nurse-led lymphoma 
survivorship model of care was able to accommodate the needs of both 
survivors and GPs. 
 
Assessment measures were utilised to assess and evaluate survivorship, 
distress, adjustment and coping and empowerment post-treatment at three 
time points. This assisted with discussion and targeting of resources during 
the nurse-led lymphoma survivorship clinic appointments for the 
intervention group. It may have also assisted those in the usual care (control) 
group to identify areas they may have discussed with their haematologist or 
GP. The unique lymphoma SCPTS was patient-centred and allowed 
intervention participants an opportunity to seek support on the issues and 
health goals that were important to them at their life stage. This has not been 
a feature of any SCPTS found in the published literature at the time of 
development. Motivational interviewing techniques require a particular skill 
set, and fortunately, the researcher was competent in this area. Utilising this 
skill and assisting the intervention participants to understand the impact of 
continuing unhealthy lifestyle behaviours, was an important promoter for 
change that they were empowered to make. This was an important element 
of the conceptual framework developed when the research was planned to 
aid recovery of health and well-being and engagement in healthy lifestyle 
behaviours to improve quality of life. 
 
The research allowed participants an opportunity to debrief after a life-
changing and often traumatic experience, such as a cancer diagnosis. This 
was an aspect that was highlighted in the qualitative interviews and 
anecdotally to the researcher during the face-to-face appointments. The 
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nurse-led lymphoma survivorship model of care provided normalisation of 
some of the long-term effects such as fatigue, fear of recurrence and/or 
cognitive impairment, with provision of further information. This was 
likewise perceived by many participants as missing from haematology 
follow-up care. The researcher suggests debriefing and normalisation, along 
with information, resources and support may help to mitigate these issues 
continuing in the longer-term.  
 
Lastly, an important strength was the use of and collaboration with the 
haematology survivorship research advisory committee which consisted of 
academic, clinical health and community support group professionals and 
lymphoma survivor consumers. The input of the consumers provided 
significant insight into current lymphoma post-treatment follow-up and on 
gaps they perceived in their own cancer survivorship journey. 
 
Chapter Summary 
This chapter summarises the key findings from the four phases of this thesis 
study. In keeping with a pilot pragmatic RCT design, the small numbers of 
participants recruited limited the power of this study to potentially 
demonstrate statistically significant results. Nevertheless, this study provides 
a valuable contribution for future rigorous testing of nurse-led survivorship 
models of care to transition patients from treatment into the survivorship 
phase. The large body of work presented in this PhD thesis by publication 
exceeds the minimum requirement of four published manuscripts. The final 
publication, currently undergoing preparation for publication will report the 
LMM data from the pragmatic pilot RCT and provide evidence to generate 
sample size calculations to support future RCT studies. 
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Providing individualised and tailored information, support, resources and a 
patient-centred survivorship care plan and treatment summary in the early 
survivorship period may lead to less unmet needs and better recovery of 
health and well-being in the future. 
 
The final chapter will conclude this thesis and discuss the implications of this 
type of research. Furthermore, it will provide recommendations for clinical 
nursing, future research and education in survivorship care for nurses who 
are a valuable and integral component of high-quality supportive 
survivorship care.  
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Chapter Eight — Conclusion 
 
 
 
 
 
 
 
 
 
 
“But to know that look, don’t worry, after treatment you are going to see a 
nurse, that would have been very calming for me” F_64yo_HL 
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8.0 Implications and Recommendations 
Implications 
Provision of evidence-based cancer survivorship care must be a common 
goal throughout the healthcare system, as cancer diagnoses and survival 
rates continue to increase. The impact of cancer does not end with active 
treatment as cancer survivors continue to have numerous diverse and varied 
needs at different time points along the survivorship trajectory. Efficient 
targeting and provision of clinical services is key to meeting and improving 
the care of cancer patients at all stages.  
 
This study was based on the assumption that the current model of 
lymphoma follow-up, which is haematologist-led, has been unable to 
comprehensively provide the supportive care required to transition patients 
from the treatment phase into the survivorship phase. Consequently, a 
nurse-led lymphoma survivorship model of care was conceptualised, 
successfully developed and tested within this research.  
 
Sixty lymphoma patients from one haematology department in Perth, 
Western Australia were recruited and randomised. While not the aim of a 
pilot study, many findings were not statistically significant, likely due to the 
small number of participants. The intervention participants did demonstrate 
less unmet informational and practical needs, less depression, anxiety and 
stress while demonstrating higher levels of coping and empowerment 
compared with the control (usual care) group. As intended, the study did 
produce data that can be used to power larger randomised trial studies for 
future competitive funding applications.  
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Psychological concerns among patients are often not addressed by clinicians 
in follow-up due to a number of limitations on their time and the availability 
of routine screening mechanisms. Clinicians will often assess for signs of 
depression, which is common following a cancer diagnosis (Mitchell, 
Ferguson, Gill, Paul, & Symonds, 2013) without addressing the levels of 
anxiety and stress which can be a major concern for cancer survivors 
(Marker, 2015; Mitchell et al., 2011). Findings from this study suggest anxiety 
and stress can remain elevated over time and was notable in the control 
group where scores were higher in comparison with the intervention group 
who had an opportunity to discuss concerns and issues. Therefore, future 
interventions may need to consider anxiety-related issues such as fear of 
recurrence, thereby normalising the need for psychosocial support when 
developing cancer survivorship support and resources.  
 
Participants in the 30–59-year-old age group across both the control and 
intervention groups exhibited higher levels of unmet practical concerns and 
less empowerment, a finding that corresponds to this life stage where 
patients are often juggling family, employment and financial issues. This 
study has confirmed the need that lymphoma patients require support and 
resources that are targeted to their life stage, and which can support them to 
re-establish their lives post-treatment. A finding supported by the qualitative 
interviews which revealed patients appreciated the individualised aspect of 
the nurse-led lymphoma survivorship model of care, valued the opportunity 
to discuss their concerns and issues and had a plan for monitoring potential 
late effects in the future, regardless of their age and life circumstances. 
 
Lack of resources and support for survivors was evident in Phase Two of this 
study when a resource pack was developed. It would be difficult in the 
limited time survivors have in their haematologist appointments to provide 
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and discuss all the information and support an individual lymphoma 
survivor might need at that time. Therefore nurse-led survivorship models of 
care may provide the time and space to assist with this issue.  
 
Recommendations 
The results of this cancer nursing thesis have provided phase II evidence of 
the need for future research on nurse-led survivorship models of care in 
unique and rarer cancer groups such as lymphoma. The research highlighted 
the need for nurses to consider the whole cancer trajectory, not just the 
diagnosis and treatment phases of cancer care. The wider implications of the 
long-term and late effects of diagnosis and treatment for cancer survivors are 
equally imperative. Delivering cancer survivorship care that is evidence-
based, holistic, cost-effective and adaptable to different health care settings is 
a continual challenge. Regardless of this, the provision of quality care and 
improvement in overall quality of life should be a greater focus in effective 
healthcare initiatives than just successful medical treatment. The following 
recommendations could enhance research in the area of cancer survivorship. 
 
Clinical Nursing 
 Experienced and senior cancer nurses should provide training and 
education on the use of assessment measures in survivorship to all nurses 
working in cancer care. 
 Cancer nurses should be encouraged to identify and refer patients to 
appropriate health care providers for psychological and emotional 
support. 
 Cancer nurses should be encouraged to undertake research and 
professional development to address the gaps in information and 
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resources provided to patients during their treatment and survivorship 
phases. 
 Experienced cancer nurses should be provided with additional time to 
provide holistic follow-up on survivorship needs post-treatment.  
 Cancer nurses should be offering educational forums to survivors to 
enhance post-treatment coping skills, healthy lifestyle behaviour choices 
and normalisation of treatment effects. 
 Cancer nurses should be encouraged to provide input into the 
development and delivery of SCPTS for all cancer survivors. 
 Cancer nurses should find opportunities to communicate with GPs to 
ensure survivorship needs will be addressed in the future. 
 
Research 
 Further research should be undertaken to promote and support the 
development, testing and evaluation of survivorship models of care. 
 Further research on nurse-led survivorship models of care should be 
undertaken with survivors of: 
o Other haematological cancers 
o Other cancers. 
 Further research should include the recruitment of cancer patients from 
rural/regional areas and evaluate the provision of localised support.  
 Exploring options for providing targeted support to carers during cancer 
treatment and post-treatment requires further investigation. 
 Further examination of debriefing mechanisms during and after 
treatment for patients is required. 
 Research that encourages advocacy and peer support among survivors is 
required: 
o Investigation of the types of peer support mechanisms currently 
available 
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o Development of peer support for patients of all stages of the cancer 
trajectory. 
 Longitudinal studies are required to determine: 
o If participants follow through recommendations with their GP 
when haematologist follow-up is completed 
 If this impacts earlier diagnosis and management of late 
effects  
o If healthy lifestyle choices were maintained and how motivation to 
continue was sustained.  
 Future studies in the primary care arena to deliver nurse-led survivorship 
models of care would be valuable. 
 Larger phase III multi-centre studies are required to explore nurse-led 
survivorship models of care that deliver patient-centred options for 
frequency and type of contact, such as face-to-face or telephone support. 
 Further studies in the development and examination of psychometrically 
sound measures that capture the unique needs of survivors of less 
common cancers, such as lymphoma are essential. 
 
Education 
 Findings from this study could be used to increase public awareness of 
resources that can normalise and provide support for the issues and 
concerns that occur post-treatment. 
 Findings from this study could be used in hospitals to provide greater 
awareness of community-based support organisations 
o Carer support mechanisms. 
 An awareness of and provision of multi-cultural support and information 
requires further development and testing. 
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 Further education is necessary to provide relevant information and 
support resources to regional and rural Australia to enable improved 
referral pathways and communication between health care providers. 
 Further research and education is required to increase support for 
employees and employers where identified employment concerns may 
arise 
o Provide access to information on support services and employee 
entitlements 
o Identify barriers that inhibit employers from implementing 
supportive policies in the workplace 
o Provide better mechanisms for transitioning back into the 
workforce or retraining. 
 Increased flexibility in accessing financial government funding and 
effective utilisation. 
 Promotion of the re-evaluation of funding allocation for rarer cancers is 
required by cancer agencies and professional health organisations to 
ensure equity of research and services.  
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Appendix D 
Patient Information and Consent Form 
 
 
SIR CHARLES GAIRDNER HOSPITAL 
 
Participant Information Sheet/Consent Form 
 
Effect of a Nurse-Led Lymphoma Survivorship Clinic: A Pilot Randomised 
Controlled Trial 
 
Protocol Number: 2015-020 
Project Sponsor: University of Notre Dame Australia 
Coordinating Principal Investigator: Professor Leanne Monterosso 
Principal Investigator: Karen Taylor 
Associate Investigators: Dr David Joske, Violet Platt, Kendall Stratton, Professor 
Max Bulsara 
 
What does my participation involve? 
You are invited to take part in this research project, which is called the effect of a 
nurse-led lymphoma survivorship clinic. You have been invited because you have 
received treatment for lymphoma cancer: either Hodgkin’s lymphoma or Non-
Hodgkin’s lymphoma. This research is specifically for patients who have completed 
treatment and are entering into the post treatment or ‘survivorship’ phase. Your 
haematologist has recommended you and has provided your contact details as you 
are about to, or have already finished treatment. 
  
This Participant Information Sheet/Consent Form explains the processes involved 
with taking part. Knowing what is involved will help you decide if you want to take 
part in this study. 
 
Please read this information carefully. Ask questions about anything that you don’t 
understand or want to know more about. Before deciding whether or not to take part, 
you might want to talk about it with a relative, friend or your treating doctor. 
 
Your participation is voluntary. If you don’t wish to take part, you don’t have to.  
If you decide you want to take part, you will be asked to sign the consent section. By 
signing it you are telling us that you: 
• Understand what you have read 
• Consent to take part in this research 
• Consent to be involved in the research described 
• Consent to the use of your personal and health information as described. 
 
You will be given a copy of this Participant Information and Consent Form to keep. 
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What is the purpose of this research? 
“Survivorship” is a term that is commonly used to describe the experience of living 
with, through and beyond a diagnosis of cancer. People who have completed 
treatment for a blood (haematological) cancer such as lymphoma can have 
problems that impact on the practical, physical and emotional quality of their life. 
This study will test a nurse-led lymphoma survivorship clinic that will provide 
information, education and practical support to people like yourself who have just 
finished treatment. This will help in moving (transitioning) on from hospital care. 
Information will also be passed onto your General Practitioner (GP) about the 
treatment you have received and what to expect in the future. This will be in the form 
of a survivorship care plan treatment summary, which has been suggested as a way 
to help patients and GPs find out about the treatment received and the issues that 
may require further assessment and support with.  
Western Australia has no formal survivorship care and this research aims to identify 
whether a survivorship clinic would be acceptable to patients like yourself to help 
reduce the number of problems encountered after treatment ends and to provide 
information to enable a healthy lifestyle. This pilot research will form the basis for 
future expansion of survivorship care for all blood cancer survivors across Western 
Australia.  
 
Who is organising and funding the research? 
This research is being conducted by Karen Taylor who is a PhD student at the 
University of Notre Dame Australia, under the supervision of the coordinating 
principal investigator Professor Leanne Monterosso. Karen is an experienced 
haematology cancer nurse. Other members of the research team include Dr David 
Joske from the SCGH Haematology Department, Violet Platt, Director of Nursing at 
the WA Cancer and Palliative Care Network, Kendall Stratton from the Youth 
Cancer Service and Professor Max Bulsara who is a leading biostatistician. This 
research is funded by the University of Notre Dame Australia.  
No member of the research team will receive a personal financial benefit from your 
involvement in this research project. 
 
What does participation in this research involve? 
Consent 
If you decide to participate in this study, please sign the consent form and bring it to 
your next haematologist appointment at SCGH. Karen will contact you on that day 
either before or after your appointment. Karen will need to check that you are 
eligible for the study by asking about your diagnosis and treatment. Your medical 
records will need to be accessed, but this will not occur without your consent. 
Once you have consented, Karen will ask you to fill out four (4) questionnaires. 
These will be used to assess whether you have any particular needs related to 
practical, physical, emotional or social issues that are known to possibly affect 
patients after treatment for cancer such as lymphoma. These questionnaires my 
take up to an hour to complete. 
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Study Design 
This study is called a randomised controlled trial. This means half the participants 
will get usual care with their haematologist and the other half will receive usual care 
and will participate in the nurse-led lymphoma survivorship clinics. This will be 
decided randomly. Once you have completed the questionnaires you will be asked 
to open a sealed envelope which will identify the group to which you will be 
assigned. 
 
Control Group 
If you open an envelope that indicates you are part of the control group you will be 
sent the same set of four (4) questionnaires at 3 months and 6 months. We ask that 
you complete them at home as soon as possible and send them back in the reply-
paid envelope. If we haven’t received them in two weeks’ time, another research 
team member will call to check you have received them and that you have filled 
them in. At 6 months, once you complete the last set of questionnaires, your 
participation in the study will stop. All questionnaires will be checked by Karen once 
they are sent back and if at any time you have indicated you are struggling with an 
issue or concern, contact will be made with your haematologist to let them know so 
they can follow up with you.  
Intervention Group 
If you open an envelope that indicates you are part of the intervention group, an 
appointment will be made with you to come to the first of three (3) nurse-led 
lymphoma survivorship clinics run by Karen. The first clinic session will take place 
within a week of the initial questionnaires being completed. You are welcome to 
bring a partner, friend or family member to all the nurse-led lymphoma survivorship 
clinics. At the first clinic appointment any issues or concerns that you have 
highlighted on the questionnaires will be discussed. During this clinic, education on 
healthy lifestyle behaviours will be provided. You will also receive a resource pack of 
information designed to meet your individual needs or concerns. A survivorship care 
plan treatment summary will be completed by yourself and Karen to ensure you 
agree with the contents. How these documents will help you will be explained. The 
survivorship care plan treatment summary will also be sent to your GP and you are 
asked to take this document with you if you see your GP. At three and six months 
after baseline, you will be asked to return to the nurse-led lymphoma survivorship 
clinic and the same four questionnaires will be filled in by yourself and any issues or 
concerns discussed and support and information given.  
After the six month clinic appointment, if you have consented to an interview, you 
may be contacted to give some feedback on the value, function and benefit of the 
nurse-led lymphoma survivorship clinic. Approximately 10 participants will be asked 
for this feedback in a telephone interview at a time that is convenient to you. It is not 
anticipated that this interview will take longer than an hour. This interview will be 
digitally recorded and typed into a document. All names and identifying information 
will be removed to protect your identity before analysis takes place.  
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We ask that you do not share the resources, information, survivorship care plan 
treatment summary with any other patients in the haematology clinics as this will 
affect the study results.  
 
Monitoring of the study 
This study will be monitored in accordance with the research protocol and the 
National Statement on Ethical Conduct in Human Research (2007) and the 
Australian Code for the Responsible Conduct of Research (2007).  
 
Venue and Commitment required 
The study will be conducted onsite at Sir Charles Gairdner Hospital (SCGH) and we 
ask that you complete all aspects of the study including: completing all 
questionnaires; returning questionnaires promptly and attending all clinic 
appointments as required. Questionnaires may take up to 30 minutes to complete. 
The nurse-led lymphoma survivorship clinics including questionnaire completion will 
be approximately one(1) hour. This study requires a commitment of six months. 
 
Access to Personal Records and Confidentiality 
Your medical records will need to be accessed to gain the information required to fill 
in the treatment summary and partially fill the survivorship care plan prior to the first 
nurse-led lymphoma survivorship clinic. This includes information such as your 
name, date of birth, address, gender, marital status, education, diagnosis and 
treatment.  
 
Bias 
This research project has been designed to make sure the researchers interpret the 
results in a fair and ethical way. 
 
Costs 
There are no direct costs associated with participating in this research project, nor 
will you be paid. If required, you may be asked to give up your time to travel to the 
first nurse-led lymphoma survivorship clinic and group session, which may incur 
travel and parking costs. The second and third nurse-led lymphoma survivorship 
clinic appointments will be scheduled to coincide with your routine three (3) monthly 
haematologist review appointments. 
 
Do I have to take part in this research project? 
Participation in any research project is voluntary. If you do not wish to take part, you 
do not have to. If you decide to take part and later change your mind, you are free to 
withdraw from the project at any stage. 
Your decision whether to take part or not, or to take part and then withdraw, will not 
affect your routine care, your relationship with professional staff or your relationship 
with Sir Charles Gairdner Hospital. 
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What are the possible benefits of taking part? 
We cannot guarantee or promise that you will receive any benefits from this 
research. However, possible benefits may include identification of issues and 
concerns earlier in the post treatment period and referral to services that may assist 
with these issues.  
Participant Information Sheet/Consent Form 22 August 2016 Version 6 It is intended the findings 
from this research will guide the development of expanded nurse-led survivorship 
clinics for all haematology patients and an expansion to other cancer patient. 
 
What are the possible risks and disadvantages of taking part? 
You may feel that some of the questions we ask are upsetting. If you do not wish to 
answer a question, you may skip it. If you become upset or distressed as a result of 
your participation in the study, the research team will arrange for counselling or 
other appropriate support. This will be provided free of charge by qualified staff who 
are not members of the research team. 
 
What if I withdraw from this research project? 
If you decide to withdraw from the project, please notify Karen. She will not collect 
additional information from you, although personal information already collected will 
be retained to ensure that the results can be measured properly and to comply with 
the law. You should be aware that data collected up to the time you withdraw will 
form part of the research project results. If you do not want your data to be included, 
you must tell Karen when you withdraw from the research project. 
 
What happens when the research project ends? 
At the end of the study Karen will send you a summary of the study results. The 
results may not be available for up to 2 years after the study has finished for you as 
it depends on the length of time it takes to recruit all the patients required and for 
Karen to complete her PhD studies.  
 
What will happen to information about me? 
By signing the consent form you consent to the collection and use of your personal 
information for the research project. Your information will only be used for the 
purpose of this research and will only be disclosed with your permission, except as 
required by law. All information will remain confidential and will be kept in the locked 
office of Professor Leanne Monterosso at the University of Notre Dame Fremantle 
campus during the study. Information will be de-identified and stored in a locked 
archive for 15 years from the time the study is closed and published. After that time 
it will be destroyed. 
 
Your health records and any information obtained during the research project are 
subject to inspection (for the purpose of verifying the procedures and the data) by 
the relevant authorities and authorised representatives of the Sir Charles Gairdner 
Hospital Human Research and Ethics Committee, relevant to this Participant 
Information Sheet, or as required by law. By signing the Consent Form, you 
authorise release of, or access to, this confidential information to the relevant 
research personnel and regulatory authorities. 
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It is anticipated that the results of this research project will be published and/or 
presented in a variety of forums. In any publication and/or presentation, information 
will be provided in such a way that you cannot be identified, except with your 
express permission.  
 
In accordance with relevant Australian and/or Western Australian privacy and other 
relevant laws, you have the right to request access to the information about you that 
is collected and stored by the research team. You also have the right to request that 
any information with which you disagree be corrected. Please inform the research 
team member named at the end of this document if you would like to access your 
information. 
 
Complaints and compensation 
Any complaint or concern will be treated in confidence and fully investigated. You 
will be informed of the outcome. In the unlikely event that you experience any 
research-related harm as a result of taking part in this study, you will be provided 
with medical treatment/care at no cost to you. The term “research-related harm” 
means both physical and mental injury caused by the study drug, study product or 
study procedures required by the trial. Your consent to participate in this study does 
not affect your right to pursue a legal remedy from any party involved with the study, 
in respect to an injury alleged to have been suffered by you as a result of your 
participation. 
 
Who has reviewed the research project?  
All research in Australia involving humans is reviewed by an independent group of 
people called a Human Research Ethics Committee (HREC). The ethical aspects of 
this research project have been approved by the HREC of Sir Charles Gairdner 
Hospital and the University of Notre Dame Australia. This project will be carried out 
according to the National Statement on Ethical Conduct in Human Research (2007). 
This statement has been developed to protect the interests of people who agree to 
participate in human research studies. 
 
Further information and who to contact 
The person you may need to contact will depend on the nature of your query. If you 
want any further information concerning this research or if you have any problems 
which may be related to your involvement, you can contact the researcher  
Karen Taylor Survivorship Cancer Nurse Coordinator, Telephone contact: 0428 411 
309, Email: Karen.Taylor@health.wa.gov.au Or Professor Leanne Monterosso (ph) 
9433 0103. 
 
Complaints contact person  
If you have any complaints about any aspect of the project, the way it is being 
conducted or any questions about being a research participant in general, then you 
may contact the Executive Officer of the Sir Charles Gairdner and Osborne Park 
Health Care Group Human Research Ethics Committee on (08) 6457 2999, 
HREC.SCGH@health.wa.gov.au. Or the Executive Officer of the Human Research 
Ethics Committee, Research Office, The University of Notre Dame Australia, on (08) 
9433 0943, research@nd.edu.au 
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                               Consent Form  
 
Effect of a Nurse-Led Lymphoma Survivorship Clinic: A Pilot 
Randomised Controlled Trial 
 
Protocol Number: 2015-020 
Project Sponsor: University of Notre Dame Australia 
Coordinating Principal Investigator: Professor Leanne Monterosso 
Principal Investigator: Karen Taylor 
Associate Investigators: Dr David Joske, Violet Platt, Kendall Stratton, Professor 
Max Bulsara 
 
Declaration by Participant 
 
I have read the Participant Information Sheet or someone has read it to me in a 
language that I understand.  
 
I understand the purposes, procedures and risks of the research described in the 
project. 
 
I have had an opportunity to ask questions and I am satisfied with the answers I 
have received. 
 
I freely agree to participate in this research project as described and understand that 
I am free to withdraw at any time during the project without affecting my future care. 
 
I understand that I will be given a signed copy of this document to keep. 
 
 
Signature 
   
Date 
  
 
Declaration by Researcher† 
 
I have given a verbal explanation of the research project, its procedures and risks 
and I believe that the participant has understood that explanation. 
 
 Name of Researcher (please print)   
 
Signature 
   
Date 
  
 
 
† An appropriately qualified member of the research team must provide the explanation of, and 
information concerning, the research project.  
 
Note: All parties signing the consent section must date their own signature. 
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Appendix E 
Assessment Measures 
E.1 Demographic Questionnaire 
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E.2 Short-Form Survivor Unmet Needs Survey 
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E.3 Depression Anxiety Stress Scale 
DAS S 21                                   Name:                                              Date: 
Please read each statement and circle a number 0, 1, 2 or 3 which indicates how much the 
statement applied to you over the past week. There are no right or wrong answers. Do not 
spend too much time on any statement. 
The rating scale is as follows: 
0  Did not apply to me at all 
1  Applied to me to some degree, or some of the time 
2  Applied to me to a considerable degree, or a good part of time 
3  Applied to me very much, or most of the time 
 
1 I found it hard to wind down 0      1      2      3 
2 I was aware of dryness of my mouth 0      1      2      3 
3 I couldn't seem to experience any positive feeling at all 0      1      2      3 
4 I experienced breathing difficulty (eg, excessively rapid 
breathing, 
breathlessness in the absence of physical exertion) 
0      1      2      3 
5 I found it difficult to work up the initiative to do things 0      1      2      3 
6 I tended to over-react to situations 0      1      2      3 
7 I experienced trembling (eg, in the hands) 0      1      2      3 
8 I felt that I was using a lot of nervous energy 0      1      2      3 
9 I was worried about situations in which I might panic and make 
a fool of myself 
0      1      2      3 
10 I felt that I had nothing to look forward to 0      1      2      3 
11 I found myself getting agitated 0      1      2      3 
12 I found it difficult to relax 0      1      2      3 
13 I felt down-hearted and blue 0      1      2      3 
14 I was intolerant of anything that kept me from getting on with 
what I was doing 
0      1      2      3 
15 I felt I was close to panic 0      1      2      3 
16 I was unable to become enthusiastic about anything 0      1      2      3 
17 I felt I wasn't worth much as a person 0      1      2      3 
18 I felt that I was rather touchy 0      1      2      3 
19 I was aware of the action of my heart in the absence of physical 
exertion (eg, sense of heart rate increase, heart missing a beat) 
0      1      2      3 
20 I felt scared without any good reason 0      1      2      3 
21 I felt that life was meaningless 0      1      2      3 
  
APPENDICES 
385 
E.4 Mini Mental Adjustment to Cancer Scale 
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E.5 Patient Empowerment Scale 
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Appendix F 
F.1 Lymphoma Survivorship Care Plan and Treatment Summary 
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F.2 Content Validity Evaluation Form 
Validation of the Survivorship Care Plan Treatment Summary (SCP TS) 
for use with lymphoma cancer survivors 
The Survivorship Care Plan Treatment Summary (SCPTS) has been 
developed by the chief investigator Karen Taylor (Cancer Nurse Coordinator 
Survivorship, Western Australia Cancer and Palliative Care Network 
(WACPCN) & PhD candidate, University of Notre Dame Australia (UNDA)). 
The principal supervisor for this research, Professor Leanne Monterosso 
PhD, BNurs(Hons) and the associate clinical investigator, Professor David 
Joske have assisted with the development, content and structure of the 
SCPTS. 
To assist in ensuring this document is clear, consistent and valid for use with 
lymphoma survivors, I would like to invite you to assist in this process by 
answering a number of questions that relate to each of the areas this SCP 
TS covers. This will determine the content clarity, apparent internal 
consistency and content validity of the Survivorship Care Plan Treatment 
Summary (SCP TS) that has been developed for use with lymphoma cancer 
survivors.  
If you have any questions before or after you have completed this 
questionnaire, please contact Karen Taylor 0428 411 309 or 
Karen.Taylor@health.wa.gov.au  
Please read the following directions carefully and fill in all sections of the 
table. 
Your participation in this part of my research project is invaluable and greatly 
appreciated.  
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Evaluation of the Survivorship Care Plan Treatment Summary (SCP TS) 
The components of this questionnaire will be scored as either a Yes/No 
answer or on a 4-point Likert-type scoring scale: 
1. Clarity - refers to whether each item is clearly defined – Y = yes or N = 
no 
2a. Apparent internal consistency – refers to whether each item belongs 
in the SCPTS – Y = yes or N = no 
2b. Apparent internal consistency – refers to whether each item generally 
belongs within the SCPTS – Y = yes or N = no 
3. Content validity index – refers to the level of relevance each item has 
when assessing the question inclusion for the SCPTS.  
Please score in this column according to the following 4-point Likert-type 
scoring scale 
Not 
Relevant=1 
Somewhat 
Relevant=2 
Quite 
Relevant=3 
Highly 
Relevant=4 
 
The tables are divided into three sections: 
 Table 1 refers to the Survivorship Care Plan section 
 Table 2 refers to the Treatment Summary section 
 Table 3 refers to the General Health and Screening section 
 
Please look at the section each table refers to and use the following table to 
assess each item. 
Please add any comments/suggestions in the box provided. 
  395 
Table 1 Survivorship Care Plan 
 
  
Content 1. Is this 
heading/infor
mation clear? 
 
Y/N 
2a. Should 
this 
information 
be included 
in a 
survivorship 
care plan? 
Y/N 
2b. Does this 
information 
generally fit 
with the other 
information 
 
Y/N 
3. How 
relevant is 
this 
information 
for a 
survivorship 
care plan? 
Score 
between 1-4 
Please indicate 
whether you are: 
Lymphoma 
Survivor (LS); 
GP (GP); 
Haematologist 
(H) or Nurse (N) 
Comments 
Possible late effect 
column 
      
Follow-up 
recommended 
      
Discussion notes       
My main health 
concerns 
      
My main health 
goals 
      
Haematologist 
details 
      
Survivorship 
coordinator details 
      
GP details       
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Table 2 Treatment Summary 
Information 1. Is this 
information 
clear? 
 
Y/N 
2a. Should 
this 
information 
be included 
in a treatment 
summary? 
 
Y/N 
2b. Does this 
information 
generally fit 
with the other 
information?  
 
Y/N 
3. How 
relevant is 
this 
information 
for a 
treatment 
summary? 
Score 
between 1-4 
Please indicate 
whether you are: 
Lymphoma 
Survivor (LS); 
GP (GP); 
Haematologist 
(H) or Nurse (N) 
Comments 
Date of diagnosis       
Age at diagnosis       
New or relapse       
Subtype       
Location of disease       
Extra-nodal sites       
Major co-morbid 
conditions 
      
Goal of treatment       
Chemotherapy 
regimen 
      
Clinical trial       
Chemotherapy 
start date 
      
Chemotherapy end 
date 
      
Number of cycles 
planned 
      
Number of cycles 
given 
      
Reasons for 
stopping 
      
Planned       
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maintenance 
Blood product 
support 
      
Toxicities       
Major side-effects       
Current side-
effects 
      
Treatment drug 
summary 
      
Radiotherapy start 
date 
      
Radiotherapy end 
date 
      
Region treated       
Dose       
Response       
Contact details       
Stem cell 
transplant 
      
Allied health 
providers 
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Table 3 General Health and Screening 
Thank You for taking the time to fill in this questionnaire 
 Your contribution will assist in improving patient services/outcome 
Information 1. Is this 
information 
clear? 
 
Y/N 
2a. Should 
this 
information 
be included 
in general 
health and 
screening? 
 
Y/N 
2b. Does this 
information 
generally fit 
with the other 
information?  
 
Y/N 
3. How 
relevant is 
this 
information 
for general 
health and 
screening? 
 
Score 
between 1-4 
Please indicate 
whether you are: 
Lymphoma 
Survivor (LS); 
GP (GP); 
Haematologist 
(H) or Nurse (N) 
Comments 
New symptoms to 
watch for 
      
Possible effects of 
treatment 
      
Staying healthy table       
Diet       
Exercise       
Sun Smart       
Weight       
Alcohol       
Smoking       
Screening       
Mental health       
Resources       
General screening 
recommendations 
      
       
APPENDICES 
399 
 
 
Appendix G 
Control Group Letter 
 
 
 
Sir Charles Gairdner Hospital      [Date]  
Haematology Clinic 
 
 
Dear [insert name], 
 
Nurse-led Lymphoma Survivorship Trial 
 
You have agreed to be part of a study to test the effect of a nurse-led 
lymphoma survivorship clinic against the usual standard of follow-up care.  
 
As part of your commitment to this research, we are asking you to fill in the 
same 4 questionnaires you did 3 months ago and return them in the provided 
reply-paid envelope. We would ask you to do this as soon as possible after 
receiving them. 
 
We appreciate your participation as your commitment to this research will 
assist in the development of survivorship services in Western Australia. 
 
If you have any questions or would like further information then please do not 
hesitate to contact me on 0428 411 309. 
 
Yours sincerely 
 
Karen Taylor 
Survivorship Cancer Nurse Coordinator 
PhD Candidate 
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Appendix H 
GP Letters and Evaluation 
H.1 GP cover letter for SCPTS 
 
 
 
Sir Charles Gairdner Hospital      [Date] 
Haematology Clinic 
 
Dear Doctor [insert name] 
 
Lymphoma Survivorship Trial 
 
Your patient, [insert name] s participating in a randomised controlled trial to test the effect of 
a nurse-led lymphoma survivorship clinic against the usual standard of follow-up care. This 
clinic is for lymphoma patients who have finished their chemotherapy treatment. As part of 
this clinic intervention a “Survivorship Care Plan & Treatment Summary” has been 
developed in conjunction with the Consulting Haematologist, the patient and myself.  
 
Survivorship care plans and treatment summaries have been proposed as a way to improve 
communication between clinicians and the patient. Cancer patients treated with 
chemotherapy may be at increased risk of certain health problems. The purpose of this 
document is to: 
 summarise the treatment given;  
 list possible current and late effects of treatment and recommended follow-up; 
 identify the patient’s major health concerns and goals; and 
 provide general health information to promote wellness. 
The patient may make an appointment to meet with you to discuss their recommended 
follow-up care. 
 
If you have any urgent clinical concerns these should be directed to the Haematology 
Department at SCGH who will continue to follow up this patient and send their usual clinic 
letter documentation.  
EviQ can be accessed to provide further up to date, evidence-based cancer treatment 
information. Free access is available at: www.eviq.org.au. Username: phc. Password: phc. 
 
As part of the assessment of this Survivorship Care Plan & Treatment Summary, an 
evaluation form will be sent to you in six months to gauge your use of the Survivorship Care 
Plan & Treatment Summary, and your thoughts on its usefulness.  
 
If you have any questions or would like further information about this survivorship study, 
please do not hesitate to contact me. 
 
Yours sincerely 
 
Karen Taylor 
Survivorship Cancer Nurse Coordinator/PhD Candidate 
Karen.Taylor@health.wa.gov.au 
0428 411 309 
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H.2 GP Cover Letter for Evaluation 
 
 
 
Sir Charles Gairdner Hospital     [Date] 
Haematology Clinic 
 
 
Dear Doctor [insert name] 
 
Lymphoma Survivorship Trial 
 
Your patient [insert name] has been part of a randomised controlled trial to 
test the effect of a nurse-led lymphoma survivorship clinic against the usual 
standard of follow-up care.  
 
We would like your feedback as to whether the information we provided in 
the Survivorship Care Plan & Treatment Summary has been helpful to you. A 
plan for this patient should have been posted to you six months ago when the 
patient commenced in the trial. A copy has been attached with this letter. 
 
Please complete the attached questionnaire and return in the provided reply-
paid envelope. Alternatively, it can be faxed back “Attention Karen Taylor 
Survivorship CNC” to 6457 4432 or scanned to the email address below. 
 
We appreciate all the information that you are able to give as this will assist 
in the evaluation of survivorship services. 
 
If you have any questions or would like further information then please do not 
hesitate to contact me. 
 
Yours sincerely 
 
Karen Taylor 
Survivorship Cancer Nurse Coordinator 
PhD Candidate 
Karen.Taylor@health.wa.gov.au 
0428 411 309 
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H.3 GP Evaluation of SCPTS 
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Appendix I 
Interview Questions 
Interview guide for patient participants 
 
Thank you for volunteering for this interview and for participating in the 
survivorship study. I would like to talk to you about your experience of the 
survivorship clinic and record your thoughts about this and any suggestions 
you may have to improve the experience for future patients. As you may be 
aware, the study involves a ‘nurse-led cancer survivorship clinic’ – something 
that hasn’t been offered to cancer patients before. The study was focusing on 
the development and testing of this new form of cancer survivorship or follow-
up care after treatment has finished. 
 
From your perspective what are your thoughts about the 
questionnaires you were asked to complete at each clinic visit?  
 
1. Did you have any concerns or needs that weren’t addressed by any of the 
questions?  
- if yes, can you please tell me what these were? 
 
2. The time it took to answer all the questions?  
 
3. Did you think any questions were too intrusive? 
 
We are hoping survivorship care will become routine for all cancer 
patients when they finish treatment at the hospital. As you know at the 
moment the survivorship clinic is offered after all treatment is 
completed. 
 
4. Would you have preferred to know about this clinic after diagnosis or 
earlier in the treatment phase? 
       - would this have helped you think beyond the treatment phase 
to what   
        comes after treatment finishes?  
       - why do you feel this way, can you explain? 
 
5. What aspects of the clinic would you want to stay the same for other 
cancer patients in the future?  
 
6. Can you please describe the difference (if any) this clinic has made for you 
after finishing your treatment phase? 
6.1 What do you consider the best part of coming?  
6.2 Were there are any downsides to coming?  
6.3 If you could change anything about the clinic, what would you 
change? 
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7.  Would you recommend the clinic for other patients who are about to finish 
treatment? 
  -  why or why not? 
 
Now I would like to ask some questions on your thoughts of the 
survivorship care plan and treatment summary you received. This is the 
document Karen gave you. 
 
8. Did you find the treatment summary section a helpful summary of your 
diagnosis and treatment? (This is page 1) 
  -  would you like to see more information on that part?  
 -  did you feel any information was not explained enough or 
difficult to  
      understand?  
 
9. What were your thoughts and reactions to the potential late effects 
information you were given? (These are on the first page under the treatment 
summary). 
  - were they as you expected? 
  - did they add to your worry about the cancer treatment? 
  - had this information been given to you before by your 
doctors? 
 
10. How did you feel about having the health concerns, goals and actions 
individualised to yourself? (This was the second page). 
  - did you find it useful to explore your needs in this way? 
- were you concerned this information would be shared with 
your medical team? 
 
11. Do you have any thoughts on the general health and screening 
information? (This was the 2 page sheet). 
- did you find it useful? 
  - were there parts you found more useful than others? 
 
12. Did you discuss the survivorship care plan and treatment summary with 
your GP?  
- did they have any thoughts on this document they shared with 
you? 
 
13. Overall how useful was the survivorship care plan and treatment 
summary to you? 
 
Thank you for patience, these few questions relate to finding out about 
the study.  
 
14. Did your haematology Dr mention the study to you prior to the researcher 
Karen contacting you? 
14.1 Did your haematology Dr discuss the survivorship care plan and 
treatment summary with you? 
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Lastly these questions are about Karen’s nurse-led clinic – these are 
not about the treatment clinic or Dr appointments.  
 
From your perspective what are your thoughts about:  
 
15. Its location? Would you have preferred to be away from the hospital? 
 
16. The timing of the visit? 
5.1 Do you have any thoughts about when the clinic should 
commence?  
- just before the last treatment? 
- immediately after the last treatment? 
- later than 3 months after treatment has completed? 
 
17. The length of each clinic visit? 
 
18. The information you were given?  
 -  was it too much or too little? 
-  was the timing of the information right? 
 -  how relevant was the information to you? 
 
19. Do you have any other thoughts or issues to raise that we haven’t 
discussed today? 
 
I appreciate the time you have given today and your insights and 
thoughts in relation to your experience. Thank you for agreeing to this 
interview, and for your participation throughout 
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Appendix J 
J.1 Checklist for Nurse-led Lymphoma Survivorship Clinic 
Appointment 
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J.2 Motivational Chart 
Motivational chart 
Behaviour/Problem: 
 
LIKE DISLIKE 
Stay the Same 
 
 
 
 
 
 
 
 
 
 
 
 
List what you like about 
the behaviour 
 
 
 
 
 
 
 
 
 
 
 
List what you don’t like 
about the behaviour 
Change 
 
 
 
 
 
 
 
 
 
 
 
 
List what you think will 
be better  
 
 
 
 
 
 
 
 
 
 
 
List what you think will 
be difficult 
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Appendix K 
K.1 SPIRIT Checklist for Protocol  
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K.2 CONSORT Statement for Pragmatic RCT 
CONSORT 2010 checklist of information to include when reporting a randomised trial 
Section/Topic 
Item 
No Checklist Item 
Reported 
on Page No 
Title and abstract 
 1a Identification as a randomised trial in the title i 
1b Structured summary of trial design, methods, results, and conclusions  11 
Introduction 
Background 
and objectives 
2a Scientific background and explanation of rationale 2-6 
2b Specific objectives or hypotheses 7 
Methods 
Trial design 3a Description of trial design (such as parallel, factorial) including allocation ratio 8 
3b Important changes to methods after trial commencement (such as eligibility criteria), 
with reasons 
NA 
Participants 4a Eligibility criteria for participants 131 
4b Settings and locations where the data were collected 131 
Interventions 5 The interventions for each group with sufficient details to allow replication, including 
how and when they were actually administered 
137-138 
Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including 
how and when they were assessed 
127-128 
6b Any changes to trial outcomes after the trial commenced, with reasons NA 
  413 
Sample size 7a How sample size was determined 133 
7b When applicable, explanation of any interim analyses and stopping guidelines NA 
Randomisation:    
 Sequence 
generation 
8a Method used to generate the random allocation sequence 136 
8b Type of randomisation; details of any restriction (such as blocking and block size) 136 
 Allocation 
concealment 
mechanism 
9 Mechanism used to implement the random allocation sequence (such as sequentially 
numbered containers), describing any steps taken to conceal the sequence until 
interventions were assigned 
136 
 
Implementation 
10 Who generated the random allocation sequence, who enrolled participants, and who 
assigned participants to interventions 
136 
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, 
care providers, those assessing outcomes) and how 
NA 
11b If relevant, description of the similarity of interventions  
Statistical 
methods 
12a Statistical methods used to compare groups for primary and secondary outcomes 146-148 
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses 170 
Results 
Participant flow 
(a diagram is 
strongly 
recommended) 
13a For each group, the numbers of participants who were randomly assigned, received 
intended treatment, and were analysed for the primary outcome 
149 
13b For each group, losses and exclusions after randomisation, together with reasons 149 
Recruitment 14a Dates defining the periods of recruitment and follow-up 148 
  414 
14b Why the trial ended or was stopped 148 
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group 151-152 
Numbers 
analysed 
16 For each group, number of participants (denominator) included in each analysis and 
whether the analysis was by original assigned groups 
154-155 
Outcomes and 
estimation 
17a For each primary and secondary outcome, results for each group, and the estimated 
effect size and its precision (such as 95% confidence interval) 
156-173 
17b For binary outcomes, presentation of both absolute and relative effect sizes is 
recommended 
156-173 
Ancillary 
analyses 
18 Results of any other analyses performed, including subgroup analyses and adjusted 
analyses, distinguishing pre-specified from exploratory 
175-212 
Harms 19 All important harms or unintended effects in each group  NA 
Discussion 
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, 
multiplicity of analyses 
234-237 
Generalisability 21 Generalisability (external validity, applicability) of the trial findings 223 
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering 
other relevant evidence 
223-232 
Other information  
Registration 23 Registration number and name of trial registry 122 
Protocol 24 Where the full trial protocol can be accessed, if available 122-143 
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders xxii 
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Appendix L 
Quantitative Analysis Tables 
23Table 1 Reliability of Assessment Measures  
Measure Domain Original 
study 
Cronbach’s 
alpha 
Current study Cronbach’s 
alpha 
Time 1 
N=60 
Time 2 
N=59 
Time 3 
N=58 
SF-
SUNS 
Information (3 items) 0.85a 0.70  0.80 0.82 
Financial Concerns (8 
items) 
0.90a 0.74 0.90 0.88 
Access and Continuity of 
Care (6 items) 
0.90a 0.89 0.85 0.88 
Relationships and 
emotional health (13 items) 
0.95a 0.92 0.96 0.96 
DASS21 Depression (7 items) 0.94b 0.90 0.93 0.92 
Anxiety (7 items) 0.87b 0.79 0.79 0.83 
Stress (7 items) 0.91b 0.86 0.94 0.92 
Mini-
MAC 
Helplessness/Hopelessness 
(8 items) 
0.87c 0.89 0.87 0.90 
Anxious Preoccupation (8 
items) 
0.88c 0.87 0.88 0.92 
Fatalism (5 items) 0.62c 0.62 0.61 0.68 
Fighting Spirit (4 items) 0.76c 0.61 0.59 0.58 
Cognitive Avoidance (4 
items) 
0.74c 0.82 0.85 0.89 
PES 15 items 0.93d,e 0.75 0.79 079 
a Campbell et al. (2014); b Antony et al. (1998); c Watson et al. (1994); d Bulsara, Styles, 
Ward, and Bulsara (2006); e Pearson’s Separation Index (Cronbach’s alpha 
equivalent)  
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24Table 2 Intervention Group Wilcoxon Signed Rank Test  
Measure 
 
Mean (SD) 
Median 
Wilcoxon 
Signed Rank 
Effect 
Size 
SF-SUNS 
Time 1 – 
Time 2 Total scale scores 
 
Time 1 – 
Time 2 Information 
 
Time 1 – 
Time 2 Financial concerns 
 
Time 1 – 
Time 2 Access and continuity of care 
 
Time 1 – 
Time 2 Relationships and emotional health 
 
Time 1 - 
Time 3 Total scale scores 
 
Time 1 – 
Time 3 Information 
 
Time 1 – 
Time 3 Financial Concerns 
 
Time 1 – 
Time 3 Access and continuity of care 
 
Time 1 – 
Time 3 Relationships and emotional health 
 
27.33 (20.63) 18.50 
26.27 (22.81) 22.00 
 
2.97 (3.18) 2.50 
2.33 (2.00) 2.00 
 
6.70 (5.93) 6.50 
7.63 (7.58) 6.00 
 
3.97 (5.88) 1.50 
2.24 (3.43) 0 
 
13.70 (10.87) 12.50 
13.90 (12.75) 11.50 
 
27.33 (20.63) 18.50 
21.41 (22.95) 16.00 
 
2.97 (3.18) 2.50 
1.97 (2.34) 2.00 
 
6.70 (5.93) 6.50 
5.76 (6.36) 4.00 
 
3.97 (5.88) 1.50 
2.24 4.75) 0 
 
13.70 (10.87) 12.50 
11.45 (12.28) 8.00 
 
z -0.35 p .726 
 
 
z -1.12 p .262 
 
 
z -0.10 p .923 
 
 
z -1.69 p .090 
 
 
z -0.19 p .846 
 
 
z -2.15 p .031 
 
 
z -1.37 p .169 
 
 
z -1.71 p .088 
 
 
z -2.31 p .021 
 
 
z -1.69 p .091 
 
r .05 
 
 
r .15 
 
 
r .01 
 
 
r .22 
 
 
r .03 
 
 
r .28 
 
 
r .18 
 
 
r .22 
 
 
r .30 
 
 
r .22 
DASS21 
Time 1 – 
Time 2 Total scale scores 
 
Time 1 – 
Time 2 Depression 
 
Time 1 – 
Time 2 Anxiety 
 
Time 1 – 
Time 2 Stress 
 
 
12.67 (12.01) 10.00 
15.63 (15.61) 9.50 
 
4.03 (4.75) 2.00 
5.30 (5.78) 2.50 
 
3.47 (3.36) 3.00 
3.53 (3.67) 3.00 
 
5.17 (5.05) 4.00 
6.80 (6.97) 4.50 
 
 
z -1.24 p .214 
 
 
z -1.14 p .255 
 
 
z -0.08 p .940 
 
 
z -1.62 p .106 
 
 
 
r .16 
 
 
r .15 
 
 
r .01 
 
 
r .21 
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Time 1- 
Time 3 Total scale scores 
 
Time 1 – 
Time 3 Depression 
 
Time 1 – 
Time 3 Anxiety 
 
Time 1 – 
Time 3 Stress 
12.67 (12.01) 10.00 
15.61 (13.40) 8.00 
 
4.03 (4.75) 2.00 
4.14 (5.38) 1.00 
 
3.47 (3.36) 3.00 
3.45 (3.93) 2.00 
 
5.17 (5.05) 4.00 
5.66 (5.75) 4.00 
z -0.03 p .976 
 
 
z -0.05 p .957 
 
 
z -0.05 p .961 
 
 
z -0.42 p .675 
r .004 
 
 
r .006 
 
 
r .006 
 
 
r .05 
Mini-MAC 
Time 1 – 
Time 2 Total scale scores 
 
Time 1 – 
Time 2 Fatalism 
 
Time 1 – 
Time 2 Fighting Spirit 
 
Time 1 – 
Time 2 Helplessness/Hopelessness 
 
Time 1 – 
Time 2 Anxious preoccupation 
 
Time 1 – 
Time 2 Cognitive avoidance 
 
Time 1 - 
Time 3 Total scale scores 
 
Time 1 – 
Time 3 Fatalism 
 
Time 1 – 
Time 3 Fighting Spirit 
 
Time 1 – 
Time 3 Helplessness/Hopelessness 
 
Time 1 – 
Time 3 Anxious preoccupation 
 
Time 1 – 
 
65.30 (12.62) 64.50 
64.27 (13.44) 63.50 
 
14.13 (3.03) 14.00 
14.30 (2.81) 14.00 
 
12.40 (2.59) 13.00 
11.33 (2.32) 11.00 
 
12.77 (4.88) 11.50 
12.83 (4.79) 12.50 
 
17.27 (5.84) 16.00 
17 (6.07) 16.50 
 
8.73 (3.17) 8.50 
8.80 (3.26) 9.00 
 
65.30 (12.62) 64.50 
62.59 (15.03) 64 
 
14.13 (3.03) 14.00 
13.76 (3.44) 14.00 
 
12.40 (2.59) 13.00 
11.55 (2.43) 12.00 
 
12.77 (4.88) 11.50 
12 (4.74) 9.00 
 
17.27 (5.84) 16.00 
16.76 (6.34) 17 
 
8.73 (3.17) 8.50 
 
z -0.64 p .524 
 
 
z -0.35 p .732 
 
 
z -2.60 p .009 
 
 
z -0.04 p .969 
 
 
z -0.41 p .686 
 
 
z -0.17 p .865 
 
 
z -1.17 p .241 
 
 
z -1.11 p .266 
 
 
z -1.80 p .073 
 
 
z -1.31 p .190 
 
 
z -0.50 p .616 
 
 
z -0.59 p .556 
 
r .08 
 
 
r .05 
 
 
r .34 
 
 
r .08 
 
 
r .05 
 
 
r .02 
 
 
r .15 
 
 
r .14 
 
 
r .23 
 
 
r .17 
 
 
r .07 
 
 
r .08 
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Time 3 Cognitive avoidance 8.52 (3.94) 8.00 
PES 
Time 1 – 
Time 2 
 
Time 1 – 
Time 3 
 
48.33 (5.11) 48.50 
49.50 (5.63) 50.50 
 
48.33 (5.11) 48.50 
50.21 (5.63) 52.00 
 
z -1.16 p .246 
 
 
z -1.78 p .075 
 
r .15 
 
 
r .23 
Note. Significance level 0.05 (2-tailed); Effect size: 0.2=small effect, 0.5=moderate 
effect, 0.8=large effect 
 
 
 
25Table 3 Linear Mixed Model Results of SF-SUNS Total Scale  
Variable Beta 
Estimate 
Std. 
Error 
95% Confidence 
Interval 
P 
Value 
Lower Upper 
Intercept 35.79 8.93 17.91 53.67 .000 
Group—Controla –3.61 6.02 –15.67 8.45 .551 
Lymphomab (NHL) 13.82 7.32 –0.85 28.50 .064 
Genderc (Male) –11.39 5.97 –23.35 0.56 .061 
Time 1d 3.46 2.09 –0.68 7.59 .101 
Time 2d 3.79 2.09 –0.35 7.93 .072 
Age –0.27 0.16 –0.60 0.06 .109 
Note. a Comparison group set to zero (Intervention); b Comparison group set to zero (HL);  
c Comparison group set to zero (Female); d Comparison group set to zero (Time 3) 
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26Table 4 Linear Mixed Model Results of Mini-MAC Domains  
Variable Beta 
Estimate 
Std. 
Error 
95% Confidence 
Interval 
P 
Value 
Lower Upper 
Helplessness/Hopelessness Domain      
Intercept 14.18 1.74 10.70 17.67 .000 
Group—Controla –0.67 1.17 –3.00 1.68 .571 
Lymphomab (NHL) 0.11 1.42 –2.74 2.96 .938 
Genderc (Male) –1.97 1.16 –4.29 0.35 .094 
Time 1d 0.36 0.49 –0.62 1.34 .465 
Time 2d 0.43 0.49 –0.55 1.41 .383 
Age –0.01 0.03 –0.07 0.05 .735 
Anxious Preoccupation Domain      
Intercept 20.40 2.28 15.84 24.96 .000 
Group—Controla 1.33 1.54 –1.75 4.42 .389 
Lymphomab (NHL) –0.73 1.87 –4.48 3.02 .698 
Genderc (Male) –2.05 1.52 –5.10 1.01 .185 
Time 1d 0.96 0.49 –0.02 1.93 .055 
Time 2d 0.38 0.49 –0.60 1.36 .440 
Age –0.04 0.04 –0.12 0.05 .360 
Cognitive Avoidance Domain      
Intercept 10.71 1.22 8.28 13.15 .000 
Group—Controla 1.19 0.81 –0.44 2.82 .150 
Lymphomab (NHL) –0.38 0.99 –2.37 1.60 .700 
Genderc (Male) –1.22 0.81 –2.84 0.40 .137 
Time 1d –0.09 0.36 –0.81 0.63 .802 
Time 2d 0.30 0.36 –0.42 1.02 .409 
Age –0.02 0.02 –0.06 0.03 .387 
Note. a Comparison group set to zero (Intervention); b Comparison group set to zero (HL);  
c Comparison group set to zero (Female); d Comparison group set to zero (Time 3) 
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27Table 5 Descriptive Data of the Multi-item Measures by Group at Each Time Point and Between Time Points 
Measure Baseline (Time 1)# 3 months (Time 2)# 6 Months (Time 3)# Time differences^ 
C
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(C
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 d
) Time 1 – Time 2  Time 1 – Time 3 
Control Intervention Control Intervention 
SF-SUNSa 26.53 
(21.84) 
27.33 
(20.63) 
.885 
(-.04) 
28.62 
(27.82) 
26.27 
(22.81) 
.723 
(.09) 
25.72 
(25.99) 
21.41 
(22.95) 
.506 
(.18) 
t (28) -0.46 
p .648 
t (29) 0.39 p 
.698  
t (28) 0.32 
p .753 
t (28) 1.99 p 
.057  
Information  3.30 
(2.58) 
2.97 
(3.18) 
.657 
(.12) 
3.21 
(3.29) 
2.33 
(2.01) 
.221 
(.27) 
2.76 
(2.82) 
1.97 
(2.34) 
.249 
(.31) 
t (28) 0.43 
p 0.673 
t (29) 1.20 p 
.240 
t (28) 1.36 
p .185 
t (28) 1.52 p 
.139  
Financial 
concerns 
7.03 
(6.13) 
6.70 
(5.93) 
.831 
(.05) 
6.38 
(8.38) 
7.63 
(7.58) 
.549 
(-.16) 
6.28 
(7.77) 
5.76 
(6.36) 
.782 
(.07) 
t (28) 0.62 
p .538 
t (29) -0.89 p 
.383  
t (28) 0.68 
p .505 
t (28) 1.02 p 
.317  
Access and 
continuity of 
care 
2.60 
(4.35) 
3.97 
(5.88) 
.310 
(.27) 
3.28 
(4.32) 
2.40 
(3.43) 
.391 
(.23) 
2.34 
(2.87) 
2.24 
(4.75) 
.920 
(.03) 
t (28) -0.98 
p .338 
t (29) 1.88 p 
.070  
t (28) 0.34 
p .737 
t (28) 2.47 p 
.020  
Relationships 
and emotional 
health 
13.60 
(11.51) 
13.70 
(10.87) 
.973 
(.01) 
15.76 
(13.79) 
13.90 
(12.75) 
.593 
(.14) 
14.34 
(14.10) 
11.45 
(12.28) 
.408 
(.22) 
t (28) -0.93 
p .361 
t (29) -0.19 p 
.907  
t (28) -0.22 
p .826 
t (28) 1.32 p 
0.199 
DASS21b 15.57 
(13.91) 
12.67 
(12.01) 
.391 
(.22) 
14.17 
(13.67) 
15.63 
(15.61) 
.704 
(-.10) 
15.14 
(13.76) 
13.03 
(13.40) 
.558 
(.16) 
t (28) 0.75 
p .462 
t (29)=-1.53 p 
.136 
t (28) 0.24 
p .812 
t (28) - 0.19 p 
.853  
Depression 4.33 
(5.37) 
4.03 
(4.75) 
.819 
(.06) 
4.59 
(5.44) 
5.30 
(5.78) 
.627 
(-.13) 
4.83 
(5.56) 
4.14 
(5.38) 
.633 
(.13) 
t (28) -0.28 
p 0.79 
t (29)=-1.58 p 
0.13  
t (28) -0.58 
p 0.57 
t (28) -0.06 p 
0.95 
Anxiety 4.60 
(5.05) 
3.47 
(3.36) 
.310 
(.27) 
3.63 
(4.18) 
3.53 
(3.67) 
.932 
(.02) 
3.55 
(3.95) 
3.45 
(3.93) 
.921 
(.03) 
t (28) 1.22 
p .232 
t (29) -0.14 p 
.888 
t (28) 1.38 
p .179 
t (28) -0.06 p 
.892 
Stress 6.63 5.17 .270 5.97 6.80 .617 6.76 5.66 .471 t (28) 0.67 t (29) -1.85 p t (28) -0.22 t (28) -0.65 p 
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(5.15) (5.05) (.29) (5.69) (6.97) (-.13) (5.82) (5.75) (.19) p .510 .074 p .825 .522 
Mini-MACs 68.47 
(12.74) 
65.30 
(12.62) 
.337 
(.25) 
67.72 
(15.22) 
64.27 
(13.44) 
.359 
(.24) 
65.38 
(15.52) 
62.59 
(15.03) 
.489 
(.18) 
t (28) 0.51 
p .614 
t (29)=0.61 p 
.547 
t (28) 1.81 
p .081 
t (28) 1.35 p 
.188 
Fatalism 14.27 
(3.29) 
14.13 
(3.03) 
.871 
(.04) 
13.79 
(3.58) 
14.30 
(2.81) 
.547 
(-.16) 
13.28 
(3.56) 
13.76 
(3.44) 
.603 
(-.14) 
t (28) 0.80 
p .428 
t (29) -0.39 p 
.701  
t (28) 1.94 
p .062 
t (28) 1.13 p 
.267  
Fighting spirit 12.47 
(2.13) 
12.40 
(2.59) 
.914 
(.03) 
12.07 
(2.61) 
11.33 
(2.32) 
.257 
(.30) 
11.24 
(2.91) 
11.55 
(2.43) 
.661 
(-.12) 
t (28) 0.96 
p .345  
t (29) 2.80 p 
.009 
t (28) 3.50 
p .002 
t (28) 2.13 p 
.042  
Helplessness/h
opelessness 
12.47 
(4.31) 
12.77 
(4.88) 
.802 
(-.07) 
12.66 
(4.76) 
12.83 
(4.79) 
.887 
(-.03) 
12.62 
(4.41) 
12.00 
(4.74) 
.608 
(.14) 
t (28) -0.04 
p .968 
t (29) 1.11 p 
.909  
t (28) 0.00 
p 1.00 
t (28) 1.39 p 
.176  
Anxious 
preoccupation 
19.47 
(5.34) 
17.27 
(5.84) 
.133 
(.40) 
18.66 
(5.68) 
17.00 
(6.07) 
.284 
(.28) 
18.10 
(6.14) 
16.76 
(6.34) 
.415 
(.22) 
t (28) 1.46 
p .154 
t (29) 0.33 p 
.742  
t (28) 2.20 
p .037 
t (28) 0.65 p 
.521  
Cognitive 
avoidance 
9.80 
(3.13) 
8.73 
(3.17) 
.195 
(.03) 
10.55 
(3.25) 
8.80 
(3.26) 
.043 
(.54) 
10.14 
(3.06) 
8.52 
(3.94) 
.086 
(.46) 
t (28) -1.68 
p .105 
t (29) -0.14 p 
.888 
t (28) -0.73 
p .474 
t (28) 0.16 p 
.876 
PESd 48.77 
(6.03) 
48.33 
(5.11) 
.765 
(.80) 
45.79 
(5.85) 
49.50 
(5.63) 
.016 
(-.65) 
47.21 
(6.07) 
50.21 
(5.63) 
.056 
(-.50) 
t (28) 3.06 
p .005 
t (29) -1.45 p 
.158 
t (28) 1.41 
p .170 
t (28) -1.97 p 
.059 
Note. *Data given as mean (SD); Bolded p value indicates statistical significance p<.05; # Independent T-test results; ^ Paired-sample T-test results; aHigher 
scores represent higher levels of need; bHigher scores represent higher levels of psychological need; cHigher scores represent more endorsement of the domain 
trait; dHigher scores represent more empowerment; SF-SUNS: Short-Form Survivor Unmet Needs Survey; DASS21: Depression, Anxiety Stress Scale; Mini-
MAC: Mental Adjustment to Cancer Scale; PES: Patient Empowerment Scale; Cohen’s d: 0.2=small effect, 0.5=moderate effect, 0.8=large effect   
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28Table 6 Age Differences Across Measures at Each Time Point within the Control and Intervention Groups 
 Control Group Intervention Group 
Measure Age Group 1  
18–29 years  
N=5 
Age Group 2 
30–59 years 
N=14 
Age Group 3 
>60 years 
N=11 
Group 
Comparison* 
Age Group 1  
18–29 years  
N=8 
Age Group 2 
30–59 years 
N=12 
Age Group 3 
>60 years 
N=10 
Group 
Comparison* 
Mean(SD) 
Median 
Mean(SD) 
Median 
Mean(SD) 
Median 
Mean(SD) 
Median 
Mean(SD) 
Median 
Mean(SD) 
Median 
SF-SUNS Time 1         
Total scale scores 17 (9.25) 18 36.36 (25.49) 25.5 18.36 (15.84) 13 X2 8.31, p .016 30.50 (14.37) 34 28.75 (27.11) 15 23.10 (16.75) 18 X2 1.06, p .587 
Information 2 (2.35) 1 4.57 (2.44) 4 2.27 (2.24) 2 X2 5.47, p .065 4.13 (3.40) 4 3.17 (3.71) 1.5 1.80 (1.99) 1.5 X2 1.94, p .380 
Financial concerns 2.60 (2.07) 3 9.93 (7.05) 9 5.36 (4.23) 6 X2 7.88, p .019 6 (3.34) 7 7.42 (8.57) 5 6.40 (3.69) 5 X2 0.57, p .751 
Access and continuity of 
care 
0.80 (0.84) 1 4.57 (5.75) 2.5 0.91 (1.22) 1 X2 8.89, p .012 3.88 (3.14) 3.5 5.42 (8.30) 2 2.30 (3.71) 1 X2 1.78, p .411 
Relationships and 
emotional health 
11.60 (7.83) 12 17.29 (13.02) 13.5 9.82 (10.14) 5 X2 5.16, p .076 16.50 (10.94) 16 12.75 (11.16) 13.5 12.60 (11.23) 9 X2 0.68, p .713 
SF-SUNS Time 2         
Total Scale scores 18.60 (8.26) 17 39.31 (33.92) 28 20.55 (22.08) 12 X2 2.81, p .245 22.50 (12.81) 22 36.17 (30.94) 28 17.40 (12.20) 16 X2 2.23, p .327 
Information 2.20 (1.64) 3 4.15 (3.56) 3 2.55 (3.45) 0 X2 2.13, p .344 2 (1.51) 2 2.75 (2.61) 3 2.10 (2.13) 2 X2 0.83, p .662 
Financial concerns 3.20 (2.59) 3 9.23 (10.16) 5 4.45 (7.10) 2 X2 2.18, p .336 4.75 (2.87) 5.5 12.08 (10.15) 13.5 4.60 (2.99) 6 X2 2.58, p .275 
Access and continuity of 
care 
1 (1.73) 0 4.92 (5.20) 3 2.36 (3.38) 1 X2 3.80, p .149 2.63 (2.97) 2 4.08 (4.19) 2.5 0.20 (0.83) 0 X2 8.88, p .012 
Relationships and 
emotional health 
12.20 (8.20) 13 21 (16.03) 16 11.18 (10.47) 10 X2 2.43, p .296 13.13 (8.71) 12 17.25 (16.89) 11 10.50 (9.38) 9 X2 0.66, p .717 
SF-SUNS Time 3         
Total Scale scores 17.60 (9.94) 20 36.69 (31.32) 22 16.45 (19.76) 7 X2 4.14, p .126 14.71 (11.19) 16 26.92 (31.18) 18.5 19.50 (16.95) 14 X2 0.48, p .787 
Information 2 (1.23) 2 3.85 (3.05) 4 1.82 (2.79) 0 X2 3.69, p .158 0.71 (1.25) 0 2.17 (2.92) 1 2.60 (1.96) 3.5 X2 3.76, p .153 
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Financial concerns 3.20 (1.92) 4 9.46 (10.30) 5 3.91 (4.4) 3 X2 1.84, p .399 2.71 (2.69) 2 8.58 (8.91) 6 4.50 (2.07) 4 X2 2.04, p .361 
Access and continuity of 
care 
1 (1.23) 1 3.85 (3.24) 4 1.18 (2.14) 0 X2 7.54, p .023 0.71 (1.50) 0 3.83 (6.99) 1 1.40 (1.71) 1 X2 1.84, p .399 
Relationships and 
emotional health 
11.40 (9.71) 11 19.54 (16.21) 15 9.55 (11.80) 4 X2 3.16, p .206 10.57 (7.83) 11 12.33 (14.46) 8.5 11 (13.07) 6.5 X2 0.33, p .847 
DASS21 Time 1         
Total scale scores 10 (5.79) 9 18.79 (15.72) 13 14 (13.92) 10  X2 1.87, p .392 14.63 (10.03) 12.5 12 (14.14) 8 11.90 (11.74) 7.5 X2 1.84, p .398 
Depression 2 (2.35) 1 5.50 (6.19) 2.5) 3.91 (5.19) 1 X2 1.61, p .446 3.75 (3.96) 2 3.67 (5.12) 1.5 4.70 (5.25) 3 X2 1.26, p .533 
Anxiety 2 (2.45) 2 5.86 (5.64) 4.5 4.18 (4.94) 3 X2 2.17, p .338 4 (3.42) 3 3.42 (3.73) 2 3.10 (3.14) 2.5 X2 0.63, p .732 
Stress 6 (1.58) 6 7.43 (5.60) 6.5 5.91 (5.79) 5 X2 1.03, p .599 6.88 (5.14) 5.5 4.92 (5.81) 4 4.10 (4.04) 3 X2 2.98, p .226 
DASS21 Time 2         
Total scale scores 11.80 (7.53) 9 17.15 (15.96) 11 11.73 (13.18) 5 X2 1.27, p .530 11.75 (12.90) 6 19.33 (19.76) 10 14.30 (12.05) 13.5 X2 0.58, p .749 
Depression 2.40 (3.78) 1 6.38 (6.50) 5 3.45 (4.28) 1 X2 2.07, p .355 3.50 (3.82) 1.5 6.50 (7.44) 3 5.30 (4.88) 4 X2 1.002, p .606 
Anxiety 2.20 (1.79) 2 4 (4.71) 2 3.82 (4.45) 1 X2 0.24, p .885 2.63 (2.93) 2 4.33 (4.72) 3.5 3.30 (2.83) 3.5 X2 0.72, p .698 
Stress 7.20 (3.27) 6 6.77 (6.34) 5 4.45 (5.84) 4 X2 2.70, p .259 5.63 (6.74) 3.5 8.50 (8.43) 5.5 5.70 (5.27) 5 X2 0.37, p .831 
DASS21 Time 3         
Total scale scores 8.60 (7.67) 6 17.62 (14.97) 12 15.18 (14.44) 12 X2 1.19, p .552 12.57 (8.85) 15 12.75 (16.97) 5.5 13.70 (12.40) 8 X2 1.14, p .566 
Depression 1.20 (2.17) 0 6.46 (5.88) 4 4.55 (5.75) 2 X2 4.67, p .097 3.57 (3.91) 3 3.42 (5.81) 1 5.40 (5.99) 4.5 X2 0.57, p .753 
Anxiety 2.20 (2.28) 2 3.85 (3.98) 3 3.82 (4.65) 2 X2 0.38, p .826 2.43 (2.51) 2 3.5 (4.52) 1.5 4.10 (4.20) 3.5 X2 0.27, p .874 
Stress 5.20 (4.15) 5 7.31 (6.63) 5 6.82 (5.81) 8 X2 0.35, p .841 6.71 (4.96) 8 5.92 (7.19) 2.5 4.60 (4.58) 3.5 X2 0.64, p .728 
Mini-MAC Time 1         
Total scale scores 64 (7.28) 64 74.29 (13.30) 72.5 63.09 (11.42) 63 X2 6.45 p .040 69.75 (13.42) 72.5 62 (13.67) 64.5 65.70 (10.61) 62 X2 2.05, p .358 
Fatalism 11.40 (1.95) 12 14.93 (3.29) 16  14.73 (3.29) 15 X2 5.28, p .071 13.75 (2.32) 14 13.17 (3.04) 13 15.60 (3.20) 15.5 X2 3.65, p .162 
Fighting spirit 12.60 (1.52) 13 12.71 (1.98) 13 12.09 (2.63) 13 X2 0.22, p .896 12.50 (2.45) 12.5 12.33 (3.20) 13.5 12.40 (2.12) 12.5 X2 0.09, p .958 
Helplessness/hopelessness 11.40 (4.22) 9 13.5 (4.62) 14.5 11.64 (4.01) 10 X2 1.59, p .451 14 (5.76) 12.5 12.33 (5.05) 11.5 12.30 (4.24) 11 X2 0.41, p .814 
Anxious preoccupation 19.40 (2.07) 19 21.57 (5.14) 21.5 16.82 (5.71) 18 X2 4.67, p .097 19.75 (6.86) 20.5 16.42 (5.92) 15 16.30 (4.79) 16 X2 1.46, p .481 
Cognitive avoidance 9.20 (1.92) 10 11.57 (2.77) 12 7.82 (2.86) 8 X2 10.52, p .005 9.75 (2.87) 10 7.75 (2.30) 8 9.10 (4.15) 8.5 X2 2.71, p .258 
Mini-MAC Time 2         
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Total scale scores 58.4 (8.26) 59 76.69 (12.33) 77  61.36 (15.71) 63 X2 8.82, p .012 67.38 (13.79) 71.5 62.83 (14.22) 61.5 63.50 (13.24) 62.5 X2 0.84, p .657 
Fatalism 10.20 (1.64) 11 14.08 (2.9) 14 15.09 (4.04) 16 X2 7.07, p .029 13.88 (2.85) 14 13.50 (2.36) 13.5 15.60 (3.06) 15 X2 2.62, p .270 
Fighting spirit 12.20 (2.68) 11 13.15 (1.95) 13 10.73 (2.83) 12 X2 4.67, p .097 11.63 (2.07) 11.50 11/17 (2.66) 11 11.30 (2.31) 11.5 X2 0.17, p .92 
Helplessness/hopelessness 9.60 (2.61) 8 15.46 (4.24) 15 10.73 (4.50) 8 X2 9.08, p .011 13.25 (3.92) 14 13.42 (5.57) 12.5 11.80 (4.73) 9.5 X2 1.20, p .550 
Anxious preoccupation 17 (2.83) 15 22 (4.28) 21 15.45 (6.17) 14 X2 9.07, p .011 19.13 (6.92) 20 16.25 (6.14) 16.5 16.20 (5.47) 14.5 X2 1.14, p .567 
Cognitive avoidance 9.40 (2.30) 9 12 (2.35) 12 9.36 (3.98) 10 X2 4.21, p .122 9.50 (2.73) 10/5 8.50 (3.37) 8.5 8.60 (3.75) 9 X2 1.25, p .536 
Mini-MAC Time 3         
Total scale scores 55.20 (14.87) 61 73.69 (14.20) 73 60.18 (13.14) 57 X2 7.97, p .019 65.43 (14.97) 71 58.92 (18.41) 54.5 65 (10.41) 65.5 X2 1.55, p .461 
Fatalism 10.20 (3.42) 11 13.85 (3.85) 15 14 (2.79) 14 X2 4.42, p .110 13.14 (3.29) 13 12.75 (3.67) 14 15.40 (2.91) 15 X2 2.93, p .231 
Fighting spirit 10.20 (4.27) 10 12 (1.87) 12 10.82 (3.28) 11 X2 1.43, p .489 12.29 (1.70) 13 11 (3.16) 11.5 11.70 (1.83) 11.5 X2 0.73, p .694 
Helplessness/hopelessness 9.80 (2.05) 9 14.46 (3.80) 14 11.73 (5.12) 8 X2 5.69, p .058 12.29 (5.02) 9 11.50 (5.32) 9 12.40 (4.22) 11 X2 0.83, p .659 
Anxious preoccupation 16.20 (5.81) 17 21.69 (4.96) 22 14.73 (5.61) 15 X2 7.51, p .023 18.29 (7.18) 20 15.33 (7.30) 12 17.40 (4.53) 18 X2 1.72, p .422 
Cognitive avoidance 8.80 (3.11) 9 11.69 (2.75) 12  8.91 (2.74) 9 X2 8.17, p .017 9.43 (3.65) 9 8.33 (4.46) 7.5 8.10 (3.78) 8 X2 0.53, p .767 
PES Time 1 45.80 (3.49) 46 46.71 (5.37) 47 52.73 (5.95) 54 X2 9.13, p .010 47 (4.90) 47 49.42 (4.72) 50 48.10 (5.92) 48.5 X2 0.99, p .610 
PES Time 2 45.40 (4.93) 44 42.54 (5.30) 44 49.82 (4.54) 50 X2 8.97, p .011 49.13 (4.49) 49.5 49.17 (4.91) 49.5 50.20 (7.48) 51.5 X2 0.50, p .778 
PES Time 3 46 (5.66) 44 44.31 (5.19) 45 51.18 (5.4) 51 X2 7.46, p .024 49.86 (5.11) 52 51.08 (4.81) 51.5 49.40 (7.14) 51 X2 0.33, p .849 
Note. *Kruskal–Wallis test results; Bolded p value indicates statistical significance p<.05  
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29Table 7 Gender Differences Across Measures at Each Time Point within the Control and Intervention Groups 
 Control Group Intervention Group 
Measure Male 
N=12 
Female 
N=18 
Group 
Comparison* 
Male 
N=22 
Female 
N=8 
Group 
Comparison* 
Mean(SD) 
Median 
Mean(SD) 
Median 
Mean(SD) 
Median 
Mean(SD) 
Median 
SF-SUNS Time 1       
Total Scale scores 17.42 (11.07) 17 32.61 (25.24) 24 X2 4.49, p .034 23.64 (20.66) 16 37.50 (17.91) 41 X2 3.98, p .046 
Information 2.25 (2.22) 2.5 4 (2.61) 4 X2 3.24, p .072 2.73 (3.41) 1.5 3.63 (2.50) 4 X2 1.13, p .288 
Financial concerns 6.08 (4.27) 6 7.67 (7.15) 6 X2 0.05, p .815 6.45 (6.47) 5 7.38 (4.37) 7 X2 1.03, p .310 
Access and continuity of care 1.92 (1.93) 1.5 3.06 (5.42) 1 X2 0.06, p .811 3.68 (5.80) 1.5 4.75 (6.43) 2 X2 0.23, p .631 
Relationships and emotional health 7.17 (4.63) 5.5 17.89 (12.79) 13 X2 8.09, p .004 10.77 (10.27) 7 21.75 (8.52) 21 X2 7.18, p .007 
SF-SUNS Time 2       
Total Scale scores 20.73 (20.42) 16 33.44 (31.05) 24.5 X2 1.37, p .242 25.27 (24.21) 20.5 29 (19.66) 26 X2 0.67, p .412 
Information 2.27 (2.65) 2 3.78 (3.57) 3.5 X2 1.26, p .261 2.36 (2.04) 2.5 2.25 (2.05) 2 X2 0.03, p .867 
Financial concerns 5.55 (7.33) 2 6.89 (9.13) 3.5 X2 0.12, p .733 7.73 (7.75) 6 7.38 (7.60) 6 X2 0.002, p .962 
Access and continuity of care 2.36 (3.26) 2 2.5 (3.28) 1.5 X2 0.34, p .563 2.55 (3.46) 0.5 2 (3.55) 0 X2 0.29, p .593 
Relationships and emotional health 10.55 (8.14) 10 18.94 (15.68) 13 X2 1.48, p .224 12.64 (13.93) 9.50 17.38 (8.55) 16.5 X2 3.02, p .082 
SF-SUNS Time 3       
Total Scale scores 17.82 (16.41) 15 30.56 (29.81) 21.5 X2 1.37, p .242 22.81 (25.90) 17 17.75 (12.99) 14 X2 0.001, p .981 
Information 2.27 (2.15) 2 3.06 (3.19) 2 X2 0.17, p .678 2.52 (2.40) 2 0.50 (1.41) 0 X2 5.12, p .024 
Financial concerns 5.18 (5.76) 3 6.94 (8.88) 4 X2 0.10, p .750 6.19 (7.11) 4 4.88 (3.98) 4.5 X2 0.01, p .922 
Access and continuity of care 2.09 (2.17) 2 2.5 (3.28) 1.5 X2 0.002, p .963 2.38 (5.22) 1 1.88 (3.48) 0 X2 0.20, p .654 
Relationships and emotional health 8.27 (7.53) 6 18.06 (15.99) 14 X2 2.71, p .100 11.81 (13.79) 8 10.50 (7.64) 8.5 X2 0.22, p .642 
DASS21 Time 1       
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Total scale scores 9.42 (5.38) 9 19.67 (16.33) 15.5 X2 1.96, p .161 11.14 (12.67) 7.5 16.88 (9.42) 16 X2 3.71, p .054 
Depression 2.17 (3.54) 1 5.78 (5.97) 2.5 X2 4.27, p .039 3.59 (5.08) 1.5 5.25 (3.69) 4 X2 3.25, p .072 
Anxiety 2.33 (1.67) 2 6.11 (5.97) 5 X2 2.31, p .128 3.05 (3.30) 2.5 4.63 (3.46) 3.5 X2 2.10, p .147 
Stress 4.92 (2.84) 5 7.78 (6.04) 6.5 X2 1.53, p .217 4.50 (4.98) 3.5 7 (5.07) 5.5 X2 3.14, p .077 
DASS21 Time 2       
Total scale scores 6.36 (6.20) 5 18.64 (14.89) 16 X2 5.27, p .022 13.95 (16.07) 8.5 20.25 (14.19) 22 X2 1.61, p .205 
Depression 1.64 (2.54) 0 6.39 (5.98) 6 X2 5.77, p .016 4.82 (6.10) 2 6.63 (4.90) 8.5 X2 1.18, p .277 
Anxiety 1.36 (1.50) 1 5 (4.70) 3.5 X2 5.70, p .017 3.23 (3.88) 2 4.38 (3.11) 4 X2 1.41, p .235 
Stress 3.36 (3.01) 4 7.56 (6.40) 6.5 X2 3.22, p .073 5.91 (6.64) 4 9.25 (7.70) 7 X2 1.50, p .220 
DASS21 Time 3       
Total scale scores 8.82 (7.14) 6 19 (15.50) 17 X2 2.48, p .115 12.86 (14.53) 8 13.50 (10.69) 16.5 X2 0.24, p .625 
Depression 2.55 (3.08) 2 6.22 (6.32) 4 X2 1.68, p .195 4.43 (5.69) 2 3.38 (4.72) 0.5 X2 0.36, p .546 
Anxiety 1.64 (1.50) 1 4.72 (4.54) 4 X2 2.41, p .121 3.10 (3.83) 2 4.37 (4.31) 4 X2 0.46, p .498 
Stress 4.64 (3.41) 4 8.06 (6.66) 9.5 X2 1.12, p .289 5.52 (6.22) 3 6 (4.63) 5.5 X2 0.32, p .572 
Mini-MAC Time 1       
Total scale scores 65.83 (10.21) 64.5 70.22 (14.19) 69.5 X2 1.04, p .309 63.41 (13.50) 62 70.50 (8.40) 71.5 X2 2.26, p .133 
Fatalism 14.67 (3.09) 15.5 14 (3.48) 14.5 X2 0.28, p .594 13.55 (2.96) 13.5 15.75 (2.77) 16 X2 3.30, p .069 
Fighting spirit 12.83 (1.53) 13 12.22 (2.46) 12.5 X2 0.36, p .549 12.32 (2.64) 13 12.63 (2.62) 13 X2 0.05, p .832 
Helplessness/hopelessness 11.33 (3.68) 10 13.22 (4.62) 15.5 X2 1.23, p .267 12.18 (4.97) 10.5 14.38 (4.53) 12.5 X2 2.30, p .130 
Anxious preoccupation 18.08 (4.50) 19 20.39 (5.76) 20.5 X2 1.63, p .201 16.91 (6.14) 16 18.25 (5.15) 18.5 X2 0.60, p .437 
Cognitive avoidance 8.92 (3.0) 9.5 10.39 (3.17) 11 X2 1.43, p .232 8.45 (3.10) 9 9.50 (3.46) 8 X2 0.11, p .739 
Mini-MAC Time 2       
Total scale scores 64.64 (14.42) 64 69.61 (15.79) 67.5 X2 0.66, p .418 62.86 (13.65) 61.5 68.13 (12.91) 73 X2 1.32, p .250 
Fatalism 14.36 (4.37) 15 13.44 (3.09) 14 X2 0.70, p .403 13.82 (2.54) 14 15.63 (3.25) 16.5 X2 2.49, p .114 
Fighting spirit 12.36 (2.58) 12 11.89 (2.68) 12 X2 0.17, p .683 11.55 (2.15) 11.5 10.75 (2.82) 11 X2 0.44, p .508 
Helplessness/hopelessness 11.36 (4.06) 10 13.44 (5.09) 14 X2 1.35, p .246 12.64 (4.95) 11.5 13.38 (4.60) 13.5 X2 0.27, p .602 
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Anxious preoccupation 17 (4.90) 19 19.67 (6.02) 19.5 X2 1.17, p .279 16.41 (6.26) 15.5 18.63 (5.55) 21 X2 1.22, p .270 
Cognitive avoidance 9.55 (3.45) 11 11.17 (3.05) 11 X2 0.99, p .319 8.45 (3.13) 8.5 9.75 (3.66) 10 X2 0.99, p .320 
Mini-MAC Time 3       
Total scale scores 63.73 (12.66) 63 66.39 (17.31) 67.5 X2 0.55, p .458 60.33 (15.86) 61 68.50 (11.36) 71) X2 1.87, p .171 
Fatalism 14.45 (3.53) 15 12.56 (3.52) 12.5 X2 1.90, p .168 13.05 (3.31) 13 15.63 (3.25) 15.5 X2 2.87, p .090 
Fighting spirit 12.27 (2.53) 12 10.61 (3.01) 10.5 X2 1.61, p .204 11.43 (2.62) 12 11.88 (1.96) 12.5 X2 0.06, p .806 
Helplessness/hopelessness 10.55 (3.14) 9 13.89 (4.66) 13 X2 3.51, p .061 11.76 (4.80) 9 12.63 (4.84) 10 X2 0.76, p .383 
Anxious preoccupation 16.27 (5.48) 17 19.22 (6.39) 20 X2 1.23, p .268 16.33 (6.95) 15 17.88 (4.55) 20 X2 0.96, p .327 
Cognitive avoidance 10.18 (3.16) 11 10.11 (3.09) 10.50 X2 0.19, p .666 7.76 (3.53) 8 10.50 (4.50) 11 X2 2.65, p .104 
PES Time 1 50.92(6.11) 51.5 47.33(5.69) 47 X2 2.81, p .094 48.86 (5.43) 51 46.87 (4.05) 48 X2 1.72, p .279 
PES Time 2 48.55(5.63) 48 44.11(5.46) 44 X2 4.40, p .036 49.41 (5.37) 49.5 49.75 (6.67) 52.5 X2 0.43, p .510 
PES Time 3 47.73(6.07) 47 46.89(6.23) 46.5 X2 0.13, p .718 50.29 (4.98) 51 50 (7.46) 52.5 X2 0.05, p .825 
Note. *Kruskal–Wallis test results; Bolded p value indicates statistical significance p<.05 
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30Table 8 Lymphoma Differences Across Measures at Each Time Point within the Control and Intervention Groups 
 Control Group Intervention Group 
Measure NHL 
N=24 
HL 
N=6 
Group 
Comparison* 
NHL 
N=18 
HL 
N=12 
Group 
Comparison* 
Mean(SD) 
Median 
Mean(SD) 
Median 
Mean(SD) 
Median 
Mean(SD) 
Median 
SF-SUNS Time 1       
Total Scale scores 28.17 (24.14) 23 20 (4.69) 18.5 X2 0.08, p .775 26.72 (23.56) 17.5 28.25 (16.21) 26 X2 0.55, p .459 
Information 3.38 (2.65) 3.5 3 (2.45) 3 X2 0.10, p .753 2.33 (3.33) 0 3.92 (2.81) 3 X2 3.28, p .070 
Financial concerns 7.92 (6.49) 7 3.5 (2.26) 4 X2 3.12, p .077 7.22 (7.08) 5 5.92 (3.75) 7 X2 0.002, p .966 
Access and continuity of care 3 (4.78) 1.5 1 (0.89) 1 X2 0.92, p .339 4.61 (7.14) 1.5 3 (3.28) 1.5 X2 0.01, p .914 
Relationships and emotional health 13.88 (12.68) 11.5 12.50 (5.21) 11.5 X2 0.11, p .735 12.56 (11.03) 10 15.42 (10.88) 13.5 X2 0.49, p .484 
SF-SUNS Time 2       
Total Scale scores 30.87 (30.71) 22 20 (8.44) 21 X2 0.003, p .957 28.72 (28.21) 19.5 22.58 (10.84) 23 X2 0.02, p .882 
Information 3.48 (3.59) 2 2.17 (1.47) 2.5 X2 0.17, p .680 2.17 (2.15) 2 2.58 (1.83) 2.5 X2 0.45, p .504 
Financial concerns 7.43 (9.12) 4 2.33 (1.63) 2 X2 1.50, p .220 9 (8.96) 6 5.58 (4.46) 6 X2 0.33, p .564 
Access and continuity of care 3.87 (4.62) 3 1 (1.67) 0 X2 2.68, p .102 2.39 (3.87) 0 2.42 (2.81) 1 X2 0.06, p .800 
Relationships and emotional health 16.09 (15.16) 11 14.50 (7.15) 14.5 X2 0.16, p .686 15.17 (15.11) 11 12 (8.33) 11.5 X2 0.01, p .916 
SF-SUNS Time 3       
Total Scale scores 27.17 (28.78) 18 20.17 (9.52) 22 X2 0.19, p .666 24.11 (27.51) 14.5 17 (12.38) 16 X2 0.06, p .805 
Information 2.78 (3.10) 2 2.67 (1.51) 3 X2 0.28, p .600 2.28 (2.63) 2 1.45 (1.75) 0 X2 0.55, p .458 
Financial concerns 7.22 (8.45) 4 2.67 (2.16) 3.5 X2 1.07, p .301 7.28 (7.40) 4.5 3.27 (3.00) 4 X2 2.04, p .154 
Access and continuity of care 2.57 (3.12) 2 1.5 (1.52) 1.5 X2 0.20, p .654 3.06 (5.84) 1 0.91 (1.45) 0 X2 1.30, p .254 
Relationships and emotional health 14.61 (15.36) 9 13.33 (8.62) 16 X2 0.14, p .705 11.50 (14.52) 7 11.36 (7.99) 11 X2 0.81, p .368 
DASS21 Time 1       
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Total scale scores 16.92 (15.12) 11 10.17 (5.19) 9 X2 0.69, p .405 12.72 (13.91) 8 12.58 (9.02) 11 X2 0.52, p .471 
Depression 4.92 (5.81) 2 2 (2) 1 X2 0.12, p .732 4.56 (5.53) 2.5 3.25 (3.31) 2 X2 0.04, p .847 
Anxiety 5.25 (5.34) 3.5 2 (2.53) 1 X2 1.93, p .164 3.11 (3.64) 1.5 4 (2.95) 3 X2 1.77, p .184 
Stress 6.75 (5.72) 5.5 6.17 (1.72) 6 X2 0.08, p .774 5.06 (5.32) 4 5.33 (4.83) 5 X2 0.44, p .509 
DASS21 Time 2       
Total scale scores 14.78 (14.95) 8 11.83 (7.39) 10 X2 0.11, p .746 18.11 (17.61) 10.5 11.92 (11.75) 7 X2 0.65, p .421 
Depression 4.87 (5.83) 2 3.5 (3.73) 3 X2 0.19, p .661 6.28 (6.52) 3 3.83 (4.30) 1.5 X2 1.70, p .193 
Anxiety 4 (4.57) 2 2.17 (1.60) 2 X2 0.15, p .703 3.78 (4.22) 3 3.17 (2.79) 2.5 X2 0.00, p .983 
Stress 5.91 (6.15) 4 6.17 (3.87) 5.5 X2 0.50, p .480 8.06 (7.60) 5.5 4.92 (5.68) 3.5 X2 0.69, p .406 
DASS21 Time 3       
Total scale scores 16.78 (14.69) 12 8.83 (7.14) 9 X2 1.22, p .269 13.17 (15.57) 7 12.82 (9.53) 15 X2 0.25, p .620 
Depression 5.39 (6.01) 2 2.67 (2.66) 2.5 X2 0.50, p .479 4.28 (6.21) 1 3.91 (3.91) 4 X2 0.04, p .835 
Anxiety 4 (4.22) 3 1.83 (2.14) 1 X2 0.91, p .339 3.44 (4.29) 1.5 3.45 (3.47) 3 X2 0.16, p .694 
Stress 7.39 (6.11) 7 4.33 (4.08) 3.5 X2 1.05, p .304 5.72 (6.34) 3.5 5.55 (4.91) 4 X2 0.00, p 1.00 
Mini-MAC Time 1       
Total scale scores 68.96 (13.85) 69 66.5 (7.26) 68 X2 0.05, p .815 60.56 (12.65) 58 72.42 (8.98) 72.5 X2 6.90, p .009 
Fatalism 15 (3.02) 16 11.33 (2.81) 12 X2 6.15, p .013 13.72 (3.20) 13.5 14.75 (2.77) 14 X2 0.76, p .383 
Fighting spirit 12.79 (2.21) 13 11.17 (1.17) 11 X2 3.56, p .059 12.06 (2.69) 12 12.92 (2.47) 13.5 X2 0.76, p .382 
Helplessness/hopelessness 12.21 (4.48) 10.5 13.5 (3.67) 15 X2 0.52, p .472 11.94 (4.88) 10.5 14 (4.82) 12.5 X2 2.17, p .140 
Anxious preoccupation 19.38 (5.90) 19 19.83 (2.14) 19 X2 0.00, p 1.00 15.17 (5.51) 13 20.42 (4.98) 20.5 X2 6.61, p .010 
Cognitive avoidance 9.58 (3.28) 10 10.67 (2.50) 11.5 X2 1.45, p .229 7.67 (2.70) 8 10.33 (3.26) 10 X2 4.34, p .037 
Mini-MAC Time 2       
Total scale scores 68.87 (16.04) 66 63.33 (11.73) 64 X2 0.57, p .451 62.44 (14.46) 61 67 (11.81) 70 X2 1.08, p .299 
Fatalism 14.65 (3.33) 15 10.5 (2.59) 10 X2 6.62, p .010 14.17 (2.81) 14 14.50 (2.91) 15 X2 0.16, p .686 
Fighting spirit 12.39 (2.76) 13 10.83 (1.47) 10.5 X2 3.03, p .082 11.44 (2.15) 11 11.17 (2.66) 11.5 X2 0.029, p .864 
Helplessness/hopelessness 12.74 (5.07) 13 12.33 (3.67) 13 X2 0.003, p .956 12.44 (5.24) 11.5 13.42 (4.19) 14 X2 1.10, p .294 
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Anxious preoccupation 18.61 (6.24) 19 18.83 (3.06) 20 X2 0.06, p .808 16 (6.16) 15 18.50 (5.85) 17.5 X2 1.36, p .244 
Cognitive avoidance 10.48 (3.46) 11 10.83 (2.48) 11.5 X2 0.03, p .871 8.39 (3.20) 9 9.42 (3.40) 9.5 X2 0.77, p .381 
Mini-MAC Time 3       
Total scale scores 67.30 (15.46) 69 58 (14.64) 62 X2 1.54, p .215 61.67 (16.08) 62 64.09 (13.73) 70 X2 0.52, p .471 
Fatalism 14.13 (3.09) 14 10 (3.69) 10 X2 5.92, p .015 13.78 (3.57) 14 13.73 (3.38) 13 X2 0.05, p .821 
Fighting spirit 11.78 (2.76) 12 9.17 (2.71) 10 X2 4.26, p .039 11.56 (2.55) 12 11.55 (2.34) 12 X2 0.01, p .946 
Helplessness/hopelessness 13.09 (4.80) 13 10.83 (1.60) 11.5 X2 0.82, p .367 11.94 (4.82) 9.5 12.09 (4.83) 9 X2 0.00, p 1.00 
Anxious preoccupation 18.13 (6.48) 19 18 (5.10) 19.5 X2 0.04, p .850 16.06 (6.28) 15.5 17.91 (6.56) 20 X2 0.74, p .391 
Cognitive avoidance 10.17 (3.03) 11 10 (3.46) 11 X2 0.01, p .935 8.33 (4.10) 8 8.82 (3.84) 9 X2 0.10, p .751 
PES Time 1 50.13 (5.78) 50.5 43.33 (3.56) 43.5 X2 6.62, p .010 48.89 (5.31) 50 47.50 (4.89) 48 X2 0.43, p .510 
PES Time 2 47 (5.84) 47 41.17 (2.99) 41 X2 6.05, p .014 49.33 (4.91) 49.5 49.75 (6.78) 52.5 X2 0.24, p .625  
PES Time 3 48.13 (5.96) 48 43.67 (5.61) 42 X2 2.80, p .094 50.56 (5.07) 51.5 49.64 (6.67) 52 X2 0.04, p .839 
Note. *Kruskal–Wallis test result; Bolded p value indicates statistical significance p<.05 
